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This chapter will provide a literature overview of 
methods used for protein modification, which is a 
field that has largely evolved in the last 15 years. 
In the 1990s, protein modification was either 
achieved via natural amino acid residue labeling, or 
by using biology inspired methods like Sortase or 
expressed protein ligation.  
Ever since, many new reactions have been developed, 
including those that do not involve naturally 
occurring functional handles. Especially the 
development of these so-called bioorthogonal 
ligations have significantly contributed to the study 
of biological processes. 
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1.1 Bioconjugation 
Bioconjugation is the process of linking two or more molecules, of which at least 
one is a biomolecule, together. In this manner, the properties of the individual 
components are combined.
1
 Chemically, clearly, examples of reactions ligating 
two or more molecules have been numerous for decades. However, biomolecule 
labeling poses large limitations on reaction conditions, e.g. solvent use, 
concentration, and available reactive groups. 
In general, biological systems flourish best in an aqueous environment. This 
means that the reagents will need to be stable in aqueous systems, and the 
reaction needs to proceed in water. In addition, biomolecules are only present in 
low concentrations, let alone the concentration of the reactive group in these 
biomolecules. Therefore, reaction speed needs to be high in order to obtain 
significant modification over a convenient time span.  
Apart from these requirements, in proteins only limited reactive groups are 
available, i.e. amines, thiols, phenols and indoles. This implies that for 
modification of proteins suitable reaction partners will have to be identified that 
react selectively with either of these functional handles. Alternatively, new, non-
biologically present, labels can be introduced into the biological system. With this 
realization, the development of bioorthogonal reactions hit the road. For a reaction 
to be bioorthogonal, apart from the requirements as mentioned for bioconjugation, 
it needs to be selective for its target, and not give cross-reactivity with any of the 
functional groups present in biological systems.  
Apart from expanding the scope of biomolecule modification, bioorthogonal 
ligation also allows for the selective and controlled introduction of labels, not only 
on single proteins, but also on cell-surfaces, in living cells, and even in live 
animals. These features open many opportunities for studying biological 
processes, which are not possible when using for example lysine or cysteine 
labeling. 
Although the complete genome of many organisms has been elucidated, many 
biological processes like post-translational modifications, protein-protein 
interactions, and protein translocation are not yet understood. With new 
bioorthogonal ligation reactions it has been possible to e.g. study protein formation 
during embryogenesis,
2
 image tumors,
3
 and track glycan formation and 
translocation.
4
 
In the last decade, research on bioconjugation has grown at an incredible pace, 
and thousands of papers have been published on new ligation methods or 
applications thereof. In this chapter an overview is given of the different ligation 
strategies available for protein modification. The aim is to give an impression of 
different types of ligation strategies and how they can be used in biological 
research. This chapter will not provide a complete overview of all methods known, 
and/or all applications possible, as this would  be prohibitively extensive as an 
introduction to a thesis. Instead, reviews are often cited which give a more 
elaborate description of certain topics. Due to the extreme expansion of the field 
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since the start of the research which led to this thesis (november 2008), some 
research described in this chapter will overlap with research from this thesis. 
In this chapter first all different labeling methods are described, i.e. nature 
inspired modifications (section 1.2), labeling naturally occurring reactive groups 
(section 1.3), with a specific section on thiol-mediated ligation (section 1.4), and 
bioorthogonal reactions (section 1.5). In all these sections, only direct introduction 
of a label (e.g. fluorescent dye, liposome, or radiolabel) is described. In case one 
of the afore mentioned methods is used for the introduction of a non-natural 
functional handle (instead of a label) this is described in section 1.6, which 
elaborates on the different methods to introduce these reactive partners. Lastly, as 
azide-related chemistry is currently the most-studied bioorthogonal reaction, 
section 1.7 describes the different azide-reactive probes developed and highlights 
a few applications of these reactions. 
 
1.2 Nature inspired modifications 
During evolution, nature has developed a wide range of tools for fast and 
selective modifications of biomolecules. For example, nature uses enzymes to 
cleave proteins, ligate proteins, or functionalize proteins. In addition, nature uses 
certain sequences which are used for either recognition of substrates or for post-
translational modifications. Modifying these techniques as used in nature such that 
they can be performed outside living systems in a controlled fashion, can result in 
methods for labeling of specific biomolecules. In recent research, some of the 
known biological tools have found application for protein modification and cell 
surface modification.
5
 
 
1.2.1 Sortase ligations 
Sortases are enzymes produced by Gram-positive bacteria which covalently 
attach cell surface proteins to the cell wall.
6
 In protein modifications, the most 
commonly used Sortase is Sortase A (SrtA), mainly because bioactive and water-
soluble variants of SrtA are widely available.
7
 When SrtA recognizes a small so-
called “sorting signal”, i.e. LPXTG, the active cysteine residue of SrtA cleaves the 
bond between glycine and threonine, leaving an activated thio-ester. Next, the N-
terminus of a peptide or protein can attack on the activated ester, thereby forming 
the desired conjugate, as depicted in Scheme 1.
8
 This method then, in general, 
leads to C-terminally functionalized proteins, albeit also methods resulting in N-
terminal functionalization have been reported.
9, 10
 These sortases have, among 
others, been used for the preparation of peptide-peptide, protein-protein, peptide-
nucleic acid, protein-lipid, and protein-glycopeptide conjugates.
6, 7
 Recently, it was 
also shown that SrtA can be used to ligate and cyclize proteins in different cellular 
compartments.
11
  
In addition to these numerous ligations, SrtA has been used to site-specifically 
label living cells. Ploegh et al. showed that surface protein CD40L, containing a C-
terminal LPETG-tag, could be expressed on the surface of HEK-cells.
12
 When 
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these cells were subsequently incubated in SrtA containing medium, together with 
biotinylated-pentaglycine, cells were equipped with a biotin label. Nagamune and 
co-workers later extended this methodology by reporting the N-terminal labeling of 
enhanced cyan fluorescent protein (ECFP), which was targeted to the cell-surface 
of HEK cells. 
 
Scheme 1. Mechanism for Sortase-mediated ligation. 
 
1.2.2 Transglutaminase 
Transglutaminases (TGases) are enzymes causing protein cross-linking and 
introduction of primary alkylamines. The enzymes are involved in, for example, 
blood coagulation, apoptosis, epidermal differentiation, and reproductive 
processes.
13
 The cysteine in the active site of TGases can attack on the 
carboxyamide of the glutamine side chain. Attack of the ε-amine of lysines, or 
small alkylamines, on the resulting thio-ester then results in protein-crosslinkage 
or introduction of a small alkyl-spacer to proteins, as shown in Scheme 2.
13
 In 
addition, under certain conditions, also water or small alcohols can attack on the 
thio-ester, forming free acids or esters, respectively. 
 
Scheme 2. Mechanism for transglutaminase-mediated ligations. 
To be able to use TGases for protein labeling, the protein of interest needs to be 
equipped with a recognition peptide. To this end, Sato et al. attached a TGase 
recognition peptide to Interleukin-2 at the N-terminus or the C-terminus. The thus 
introduced glutamine was now equipped with either a dansyl-group,
14
 or a PEG-
tail.
15
 In a similar manner, other proteins have also been PEGylated.
16
 Taki and 
co-workers, introduced a TGase recognition site to glutathione S-transferase at 
 1  Bioconjugation: Unlimited opportunities  13 
 
 
either the N-terminus or the C-terminus, and subsequently labeled the protein with 
fluorescein.
17
 
In spite of the great potential this class of enzymes displays, only limited 
examples of protein labeling using TGases are known.
18
 The main problem is that 
no general consensus is found for the peptide sequence recognized by TGases.
19
 
Therefore, research mainly focusses on the identification of TGase substrates and 
recognition peptides using biotin-labels or fluorescent tags. 
 
1.2.3 Tags based on biological interactions 
A highly efficient and selective way of labeling proteins is by using protein-based 
chemical tags.
20
 These tags are created based on naturally occurring interactions 
between proteins and small molecules. Common tags are the tetracysteine tag 
(FlAsH-tag), the trimethoprim (TMP)-tag, and the SNAP-tag.  
 
Figure 1. Schematic representation of FlAsH-tag, TMP-tag, and SNAP tag. 
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The FlAsH-tag is inspired by the binding of trivalent arsenic to paired cysteine-
residues of the cofactor lipoic acid, which is largely responsible for the toxic effect 
of arsenic compounds. In short, the protein of interest is equipped with the FlAsH-
tag (a 15 amino acid tag, with a tetracysteine core, CCXXCC).
21
 Subsequently, the 
modified protein can be ligated to a fluorogenic bisarsenical fluorescein ligand. 
Advantage of the tag is its small size. Disadvantages, on the other hand, are that 
in cysteine-rich environments a high degree of aspecific labeling is obtained, and 
that the bisarsenical fluorescein ligand is toxic.
22
 Nonetheless, the FlAsH-tag has 
successfully been applied for labeling in many types of mammalian cells, bacterial 
cells, and even in vivo in Drosophilia eyes.
22
 In addition, the FlAsH tag has also 
been used for the examination of the trafficking and signaling of proteins in 
neurons,
23
 and for FRET studies together with CFP to investigate protein-protein 
interactions and conformational changes.
24, 25
 As alternative for the FlAsH-tag, a 
tetraserine motif was developed which selectively recognizes bis-boronic acids.
26
  
The TMP-tag is based on the interaction of dihydrofolate reductase (DHFR) with 
antibiotic trimethoprim (TMP), which shows high binding affinity and selectivity. To 
use this tag for protein labeling, DHFR is attached to the protein of interest; next, 
the protein can be labeled by the addition of a TMP-fluorophore.
27-29
 The TMP-tag 
has been used for the labeling of intracellular proteins in live cells,
30, 31
 and 
imaging of the spliceosome.
32
  
Probably the most applied tag in tag-based labeling is the SNAP-tag. For this 
strategy, a protein is fused with human repair protein O
6
-alkylguanine-DNA 
alkyltransferase. This fusion protein then forms a covalent bond with a labeled O
6
-
benzylguanine.
33, 34
 The SNAP-tag has been used for the imaging of different 
proteins in mammalian and yeast cells,
33, 34
 imaging of the spliceosome,
32
 the 
visualization of protein-protein interactions,
35
 studying of cellular processes like 
endocytosis
36
 and HIV-cell interactions,
37
 and for the imaging of tumor 
xenographts.
38
  
 
1.2.4 Expressed protein ligation 
A crucial process in protein synthesis is post-translational modification. A 
prominent example is the exclusion of a precisely defined part of the protein (the 
so-called intein) and the subsequent conjugation of the N-extein and C-extein.
39, 40
 
With few exceptions, there are no limitations to the amino acids present in the 
exteins, however, inteins are characterized by several sequence constraints, e.g. 
an N-terminal and C-terminal serine, cysteine or threonine, and an asparagine at 
the C-terminal end of the intein.
40
 At this moment, over 500 different inteins have 
been identified.
41
 One of the sequential similarities between almost all inteins is 
the cysteine, threonine, or serine at the N-terminal site of the intein. The thiol or 
alcohol moiety of the N-terminal residue attacks on the amide bond, thereby 
forming an activated thio-ester or ester bond. Subsequently, the thiol or alcohol 
from a Cys/Ser/Thr at the C-terminal site of the intein attacks on this activated 
ester. A cyclization reaction caused by attack of the amide of the asparagine 
 1  Bioconjugation: Unlimited opportunities  15 
 
 
residue which is always conserved removes the intein. After an S-N or O-N acyl 
shift, the two exteins are fused by the formation of a stable amide bond. A 
schematic representation of this process is shown in Scheme 3.
40
 
 
Scheme 3. Mechanism for protein splicing. Two exteins are ligated together by removal of an 
intein. 
The implementation of this methodology on the labeling of proteins by introducing 
different peptides containing for example a fluorescein or biotin was first applied 
by Muir et al.
42
 and Xu and co-workers.
43
 This protein labeling strategy, named 
expressed protein ligation (EPL), was based on the finding that mutation of the C-
terminal site of the intein obstructed protein splicing, but still allowed for thio-ester 
formation.
44, 45
 In this methodology, the protein of choice is produced as a fusion 
protein, C-terminally linked to a modified intein and a binding domain, e.g. a chitin 
binding binding (CBD). Upon treatment with a small thiol, the fusion protein is 
released from the intein, and the remaining thio-ester can react with a peptide-like 
compound containing an N-terminal cysteine in a Native Chemical Ligation (NCL) 
type reaction,
46
 as depicted in Scheme 4. Over the last 15 years, many different 
applications of this EPL technique have been published,
47
 especially since the 
constructs became better accessible by the commercial availability of Intein-
Mediated Purifcation with an Affinity Chitin-binding Tag (IMPACT) kits.
48
 
 
Scheme 4. Mechanism for expressed protein ligation. 
EPL has widely been used for the introduction of fluorescent probes,
49-51
 
attachment of proteins to solid supports,
52
 protein cyclization,
53
 and selective 
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isotope-labeling of proteins.
54
 In addition to this, EPL has also been used to attach 
proteins to micelles,
55
 liposomes,
56
 and magnetic nanoparticles.
57
 In all these 
examples the surface of the micelles, liposomes, or nanoparticles was equipped 
with cysteines. The thiol-groups of these cysteine residues then reacted with the 
thio-ester of a protein, which was formed by splicing of the intein using a small 
thiol.  
 
1.3 Naturally occurring reactive groups 
Apart from using enzymes and the recognitionpatterns of protein fragments to 
perform protein modifications, also the side-chains of some natural amino acids 
contain attractive functional groups to perform ligations. Most prominent in 
literature are modifications of cysteine-residues, which will be discussed in section 
1.4, and lysine-residues.  
 
1.3.1 Lysine labeling 
Probably, the most commonly used reagents for lysine modification, and protein 
modification in general, are NHS-esters, isocyanates and isothiocyanates. These 
modifications simply require mixing of the protein and the reagent at the right pH 
(between 8 and 9 for NHS-esters, between 9 and 10 for NCS- and NCO-based 
ligations). Since many dyes, affinity labels, and metal chelators are available as 
amine-reactive reagents, labeling of proteins is greatly facilitated in this manner. In 
addition to these ligation reactions, lysines can also be modified using reductive 
amination with aldehydes,
58
 or using sulfonyl chlorides.
1, 59, 60
 Notably, 
modifications that apply to the ε-amine of lysines, can also modify the N-terminus.  
Although most of these modifications are relatively straightforward, disadvantage 
is that no selectivity concerning the site of modification and number of 
modifications is achieved during labeling. In general, if the success of the 
experiment is independent of the site or degree of modification, lysine-modification 
is an almost perfect option. On the other hand, when lysines are involved in for 
example enzyme functioning or epitope binding (e.g. antibodies) a different 
strategy is required.  
 
1.3.2 Glutamate and aspartate labeling 
An alternative to lysine-modification, is the modification of glutamate and 
aspartate residues. The acid moieties of these residues can be activated by 
adding EDC, if desired in combination with HOBt, and subsequently reacted with 
an amine.
60
 However, also for this method, no selectivity can be obtained as also 
glutamate and aspartate residues are highly abundant in proteins.  
 
1.3.3 Tyrosine and tryptophan labeling 
If more selectivity is required, tyrosine and tryptophan residues are better 
alternatives, as these are less abundant on protein surfaces.  
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The tyrosine-residue can be modified using electrophilic aromatic substitution, 
and metal-catalyzed reactions. Metal-catalyzed labeling can be achieved using 
Ni(OAc)2 and a labeled phenol, leading to formation of a C-C bond between the 
two carbon-atoms at the ortho-position with respect to the alcohol-functionalities 
(not shown).
61, 62
 Alternatively, Pd(OAc)2 in combination with an allylic ester, 
carbamate, or carbonate can be used to label the tyrosine alcohol, Scheme 5, 
route A.
63
 
By means of electrophilic aromatic substitution, iodides
64
 and nitro groups
65
 can 
be introduced, but the most general method involves reaction of the tyrosine 
alcohol with diazonium salts.
66
 A wide range of diazonium salts can be prepared 
by treating an aniline with sodium nitrite under acidic conditions. Treatment of the 
protein with these diazonium salts results in the modification of a tyrosine residue, 
ortho to the alcohol functionality, as shown in Scheme 5, route B. This process 
proceeds in high yield when electron-poor anilines are used as starting material, 
and results in limited labeling for electon-rich anilines.
67, 68
  
Alternatively, electrophilic aromatic substitution can be achieved using Mannich-
type reactions, shown in Scheme 5, route D.
69
 First, an imine is formed from an 
aldehyde and an electron-rich amine. The phenyl ring of the tyrosine then attacks 
on the imine, again introducing the functionality ortho with respect to the alcohol 
functionality. This reaction proceeds best with electron-rich anilines, making it 
complementary to the diazonium-coupling reaction. Recently, Barbas et al. 
showed that a similar reaction can also take place when a cyclic 
diazodicarboxamide is used, Scheme 5, route C.
70
 
 
Scheme 5. Methods used for tyrosine labeling. 
Among others, these tyrosine-based labeling strategies were used for lipidation 
(using route A),
63
 PEGylation (via route B),
71
 fluorescent labeling (route C),
70
 or for 
the introduction of peptides (route D).
72
  
The least abundant amino acid residue in proteins is tryptophan. Francis et al. 
demonstrated that this residue can be modified using a Rh-carbenoid, which 
reacts with the indole of tryptophan, yielding a mixture of N-alkyl and 2-alkyl 
labeled sidechains.
73
 This labeling was recently shown to be applicable in the 
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identification of binders to FynSH3 domain, an important therapeutic target for 
cancer treatment.
74
 To achieve this, potential binders were equipped with a 
rhodium catalyst, followed by the formation of the Rh-carbenoid. In the end, 
proximity-driven modification led to the ligation of peptide and protein. 
 
1.3.4 Modification of the N-terminus 
Probably the most specific labeling targets in a protein are the C-terminus and 
N-terminus, as of both only one is present in each protein. While for the C-
terminus EPL is the only widely applicable strategy, multiple modification 
strategies of the N-terminus have been reported, most of them involving specific 
amino acid residues at this terminus. One method being independent of the N-
terminal residue is acylation and alkylation (as described for lysine modification). 
The lower pKa of the N-terminus compared to the lysine side chains, makes 
selective modification of the N-terminus over the ε-amines possible.75 
NCL is, clearly, not only a suitable strategy for C-terminal modification, but can 
also be used for modification of a protein at the N-terminus, with as requisite that 
the N-terminal residue is a cysteine. If this is the case, the protein can react with a 
thio-ester, either formed synthetically or by using EPL.
42
 
Alternatively, the N-terminal cysteine can also be used for formation of a 
thiazolidine in reaction with an aldehyde. This reaction can also occur with N-
terminal serine, threonine, histidine, tryptophan, and asparagine residues, forming 
different cyclic products, as shown in Scheme 6.
76
 In addition, the N-terminal 
tryptophan can be used in a Pictet-Spengler reaction, forming a similar tricyclic 
structure.
77
 
 
Scheme 6. N-terminal labeling of Trp, Cys, Ser, Thr, Asn, and His using an aldehyde. 
Lastly, modifications of the N-terminus are known which do not directly introduce 
a label, but introduce a functionalizable handle instead. This handle can then 
subsequently be used for introduction of a label. This type of modification will be 
discussed in section 1.6. 
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1.4 Labeling of cysteine residues 
The amino acid least accessible for modification in nature is cysteine, since this 
residue, in general, occur as di-thiol-bridges.
60
 Only upon reduction of these 
disulfide bond, labeling of thiols can be achieved. However, this often has an 
effect on the tertiary structure. A free thiol can also be introduced using a so-called 
N-Succinimidyl S-Acetylthioacetate (SATA)-modification.
78
 This is an NHS-based 
reagent, introducing a protected thiol to lysine residues, which can, after 
deprotection, be used for labeling. Clearly, this makes thiol-related labeling as 
aspecific as other lysine-modifying strategies. Alternatively, an additional cysteine 
residue can be introduced via site-directed mutagenesis, yielding only one 
functionalizable amino acid. Disadvantage of this method is that it sometimes 
leads to unwanted disulfide bond formation and thereby disruption of the tertiary 
structure. 
 
1.4.1 Traditional thiol-labeling  
The most commonly used reagents for the labeling of thiols are maleimides, 
iodoacetamides, vinyl sulfones, and disulfides, Scheme 7. All except the latter are 
based on nucleophilic attack of the reactive SH on the activated carbon-atom 
(resulting in a Michael-type addition or substitution of the iodide). In general, these 
reactions are selective for thiols, and no labeling of lysines is observed. If 
necessary, lysine labeling can be further reduced by lowering the pH.  
 
Scheme 7. Traditional thiol-labeling reactions. 
 
Thiol-maleimide ligation 
The value of the thiol-maleimide ligation (pathway A, Scheme 7) is probably best 
underscored by the commercial availability of a wide range of reagents (e.g. 
fluorescent dyes and affinity tags). A nice example of thiol-introduction followed by 
thiol-maleimide ligation was published by Blankenberg et al.
79
 They published the 
introduction of a tag, containing one cysteine, to vascular endothelial growth factor 
(VEGF). Subsequently, a metal-chelator was ligated to VEGF using thiol-
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maleimide ligation and next labeled with technetium. Ultimately, this conjugate 
was used for biodistribution studies.  
A comparable reaction was published by Finn et al., who showed that 
oxanorbornadienes as shown in Scheme 8 give a Michael-type addition.
80
 The 
thus obtained conjugates undergo a retro-Diels-Alder (rDA) reaction, releasing 
substituted furans, Scheme 8. In a follow-up paper it was shown that the rate for 
this rDA cleavage can be controlled by variation of the substituents, making it a 
potential reaction for drug-delivery.
81
 Notably, upon prolonged reaction, also 
lysine-residues were labeled. These lysine-conjugates proved more stable and 
rDA cleavage was significantly slower. 
 
Scheme 8. Protein labeling using a thiol-oxanorbornadiene ligation, followed by a retro-Diels-Alder 
reaction. 
 
Labeling using iodoacetamide 
Similarly to the maleimides, iodoacetamide reagents (pathway B, Scheme 7) 
containing metal-chelators
82
 or dyes
83
 have been developed. Bruschi et al. 
prepared two new iodoacetamide dyes and subsequently showed the use of these 
dyes in the analysis of the oxidation damage in patients with glomerulosclerosis, 
based on that thiols become unreactive upon oxidation.
83
 In addition to these 
labeling applications, iodoacetamide is often used prior to tryptic digest, to prevent 
refolding of the protein, and it can be used to prevent thiols from giving undesired 
labeling.
84
 
 
Thiol-vinyl sulfone labeling 
Thiol-vinyl sulfone labeling (pathway C, Scheme 7) is based on a Michael-type 
addition of the free thiol to the conjugated double bond. Gonzalez et al. used this 
reaction for the immobilization of vinyl sulfone saccharides on glass plates and for 
the attachment of neoglycoproteins. Subsequently, the synthesized 
neoglycopeptides were added to the glass plates and the carbohydrate-binding 
proteins were identified.
85
 In addition, this method was used for the PEGylation of 
proteins,
86
 and the immobilization of proteins to nanoparticles.
87-89
  
 
Disulfide-based reagents 
Labeling using disulfide reagents (pathway D, Scheme 7) relies on the intrinsic 
tendency of thiols to form disulfide bonds. Upon addition of a disulfide an 
exchange takes place, thus forming a mixed disulfide linkage. This type of reaction 
works best when a symmetrical disulfide is used, or when upon exchange, the 
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remaining disulfide rearranges to a non-reactive species. Ellmann’s reagent (used 
to determine the concentration of thiol-functionalities in a sample) is based on this 
disulfide exchange, as is the introduction of a nitroxide paramagnetic spin label to 
proteins using S-(2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl methane 
sulfonothioate (MTSL). 
A special property of the disulfide bond formation is that the reaction is 
reversible; upon entering a reductive environment, the bond is cleaved. This 
feature of the disulfide bond has proven useful in drug delivery studies.
90
 For 
example, Zalipsky and co-workers showed that lipopolymers with a disulfide bond 
between the PEG-part and the lipid-part can be created.
91
 The liposomes prepared 
from this type of lipopolymers could be used for the triggered release of 
doxorubicin.
92
 
 
1.4.2 Thiol-ene and thiol-yne ligation 
The reaction between a free thiol and an alkene (the thiol-ene reaction, Scheme 
9) was reported over a century ago by Porter.
93
 The finding that the thiol-ene 
reaction proceeds according to a free radical mechanism was reported four 
decades later by Kharasch et al.
94
 However, it was not until 2007 that this reaction 
was first used for the modification of proteins. Kunz et al. reported the preparation 
of synthetic vaccines by the conjugation of a tumor-associated glycopeptide to 
BSA.
95
 The protein was first equipped with either a thiol or an alkene, using an 
EDC-coupling, thereby labeling the lysines. Next, glycopeptides were prepared 
with either a thiol or an alkene, and eventually photochemically conjugated to 
BSA. However, since EDC-coupling was used to introduce one of the functional 
handles, no specificity was obtained (24 and 25 labels were introduced for both 
cases). Later, Dondoni and co-workers used the thiol-ene reaction for the 
glycosylation of BSA.
96
 Dondoni equipped sugar moieties with an alkene handle, 
and photochemically ligated these to the free thiols of BSA. In addition to 
synthesis of glycosylated proteins,
97
 the thiol-ene ligation was used for the 
coupling of ubiquitin molecules
98
 and site-specific protein acetylation.
99
 With the 
latter, an excellent mimic for native acetylated residues was formed and it was 
shown that histones acetylated in this manner were still recognized by histone 
deacetylases. 
 
Scheme 9. Thiol-ene (left) and thiol-yne (right) ligation. 
An alternative for the thiol-ene reaction is the thiol-yne ligation, Scheme 9. 
Originally, this reaction was reported by Jones et al. in 1949.
100
 Using this 
reaction, two thiols can add to a single reagent. However, it was not until 2011 that 
this was used for the dual modification of BSA, introducing a sugar-moiety and a 
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fluorescein.
101
 Until now, this is the only example known for protein modification. 
The reaction has been more widely applied in material science for e.g. the creation 
of dendrimer like structures and surface modifications.
102
  
 
1.4.3 Thiol bridging reagents 
All thiol-related ligations described earlier require either the breaking of a 
disulfide bridge or the introduction of an additional thiol via site-directed 
mutagenesis. Disadvantage of the first is that the tertiary structure could 
potentially be destabilized or disturbed, disadvantage of the latter is that 
dimerization or disulfide scrambling can occur.
103
 An alternative was published by 
Brocchini et al.
104, 105
 An α,β-unsaturated ketone containing a β’-sulfonyl leaving 
group was prepared, Scheme 10. Addition to a protein with a reduced disulfide 
bridge resulted in Michael addition, followed by elimination of the sulfonyl group. 
Subsequently, the second thiol can react with the reformed α,β-unsaturated 
ketone, summarized in Scheme 10. In this manner, different proteins were 
PEGylated, while retaining the stability normally rendered by the disulfide bond. 
This was confirmed by enzyme activity and immunogenicity studies.
104
  
 
Scheme 10. PEGylation via cysteine ligation reforming the broken disulfide bridge. 
Alternatively, Baker et al. reported that also bromomaleimides can be used for 
this purpose, allowing for either reformation of the thiol-bridge or introduction of an 
additional functionality (e.g. a glucose). The distinguishing characteristic of this 
reaction is that labeling can be reversed by the addition of large excess of 
glutathione, Scheme 11.
106
 
 
Scheme 11. Reversible cysteine labeling. 
Disadvantage of both methods described above is that reduction of the disulfide 
bond needs to be performed prior to addition of the labeling agent, which could still 
cause protein unfolding. To circumvent this, Baker et al. published a maleimide 
with two thiophenols, which could be added together with the reducing agent.
107
 
Haddleton et al. showed that this reagent was so stable that it could survive atom 
transfer radical polymerisation (ATRP) conditions. Thus a maleimide-
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functionalized poly(methacrylate) was prepared, and used for the conjugation of 
this polymer to a disulfide bridge containing hormone (salmon calcitonin).
108
 
 
1.5 Bioorthogonal reactions 
Labeling of proteins, by modifications inspired by nature, using chemical tags or 
enzyme-mediated modification (section 1.2), or by the labeling of naturally 
occurring amino acids (section 1.3 and 1.4) still suffers from some significant 
disadvantages. For nature inspired modifications often large reagents and/or the 
introduction of large recognition parts are required. Alternatively, for the 
modification of naturally occurring amino acids selectivity is hard to achieve. Even 
though some amino acids (like tyrosine and cysteine) are low abundant and can 
be used for selective protein labeling, problems are likely to arise when applying 
these ligations in bigger biological systems (e.g. in cells or in vivo). In these 
systems, reagents need to be stable in aqueous environment (unlike diazonium 
salts or imines), catalyst requirements pose large challenges, and thiol-reactive 
probes are likely to give cross-reactivity with other proteins and thiol-containing 
reagents. 
To avoid biological interference and allow for live cell and in vivo labeling, in the 
last decade many groups have focussed on the development of bioorthogonal 
reactions. These reactions can occur in living systems, and show no cross-
reactivity with reagents present in biological systems, like lysines, cysteines, and 
glutathione.  
Since the first modification of a biological system using an unnatural functional 
group in 1996,
109
 many new bioorthogonal reactions have been published. 
Handles which have been shown to be bioorthogonal and applicable in biological 
system modification are aldehydes, azides, nitrones, nitrile oxides, tetrazines, 
tetrazoles, quadrocyclanes, and alkenes. All bioorthogonal reactions used in 
bioconjugation are summarized in Table 1. 
 Introduction of the functional handles to proteins or cell surfaces will be 
discussed in section 1.6. 
 
1.5.1 Ligations with ketones and aldehydes 
The first non-natural functional handle to be used for the modification of proteins 
was the carbonyl-functionality (aldehydes and ketones). Although these can react 
with amine-groups forming imines, in physiological media the carbonyl lies on the 
favored site of the equilibrium. On the other hand, ketones and aldehydes do form 
stable conjugation products with alkyloxyamines (entry 1) and hydrazines (entry 
2), forming oximes and hydrazones, respectively.
110
 These reactions have been 
used for the labeling of proteins
109
 including in living cells,
111
 virus particles,
68
 and 
on cell surfaces.
112
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Table 1. Summary of bioorthogonal reactions used in biological system modification. 
Entry 
Functional 
handle 
Reaction partner Product Catalyst 
1 
 
 
 
None 
2 
  
None 
3 
 
  
Cu(I) or Ru(II)
a 
4 
  
None 
5 
  
None 
6
b 
 
 
None 
7 
 
 
 
Cu(I) or Ru (II)
c 
8 
 
 
None 
9 
  
None 
10
b 
 
 
None 
11
b 
  
 
None 
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12 
 
 
 
None 
13 
 
 
None 
14 
 
 
None 
15
b
 
 
 
None 
16
b 
 
 
 
UV-light 
17 
 
 
UV-light 
18
b 
 
 
UV-light 
19
b 
  
 
none 
20    
Grubbs’ catalyst 
21 
 
  
Pd(OAc)2(ligand)2 
22 
  
Pd(OAc)2(ligand)2 
[a] Cu(I) catalysis yields the 1,4-isomer, Ru(II) yields the 1,5-isomer. 
[b] Both regioisomers are obtained, although only one is shown in the table.  
[c] Catalyst is only required when regioselective control is desired, Cu(I) yielding the 1,4 -isomer, Ru(II) yielding 
the 1,5 isomer. 
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1.5.2 Ligations with azides 
Currently, azides are the most commonly used bioorthogonal reagent in the 
modification of biological systems. Its popularity can be explained by the inertness 
and small size of the azide moiety, the facile introduction and, most important, the 
unique reactivity. In addition to that, introduction of an azide onto a substrate 
generally has only minimal effect on its structure.
113
 Reaction of azides in a 
Staudinger reduction and the Huisgen 1,3-dipolar cycloaddition were already well 
established in the previous century, however, they either do not form a bond 
between the two reaction partners, or require too harsh conditions for protein 
labeling.  
In 2000, Bertozzi et al. developed a Staudinger ligation (entry 4). This reaction is a 
modification of the long-known Staudinger reduction which was now applied for 
the formation of an amide bond via rearrangement of the aza-ylide intermediate.
114
 
An alternative was developed by Raines and co-workers, who combined the 
Staudinger reduction with an NCL (entry 5). 
115
  
A more biocompatible version of the 1,3-Huisgen dipolar cycloaddition was 
discovered independently by Meldal
116
 and Sharpless
117
 who found that the 1,3-
dipolar cycloaddition of azides and acetylenes can be catalyzed by sources of 
copper(I) (entry 3). Copper was found to catalyze the [3+2]-cycloaddition of azides 
and acetylenes in aqueous solvents at physiological pH and temperature and the 
reaction is compatible with biomolecules like sugars, proteins and nucleic acids. 
The resulting 1,4-disubstituted triazole adducts are formed with exclusive 
regioselectivity and high yield. Although the reaction has found many applications, 
the required Cu(I) is toxic to cells and binds to for example active sites of enzymes 
and metal chelators. To avoid the use of this catalyst, Cu-free cycloadditions using 
strained alkynes were developed. 
Already in 1953, Blomquist and Liu published the first synthesis of cyclooctyne 
and its suspected ring-strain, which became apparent from the reported explosive 
reaction of cyclooctyne and phenyl azide.
118
 The structural identity of the resulting 
liquid was later corroborated as the product of a 1,3-dipolar cycloaddition.
119
 Ever 
since, many different cycloalkynes have been reported. It was noted that a 
cyclooctyne is the smallest cycloalkyne which can be isolated. However, when 
bigger atoms are added (e.g. Si or S), also cycloheptynes could be isolated, 
especially when stabilized by the addition of methyl-groups adjacent to the 
alkyne.
120
 
In spite of all this work, mainly performed in the 1960s and 1970s, it was not until 
2004 that Bertozzi and co-workers realized the potential of these strained alkynes 
in the strain-promoted azide alkyne cycloaddition (SPAAC, entry 6).
121
 Since this 
first publication many other (dibenzo)cyclooctynes have been developed, and 
applications of SPAAC are numerous. In addition also oxanorbornadienes
122
 and 
thiacycloheptynes
123
 were shown to react with azides (not shown in Table 1)). 
Since the developed reaction partners for azides and examples of bioconjugation 
with azides are numerous, this will be further elaborated in section 1.7. 
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1.5.3 Ligations with nitrile oxides and nitrones 
Compared to azides, nitrile oxides and nitrones are stronger 1,3-dipoles, making 
them faster partners in cycloadditions. Unfortunately, this also makes them less 
stable and therefore more troublesome in biochemical applications. Advantage of 
using nitrile oxides is that, because of their increased reactivity, they react with 
simple terminal alkynes without the need of a catalyst (entry 7). This feature has 
mainly been applied by Heaney et al. for the modification of ribonucleosides.
124
 In 
addition, Ravoo and co-workers showed that this reaction can be used for surface 
modification.
125
 Carell et al. showed that nitrile oxides can also be used for the 
reaction with alkenes (entry 8) and norbornenes (entry 9). Here, nucleotides were 
equipped with norbornenes or alkenes and subsequently used for the synthesis of 
oligonucleotides, and lastly reacted with in situ formed nitrile-oxides.
126, 127
 In the 
study involving alkene-nitrile oxide ligation, not only the alkene-functionality but 
also alkyne-groups were introduced. It was shown that the alkynes could first be 
labeled using CuAAC, whereupon the alkenes were labeled with nitrile oxides.
127
  
Most recently it was shown that nitrile oxides also react with cyclooctynes (the 
so-called Strain-Promoted Alkyne Nitrile Oxide Cycloaddition (SPANOC), entry 
10).
128, 129
 This reaction showed almost a 100-fold rate increase compared to 
SPAAC, and was used for the modification of oligosaccharides,
128
 small 
peptides,
129
 and DNA modification on solid phase.
130
  
Disadvantage of using nitrile-oxides is that their reactivity also makes them 
unstable, and in situ preparation directly followed by cycloaddition is required. 
Nitrones, on the other hand, appeared to be more stable and still react in a fast 
and selective manner with cyclooctynes in a Strain-Promoted Alkyne Nitrone 
Cycloaddition (SPANC, entry 11).
131, 132
 
For this reaction, the reactivity largely depended on the nature of the nitrone, 
with rate constants ranging within 3 orders of magnitude. Cyclic nitrones were 
found to be most efficient.
133, 134
 SPANC has found multiple applications in cancer 
research. Pezacki et al. targeted human breast cancer cells with epidermal growth 
factor (EGF), which was functionalized with cyclic nitrones using NHS-based 
chemistry. The cells could subsequently be labeled using a biotin-functionalized 
cyclooctyne, and imaged with a fluorescent streptavidin.
133
 Prosperi and co-
workers showed that SPANC could be used for the attachment of nitrone-
functionalized antibodies to magnetic nanoparticles. After modification, these 
particles still showed affinity for tumor marker HER2.
135
 
 
1.5.4 Ligations with tetrazines 
An interesting alternative to the 1,3-dipolar cycloadditions as described above, 
are the tetrazine-based ligations. These reactions are inverse electron-demand 
Diels-Alder reactions, followed by a retro-Diels-Alder reaction, eliminating N2, 
shown in Scheme 12. As for the reaction between cyclooctynes and azides, older 
literature already shows extensive investigations into cycloadditions between 
tetrazines and strained alkenes and alkynes. In these reports, the effect of ring-
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strain, double bond stereochemistry, and the presence of heteroatoms in rings on 
the reaction rate have already been extensively investigated.
136, 137
 In spite of this 
research, only in 2008 Hilderbrand and Fox almost simultaneously published the 
modification of proteins and cell surfaces using tetrazine-based ligations (Scheme 
12).  
 
Scheme 12. Inverse-electron demand Diels-Alder reaction followed by a retro-Diels-Alder reaction.  
Hilderbrand and co-workers demonstrated that norbornenes react with tetrazines 
(entry 13) with similar rates (1.6-1.9 M
-1
s
-1
)
138
 as the fastest SPAAC reactions (1.5 
M
-1
s
-1
 being the fastest rate reported).
139
 This reaction was successfully applied in 
the labeling of tumor cells.  
Fox et al. showed that tetrazines react extremely fast with different trans-
cyclooctenes (entry 12, rate constants of 1-22 × 10
3
 M
-1
s
-1
) compared to the 
SPAAC reaction.
140, 141
 This reaction has for example been applied for the 
intracellular labeling of anti-cancer drug taxol, and the preparation of 
18
F-PET 
tracers.
142
 Interestingly, the incredible speed of these reactions, also allowed for 
pretargeting. It was shown that sequential incubation of tumor cells with trans-
cyclooctene labeled antibodies, followed by tetrazine-functionalized nanoparticles, 
led to a higher degree of labeling as for the full antibody-nanoparticle construct.
143
 
Rossin et al. showed the potential of this reaction for in vivo labeling. They 
pretargeted tumors in mice with trans-cyclooctene functionalized antibodies, and 
then separately injected an In
3+
-labeled tetrazine and showed successful tumor 
labeling.
3
 Advantage of this last method is that the small tetrazine is cleared within 
several hours from the blood, whereas the full antibody takes over 24 hours before 
clearance. This significantly decreases the time between injection and imaging, 
which especially might turn out useful for fast decaying radioisotopes. 
In addition, it was recently shown that tetrazines react with cyclooctynes (entry 
14),
144
 which was applied for protein modification.
145, 146
 Interestingly, 
monosubtituted tetrazines do react at much lower rate with dibenzocyclooctynes, 
compared to cyclooctynes. Disubstituted tetrazines give no cycloaddition product 
at all with dibenzocyclooctynes.
147
 Another interesting, newly arisen probe used 
for tetrazine-based ligation is the cyclopropene (entry 15),
148
 which already found 
application in cell surface labeling.
148, 149
 
Notably, not all tetrazines are stable in serum, some degrading in water and/or 
by the addition of thiols. Hilderbrand et al. prepared a wide range of tetrazines and 
tested them for reactivity and serum stability.
150
 In addition, they prepared 
tetrazines which become fluorescent upon reaction.
151
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1.5.5 Ligations with tetrazoles 
Tetrazoles themselves are no reactive partners in cycloaddition reactions. 
However, it was shown that upon irradiation with UV-light, nitrogen is excluded 
and a nitrile imine 1,3-dipole is formed.
152
 In the absence of a reactive partner for 
this dipole, formation of a water-adduct was observed, however, in the presence of 
acrylamides (entry 16),
153
 norbornenes (entry 17)
154
 and cyclopropenes (entry 
18)
155
 the nitrile imines rapidly form pyrazolines, as shown in Scheme 13. The 
reactivity of the 1,3-dipole depends on substituents on the nitrile imine.
156
 It was 
shown that this reaction can be used for labeling of proteins, also inside cells,
157
 
for example towards studying perturbing protein localization.
158
 Notably, the 
reaction only occurs upon UV irradiation, thereby allowing temporal and spatial 
control over the ligation. 
 
Scheme 13. Formation of nitrile imines from tetrazoles, followed by a 1,3-dipolar cycloaddition with 
alkenes. 
 
1.5.6 Other bioorthogonal ligation reactions 
In the last couple of years also metal-catalyzed reactions have found application 
in the modification of proteins. For example, Davis et al. showed that cross-
metathesis can be used for protein modification (entry 20). For this modification, 
an S-allyl cysteine or Se-allyl functionality is required which reacts with allyl-
functionalized saccharides or small ethylene glycol tails.
159, 160
 It was also 
demonstrated that the Suzuki-Miyaura coupling (entry 22) 
161
 and the Sonogashira 
reaction (entry 21)
162
 can be applied for the labeling of proteins. 
A completely new bioorthogonal reaction was recently developed by Sletten and 
Bertozzi, who sought to develop a new reaction, orthogonal to the known cohort of 
bioconjugations.
163
 They encountered that quadrocyclanes have a large ring-strain 
which makes them likely to react fast with a suitable reaction partner, which was 
found in Ni(dithiolene)2 complex (entry 19). The obtained cycloaddition product 
however slowly decomposed, unless a metal-chelator was added. This reaction 
could be used for protein modification and proved orthogonal to SPAAC and 
oxime-formation. 
 
1.6 Introduction of bioorthogonal functionalities 
The advantage of bioorthogonal chemistry is that selective labeling can be 
obtained without the interference of biological substrates. This automatically 
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implicates that the functional handle will have to be introduced prior to labeling. 
The methods by which the introduction has been achieved can roughly be divided 
in three sections. The most straightforward way is by using either nature-inspired 
methods or by using amino acid modification. In the latter case, no selectivity in 
labeling site and number of modifications can be achieved. For protein 
modification, full selectivity can be achieved when non-natural amino acids are 
incorporated. In this manner, either a natural amino acid is substituted for a non-
natural one, or the stop-codon is used for the introduction of a 21
st
 amino acid.
164
 
For cell-surface labeling, a widely applied strategy is by growing cells in the 
presence of a functionalized sugar-moiety. In this manner, the cell’s metabolism 
partially incorporates the functionalized sugar instead of the natural version, 
thereby introducing a functional handle to the glycans.
112, 114
 
 
1.6.1 Chemical Introduction of handles to proteins 
The most straightforward but least selective method for the introduction of 
handles to proteins has been the modification of lysines. In this manner, for 
example, tetrazoles,
153
 nitrones,
133
 trans-cyclooctenes,
3
 norbornenes,
165
 and 
quadrocyclanes
163
 were introduced. In addition, it was shown that ε-amines of 
lysines can be converted into azides, using a diazo-transfer reaction.
166
 
Alternatively, also cysteine- and tyrosine-residues can be labeled. By cysteine-
labeling, trans-cyclooctenes were incorporated using a thiol-maleimide ligation
140
 
and S-allyl-groups required for metathesis were formed via cysteine alkylation.
167
 
Francis et al. showed that ketones could be introduced to virus particles via 
diazonium-coupling to tyrosine.
68
 Subsequently, the ketones could be used for 
oxime formation with labeled hydroxylamines. 
A more selective site for modification is the N-terminus. A general method for 
introduction of an aldehyde at the N-terminus proceeds via either PLP-oxidation or 
NaIO4 oxidation. Pyridoxal phosphate (PLP) can transform the N-terminal NH2 into 
an aldehyde, as shown in Scheme 14.
168
 This reaction works excellent for Ala, 
Gly, Asp, and Asn, other N-terminal residues could also be modified, only less 
efficient.
169
 Using NaIO4, the N-termini of proteins with an N-terminal serine and 
threonine were altered to an aldehyde.
170
  
 
Scheme 14. Mechanism of PLP-oxidation of N-termini. 
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Alternatively, aldehydes can also be introduced using formylglycine-generating 
enzyme (FGE). This enzyme requires CxPxR as recognition domain and 
subsequently converts the cysteine to formylglycine.
171
 It was shown that 
aldehydes can be introduced in E. coli
171
 and mammalian cells.
172
 The thus formed 
aldehydes could be used for protein labeling (using hydroxylamines or 
hydrazones), however, they could also be used for the formation of nitrones. To 
this end, the aldehyde was reacted with N-alkylhydroxylamines yielding the 
nitrone.
132
 
Other handles that were introduced using biology-inspired methods are alkynes, 
azides, and tetrazoles. Azides and cyclooctynes could be introduced at either the 
N-terminus or the C-terminus using Sortase (see section 1.2.1).
10
 C-terminally, a 
protein was converted to its thio-ester using Sortase, followed by addition of an 
azide or cyclooctyne containing peptide. For N-terminal modification, the functional 
handle was attached to a peptide containing the Sortase-recognition sequence. 
The thio-ester formed by Sortase could then react with the N-terminus of a protein 
of interest.  
Recently, it was also shown that transglutaminases can be used for the 
introduction of alkynes and azides.
173, 174
 The handle was attached to an 
alkylamine, to resemble the lysine side chain, which is essential for efficient 
recognition. The thus introduced alkyne and azide could subsequently be labeled 
using either CuAAC or SPAAC. In addition, van Geel et al., showed that this 
process can also be applied in live cells (HEK and Movas).
174
 
Lastly, also EPL and NCL were used for the introduction of azides and 
tetrazoles. Tolbert et al. produced proteins with N-terminal cysteines and ligated 
these via NCL to azide- and alkyne-containing thio-esters, thereby forming N-
terminally functionalized proteins.
175
, Via EPL, azides, alkynes, and tetrazoles 
could be introduced C-terminally by attaching them to the carboxyl-site of a 
cysteine (see also Chapter 4).
153, 176
 
 
1.6.2 Non-natural AA incorporation  
The amino acid sequence of natural proteins is encoded for by DNA. Prior to 
protein synthesis, this DNA is transcribed to mRNA, which can subsequently be 
read out by different tRNAs leading to sequence-specific protein synthesis. tRNA 
is highly folded, relatively short (around 80 bases) RNA, which contains an 
anticodon loop recognizing an mRNA triplet codon. Aminoacyl tRNA synthetase 
(aaRS) charges the tRNA with the amino acid corresponding to the mRNA codon, 
at the 3’-terminus. In this manner all 20 amino acids (encoded for by 64 triplet 
codons) can be incorporated into the protein. However, with interest growing in 
bioorthogonal functional handles, a need was born for the introduction of non-
natural amino acids. Two different methods have been developed for the 
incorporation of non-natural amino acids. Both methods rely on the mode of action 
of tRNA.  
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Tirrell et al. developed a method known as residue-specific incorporation, which 
is based on the manipulation of the aminoacylation step (coupling of the amino 
acid to the tRNA by aaRS).
164, 177
 For this method an auxotrophic strain, where the 
synthetic pathway towards one natural amino acid is blocked, is used. The 
proteins are then produced in media containing 19 natural amino acids and one 
unnatural amino acid. Consequently, the unnatural amino acid is now incorporated 
instead of the lacking natural amino acid. That is, as long as the tRNA synthetase 
of the natural amino acid also recognizes the unnatural amino acid. To improve 
the recognition, modifications to the recognition site of the aaRS can be made, 
however, care must be taken not to lose selectivity. This method has been used 
for the introduction of azides,
178
 alkynes, and alkenes
179
 into proteins. 
Subsequently, these handles were used for Staudinger ligation,
178
 CuAAC,
180
 
SPAAC
113
 and thiol-ene ligation.
167
 Recently, it was shown that azidohomoalanine 
and homopropargylglycine can also be metabolically incorporated in live zebrafish. 
Labeling the obtained functional handles, followed by enrichment or fluorescent 
imaging (depending on the label introduced), gave insight in protein production 
over time.
180
 
The group of Schultz pioneered the development of the site-specific introduction 
of a non-natural amino acid in a specific protein.
164, 181
 To achieve this, first a 
selective recognition pattern in the mRNA needed to be identified. This was done 
by introducing either a four base codon or an amber stop codon (UAG) at the 
desired modification site. The four base codon method suffers from misreading, 
causing frame-shift, therefore probably the amber-suppresion method found most 
application. Since E. coli scarcely uses amber stop codons, introduction of a tRNA 
which recognizes this stop codon will hardly lead to incorporation of the non-
natural amino acid into undesired proteins.  
Modification of naturally occurring tRNAs and the corresponding synthetases 
could lead to the introduction of non-natural amino acids. To this end, in general a 
tRNA/aaRS couple is taken from a different organism, which is orthogonal to all 
tRNA/aaRS couples in the organism of interest. Often tRNA
pyl
/PylRS obtained 
from Methanosarcina mazei is used, which recognizes the amber stop codon.  
The crucial factor for success is the modification of the synthetase such that it 
does not acylate any wildtype tRNA (which would cause introduction of the non-
natural amino acid instead of natural amino acids), nor should it equip the non-
natural tRNA with a natural amino acid. A general approach to the development of 
such a synthetase is by generating a library of mutant synthetases and 
subsequently select for the desired synthetase. Selection can be performed using 
a positive and negative selection protocol. As positive selection, the synthetase 
and tRNA together with natural and non-natural amino acids are added to cells 
containing a plasmid encoding for β-lactamase gene, with UAG-mutations at non-
essential sites. Production of this protein will render cells resistant to ampici llin. 
Therefore, surviving cells were able to incorporate either a natural or non-natural 
amino acid at the UAG site. As negative selection experiment, only natural amino 
acids were added. Cells dying under these circumstances contained a tRNA/tRNA-
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synthetase pair that selectively incorporated a non-natural amino acid. These cells 
could be isolated by using an exact replica plate. An alternative, in which the 
surviving cells contain the tRNA/tRNA-synthetase pair selective for the non-natural 
amino acid, is when amber stop codons are introduced at non-crucial positions of 
a toxic gene (e.g. the barnase gene).
164
 When cells are grown in media containing 
only natural amino acids, cells surviving under these circumstances contained a 
tRNA/tRNA-synthetase pair that selectively incorporated a non-natural amino acid. 
Alternatively, a similar protocol can be designed producing GFP, selecting for 
fluorescent cells in the positive selection, and for non-fluorescent cells in the 
negative selection. The development of the tRNA-synthetases is a very laborious 
process, as for each new non-natural amino acid the synthetase will have to be 
optimized.  
This method has recently found use for the introduction of a wide range of 
bioorthogonal reaction partners, i.e. alkenes,
182
 ketones
111
 (subsequently used for 
cyclooctyne or azide introduction),
183
 iodobenzenes,
184
 tetrazoles,
185
 tetrazines,
186
 
trans-cyclooctenes,
145
 norbornenes,
154, 187
 cyclooctynes,
145, 146
 and 
cyclopropenes.
155
  
Chin et al. showed that the amber-suppression technology could also be 
translated to C. elegans, incorporating non-natural amino acids into a fusion 
protein of GFP and mCherry. The linker between the two proteins contained a 
UAG codon, thereby non-natural amino acid incorporation could easily be 
confirmed by the colocalization of GFP and mCherry-related signals.
188
 Recently, it 
was also shown that fruit fly D. melanogaster can incorporate norbornenes using 
this strategy at different developmental stages, in specific tissues and subsets of 
cells within these tissues.
189
 
Although the method developed by Schultz et al. allows for the introduction of a 
wider variety of non-natural amino acids, this method is not the better choice of the 
two methods per se. The amber suppression codon technology requires the 
introduction of the amber codon into a specific protein of interest, whereas with the 
method as developed by Tirrell all proteins containing the substituted amino acid 
are modified. 
The latter method is highly suitable for proteomics and research for which 
proteins are produced in a certain time span in vitro or in vivo. On the other hand, 
with this method, multiple handles are introduced in different proteins at multiple 
sites. For the labeling of a single protein at a single site, the pyrrolysyl 
tRNA/pyrrolysyl-tRNA synthetase method is the most elegant alternative, which, 
as was recently shown, can also be used for in vivo labeling.
189
 
 
1.6.3 Cell-surface labeling 
Over 50% of the proteins are post-translationally glycosylated and changes in 
glycosylation pattern are associated with multiple cancer types and other 
diseases. However, as glycosylation processes are not template-driven, a high 
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diversity in the sugar-content is observed in glycans. This significantly complicates 
research towards this special class of proteins. 
An interesting tool for investigating glycoproteins is by introducing functional 
handles using the metabolic pathway for posttranslational modifications. It was 
shown by Reutter et al. that when the N-acetyl group of N-acetyl mannosamine 
(ManNAc) is substituted, this sugar-residue is still recognized by the post-
translational machinery, metabolically converting the modified ManNAc into 
sialosides followed by incorporation into glycoproteins.
190
 This feature was used 
by Bertozzi et al. for the incorporation of ketone
112
 and azide
114
 containing N-
acetyl mannosamine derivatives into live cells. Later, they also showed that the 
same methodology can be applied for the introduction of azide-functionalized N-
acetyl galactosamine (see also chapter 7),
191
 N-acetyl glucosamine,
192
 and N-
acetyl fucosamine derivatives.
193
  
Although azides could be introduced with ostensible ease, it was reported that 
nitrones cannot be introduced in this manner, probably due to the instability of the 
nitrone-group.
132
 Recently, it was shown that cyclopropene-functionalized sialic 
acids could be recognized by glycosyltransferases, thereby introducing 
cyclopropene functionalities to the cell surface.
149
 The azide-functionalized sugars 
could not only be introduced to cell surfaces in vitro, but also in live zebrafish,
2
 C. 
elegans,
194
 and mice.
195
  
 
1.7 Azide-related chemistry 
Among all reactive, bioorthogonal groups published, the azide is still the most 
applied functional handle. The azide is small, inert, and highly reactive in 1,3-
dipolar cycloadditions. In addition, there are numerous ways to introduce azides, 
not only chemically, but also via Sortase, EPL, non-natural amino acid 
incorporation, and metabolic introduction of azido-sugars. As already briefly 
described previously, the azide reacts in a so-called Staudinger ligation, CuAAC, 
and SPAAC. 
 
1.7.1 Staudinger Ligation 
The Staudinger ligation is a reaction between an azide and a triphenylphosphine 
analogue (PHOS). Key to the Staudinger ligation is the intramolecular trapping of 
a nucleophilic aza-ylide by an electrophilic ester, leading to a covalent amide 
bond, as shown in Scheme 15.
196
 This reaction proceeded with a rate constant of 
2.4 × 10
-3
 M
-1
s
-1
. 
 
Scheme 15. Staudinger ligation of a 2-(diphenylphosphoryl)benzoic ester with an alkyl azide. 
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The power of the Staudinger ligation for in vitro applications was elegantly 
demonstrated in the cell-surface labeling of Jurkat and HeLa cells.
114
 The 
Staudinger ligation has also been applied for cell surface remodeling,
197
 live-cell 
imaging,
198
 and the visualization of O-linked glycosylation in live mice.
199
 Mice 
were labeled with azides via the metabolic incorporation of azide-functionalized 
sugars. After 8 days the mice were sacrificed and different organs were labeled 
with PHOS-FLAG followed by FITC-FLAG. Labeling was observed in different 
organs (e.g. liver, kidney, heart, and serum). In addition, it was observed that 
ManNAz labeled different glycans than GalNAz. Later, it was shown that the 
Staudinger ligation can also be used to label the azido-sugars in live mice.
195
 The 
Staudinger ligation has also been used for protein and DNA modification, and has 
been applied in activity based profiling.
200
 A nice addition to the Staudinger ligation 
potential, was made by the development of a fluorogenic Staudinger probe, which 
turns fluorescent upon ligation.
198
  
An alternative Staudinger ligation was developed by Raines et al. However, this 
reaction requires the diphenylphosphine moiety to be linked to one of the ligating 
components via a thio-ester, thereby significantly reducing the scope of the 
reaction. Nonetheless, this reaction found application in the attachment of proteins 
to a surface.
201
 
Although the Staudinger ligation as developed by Bertozzi et al. has proven to 
be a selective and efficient reaction, some specific disadvantages can be 
recognized. First of all, because phosphines are prone to oxidation by air, shelf -
stability is limited and oxidation may take place before ligation. Secondly, the 
Staudinger ligation is relatively slow.
196
 Unfortunately, improvement of the kinetics 
and water solubility proved troublesome.
121
  
 
1.7.2 Cu-catalyzed 1,3-dipolar cycloaddition 
The discovery by Meldal
116
 and Sharpless
117, 202
 that the 1,3-dipolar 
cycloaddition of azides and acetylenes can be catalyzed by sources of copper(I) 
has been of tremendous value for organic synthesis,
203
 library synthesis of 
pharmacophores,
204
 and bioorthogonal ligations. Over the last decade, the CuAAC 
has been used in protein modification,
205
 DNA and RNA modification,
206
 and 
glycan imaging.
207
 Although the cycloaddition has found wide application in 
chemical biology research, the required Cu(I)-catalyst is found toxic to living 
systems, causing cell death, preventing cell division, and killing zebrafish 
embryos.
59
 Cu-ions are toxic mainly because they catalyze the production of 
reactive oxygen species from atmospheric oxygen.
208
 Nonetheless, it was recently 
shown that the addition of certain ligands can not only increase reaction speed but 
also significantly reduce the toxic effects.
209
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Figure 2. Cu(I)-ligands used in CuAAC for in vitro and in vivo applications. 
Finn et al. showed that when THPTA (Figure 2) was used as ligand in a 5:1 ratio 
compared to Cu(I) all cell types tested survived and showed consistent labeling 
using CuAAC. In this manner, they labeled live cells and showed that labeling did 
not affect glycan trafficking.
208
 Wu showed that a further improved ligand (BTTES, 
Figure 2) even made CuAAC applicable for live zebrafish labeling. Alkyne 
functionalities were introduced by incorporating alkyne-containing sugars and 
subsequently zebrafish were fluorescently labeled by the addition of an azide-dye 
and BTTES-Cu(I)-complex.
210
 Although toxicity issues of Cu(I) can be solved by 
the addition of ligands, intuitively bioorthogonal labeling without the need of a 
catalyst seems more straightforward. Especially in larger animals, colocalization of 
the catalyst, azide-, and alkyne-reagent is probably hard to achieve. In addition to 
that, some applications, e.g. ligation of metal-chelators, or modification of metal-
binding enzymes, require metal-free conditions. 
 
1.7.3 Strain-Promoted Azide Alkyne Cycloaddition 
Ever since Bertozzi et al. demonstrated that cyclooctynes react spontaneously 
with azides in SPAAC and that this reaction could be used for cell-surface 
labeling, many new ring-strained systems have been published. An overview of 
the published strained azide-reactants are shown in Table 2. In addition, as for 
many of these systems hydrophilicity and reaction kinetics seem to be 
contradictive, Figure 3 shows a plot of all rate constants versus 
c
logP, which is the 
logarithm of a compounds partition coefficient between n-octanol and water 
log(coctanol/cwater).   
 
Cyclooctynes 
The first cyclooctynes developed were OCT 1 (entry 2) and OCT 2 (entry 3) 
which could be synthesized in four steps (52% and 10% yield, respectively). 
Compared to the Staudinger ligation (entry 1) both probes were significantly less 
prone to oxidation, but nevertheless not fully shelf-stable since prolonged storage 
of OCT 1 and OCT 2 at -20 ºC led to decomposition. The developed 3-
alkoxycyclooctynes showed rate constants for the cycloaddition with benzyl azide 
comparable to those of the Staudinger ligation (k = 2.4 × 10
-3 
M
-1
s
-1
 for OCT 1 and 
k = 1.3 × 10
-3 
M
-1
s
-1
 for OCT 2).
121
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Table 2. Overview of azide-reactive probes, synthesis, rate constant and lipophilicity. 
Entry Azidophile Name 
 Nr of steps 
(yield in %) 
k [× 10
-3
  
M
-1
s
-1
]
a Solvent 
c
logP
b
 Ref 
1 
 
PHOS 2 (50) 2.1 CD3CN 4.74 
114
 
2 
 
OCT 1 4 (52) 2.4 CD3CN 3.21 
121
 
3 OCT 2 5 (36) 1.3 CD3CN 1.65 
211
 
4 
 
OCT 3 4 (12) 1.2 CD3CN 3.77 
211
 
5 MOFO 5 (15) 4.3 CD3CN 3.76 
211
 
6 
 
DIFO 1 10 (1.2) 76 CD3CN 1.28 
4
 
7 
 
DIFO 2 8 (27) 42 CD3CN 4.14 
212
 
8 DIFO 3 10 (21) 52 CD3CN 1.71 
212
 
9 
 
BCN 4 (15/35
c
) 110/140
c
 
CD3CN:D2O 
(3:1) 
2.01 
213
 
10 
 
TMTH 6 (0/8) 4000 CD3CN 4.00 
123
 
11 
 
DIMAC 11 (5) 3 CD3CN 0.66 
214
 
12 
 
DIBO 1 5 (10) 57 CH3OH 4.40 
215
 
13 
 
DIBO 2 5 (9) 76.3 CH3OH 5.96 
216
 
14 
 
S-DIBO 6 (18) 112 CH3OH 0.59 
217
 
15 
 
DIBAC 9 (41) 410 CD3OD 3.51 
218
 
16 
 
BARAC 6 (18) 960 CD3CN 4.20 
219
 
17 
 
COMBO 6 (11) 240 CD3CN 2.19 
220
 
18 
 
OXA 1 2 (59) 0.85 CD3OD 0.27 
122
 
19 OXA 2 2 (58) 0.41 CD3OD 0.78 
221
 
[a] 2
nd
 order reaction rate constant determined with benzyl azide as model, unless otherwise indicated.  
[b] Values are calculated by BioByte (embedded in ChemBioDraw 12.0) for the N-methylamide derivative of 
carboxylic acids and the N-methyl carbamate derivative of alcohols.  
[c] exo-BCN/endo-BCN 
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Figure 3. Reactivity versus lipophilicity of functionalized cyclooctynes, based on Table 2. 
To increase the stability of the 3-alkoxycyclooctyne derivatives, an alternative 
was developed with the alkyl-linked cyclooctyne conjugate OCT 3 (entry 4).
211
 
Indeed, the alkyl-linked cyclooctyne OCT 3 was found to be more stable than 
cyclooctyne OCT 1, however, the reactivity of OCT 3 towards azides (k = 1.2 × 10
-
3 
M
-1
s
-1
) was also a two-fold lower. 
Since the alkyl-linked cyclooctyne was found to be more stable but less reactive 
than earlier cyclooctynes, a fluoride substituent was introduced adjacent to the 
acetylene.
211
 It was assumed that lowering of the LUMO of the acetylene by a 
neighboring electron-withdrawing group would increase the reactivity towards 
azides. Indeed MOFO (entry 5) (synthesized in 15% yield over 5 steps), displayed 
a four-fold enhanced reactivity towards benzyl azide (k = 4.3 × 10
-3
 M
-1
s
-1
).
211
 
Surprisingly, when this probe was applied in cell-surface labeling and compared to 
OCT and Phos, the Staudinger ligation still outperformed the cyclooctynes, despite 
the better kinetics of MOFO. Possibly, the Staudinger ligation is more efficient with 
azides bearing electron-withdrawing or resonance-stabilizing groups.
211
 
The fact that monofluorination of the cyclooctyne system enhanced the reactivity 
was a stimulus for Bertozzi et al. to synthesize a difluorinated cyclooctyne (DIFO, 
entry 6).
4
 Although synthesis was troublesome and DIFO was obtained in a poor 
overall yield (1.2% over 10 steps), this was nicely compensated for by the 
observed rate constant. DIFO 1 reacted with BnN3 with a rate constant of 7.6 × 10
-
2
 M
-1
s
-1
, about 17-fold faster than the fastest earlier reported Cu-free ligation. The 
high reactivity of DIFO was also reflected in staining of Jurkat cells bearing 
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NeuNAz with biotinylated DIFO, which proceeded with a 20-fold higher efficiency 
than with other cyclooctynes.  
The great potential of DIFO 1 validated an alternative synthetic route. To avoid 
the cumbersome elimination step to the alkyne, Bertozzi et al. developed a 
synthesis with the ether linkage replaced by an alkyl linker.
212
 Notably, elimination 
of the triflate now proceeded with excellent yield, and the total synthesis of DIFO 2 
(entry 7) was completed in 8 steps with an overall yield of 27%.
212
 Another DIFO-
derivative, lacking the phenyl-ring in the linker (DIFO 3, entry 8), was also 
prepared (10 steps, 21% overall yield) to reduce non-specific protein and cell 
binding as a result of the lipophilic character of DIFO 2. 
Kinetic experiments of DIFOs 2 and 3, termed 2
nd
 generation DIFOs, with benzyl 
azide revealed reaction rate constants of 4.2 × 10
-2
 M
-1
s
-1
 for DIFO 2 and 5.2 × 10
-
2
 M
-1
s
-1 
for DIFO 3, slightly lower but similar to 1
st
 generation DIFO. The relative 
rate constants were also reflected in the labeling of Jurkat cells, that showed a 3-
fold higher fluorescence for DIFO 1 than for DIFOs 2 and 3. As expected, with 
respect to DIFO 2, slightly less background labeling was observed for DIFO 3, 
lacking the hydrophobic phenyl group, in flow cytometry experiments.  
A different manner to attain rate increase for cyclooctynes was published by van 
Delft et al.
213
 They envisioned that installing a cyclopropane ring in the 
cyclooctyne-ring opposite to the triple bond would result in additional ring-strain 
and thereby increased kinetics. BCN (entry 9) could be prepared in 4 steps, 
yielding both the exo- (15% yield) and endo-isomer (35% yield). In addition, the 
cyclopropane ring indeed increased ring-strain and thereby the rate constant. With 
rate constants of 0.11 M
-1
s
-1
 for exo-BCN and 0.14 M
-1
s
-1
 for endo-BCN, BCN is 
the fastest cyclooctyne known. 
Another alternative for increasing ring-strain is by decreasing ring size. Benzyne-
rings have been prepared and used in, amonst others, 1,3-dipolar cycloadditions. 
However, benzyne needs to be made in situ and cannot be isolated.
222-225
 On the 
other hand, Krebs had already summarized in 1983 that some heteroatom-
containing cycloheptynes can be prepared and isolated.
120
 Only recently, Bertozzi 
et al. showed the synthesis of a thiacycloheptyne (TMTH, entry 10) in 0.8% yield 
over 6 steps.
123
 The rate constant of the reaction of this TMTH with benzyl azide 
was found to be 4 M
-1
s
-1
. For comparison purposes, also thiacyclooctyne was 
prepared, showing a rate constant of 3.2 × 10
-4
, which is one order of magnitude 
lower than the rate observed for OCT 1. The effect of decreasing the size of the 
alkyne-containing ring with one atom, was shown to be at least four orders of 
magnitude, although it is likely that the rate constant of thiacycloheptynes would 
even be higher without the adjacent methyl-groups. Unfortunately, TMTH could not 
be equipped with a label, protein modification was however confirmed by mass 
spectrometry. 
The cyclooctynes, as described above, all consist of only carbon-atoms in the 
ring and have, without exception, negligible water solubility. Furthermore, 
background labeling was observed in biological experiments due to hydrophobic 
interactions with cell membranes and nonspecific binding to serum proteins cannot 
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be excluded. Therefore, Bertozzi et al. set out to develop a more hydrophilic 
cyclooctyne by introduction of a nitrogen to break the hydrophobic character in the 
ring.
214
 In addition, two methoxy-groups were introduced to enhance polarity and 
water-solubility. DIMAC (entry 11) showed a kinetic constant of 3.0 × 10
-3
 M
-1
s
-1
, 
slightly higher than parent OCT 1 but significantly lower than DIFO 1. 
Nonetheless, DIMAC was found suitable for detection of metabolically 
incorporated ManNAz in Jurkat cells. As expected, background labeling was 
significantly lower than for OCT 2. 
 
(Di)benzocyclooctynes 
Another interesting class of highly strained alkynes are the 
(di)benzocyclooctynes. Boons et al. envisioned that the introduction of fused aryl 
rings on the cyclooctyne system would enhance reaction kinetics by increased 
ring-strain and conjugation.
215
 To this end, they designed DIBO 1 (entry 12), and 
prepared it in 5 steps with an overall yield of 10%. In kinetic experiments, 
cycloaddition of DIBO with benzyl azide proceeded with a rate constant of (k = 
5.67 × 10
-2
) in methanol, about the same as for DIFO 1. 
In a follow-up paper with Popik et al., a photo-triggerable cyclopropenone 
system was developed that formed the alkyne functionality upon UV-irradiation at 
350 nm.
216
 Conveniently, during cyclopropenone formation one butyl group was 
hydrolyzed, thereby providing a handle for subsequent functionalization. 
Whereas the cyclopropenone showed no reaction with azides, irradiation at 350 
nm resulted in the rapid formation (1 min) of a cycloalkyne (DIBO 2, entry 13) that 
reacted with benzyl azide with a rate constant of 7.63 × 10
-2 
M
-1
s
-1
, as determined 
with a newly developed UV-based procedure. 
In addition, recently a disulfated DIBO (s-DIBO, entry 14) analogue was 
prepared, showing impressive water solubility compared to DIBO.
217
 Boons et al. 
found that s-DIBO does not cross the cell membrane whereas DIBO did. S-DIBO 
could thus be used for selective labeling of membrane glycoproteins. 
Disadvantages of all the above described dibenzocyclooctynes are that, again, 
all ring-members are carbon-atoms, and labeling of the hydroxyl via ester- or 
carbamate-linkage gave rise to problems with hydrolysis when labeling lipases.
226
 
Therefore, we envisioned that introduction of a nitrogen atom in the octyne-ring 
would break the hydrophobic character of the ring and allow for more stable 
amide-bond functionalization. This resulted in the preparation of 
dibenzoazacyclooctyne (DIBAC, entry 15) in 41% yield over 9 steps (see also 
Chapter 2).
218
 Kinetic experiments with benzyl azide showed an over 4-fold higher 
rate constant compared to DIBO 1 in reaction with benzyl azide in CD3OD (k = 
0.41 M
-1
s
-1
).  
The rate of dibenzoazacyclooctynes could be further increased by introduction of 
an amide-bond in the eight-membered ring. This was pursued by Bertozzi et al. 
who prepared BARAC (entry 16) in 6 steps and an overall yield of 18%.
219
 BARAC 
reacted with benzyl azide with a rate constant of 0.96 M
-1
s
-1
. Modeling studies by 
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Houk et al. showed that the rate increase was caused by increased bond distortion 
of the alkyne bonds.
139
  
The route towards BARAC was proven to be a highly versatile one, as several 
analogues with substituents on the benzene rings could be prepared following the 
same synthetic pathway (for additional analogues of BARAC and DIBAC see 
Chapter 3).
139
 In this research, it was shown that electron-withdrawing and 
electron-donating groups on the benzene rings have a positive effect on the rate 
constant. As expected, the electron-withdrawing groups showed a larger effect on 
the reaction speed than electron-donating groups. In addition, ortho-substitution 
with respect to the alkyne resulted in an impressive drop in cycloaddition 
reactivity. 
A non-functionalizable dibenzocyclooctadiyne has long since been known and 
used in organic synthesis, for e.g. the preparation of extended aromatic systems, 
cyclophane synthesis and metal-complex formation.
227-229
 This compound can 
react with azides twice, which theoretically would eliminate the need to introduce a 
functional handle as one of the two azides can be used to introduce a label. 
However, it was observed that the triazole-containing compound formed in the first 
cycloaddition is more reactive to a second cycloaddition to such an extent that 
always the bistriazole is formed. Opposing to this observation, Hosoya et al. 
showed that when used for protein modification the sterics of the protein avoid 
dimerization of the protein, leaving one highly strained alkyne intact.
230
 This alkyne 
can then subsequently be used for protein labeling in a second strain-promoted 
reaction (see also Chapter 6). 
Alternatively, some monobenzocyclooctynes have been prepared, to decrease 
the hydrophobicity of the probes, but keep the reactivity. Bertozzi et al. prepared 
MOBO and a difluorinated variant (DIFBO). MOBO showed a rate constant of 9.5 
× 10
-3
 M
-1
s
-1
, about one order of magnitude slower than DIBO. On the other hand, 
as expected, introduction of two fluorides resulted in a 20-fold rate increase (0.22 
M
-1
s
-1
). However, DIFBO could not be isolated unless stabilized by the addition of 
β-cyclodextrin.231 Recently, Kele et al. synthesized COMBO (entry 17), which has 
the benzene ring opposite to the alkyne. COMBO has a rate constant of 0.23 M
-1
s
-
1
, almost identical to DIFBO and about 2-fold higher then BCN (which it clearly 
resembles).
220
  
In a search for more stable, still reactive, strained alkynes, Dudley et al. 
prepared a benzocyclononyne.
232
 However, this resulted in a vast drop in rate 
constant of three orders of magnitude (k = 2 × 10
-4
 M
-1
s
-1
), making the 
cyclononynes of less interest compared to the cyclooctynes. 
 
Fluorogenic dibenzocyclooctynes 
A separate class of dibenzocyclooctynes are the fluorogenic probes. These 
molecules are not fluorescent in the alkyne state, but become fluorescent upon 
reaction with azides. This has several advantages over non-fluorogenic 
cyclooctynes. First of all, no fluorescent label needs to be introduced, thereby 
excluding the need of introducing a functionalizable handle which often 
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compromises alkyne formation. In addition, also aspecific labeling, which is often a 
problem in biological experiments, is eliminated as no triazole formation is 
required for fluorescence to occur.  
Fluorogenic azides, turning fluorescent upon cycloaddition, have been 
published. The first was based on a coumarin, but such dyes are relatively 
unstable and the emission wavelength is not suitable for biological purposes.
233, 234
 
Recently, Bertozzi et al. published a fluorogenic azide based on a fluorescein, 
which proved suitable for cell-surface labeling.
235
 In addition to fluorogenic azides, 
a fluorogenic coumarin-based alkyne was reported.
233
 Inspired by this alkyne, 
Bertozzi et al. developed a fluorogenic cyclooctyne based on BARAC, 
coumBARAC, Figure 4. This compound could be prepared in 2% yield over 6 
steps. The dibenzocyclooctyne had, however, a similar excitation pattern as 
observed for other coumarins and displayed only a moderate quantum yield. 
Another fluorogenic cyclooctyne (Fl-DIBO, Figure 4) was published by Boons et 
al.
236
 While the synthesis proceeded more smoothly (35% yield over 5 steps), the 
excitation pattern was similar to coumBARAC, still not overlapping with commonly 
used excitation lasers in biology research.  
 
Figure 4. Fluorogenic cyclooctynes. 
Oxanorbornadienes 
The concept of cycloaddition of azides to strained bonds was also investigated 
for oxanorbornadienes by Rutjes et al.
122
 It was envisioned that these 
oxanorbornadienes, apart from thiol-addition as described above,
80
 could undergo 
cycloaddition with azides. Ju et al. already discovered that the spontaneous 
reaction of electron-deficient alkynes with azides proceeded in good yields under 
aqueous conditions.
237
 Formation of an oxanorbornadiene from one of these 
electron deficient alkynes yielded OXA 1. Treatment of OXA 1 (entry 18) with an 
alkyl azide gave a triazoline intermediate that underwent retro-Diels-Alder 
reaction, leading to the triazole products and furan, Scheme 16. It was found that 
OXA 1 is partly susceptible to cycloaddition of the azide on the other double bond, 
Scheme 16. Introduction of a methyl-substituent (OXA 2, entry 19), by initial 
reaction with 3-methylfuran, effectively eliminated the latter disadvantage.
221
  
While the rate constant of the cycloaddition of OXA 1 with azide is relatively low 
(k = 8.5 × 10
-4
 M
-1
s
-1
), and even slightly lower for OXA 2 (k = 4.2 × 10
-4
 M
-1
s
-1
), 
advantages of the oxanorbornadienes system are the easy preparation and high 
water solubility. The high hydrophilicity of OXA 1 and OXA 2 is clearly shown in 
Figure 3.  
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Scheme 16. Cycloaddition of oxanorbornadiene with azide, followed by a retro-Diels-Alder 
reaction. 
The high hydrophilicity of OXA 1 and OXA 2 is clearly shown in Figure 3. This 
figure shows the relation between rate constant and lipophilicity of all azide-
reactive probes, summarized in Table 2. From this figure can be seen, that in 
general the more reactive a probe is, the more hydrophobic. An outstanding 
example is S-DIBO, which shows similar reactivity to BCN, DIFO and DIBO, but 
has a hydrophilicity compared to DIMAC and OXA, due to the introduced sulfate-
groups. 
 
1.7.4 Applications of SPAAC 
The reaction between azides and strain-promoted probes has found wide 
application in many research areas, e.g. in nuclear medicine, proteomics, 
glycobiology. Probably, the numerous ways for azide introduction, combined with 
its stability and small size render the azide a highly desirable handle for 
modification. In addition, due to the high research interest in cyclooctyne 
development, a large improvement has been made on the kinetics of cyclooctynes 
in reaction with azide. Due to this increase, fast labeling can now be achieved 
using cyclooctynes at low concentrations. 
In the last decade numerous applications of SPAAC have been published,
238
 
describing all these examples would be too elaborate for this review chapter. In 
short, SPAAC has been used for live cell labeling, protein labeling, lipid labeling, 
monitoring of non-natural amino acid incorporation, studying protein interactions, 
surface modification, preparation of radio-labeled substrates, polymer conjugation, 
proteomics, and in vivo imaging.
113, 239-241
  
An especially appealing field of applications is of course formed by the in vivo 
applications of SPAAC, as these allow for direct visualization of biological 
processes. 
Bertozzi et al. showed that SPAAC could be used for the tracking of glycan 
synthesis in zebrafish.
2
 Growing zebrafish in the presence of GalNAz, to 
incorporate azide-handles in glycoproteins, followed by labeling resulted in 
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observed glycan formation after 24 hours post fertilization. Especially between 60 
and 72 hours after fertilization a large increase in fluoresence was observed in jaw 
region, pectoral fins, and olfactory organs. Further investigation was performed by 
labeling with different dyes at separate time points, thereby further elucidating the 
synthesis of glycans in live zebrafish. Later is was shown that glycans could be 
imaged as soon as 7 hours post fertilization, albeit that the azido-sugar needed to 
be micro-injected.
242
 
It was also shown that SPAAC can be used for labeling of mice splenocytes. To 
this end, mice were fed with azido-sugars for 7 days, whereupon different FLAG-
labeled cyclooctynes were administered. After 3 hours, the mice were sacrificed 
and different splenocytes were analyzed for labeling. Using different azide-reactive 
probes (PHOS, DIMAC, and DIFO) labeling of proteins in liver, heart and 
intestines was possible. Notably, when OCT 2 was used no protein labeling was 
observed, likely due to the low kinetics and limited absorption from the peritoneal 
cavity (where the cyclooctynes were injected) into the blood stream.
195
 
 
1.8 Conclusions and Outlook 
This literature overview makes clear that the field of bioconjugation, and more 
recently bioorthogonal ligation reactions, is still emerging. In recent years, many 
highly promising reactions have been developed and applications have become 
numerous.  
For reactions to be applicable in biological systems, they need to fulfill several 
requirements. Hydrophilicity, reaction kinetics, and selectivity are probably the 
most important factors for a ligation to be successful. With these requirements in 
mind, the tetrazine-based ligations with trans-cyclooctenes or cyclopropenes, 
seem the most suitable reactions. These ligations show amazing rate constants 
(10
3
-10
4
 M
-1
s
-1
) and high selectivity. However, as the tetrazine is a relatively large 
residue and relatively hard to selectively introduce compared to the azide, protein 
functions are more likely to be disturbed. Azides, on the other hand, are easily 
introducable small residues, forming a peptide bond isostere upon cycloaddition. 
Overall, it can be concluded that for each application a different ligation might be 
best. For example, lysine or cysteine modification is ideal if the aim is to prepare a 
labeled protein without interest in modification site or number of labels introduced. 
On the other hand, introduction of azides to multiple proteins can relatively easily 
be achieved in vitro and in vivo. Subsequent labeling with CuAAC or SPAAC 
allows for proteomics and in vivo imaging of glycan synthesis.
2
 Tetrazine-based 
ligations are most suitable when fast reaction is required, e.g. for in vivo 
radiolabeling,
3
 or when interest is in a single protein.
145
 
As bioconjugation has proven its value more and more in the last decade, it is 
likely that more research areas will pick up on bioorthogonal ligation reactions. 
Currently, mainly biology-oriented chemists and macromolecular chemists have 
discovered this chemistry. However, with more and more reagents, e.g. 
cyclooctynes and tetrazines, becoming commercially available, also biologists will 
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have access to these types of chemistry and will be able to apply it in their 
respective research fields.  
In addition, interest in the development of new bioorthogonal ligation strategies 
has still not decreased, instead the opposite appears to be true. Reactivity which 
can be achieved with SPAAC seemed to have reached its limit, however new 
reactions with superior kinetics have been developed and not optimized yet. 
Likely, apart from reaction optimization, novel bioorthogonal reactions will still be 
developed in the upcoming years, allowing for even more applications.  
 
1.9 Aim and outline of this thesis 
The bioconjugation toolbox has expanded impressively in the last 15 years. 
There seems to be a still increasing interest in the development of new 
bioorthogonal ligation reactions and new reactive probes for bioorthogonal 
reactions. For a bioorthogonal ligation reaction to be functional the main 
requirements are that the reaction proceeds fast in aqueous environment and 
reacts selectively with the complementary handle. The power of bioorthogonal 
reactions was also picked up in biology related research, significantly increasing 
opportunities for e.g. studying protein production in embryos, proteomics, and 
tumor imaging.  
At the start of the research which led to this thesis (November 2008), tetrazine, 
tetrazole, nitrile-oxide, and nitrone ligations were either just developed or not 
known at all. Therefore, the main focus was still on reactions with azides. At that 
point the fastest strained cyclooctyne was DIBO 1, just developed by Boons et 
al.
215
 It was observed that this cyclooctyne was highly hydrophobic and problems 
were encountered with the introduction of functional handles, especially when 
aiming for lipase labeling, due to the alcohol-functionality. 
To that end, a new dibenzocyclooctyne was designed, containing a nitrogen-
atom in the cyclooctyne ring, which will be described in Chapter 2. It was 
envisioned that this dibenzoazacyclooctyne would be less hydrophobic (due to the 
nitrogen-introduction), would allow for easier and more stable functionalization via 
amide-bond formation, and would be more reactive towards azides.  
In addition, synthesis of cyclooctyne and dibenzocyclooctyne analogues was not 
yet investigated, as for each new cyclooctyne a new route needed to be 
developed. It was envisioned that the route towards DIBAC, as described in 
Chapter 2, would allow for analogue synthesis without alteration of the route. In 
this manner, investigating the influence of electron-withdrawing and electron-
donating groups on the kinetics of the cycloaddition with azides would be possible. 
Synthesis of DIBAC analogues, and attempts towards the development of a 
fluorogenic dibenzocyclooctyne are described in Chapter 3. 
Next, we set out to apply the developed DIBAC in modification of a tumor-
targeting single-domain antibody (A12). Due to the small size of these single-
domain antibodies, many amino acid residues are involved in affinity binding. 
Labeling of such antibodies without disturbing the affinity therefore poses large 
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challenges as this highly limits potential modification sites. The C-terminus was 
anticipated not to be involved in affinity binding and therefore suitable for 
modification. To achieve this, A12 was cloned as a fusion protein, containing an 
intein and a chitin binding domain. Chapter 4 describes the introduction of a biotin-
handle and an azide handle to A12 using EPL. The introduced cysteine and azide 
could both be used for labeling. It was shown that labeling of the C-terminus using 
this strategy did not influence the affinity. 
Having successfully introduced two functional handles (an azide and a free 
cysteine) to A12, we set out to develop tumor-targeting polymersomes, thereby 
creating potential drug-delivery systems. Chapter 5 describes the preparation of 
BCN- and maleimide-containing polymersomes and the subsequent 
functionalization with A12. Hereupon, affinity of the A12-polymersomes for tumor-
tissue was investigated in an ELISA-essay and in vivo. 
Chapter 6 describes the efforts towards the preparation of a hybrid-catalyst 
system. Aim of this research was to conjugate Candida Antarctica Lipase A (CalB) 
to a metal-catalyst. Preparation of this hybrid system was pursued using AHA-
CalB
243
 (prepared by the incorporation of azidohomoalanine instead of methionine, 
as published by Tirrell et al.
178
), introduction of a strained alkyne via single 
reaction with dibenzocyclooctadiyne, and subsequent introduction of an azide-
containing metal-catalyst. The hybrid-system thus obtained was envisioned to 
catalyze two different reactions at the same time. In addition the active site of the 
enzyme could lead to substrate enrichment for the metal-catalyst leading to a rate 
enhancement. Lastly, the chiral environment of the enzyme could also induce 
stereoselective modifications, resulting in a stereoselective transformation. 
Apart from protein modification, azide-related ligations can also be used for cell-
surface labeling, thereby functionalizing glycoproteins by the incorporation of 
azido-sugars.
114
 Due to the high diversity in protein glycosylation and often 
troublesome analysis of these glycoproteins, research towards this class of 
proteins proceeds only slowly. Chapter 7 describes the development of new 
methodology for glycoprotein analysis. This method involved cell-surface labeling 
using either the Staudinger ligation or SPAAC, followed by enrichment for labeled 
proteins, and ultimately deglycosylation and mass spectrometry analysis. 
Overall, this thesis first describes the development of several new 
dibenzoazacyclooctynes and their kinetics (Chapters 2 and 3). Subsequently, 
different applications of bioorthogonal ligation methods have been investigated. 
Chapters 4 and 5 describe the labeling of a tumor targeting single domain antibody 
(Chapter 4), and the subsequent formation of targeting polymersomes (Chapter 5). 
In Chapter 6 SPAAC is used for the preparation of a hybrid catalyst and in Chapter 
7, SPAAC and the Staudinger ligation are used for cell-surface labeling followed 
by deglycosylation of the glycoproteins to improve mass spectrometry analysis of 
these proteins. 
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A highly strained dibenzoazacyclooctyne was prepared in 
9 steps in a 41% yield starting from ethynylaniline and 
iodobenzyl alcohol. The reactivity of the 
dibenzoazacyclooctyne was determined by performing NMR 
kinetics experiments with the cyclooctyne and benzyl 
azide. From these experiments, a rate constant of 0.41 
M
-1
s
-1 
was found. Subsequently, dibenzoazacyclooctyne and 
4-dibenzocyclooctynol were equipped with a PEG44-tail 
and used for PEGylation of the enzymes Candida 
Antarctica Lipase B (CalB) and Horse Radish Peroxidase 
(HRP). PEGylation using dibenzocyclooctynes proved 
highly efficient compared to other ligation strategies, 
as quantitative functionalization was obtained in 3 
hours with only 5 equivalents of reagent. 
 
2 
Dibenzoazacycloooctynes for 
enzyme PEGylation 
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2.1 Introduction 
Sharpless et al. introduced the term click chemistry in 2001,
1
 aiming to increase 
the popularity of high yielding reactions that occur under simple reaction 
conditions, in preferably water, without the formation of byproducts. They 
envisioned that more intensive use of these reactions could accelerate the 
discovery of useful substances, especially in the pharmaceutical area.
1
 Although 
many reactions fulfill the criteria for click chemistry, since 2002, the term click 
chemistry has become mainly associated with the Cu(I)-catalyzed Huisgen 
cycloaddition, independently discovered by Meldal
2
 and Sharpless.
3
 
Apart from the fact that this reaction has indeed found wide application in library 
synthesis of potentially biologically relevant compounds,
4, 5
 the Cu(I)-catalyzed 
Azide Alkyne Cycloaddition (CuAAC) has also proven a powerful new 
methodology for the field of bioconjugation
6-9
 with the particular benefits that the 
reaction is selective, fast and high-yielding. The Cu(I)-catalyzed 1,3-dipolar 
cycloaddition reaction has become of great use in labeling studies, the 
development of new therapeutics and in protein modification,
10-12
 e.g. for the 
synthesis of PEG-protein bioconjugates.
13, 14
 Disadvantages, however, of CuAAC 
are that Cu(I) is toxic to cells and that it can easily bind to the active site of 
enzymes, thereby blocking or reducing biological activity,
15, 16
 or to potential metal 
chelators, thus reducing labeling efficiency.  
To avoid the use of copper, Bertozzi et al. envisioned that instead of a terminal 
alkyne a highly strained alkyne, i.e. a cyclooctyne, could be reacted with an azide 
without the use of a catalyst,
17
 thereby increasing the applicability of the 1,3-
dipolar cycloaddition for biological system modification. Since then, interest has 
grown significantly in methods involving Cu-free 1,3-dipolar cycloaddition 
reactions
18, 19
 and several strain-promoted systems, such as oxanorbornadienes 
(A, Figure 1),
20
 cyclooctynes (B, Figure 1),
16
 and dibenzocyclooctynes
21
 (D, Figure 
1) have been developed. These systems have been used in the fast and selective 
reaction with azide-containing biomolecules, and have found application in e.g. 
tumor imaging,
22, 23
 glycan labeling,
16, 21
 in vivo imaging,
24
 and surface 
modification.
25
  
An interesting application for cyclooctynes in protein modification not 
investigated until now is the attachment of PEG-chains to proteins, so-called 
PEGylation. PEGylation is a procedure of growing interest in both biotechnology 
and therapeutical science
26, 27
 as it improves the bioavailablitiy of proteins by 
reducing aggregation, shielding critical protein binding sites and improving the 
water solubility.
28, 29
 Although a large variety of methods for the conjugation of 
PEG to either peptides or proteins is available,
30
 in most cases a large excess of 
PEG and prolonged reaction times are required, and nevertheless generally 
suboptimal conversions are obtained.
31-33
 In this perspective, using a highly 
reactive cyclooctyne for the PEGylation of proteins might well be of high value. 
For a cyclooctyne to be easy to handle and widely applicable it needs to be 
stable and preferably hydrophilic, apart from that it needs to react fast and 
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selectively with azides at extremely low concentrations. At the start of this project, 
DIFO (B)
16
 and dibenzocyclooctynol C
21
 (Figure 1) were the fastest cyclooctynes 
known. Unfortunately, at that point, all cyclooctynes suffered from troublesome 
synthesis, sluggish reaction rates, or low specificity towards azides. Also most 
cyclooctynes consisted of a carboskeleton, making them hydrophobic. To this end, 
we set out to develop the hybrid structure dibenzoazacycloooctyne (DIBAC, 
structure E, Figure 1), inspired by the dibenzocyclooctyne derivative (DIBO, 
structure D, Figure 1) developed by Boons et al.
21
 and dimethoxyazacyclooctyne 
(DIMAC, structure C, Figure 1) synthesized by Bertozzi et al.
34
 The 
dibenzoazacycloooctyne was designed to combine the favorable kinetics of DIBO 
(D)
21
 with the increased hydrophilicity of DIMAC (C).
34
 While kinetics are expected 
to remain comparable to DIBO, the nitrogen atom in our designed analogue should 
allow straightforward functionalization of the aniline moiety and modification of the 
system, e.g. by sulfonation. At the same time, we set ourselves the goal to 
develop a straightforward, high-yielding and fast synthetic route.  
 
Figure 1. Strain-promoted systems for Cu-free click reactions. 
 
2.2 Synthesis 
Toward the synthesis of DIBAC, compound 5 (Scheme 1) was envisioned to be a 
key intermediate. The synthetic route to this intermediate is shown in Scheme 1, 
and is based on a Sonogashira cross-coupling reaction and a reductive amination 
ring-closing step. Whereas the Sonogashira reaction under standard inert 
atmosphere initially resulted in Glaser coupling, performing the reaction under a 
N2/H2-atmosphere
35
 effectively nihilated Glaser coupling and led to the 
Sonogashira coupling product 1 in quantitative yield. Subsequent partial 
hydrogenation of the alkyne in the presence of the free amine failed and therefore 
Boc-protection, generating compound 2, was found to be essential to make partial 
hydrogenation of the acetylene to the Z-alkene possible, yielding 3 (95%). Next, 
Dess-Martin oxidation led to aldehyde 4, the precursor for the reductive amination. 
Boc-deprotection under acidic conditions resulted in immediate and exclusive 
formation of a cyclic imine, which was not isolated but immediately subjected to 
NaBH4 reduction, generating the free secondary amine (5) in quantitative yield 
over two steps. Via this high-yielding protocol the key dibenzoazacyclooctene 
intermediate 5 was synthesized in an excellent yield of 70% over five steps. 
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Scheme 1. Synthesis of dibenzodihydroazocine 5. Reagents and conditions: (a) PdCl2(PPh3)2, 
CuI, NEt3, THF, N2/H2-atmosphere, r.t., 4 h (99%); (b) Boc2O, THF, 70 ºC, 2 days (83%); (c) 10% 
Pd/BaSO4, quinoline, H2-gas, MeOH, r.t., 1.5 h (95%); (d) Dess-Martin periodinane, NaHCO3, 
CH2Cl2, r.t., 40 min (90%); (e) 1) 2 M HCl in EtOAc, r.t., 1 h; 2) NaBH4, H2O, r.t., o.n. (100%).  
 In our effort to prepare dibenzoazacycloooctyne with a free secondary 
amine (6, Scheme 2), we attempted to directly brominate compound 5. 
Uneventfully, this bromination resulted in intramolecular substitution of a bromide, 
leading to an indoline. Therefore, protection of the amine prior to formation of the 
alkyne was required. As a result, a Cbz-group was introduced generating 
compound 7 in good yield (86%). The alkene moiety could then smoothly be 
converted into dibromoalkane 8 using Br2 in 67%. Although elimination of the two 
bromides was precedented using LDA for the synthesis of DIBO,
21
 this base did 
not prove suitable for synthesis of our dibenzoazacycloooctyne system. Also, with 
other protecting groups (Boc, benzoyl, trifluoroacetyl, Fmoc) either the 
dibromination (Boc, Fmoc) or the elimination with LDA (trifluoroacetyl, benzoyl) did 
not succeed. Proceeding with the Cbz-protected compound 8 elimination was 
attempted with different concentrations of aqueous NaOH (6 and 12 M) resulting in 
elimination of a single bromide. Subsequently, n-BuLi was added to the 
monobromo-alkene which led to decomposition of the material. Ultimately, 
elimination was performed with solid KO
t
Bu yielding dibenzoazacycloooctyne 9 in 
87% yield. Compound 9, although fulfilling our aim to prepare a 
dibenzoazacyclooctyne, is clearly lacking a handle for further functionalization. 
Unfortunately, deprotection of the Cbz-group, using either acidic or basic 
conditions, did not yield the free amine (i.e. 6, Scheme 2). Instead, 6H-
isoindolo[2,1-a]indole (10) was formed, presumably via an 5-endo-dig cyclization, 
thereby relieving ring-strain by formation of the indole.  
 
Scheme 2. Synthesis of Cbz-protected dibenzoazacycloooctyne 9 and attempted deprotection to 
compound 6. Reagents and conditions: (a) Br2, CH2Cl2, 0 ºC, 2 h (67%); (b) KO
t
Bu, THF, 0 ºC to 
r.t., o.n. (87%). 
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Consequently, N-functionalization was required prior to alkyne formation. To this 
end, 5 was equipped with a small functionalizable linker, leading to compound 11 
in 94% yield (Scheme 3). Subsequent bromination (81%) and elimination with 
KO
t
Bu (88%) resulted in alkyne 14 (88%). Due to the presence of water in solid 
KO
t
Bu, not only the alkyne was formed, but also the ester was hydrolyzed, forming 
14. Unfortunately, upon upscaling the elimination, problems arose from this 
hydrolysis and not only desired compound 14 was formed, but also enol ether 15.   
To avoid hydrolysis and thereby the formation of adduct 15 a commercial 1M 
solution of KO
t
Bu in THF was used. While the reaction with solid KO
t
Bu was 
performed overnight at room temperature, using these conditions with the 
commercial solution again gave rise to undesired products. Ultimately, compound 
13 was obtained by performing the reaction using a small excess of base at -40 ºC 
for 3 hours. Finally, a functionalizable probe (14) was prepared via hydrolysis of 
the methyl ester. The thus obtained synthetic route yielded the desired 
dibenzoazacycloooctyne 14, with a functional handle, in a good overall yield of 
41% over 9 steps. 
 
Scheme 3. Synthesis of dibenzoazacycloooctyne 14. Reagents and conditions: (a) Br2, CH2Cl2, 0 
ºC, 2 h (81%); (b) KO
t
Bu, THF, 0 ºC to r.t., o.n. (varying yields and ratio of 14 and 15) or 1M KO
t
Bu 
in THF, THF, - 40 ºC (83%, only 13); (c) LiOH, THF, H2O, r.t., 3 h (92%). 
 
2.3 Kinetics 
Kinetic measurements are used to determine the reactivity of cyclooctynes with 
azides, and thereby the capability of the cyclooctyne to perform fast and efficient 
labeling of biological systems. Having successfully synthesized Cbz-protected and 
acid-functionalized DIBACs (9 and 14, respectively) rate constants were 
determined for the reaction of these DIBACs with benzyl azide in CD3OD (Scheme 
4).  
To determine the rate constant, NMR spectra were measured at preset time 
points and conversion of the reaction was determined. In this manner, conversion 
plots can be obtained showing the complete disappearance of starting material in 
less than 25 minutes, as shown in Figure 2A for 9 and Figure 2B for 14. From the 
conversion plots the second order rate plots were calculated, by fitting the data to 
equation (1). 
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Scheme 4. Reaction of dibenzoazacycloooctynes 9 and 14 with benzyl azide. 
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  (1) 
Herein, k = 2
nd 
order rate constant (M
-1
s
-1
), t = reaction time (s), [A]0 = the initial 
concentration of substrate A (mmol/mL), [B]0 = the initial concentration of substrate 
B (mmol/mL) and [P] = the concentration of the product (mmol/mL). Applying this 
formula, resulted in the graphs as shown in Figure 2B and Figure 2D for 9 and 
14,respectively. The rate constant can subsequently be established by 
determining the slope of the graph, giving rate constants of 0.30 M
-1
s
-1
 for 9 and 
0.41 M
-1
s
-1 
for 14.  
 
 
Figure 2. (A) conversion plot of reaction of compound 9 with benzyl azide, forming 16 and 17, 
reaction was performed in duplicate; (B) second order rate plot of the reaction of compound 9 with 
benzyl azide; (C) conversion plot of the reaction of compound 14 with benzyl azide, forming 18 and 
19, reaction was performed in duplo using two different concentrations; (D) second order rate plot 
of the reaction of compound 14 with benzyl azide. 
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Table 1. Rate constants of the different cyclooctyne systems. 
Entry Compound Solvent k (M
-1
s
-1
) 
1 DIBAC (9) CD3OD 0.30 ± 0.05 
2 DIBAC (14) CD3OD 0.4 ± 0.1 
 
Much to our satisfaction, the kinetic parameters of our new system proved 
slightly better than DIBO (k = 0.17 M
-1
s
-1
)
21
 and DIFO (k = 0.076 M
-1
s
-1
)
16
 and 
reacted approximately 100-fold faster than the hydrophilic DIMAC-system (k = 
3·10
-3
).
34
 
 
2.4 Protein modification 
To investigate the applicability of the Cu-free 1,3-dipolar cycloaddition in the 
conjugation of polyethylene glycol to proteins, dibenzoazacyclooctyne analogue 14 
was functionalized with H2N-PEG44-OMe via an EDC-coupling, yielding DIBAC-
mPEG44 (21, Scheme 5). For comparison, DIBO-mPEG44 (22) was also prepared 
via conversion of the alcohol of 20 into a 4-nitrophenylcarbonate
21
 followed by 
substitution with H2N-PEG44-OMe.  
Scheme 5. Reagents and conditions: (a) H2N-PEG44-OMe, EDC, DMAP, CH2Cl2, 2 d, r.t.; (b) 1) 
ClCO2C6H4NO2, pyridine, CH2Cl2, 4 h, r.t.; 2) H2N-PEG44-OMe, CH2Cl2, 1 d, r.t.; (c) PBS-buffer (pH 
8.5, 30 µM), 3 h, r.t. 
Initially, azide-containing Candida Antarctica Lipase B (AHA-CalB)
36
 was used 
for the conjugation studies. This modified enzyme, obtained by recombinant 
expression in auxotrophic E. coli, contains five azidohomoalanine residues, four of 
which are concealed inside the protein. Consequently, only one azido residue is 
exposed on the exterior of the enzyme, readily available for ligation. It was 
previously reported that this enzyme underwent PEGylation selectively with the 
most accessible residue by applying the Cu(I)-catalyzed (3+2) cycloaddition 
reaction. However, full conversion could never be reached, despite the use of 20 
equivalents of acetylene-PEG110 and stirring for 1-3 days.
36
 Now, PEGylation of 
AHA-CalB was pursued by mixing AHA-CalB (1 μg/μL, corresponding to ~30 μM) 
with DIBAC-mPEG44 21 or DIBO-mPEG44 22 (one, two and five equivalents) as 
shown in Scheme 5. After three hours, the reaction was quenched with benzyl 
azide and analyzed by SDS-PAGE (Figure 3A). As can be seen from Figure 3A, 
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with five equivalents of DIBAC-mPEG44 (21) full conversion was obtained within 
three hours (Figure 3A, lane 2). 
Interestingly, not only was the enzyme fully functionalized, but it also appeared 
that one of the less accessible azides had reacted, generating di-PEGylated CalB, 
confirming the excellent reactivity of dibenzoazacycloooctyne toward azides. The 
higher reactivity of the DIBAC system is further demonstrated by the fact that a 
higher degree of PEGylation is observed than with DIBO-mPEG44 (lane 5, Figure 
3A). In both cases, the small amount of ‘unreacted’ CalB observed is not caused 
by failure to react, but can be ascribed to the fact that AHA-CalB always contains 
a small amount of non-modified enzyme.
36
 When performing the PEGylation with 
either one or two equivalents of DIBAC 21, approximately 50% conversion to the 
single PEGylated product was observed (lanes 3 and 4, Figure 3A). Using DIBO 
22 under the same conditions resulted in somewhat lower conversions (lanes 6 
and 7, Figure 3A).  
 
Figure 3. SDS-PAGE gel of PEGylated AHA-CalB (1 μg/μL) (A) and HRP (1 μg/μL) (B) using 
various equivalents of cyclooctynes 21 or 22. 
The fast and quantitative ligation of both reagents to AHA-CalB shows the high 
potential of these systems. To investigate the reactivity and efficiency of the 
reagents towards other enzymes, horse radish peroxidase (HRP) was modified via 
diazotransfer as was previously developed in our group.
37
 The resulting HRP-N3 
was then reacted with either 21 or 22 following the same procedure as applied to 
AHA-CalB, giving almost identical results (Figure 3B). The 
dibenzoazacycloooctyne is in both cases more reactive than the 
dibenzocyclooctyne, especially when only one or two equivalents were used. 
Nevertheless, in comparison to the Cu(I)-catalyzed cycloaddition reaction, both 
dibenzocyclooctynes show fast and efficient modification of both enzymes, clearly 
showing the power and applicability of the copper-free systems.  
 
2.5 Conclusions and outlook 
In the search for more reactive, more stable and better functionalizable 
cyclooctynes a dibenzoazacycloooctyne was developed. Functionalization of the 
dibenzoazacycloooctyne is achieved through stable amide bonds which can not 
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easily be hydrolyzed. This azadibenzocyclooctyne was accessible in 9 steps in a 
total yield of 41%. Although different routes towards key intermediate 
dihydroazocine 5 leading to comparable dibenzoazacycloooctynes have been 
published in due time,
38, 39
 yields were significantly lower for these routes (25%
38
 
or 46%
39
 for intermediate 5, and 7%
38
 or 17%
39
 for the dibenzoazacycloooctyne). 
In addition, dibenzoazacycloooctynes 9 and 14 showed outstanding reaction 
kinetics with rate constants of 0.30 M
-1
s
-1
 for 9 and 0.4 M
-1
s
-1
 for 14. The rate 
constants make DIBAC one of the fastest reacting cyclooctynes known and the 
probe is highly suitable for bioconjugation purposes. 
The potential of DIBAC was underlined by the effective PEGylation of enzymes, 
which was shown to proceed quantitatively with only little excess of reagent. Also 
in the labeling of enzymes DIBAC proved superior over other cyclooctynes. 
 
Figure 4. Structures of exo- and endo-BCN and BARAC. 
Since the development of DIBAC, new cyclooctynes and dibenzocyclooctynes 
have been synthesized. Van Delft et al. published a bicyclo[6.1.0]non-4-yne 
(BCN), which has increased ring-strain compared to normal cyclooctynes due to a 
fused cyclopropane ring opposite to the alkyne, shown in Figure 4. BCN can be 
prepared in exo- and endo-form in only 4 steps in 15 and 35%, respectively. Both 
BCNs showed a rate constant of around 0.1 M
-1
s
-1
, therewith displaying the same 
order of reactivity as other cyclooctynes and dibenzocyclooctynes.
40
 Bertozzi et al. 
published another dibenzoazacyclooctyne (BARAC, shown in Figure 4), which has 
an amide bond in the 8-membered ring, instead of the benzylic amine in DIBAC. 
This resulted in a 2-fold rate increase compared to DIBAC, with a rate constant of 
0.96 M
-1
s
-1
.
41
 Disadvantages of BARAC are that it suffers from lower stability in 
water (hydrolysis of the amide bond) and reduced selectivity towards azides as it 
also reacts with thiols, although at a much lower rate. To improve the properties of 
dibenzoazacyclooctynes, analogue synthesis is of interest in order to e.g. increase 
reactivity and/or selectivity, to obtain better water soluble probes, or to obtain 
probes with multiple labels. The route as developed for DIBAC was envisioned to 
be a versatile route allowing for analogue synthesis, which will be further 
described in Chapter 3.  
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2.7 Experimental Section 
2.7.1 General experimental 
Unless stated otherwise all chemicals were obtained from commercial sources and used 
without further purification. If no further details are given the reaction was performed 
under ambient atmosphere and temperature. Analytical thin layer chromatography (TLC) 
was performed on silica gel-coated plates (Merck 60 F254) with the indicated solvent 
mixture, visualization was done using ultraviolet (UV) irradiation (λ = 254 nm) and/or 
staining with KMnO4. Purification by column chromatography was carried out using 
Silicycle silica gel (0.040-0.063 mm, and ca. 6 nm pore diameter). The water used in the 
enzyme functionalization was deionized using a Labconco Water Pro PS purification 
system. The PBS-buffer was a 150 mM NaCl and 50 mM NaH2PO4 solution that was 
adjusted to pH 8. THF and CH2Cl2 were dried over an activated alumina column using an 
MBraun SPS800 solvent purification system. NEt3 was distilled under N2-atmosphere from 
CaH2. 
 
Infrared (IR) Spectroscopy: IR spectra were recorded on an ATI Matson Genesis Series 
FTIR spectrometer fitted with an ATR cell. The vibrations (ν) are given in cm -1. 
 
Nuclear Magnetic Resonance (NMR) Spectroscopy: 
1
H-NMR spectra were recorded on 
a Varian Inova 400 (400 MHz) for room temperature measurements and a Varian Inova 
500 (500 MHz) for low temperature measurements. 
13
C-NMR spectra were recorded on a 
Bruker DMX300 (75 MHz) spectrometer. Unless stated otherwise all spectra were taken at 
ambient temperature. 
1
H-NMR chemical shifts () are reported in parts per million (ppm) 
relative to a residual proton peak of the solvent,  = 3.31 for CD3OD and  = 7.26 for 
CDCl3. Broad peaks are indicated by the addition of br. Coupling constants are reported 
as a J-value in Hertz (Hz). In case of rotamers the spectrum was taken at lower 
temperature to freeze the compound in its two rotamer states, causing separate peaks for 
each rotamer. In these cases shifts, coupling constants and integrals are given of each 
separate peak. 
13
C-NMR chemical shifts () are reported in ppm relative to CD3OD ( = 
49.0) or CDCl3 ( = 77.0). If rotamers are observed in the spectrum, the minor rotamer 
peaks are labeled with *. 
 
Mass Spectrometry (MS): High Resolution Mass Analyses were performed using 
Electrospray Ionization on a JEOL AccuToF. 
 
2.7.2 Synthesis 
{2-[(2-Aminophenyl)ethynyl]phenyl}methanol (1)  
2-Iodobenzyl alcohol (4.0 g, 17.1 mmol), Pd(PPh3)2Cl2 (239 mg, 
0.34 mmol) and CuI (32.4 mg, 0.17 mmol) were added to a flame-
dried Schlenk flask. The flask was evacuated and refilled with an 
N2/H2-mixture (3:2) three times. Dry THF (40 mL) and dry NEt3 (3.8 
mL, 27.4 mmol) were bubbled through with an N2/H2-mixture (3:2) 
for 10 minutes and subsequently added to the mixture. Hereupon, 
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2-ethynylaniline (2.5 mL, 24 mmol) was added and the mixture was stirred for 4 hours 
under an N2/H2-atmosphere. The mixture was diluted with CH2Cl2 (60 mL) and washed 
with H2O (50 mL). The water layer was extracted with CH2Cl2 (2 × 50 mL). The organic 
layers were combined and washed with H2O (2 × 100 mL) and brine (100 mL) and 
subsequently dried over MgSO4. The crude product was purified by gradient column 
chromatography (EtOAc/n-heptane, 1:4 to 1:2) to obtain the product as a white solid (3.8 
g, 99%). RF = 0.2 (EtOAc/n-heptane, 1:4). 
1
H-NMR (400 MHz, CDCl3) δ: 7.55 (dd, J = 7.0, 
1.8 Hz, 1H), 7.44 (dd, J = 7.3, 1.4 Hz, 1H), 7.37-7.29 (m, 3H), 7.15 (ddt, J = 7.4, 1.6, 0.8 
Hz, 1H), 6.74-6.70 (m, 2H), 4.89 (s, 2H), 4.43 (br s, 2H), 2.00 (br s, 1H). 
13
C-NMR (75 
MHz, CDCl3) δ: 148.2, 141.8, 132.1, 132.0, 130.0, 128.5, 127.8 (2C), 122.1, 117.8, 114.4, 
107.6, 92.1, 91.1, 64.4. FT-IR νmax film: 3412, 2993, 1735, 1584, 1523, 1446, 1230, 1148, 
763 (cm
-1
). HRMS (ESI+) m/z calcd for C15H14NO [M+H]
+
 224.1075, found 224.1083.  
 
tert-Butyl (2-{[2-(hydroxymethyl)phenyl]ethynyl}phenyl)carbamate (2)  
Compound 1 (1.12 g, 5 mmol) was dissolved in THF (5 mL) and 
Boc2O (1.09 g, 5 mmol) was added. The reaction was heated to 70 
ºC in a sealed tube and stirred for 2 days. The mixture was diluted 
with CH2Cl2 (50 mL), washed with H2O (60 mL) and the water layer 
was extracted with CH2Cl2 (40 mL). The organic layers were 
combined and washed with H2O (2 × 60 mL) and brine (60 mL) and 
then dried over MgSO4. The crude product was purified by column chromatography 
(EtOAc/n-heptane, 1:4). The product was obtained as a white solid (1.34 g, 83%). RF = 
0.3 (EtOAc/n-heptane, 1:4). 
1
H-NMR (400 MHz, CDCl3) δ: 8.14 (d, J = 7.4 Hz, 1H), 7.88 
(br s, 1H), 7.58 (dd, J = 7.3, 1.7 Hz, 1H), 7.48-7.44 (m, 2H), 7.39-7.31 (m, 3H), 7.01 (dt, J 
= 7.6, 1.1 Hz, 1H), 4.92 (d, J = 4.8 Hz, 2H), 2.37 (br s, 1H), 1.57 (s, 9H). 
13
C-NMR (75 
MHz, CDCl3) δ: 152.6, 141.5, 140.0, 132.2, 131.4, 129.8, 128.8, 128.2, 127.9, 122.2, 
121.9, 118.0, 111.4, 93.8, 89.4, 81.1, 64.3, 28.3 (3C). FT-IR νmax film (cm
-1
): 3403, 2697, 
1731, 1584, 1506, 1446, 1152, 750, 603. HRMS (ESI+) m/z calcd for C20H21NNaO3 
[M+Na]
+
 346.1419, found 346.1406. 
 
tert-Butyl (2-{(Z)-2-[2-(hydroxymethyl)phenyl]ethenyl}phenyl) carbamate (3)  
Compound 2 (990 mg, 3.1 mmol) was dissolved in MeOH (25 
mL) followed by the addition of Pd/BaSO4 (10%, 43 mg) and 
quinoline (43 µL, 0.31 mmol). The mixture was placed under 
an H2-atmosphere for 1.5 hour. After completion of the 
reaction the mixture was filtered over celite and the solvents 
were removed under reduced pressure. The crude product was purified by column 
chromatography (EtOAc/n-heptane, 1:4) yielding compound 3 as a yellow solid (940 mg, 
95%). RF = 0.2 (EtOAc/n-heptane, 1:4). 
1
H-NMR (400 MHz, CDCl3) δ: 7.31 (d, J = 7.6 Hz, 
1H), 7.26 (s, 1H), 7.21-7.16 (m, 3H), 7.04-6.94 (m, 4H), 6.70 (br s, 1H), 6.66 (d, J = 12.0 
Hz, 1H), 4.75 (d, J = 6.4 Hz, 2H), 1.41 (s, 9H). 
13
C-NMR (75 MHz, CDCl3) δ: 150.4, 138.4, 
136.1, 135.6, 134.9, 131.4, 129.5 (2C), 129.0, 128.6, 128.0, 128.0 (2C), 126.2, 122.8, 
80.8, 64.1, 28.2 (3C). FT-IR νmax film (cm
-1
): 3429, 2924, 1735, 1528, 1148, 603. HRMS 
(ESI+) m/z calcd for C20H23NNaO3 [M+Na]
+
 348.1576, found 348.1557. 
 
tert-Butyl {2-[(Z)-2-(2-formylphenyl)ethenyl]phenyl}carbamate (4)   
Compound 3 (940 mg, 2.9 mmol) was dissolved in dry CH2Cl2 
(20 mL) and placed under an Ar-atmosphere in a flame-dried 
flask. Subsequently, Dess-Martin periodinane (1.51 g, 3.5 
mmol) and NaHCO3 (0.80 g, 9.5 mmol) were added and the 
mixture was stirred for 40 minutes. The reaction was quenched 
with saturated aqueous Na2SO3 (5 mL). The mixture was diluted with CH2Cl2 (20 mL), 
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washed with saturated aqueous NaHCO3 (2 × 25 mL), H2O (25 mL) and subsequently with 
brine (25 mL). Next, the organic layers were dried over MgSO4 and concentrated in vacuo. 
The crude product was purified by column chromatography (EtOAc/n-heptane, 1:6) to 
obtain compound 4 as a yellow solid (847 mg, 90%). RF = 0.35 (EtOAc/n-heptane, 1:4). 
1
H-NMR (400 MHz, CDCl3) δ: 10.23 (s, 1H), 7.88 (d, J = 8.3 Hz, 1H), 7.81 (dd, J = 7.6, 1.4 
Hz, 1H), 7.37 (dt, J = 7.5, 1.4 Hz, 1H), 7.32 (dt, J = 7.7, 1.7 Hz, 1H), 7.28 (d, J = 11.8 Hz, 
1H), 7.18 (ddd, J = 8.3, 7.7, 1.7 Hz, 1H), 7.08 (d, J = 7.5 Hz, 1H), 6.99 (dd, J = 7.7, 1.6 
Hz, 1H), 6.88 (dt, J = 7.5, 1.2 Hz, 1H), 6.78 (d, J = 11.9 Hz, 1H), 6.49 (br s, 1H), 1.44 (s, 
9H). 
13
C-NMR (75 MHz, CDCl3) δ: 192.1, 152.8, 152.4*, 138.6, 135.7*, 135.5, 134.8, 
133.5, 133.4*, 131.7*, 131.1*, 130.8, 130.3, 129.6, 129.3*, 128.4*, 128.2, 128.0, 127.2, 
126.8, 126.2*, 122.8, 120.0*, 119.8, 102.1, 80.3, 28.3 (3C). FT-IR νmax film (cm
-1
): 3382, 
2958, 1731, 1684, 1515, 1450, 1243, 1139, 1057, 737. HRMS (ESI+) m/z calcd for 
C20H21NNaO3 [M+Na]
+
 346.1419, found 346.1406. 
 
5,6-Dihydrodibenzo[b,f]azocine (5)  
2M HCl in EtOAc (25 mL) was added to compound 4 (847 mg, 2.6 
mmol) and the mixture was stirred for 1 hour. Next, NaBH4 (295 mg, 
7.6 mmol) and H2O (47 µL, 2.6 mmol) were added. After stirring 
overnight an additional portion of NaBH4 (295 mg, 7.6 mmol) was 
added and after stirring for an additional hour the reaction was 
quenched with H2O (20 mL). The water layer was extracted with EtOAc (2 × 20 mL). The 
organic layers were combined and washed with 0.2 M NaOH (2 × 40 mL), H2O (2 × 40 
mL) and brine (50 mL) and subsequently dried over MgSO4. The solvents were 
evaporated under reduced pressure to afford compound 5 as a yellow solid (540 mg, 
100%). RF = 0.45 (EtOAc/n-heptane, 1:4). 
1
H-NMR (400 MHz, CDCl3) δ: 7.27-7.23 (m, 
1H), 7.20-7.15 (m, 3H), 6.96 (dd, J = 7.8, 1.6 Hz, 1H), 6.88 (ddd, J = 8.0, 7.2, 1.6 Hz, 1H), 
6.60 (ddd, J = 7.7, 7.2, 1.2 Hz, 1H), 6.54 (d, J = 13.0 Hz, 1H), 6.48-6.45 (m, 1H), 6.35 (d, 
J = 13.1 Hz, 1H), 4.58 (s, 2H), 4.29 (br s, 1H). 
13
C-NMR (75 MHz, CDCl3) δ: 147.0, 139.2, 
138.1, 134.7, 132.7, 130.1, 128.8, 127.9, 127.6, 127.4, 127.3, 121.8, 117.9, 117.7, 49.6. 
FT-IR νmax film (cm
-1
): 3391, 3049, 2932, 1502, 746, 620. HRMS (ESI+) m/z calcd for 
C15H14N [M+H]
+
 208.1126, found 208.1107. 
 
Benzyl dibenzo[b,f]azocine-5(6H)-carboxylate (7)  
Compound 5 (100 mg, 0.48 mmol) was dissolved in CH2Cl2 (10 mL) 
after which Cbz-Cl (117.3 µL, 0.82 mmol) was added, followed by a 
solution of aqueous Na2CO3 (2 mL, 0.29 M). After 3 hours the reaction 
was quenched with H2O (10 mL) and the mixture was extracted with 
CH2Cl2 (20 mL). The organic layer was washed with H2O (3 × 20 mL) 
and brine (20 mL). Next, the organic layer was dried over MgSO4 and subsequently 
concentrated in vacuo. The crude product was purified by column chromatography 
(EtOAc/n-heptane, 1:9) to obtain compound 7 as a white solid (140 mg, 86%). RF = 0.35 
(EtOAc/n-heptane, 1:4). 
1
H-NMR (400 MHz, 273 K, CDCl3) δ: 7.37-7.27 (m, 5H), 7.25-7.18 
(m, 7.45H), 7.11-7.06 (m, 0.55H), 6.71 (d, J = 13.5 Hz, 0.72H), 6.66 (d, J = 14.0 Hz, 
0.28H), 6.58 (d, J = 13.9 Hz, 0.27H), 6.51 (d, J = 13.5 Hz, 0.72H), 5.10 (s, 0.68H), 5.07 
(br s, 1.27H), 4.73 (br s, 2H). A clear 
13
C-NMR spectrum could not be obtained as a result 
of a strong rotamer-effect. FT-IR νmax film (cm
-1
): 2967, 1692, 1489, 1403, 1299, 1242, 
1035, 612. HRMS (ESI+) m/z calcd for C23H20NO2 [M+H]
+
 342.1494, found 342.1477. 
 
Benzyl 11,12-dibromo-11,12-dihydrodibenzo[b,f]azocine-5(6H)-carboxylate (8)  
Compound 7 (140 mg, 0.41 mmol) was dissolved in dry CH2Cl2 (10 mL). The reaction 
mixture was cooled to 0 ºC and a solution of Br2 (22 µL, 0.41 mmol) in dry CH2Cl2 (3 mL) 
was added drop-wise. The reaction was stirred for 2 hours at 0 ºC and subsequently 
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quenched with saturated aqueous Na2SO3 (15 mL). The product was 
extracted with CH2Cl2 (2 × 20 mL), the organic layers were combined 
and washed once again with saturated aqueous Na2SO3 (2 × 20 mL), 
H2O (30 mL) and brine (30 mL). The combined organic layers were 
subsequently dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by gradient column chromatography 
(EtOAc/n-heptane, 1:6 to 1:1) to obtain compound 8 as a brown solid (136 mg, 67%). RF = 
0.3 (EtOAc/n-heptane, 1:4). 
1
H-NMR (400 MHz, CDCl3) δ: 7.74 (d, J = 7.7 Hz, 1H), 7.57-
7.29 (m, 1H), 7.24-7.16 (m, 5H), 7.1-6.9 (m, 5H) 6.87 (d, J = 7.3 Hz, 1H), 6.04 (d, J = 9.7 
Hz, 0.82H), 5.88 (d, J = 9.7 Hz, 0.17H), 5.65 (d, J = 14.4 Hz, 0.8H), 5.33-5.28 (m, 1.37H), 
5.14 (d, J = 9.7 Hz, 0.82H), 5.08-5.03 (m, 1.22H), 4.31 (d, J = 14.4 Hz, 0.83H). 
13
C-NMR 
(75 MHz, CDCl3) δ: 155.1, 138.3, 137.3, 136.4, 136.2, 132.7, 130.4, 130.1, 130.0, 129.7, 
129.5, 129.4, 129.1, 128.8, 128.7, 128.2, 128.0, 127.7, 127.6, 67.4, 60.9*, 59.8, 56.5, 
54.9*, 53.7, 52.9*.  FT-IR νmax film (cm
-1
): 3075, 2915, 1688, 1502, 1394, 1342, 1282, 
1203, 728. HRMS (ESI+) m/z calcd for C23H20Br2NO2 [M+H]
+ 
499.9861, found 499.9848. 
 
Benzyl 11,12-didehydrodibenzo[b,f]azocine-5(6H)-carboxylate (9)  
Compound 8 (110 mg, 0.22 mmol) was placed in a flame-dried flask 
and dissolved in dry THF (5 mL). Next, a solution of KO
t
Bu (77 mg, 
0.66 mmol) in 
t
BuOH (2 mL) was added drop-wise. The mixture was 
stirred overnight, whereupon an extra portion of KO
t
Bu (77 mg, 0.66 
mmol) was added. The reaction was stirred for an additional hour 
after which full conversion was observed. The reaction was cooled to 0 ºC and 
subsequently quenched with H2O (5 mL). The mixture was neutralized with 2 M HCl and 
the product was extracted with CH2Cl2 (2 × 20 mL). The organic layers were combined 
and subsequently washed with H2O (3 × 30 mL) and brine (30 mL). After drying over 
MgSO4 and concentrating, the crude product was purified by column chromatography 
(EtOAc/n-heptane, 1:6) to obtain 9 as a white solid (65 mg, 87%). RF = 0.5 (EtOAc/n-
heptane, 1:4). 
1
H-NMR (400 MHz, 243 K, CDCl3) δ: 7.69 (dd, J = 7.1, 1.6 Hz, 0.70H), 7.53 
(dd, J = 8.1, 0.8 Hz, 0.36H), 7.44-7.30 (m, 9H), 7.26-7.12 (m, 3H), 5.29 (d, J = 12.6 Hz, 
0.67H), 5.10 (d, J = 11.9 Hz, 0.32H), 5.00 (d, J = 14.2 Hz, 0.62H), 4.93 (d, J = 11.8 Hz, 
0.29H), 4.88 (d, J = 14.4 Hz, 0.29H), 4.78 (d, J = 12.6 Hz, 0.64H), 3.93 (d, J = 14.5 Hz, 
0.28H), 3.80 (d, J = 14.0 Hz, 0.67H). 
13
C-NMR (75 MHz, CDCl3) δ: 155.6, 151.5, 147.2, 
136.3, 132.0, 129.2, 128.5, 128.3, 128.1, 127.8, 127.7, 127.5, 126.9, 126.6, 125.5, 124.2, 
121.2, 113.3, 109.1, 67.7*, 67.2, 55.8, 55.4*.
 
FT-IR νmax film (cm
-1
): 3002, 2894, 1697, 
1290, 1117, 840, 750. HRMS (ESI+) m/z  calcd for C23H17NNaO2 [M+Na]
+
 362.1157, 
found 362.1151. 
 
6H-isoindolo[2,1-a]indole (10)  
Compound 6 (10 mg, 0.03 mmol) was dissolved in HBr in AcOH (33 
wt%, 1 mL). The mixture was stirred for 5 minutes whereupon the 
solvents were removed under reduced pressure. The crude product 
was purified by column chromatography (EtOAc/n-heptane, 1:6) to 
obtain 10 as a yellow solid (6 mg, 98%). RF = 0.5 (EtOAc/n-heptane, 1:4). 
1
H-NMR (400 
MHz, CDCl3) δ: 7.71 (d, J = 7.6 Hz, 1H), 7.66 (d, J = 7.9 Hz, 1H), 7.47 (d, J = 7.5 Hz, 1H), 
7.40 (t, J = 7.5 Hz, 1H), 7.36 (dd, J = 8.1, 0.8 Hz, 1H), 7.30 (dt, J = 7.5, 1.0 Hz, 1H), 7.19 
(dt, J = 8.0, 1.1 Hz, 1H), 7.10 (dt, J = 7.9, 1.1 Hz, 1H), 6.63 (s, 1H), 5.07 (s, 2H). 
13
C-NMR 
(75 MHz, CDCl3) δ: 143.9, 141.7, 133.9, 133.0, 132.8, 128.1, 127.0, 123.5, 121.7, 121.5, 
120.9, 119.6, 109.2, 91.2, 48.4. HRMS (ESI+) m/z calcd for C15H11N [M+H]
+
 206.0970, 
found 206.0963. 
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Methyl 5-dibenzo[b,f]azocin-5(6H)-yl-5-oxopentanoate (11)  
Compound 5 (500 mg, 2.4 mmol) was dissolved in dry CH2Cl2 (40 
mL) and NEt3 (0.67 mL, 4.8 mmol) was added. The mixture was 
cooled to 0 ºC whereupon glutaric acid monomethyl ester chloride 
(0.51 mL, 3.6 mmol) was added. The reaction was stirred for 1.5 
h, after which it was quenched with H2O (10 mL). The mixture 
was diluted with CH2Cl2 (20 mL) and washed with 2 M NaOH (2 × 
40 mL), 2 M HCl (2 × 40 mL), H2O (2 × 40 mL) and brine (40 mL). 
Next, the organic layer was dried over MgSO4 and subsequently concentrated in vacuo. 
The crude product was purified using column chromatography (EtOAc/n-heptane, 1:2) to 
obtain compound 11 as a yellow oil which turned solid after storage at -20 ºC (760 mg, 94 
%). RF = 0.2 (EtOAc/n-heptane, 1:4). 
1
H-NMR (400 MHz, CDCl3) δ: 7.29-7.26 (m, 3H), 
7.25-7.23 (m, 1H), 7.20-7.12 (m, 4H), 6.78 (d, J = 13.1 Hz, 1H), 6.58 (d, J = 13.1 Hz, 1H), 
5.50 (d, J = 15.0 Hz, 1H), 4.22 (d, J = 15.0 Hz, 1H), 3.58 (s, 3H), 2.24-2.05 (m, 3H), 1.93-
1.77 (m, 3H). 
13
C-NMR (75 MHz, CDCl3), δ: 173.5, 171.7, 140.9, 136.3, 135.7, 134.7, 
132.6, 132.0, 131.1, 130.3, 129.4, 128.1, 127.9, 127.3, 127.1, 126.9, 54.5, 51.3, 33.4, 
33.0, 20.4. FT-IR νmax film (cm
-1
): 3308, 2941, 1740, 1658, 1446, 1234, 599. HRMS (ESI+) 
m/z calcd for C21H22NO3 [M+H]
+
 336.1600, found 336.1597. 
 
Methyl 5-(11,12-dibromo-11,12-dihydrodibenzo[b,f]azocin-5(6H)-yl)-5-oxopentanoate 
(12) 
Compound 11 (500 mg, 1.5 mmol) was dissolved in dry CH2Cl2 
(20 mL). The solution was then cooled to 0 ºC and a solution of 
Br2 (77 µL, 1.5  mmol) in dry CH2Cl2 (1 mL) was added drop-wise. 
After stirring for 45 minutes at 0 ºC the reaction was quenched 
with saturated aqueous Na2SO3 (5 mL). The mixture was diluted 
with CH2Cl2 and the organic layer was washed with saturated 
aqueous Na2SO3 (3 × 10 mL), H2O (2 × 15 mL) and brine (15 mL) 
and subsequently dried over MgSO4. The crude product was 
purified by column chromatography (EtOAc/n-heptane, 1:3 to 1:2) to obtain compound 12 
as a white solid (600 mg, 81%). A mixture of two stereoisomers was obtained in a ratio  of 
5.5:1. The major isomer (RF = 0.25, EtOAc/n-heptane, 1:2) was separately isolated, the 
minor isomer (RF = 0.3, EtOAc/n-heptane, 1:2) was only obtained as mixture of both 
isomers. Analytical data of the major isomer are given. 
1
H-NMR (400 MHz, CDCl3) δ: 7.72 
(d, J = 7.8 Hz, 1H), 7.25-7.12 (m, 3H), 7.08-7.02 (m, 2H), 6.98 (d, J = 7.6 Hz, 1H), 6.89 (d, 
J = 7.5 Hz, 1H), 5.92 (d, J = 9.9 Hz, 1H), 5.82 (d, J = 14.8 Hz, 1H), 5.15 (d, J = 9.9 Hz, 
1H), 4.17 (d, J = 14.8 Hz, 1H), 3.62 (s, 3H), 2.44-2.81 (m, 3H), 2.23-2.15 (m, 1H),  2.09-
1.94 (m, 2H). 
13
C-NMR (75 MHz, CDCl3) δ: 173.6, 172.7, 138.2, 137.1, 137.1, 132.9, 
130.7 (2C), 130.5, 129.6, 129.4, 128.9, 128.9, 128.6, 60.1, 55.6, 52.5, 51.5, 34.8, 33.3, 
20.4. FT-IR νmax film (cm
-1
): 2919, 1744, 1636, 1497, 1385, 1191, 655. HRMS (ESI+) m/z 
calcd for C21H22Br2N [M+H]
+
 493.9966, found 493.9960. 
 
Methyl 5-(11,12-didehydrodibenzo[b,f]azocin-5(6H)-yl)-5-oxopentanoate (13)  
Compound 12 (300 mg, 0.6 mmol) was placed in a flame-dried 
flask dissolved in dry THF (20 mL) and the solution was cooled to 
-40 ºC. Hereupon, 1 M KO
t
Bu in THF (1.2 mL, 1.2 mmol) was 
added dropwise. The reaction was stirred for 1.5 hour at -40 ºC 
whereupon another portion of 1 M KO
t
Bu in THF (0.3 mL, 0.3 
mmol) was added dropwise. After an additional 30 minutes the 
reaction was completed and the mixture was poured into a large 
amount of H2O (30 mL). Next, the product was extracted with CH2Cl2 (2 × 40 mL), the 
organic layers were combined and washed with H2O (3 × 50 mL) and brine (50 mL) and 
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dried over MgSO4. The product was purified by gradient column chromatography 
(EtOAc/n-heptane, 1:3 to 1:2) to obtain 13 as a yellow oil which solidified upon storing at -
20 ºC (170 mg, 84%)  RF = 0.2 (EtOAc/n-heptane, 1:2). 
1
H-NMR (400 MHz, CDCl3) δ: 7.69 
(d, J = 7.4 Hz, 1H), 7.42-7.25 (m, 7H), 5.15 (d, J = 13.8 Hz, 1H), 3.66 (d, J = 13.8 Hz, 1H), 
3.55 (s, 3H), 2.28 (ddd,  J = 15.5, 7.5, 6.6 Hz, 1H), 2.10 (m, 2H), 1.91 (m, 2H), 1.74 (m, 
1H). 
13
C-NMR (75 MHz, CDCl3) δ: 173.5, 172.5, 151.7, 148.0, 132.3, 128.9, 128.3, 128.3, 
128.0, 127.9, 127.7, 127.3, 127.1, 125.5, 123.0, 122.6, 115.1, 107.7,55.3, 51.4, 33.7, 
32.8, 20.6. FT-IR νmax film (cm
-1
): 3274, 2924, 1727, 1666, 1390, 1243, 1161, 754. HRMS 
(ESI+) m/z calcd for C21H20NNaO3 [M+Na]
+
 356.1263, found 356.1265. 
 
5-(11,12-Didehydrodibenzo[b,f]azocin-5(6H)-yl)-5-oxopentanoic acid (14)  
Compound 13 (70 mg, 0.2 mmol) was dissolved in THF (3 mL) and 
a solution of LiOH (19 mg, 0.4 mmol) in H2O (1 mL) was added 
dropwise. The reaction was stirred for 3 hours whereupon the 
reaction mixture was diluted with H2O (10 mL) and basified to pH 
14 with 2 M NaOH. The water layer was washed with CH2Cl2 (3 × 
20 mL) and next acidified to pH 2 with 2 M HCl. The water layer 
was extracted with CH2Cl2 (3 × 20 mL), the organic layers were 
combined, washed with brine (40 mL) and dried over MgSO4. The solvents were removed 
under reduced pressure to obtain compound 14 (62 mg, 92%). RF = 0.4 (CH2Cl2/MeOH, 
9:1). 
1
H-NMR (400 MHz, CDCl3) δ 7.69 (d, J = 7.7 Hz, 1H), 7.42-7.27 (m, 5H) 7.21-7.00 
(m, 2H), 5.16 (d, J = 13.8 Hz, 1H), 3.68 (d, J = 13.8 Hz, 1H), 2.42-2.27 (m, 1H), 2.15-2.10  
(m, 2H), 2.00-1.95 (m, 1H), 1.76-1.69 (m, 2H). 
13
C-NMR (75 MHz, CDCl3) δ 177.8, 172.8, 
151.5, 147.9, 132.3, 128.9, 128.4, 128.3, 128.2, 127.8, 127.1, 125.5, 122.6, 115.1, 107.7, 
97.5, 55.4, 33.5, 32.7, 20.3. FT-IR νmax (cm
-1
): 2933, 1740, 1628, 1398, 1187, 785, 612. 
HRMS (ESI+) m/z calcd for C20H17NNaO3 [M+Na]
+
 342.1106, found 342.1105. 
 
(E)-5-(12-methoxydibenzo[b,f]azocin-5(6H)-yl)-5-oxopentanoic acid (15)  
Compound 12 (154 mg, 0.31 mmol) was dissolved in dry THF (3 
mL) in a flame-dried Schlenk flask and placed under Argon. The 
solution was cooled to 0 ºC and solid KO
t
Bu (105 mg, 0.93 mmol) 
was added. The reaction was slowly warmed to room temperature 
and stirred overnight. Hereupon, H2O (15 mL) was added and the 
water layer was acidified to pH 3 by the addition of 1M aqueous 
HCl. The water layer was subsequently extracted with CH2Cl2 (3 × 
10 mL), the organic layers were combined and washed with 0.1M 
aqueous HCl (20 mL) and brine (20 mL). The  organic layer was dried over MgSO4 and 
the solvents were evaporated under reduced pressure. The crude product was purified by 
column chromatography (EtOAc/n-heptane, 1:1 followed by CH2Cl2/MeOH, 9:1) to obtain 
compound 15 as yellow solid. RF = 0.4 (CH2Cl2/MeOH, 9:1). 
1
H-NMR (400 MHz, CDCl3) δ 
7.22-6.95 (m, 8H), 5.73 (s, 1H), 5.44 (d, J = 14.5 Hz, 1H), 4.47 (d, J = 14.4 Hz, 1H), 3.83 
(s, 3H), 2.37 (t, J = 6.8 Hz, 2H), 2.15-2.08 (m, 1H), 1.97-1.81 (m, 3H). 
13
C-NMR (75 MHz, 
CDCl3) δ 178.0, 172.0, 158.4, 139.6, 137.6, 136.9, 133.1, 130.2, 129.7, 128.7, 128.6, 
128.5, 127.9, 127.6, 127.5, 97.5, 55.9, 53.0, 33.6, 33.2, 20.2. FT-IR νmax (cm
-1
): 2928, 
1722, 1632, 1403, 1225, 754, 603.) 
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benzyl 1-benzyl-1H-dibenzo[b,f][1,2,3]triazolo[4,5-d]azocine-8(9H)-carboxylate (16) 
and benzyl 3 benzyl-3H-dibenzo[b,f][1,2,3]triazolo[4,5-d]azocine-8(9H)-carboxylate 
(17) 
Compound 9 (3.06 mg, 9 μmol) was dissolved 
in CD3OD (0.25 mL) and a solution of 
benzylazide in CD3OD (36 mM, 250 μL) was 
added. After 1 hour at 25 ºC the solvent was 
evaporated and the crude product was purified 
by column chromatography (EtOAc/n-heptane, 
1:4). Although both regioisomers were 
successfully separated, it was not determined 
which isomer was in which fraction. Therefore, 
assignment of the regioisomers to the NMR-spectra are solely based on predictions, a 
13
C-NMR and high resolution mass spectrum were only taken from the fraction supposed 
to contain 16. 
1
H-NMR (400 MHz, CD3OD) δ for 16: 7.54 (d, J = 4.3 Hz, 2H), 7.51-7.43 (m, 
1H), 7.41-7.13 (m, 10H), 7.04 (br s, 3H), 6.90 (dd, J = 4.6, 1.5 Hz, 1H), 5.68 (br s, 2H), 
5.01 (br s, 1H), 4.71 (br s, 1H); for 17: 7.57 (d, J = 6.1 Hz, 1H), 7.51-7.36 (m, 3H), 7.38-
7.27 (m, 3H), 7.26-7.17 (m, 7H), 7.06 (br s, 2H), 7.03-6.91 (m, 2H), 5.71 (br s, 2H), 5.43 
(br s, 1H), 4.57 (br s, 1H). 
13
C-NMR (75 MHz, CD3OD) δ 156.5, 140.9, 137.8, 137.7, 
137.0, 136.6 (2C), 132.5 (2C), 131.5, 131.0, 130.8, 129.9 (4C), 129.8 (2C), 129.4, 129.1 
(2C), 128.9, 128.8, 128.7, 128.5 (3C), 68.6, 54.3, 53.9. FT-IR νmax (cm
-1
): 2487, 2068, 
1697, 1649, 1442, 1411, 1290, 962, 698. HRMS (ESI+) m/z calcd for C30H25N4O2 [M+H]
+
 
473.1978, found 473.1984. 
 
5-(1-benzyl-1H-dibenzo [b,f] [1,2,3] triazolo [4,5-d]azocin-8(9H)-yl)-5-oxopentanoic 
acid (18) and 5-(3-benzyl-3H-dibenzo [b,f] [1,2,3] triazolo [4,5-d]azocin-8(9H)-yl)-5-
oxopentanoic acid (19)  
Compound 14 (2.84 mg, 9 μmol) was 
dissolved in CD3OD (0.25 mL) and a solution 
of benzylazide in CD3OD (36 mM, 250 μL) 
was added. After 1 hour at 25 ºC the solvent 
was evaporated and the crude product was 
purified by column chromatography 
(CH2Cl2/MeOH, 9:1). The two regioisomers 
could not be separated by column 
chromatography. 
1
H-NMR (400 MHz, 
CD3OD) δ 7.61 (t, J = 7.3 Hz, 1H), 7.59-7.46 
(m, 2.5H), 7.44-7.17 (m, 7H), 7.13 (d, J = 
11.4 Hz, 1.5H), 7.01 (d, J = 7.1 Hz, 1H), 5.88 
(d, J = 8.5 Hz, 0.3H), 5.83 (d, J = 15.5 Hz, 0.3H), 5.76 (d, J = 20.8, 0.3H), 5.76 (J = 11.8 
Hz, 0.5H), 5.69 (d, J = 15.7 Hz, 0.5H), 5.58 (d, J = 15.8 Hz, 0.3H), 4.48 (d, J = 17.0 Hz, 
0.3H),  4.35 (d, J = 16.6 Hz, 0.4H). LRMS (ESI+) m/z calcd for C27H25N4O3 [M+H]
+ 
453.2, 
found 453.1. 
 
5-(11,12-Didehydrodibenzo[b,f]azocin-5(6H)-yl)-N-mPEG44-1-yl-5-oxopentanamide 
(21) 
Compound 14 (10 mg, 0.031 mmol) was dissolved in dry 
CH2Cl2 (5 mL) and cooled to 0 ºC. Subsequently, H2N-
PEG44-OMe (69 mg, 0.034 mmol), EDC·HCl (13 mg, 0.068 
mmol) and DMAP (15 mg, 0.12 mmol) were added. The 
reaction was stirred for 30 minutes at 0 ºC, slowly warmed 
to room temperature and stirred overnight. Since the 
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reaction did not go to completion another 0.2 equivalents of H2N-PEG44-OMe (12 mg, 
0.006 mmol) were added and the reaction was stirred for an additional day. The reaction 
was diluted with CH2Cl2 (15 mL) and washed with 2M HCl (3 × 20 mL), H2O (20 mL) and 
brine (20 mL) and dried over MgSO4. The crude product was purified by column 
chromatography (CH2Cl2/MeOH, 9:1) to obtain a mixture of 21 and H2N-PEG44-OMe in a 
ratio of 9:1, which was determined by comparing the methoxy-signal with the aromatic 
signals in the 
1
H-NMR spectrum. 
1
H-NMR (CDCl3, 400 MHz), δ: 7.70 (d, J = 6.4 Hz, 1H), 
7.62-7.42 (m, 5H), 7.21-7.03 (m, 2H), 5.89 (br s, 1H), 5.16 (d, J = 13.8 Hz, 1H), 3.64 (s, 
196 H), 3.60-3.54 (m, 4H), 3.49-3.46 (m, 4H), 3.38 (s, 3.3H), 2.31-2.24 (m, 1H), 2.04-1.83 
(m, 3H), 1.76-1.70 (m, 2H). The ESI-ToF spectrum showed a clear shift of the molecular 
weight distribution. In the double charge distribution a shift in molecular mass between 
starting material and product of 150.557 was observed, where a shift of 150.555 was 
expected.  
 
11,12-Didehydro-5,6-dihydrodibenzo[a,e][8]annulen-5-yl mPEG44-1-ylcarbamate (22) 
Carbonic acid 7,8-didehydro-1,2:5,6-dibenzocyclooctene-3-yl 
ester 4-nitrophenyl ester (4.9 mg, 0.013 mmol) was dissolved 
in CH2Cl2 (300 L) and NEt3 (5.2 L, 0.038 mmol) and H2N-
PEG44-OMe (33 mg, 0.016 mmol) were added. The reaction 
was stirred overnight, diluted with CH2Cl2 (5 mL) and then 
quenched with H2O (1 mL). The organic layer was washed with 
1M HCl (1 mL), H2O (1 mL) and brine (1 mL) and dried over 
MgSO4. The organic layer was concentrated in vacuo and the 
crude product was purified by gradient column 
chromatography (CH2Cl2/MeOH, 9:1 to 5:1) to obtain a mixture of 22 and H2N-PEG44-OMe 
in a ratio of 3:1. The ratio between starting material and product was determined by 
comparing the integral of the aromatic signals with the integral of the methoxy-peak in the 
1
H-NMR spectrum. 
1
H-NMR (400 MHz, CDCl3), δ: 7.53-7.51 (m, 1H), 7.38-7.27 (m, 7H), 
5.62 (br s, 1H), 5.50 (br s, 1H), 3.69 (br s, 256H), 3.48-3.45 (m, 2H), 3.42-3.39 (m, 2H), 
3.38 (s, 4H), 3.21-3.16 (m, 1H), 2.96-2.88 (m, 1H). The ESI-ToF spectrum showed a clear 
shift in the molecular weight distribution. In the double charge distribution a shift in 
molecular mass between starting material and product of 123.0643 was observed, where 
a shift of 123.0337 was expected. 
 
2.7.3 Kinetic Experiments 
General procedure for kinetic experiments: 
The alkyne (9.0 μmol) was dissolved in CD3OD (250 μL). Next, 250 μL of a BnN3 solution 
(36 mM in CD3OD) was added to reach a final volume of 500 μL. 
1
H-NMR spectra were 
taken during 30-45 minutes at preset time-intervals. The exact ratio between benzyl azide 
and alkyne was determined by comparison of the integrals of the aromatic signals and the 
benzylic protons of the alkyne. For the cycloaddition of 9 with benzyl azide, the kinetics 
were determined by comparing the decreasing signal of the benzylic protons of benzyl 
azide and the increasing signal of the same benzylic protons of the product. For the 
cycloaddition of 14 with benzyl azide, the decrease of the signal of one of the benzylic 
protons of 14 was used for determination of the kinetics, using the aromatic protons as 
standard. Both reactions gave two regioisomers, which in the kinetic experiments were 
integrated as a single product. For 9, experiments were performed in duplicate giving 
identical plots and results, for 14 experiments were performed 4 times at different 
concentrations, giving similar plots and results. The formation of the presumed products 
was confirmed by mass spectrometry and NMR-spectroscopy. 
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2.7.3 Enzyme functionalization 
 
For the functionalization of AHA-CalB, reactions were performed with 8.27 μL of an AHA-
CalB solution in PBS pH 7.8 (1.26 mg/mL, 10.4 μg) which was further diluted with PBS 
to reach a final concentration of 1 μg/μL (30 μM) after addition of 21 or 22. To these 
solutions, various amounts of 21 and 22 (1, 2 and 5 equivalents) were added. To this 
end, 4 different stock-solutions were prepared, namely, 0.55 mg/mL and 2.2 mg/mL of 
compound 21 and of compound 22, respectively. The PEG-contamination was taken into 
account in the preparation of the stock-solutions; the weighed amounts of sample were 
corrected in order to obtain the right concentration of 21 and 22. The added amounts of 
each of these stock-solutions are shown in Table 2. All reactions were shaken for 3 hours, 
after which the reactions were quenched by the addition of an excess benzyl azide (± 10 
equiv) and subsequent shaking for 15 minutes. The conjugation was analyzed using a 
12% SDS-PAGE gel followed by coomassie staining (see Figure 3A). 
 
Table 2. Amounts of compounds 21 and 22 used in the ligation with CalB-N3. 
Entry Substrate Stock 0.55 mg/mL Stock 2.2 mg/mL 
1 21 (1 equiv) 1.1 μL X 
2 21 (2 equiv) 2.1 μL X 
3 21 (5 equiv) x 1.3 μL 
4 22 (1 equiv) 1.1 μL X 
5 22 (2 equiv) 2.1 μL X 
6 22 (5 equiv) x 1.3 μL 
 
 
For the functionalization of HRP-N3, reactions were performed with 6 μL of an HRP-N3 
solution in H2O (2.5 mg/mL, 15 μg) which was further diluted with MilliQ water to reach a 
concentration of 1 μg/μL (25 μM) after addition of 21 or 22. To the solutions, various 
amounts of 21 and 22 (1, 2 and 5 equivalents) were added. To this end, 4 different stock-
solutions were prepared, namely, 0.55 mg/mL and 2.2 mg/mL of compound 21 and of 
compound 22, respectively. The PEG-contamination was taken into account in the 
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preparation of the stock-solutions; the weighed amounts of sample were corrected in 
order to obtain the right concentration of 21 and 22. The amounts added of each of these 
stock-solutions are shown in  
Table 3. All reactions were shaken for 3 hours, after which the reactions were quenched 
by the addition of an excess benzylazide (± 10 equiv) and subsequent shaking for 15 
minutes. The conjugation was analyzed using a 12% SDS-PAGE gel followed by 
coomassie staining (see Figure 3B). 
 
Table 3. Amounts of compounds 21 and 22 used in the ligation with HRP-N3. 
Entry Substrate Stock 0.55 mg/mL Stock 2.2 mg/mL 
1 21 (1 equiv) 1.6 μL X 
2 21 (2 equiv) x 0.8 μL 
3 21 (5 equiv) x 2 μL 
4 22 (1 equiv) 1.6 μL X 
5 22 (2 equiv) x 0.8 μL 
6 22 (5 equiv) x 2 μL 
 
2.8 References 
1. H. C. Kolb, M. G. Finn and K. B. Sharpless, Angew. Chem. Int. Ed., 2001, 40, 2004-
2021. 
2. C. W. Tornøe, C. Christensen and M. Meldal, J. Org. Chem., 2002, 67, 3057-3064. 
3. V. V. Rostovtsev, L. G. Green, V. V. Fokin and K. B. Sharpless, Angew. Chem. Int. 
Ed., 2002, 41, 2596-2599. 
4. J. Hou, X. Liu, J. Shen, G. Zhao and P. G. Wang, Exp. Opin. Drug Discovery, 2012, 7, 
489-501. 
5. S. G. Agalave, S. R. Maujan and V. S. Pore, Chem. Asian J., 2011, 6, 2696-2718. 
6. G. E. Means and R. E. Feeney, Bioconjugate Chem., 1990, 1, 2-12. 
7. J. Rademann, Angew. Chem. Int. Ed., 2004, 43, 4554-4556. 
8. C. P. R. Hackenberger and D. Schwarzer, Angew. Chem. Int. Ed., 2008, 47, 10030-
10074. 
9. J. M. Baskin and C. R. Bertozzi, QSAR Comb. Sci., 2007, 26, 1211-1219. 
10. B. Le Droumaguet and K. Velonia, Macromol. Rapid Commun., 2008, 29, 1073-1089. 
11. A. J. Dirks, J. J. L. M. Cornelissen, F. L. van Delft, J. C. M. van Hest, R. J. M. Nolte, A. 
E. Rowan and F. P. J. T. Rutjes, QSAR Comb. Sci., 2007, 26, 1200-1210. 
12. J.-F. Lutz and Z. Zarafshani, Adv. Drug Delivery Rev., 2008, 60, 958-970. 
13. M. A. Gauthier and H.-A. Klok, Chem. Commun., 2008, 2591-2611. 
14. M. van Dijk, D. T. S. Rijkers, R. M. J. Liskamp, C. F. van Nostrum and W. E. Hennink, 
Bioconjugate Chem., 2009, 20, 2001-2016. 
15. E. Lallana, E. Fernandez-Megia and R. Riguera, J. Am. Chem. Soc., 2009, 131, 5748-
5750. 
16. J. M. Baskin, J. A. Prescher, S. T. Laughlin, N. J. Agard, P. V. Chang, I. A. Miller, A. 
Lo, J. A. Codelli and C. R. Bertozzi, Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 16793-
16797. 
17. N. J. Agard, J. A. Prescher and C. R. Bertozzi, J. Am. Chem. Soc., 2004, 126, 15046-
15047. 
18. C. R. Becer, R. Hoogenboom and U. S. Schubert, Angew. Chem. Int. Ed., 2009, 48, 
4900-4908. 
19. E. M. Sletten and C. R. Bertozzi, Angew. Chem. Int. Ed., 2009, 48, 6974-6998. 
20. S. S. van Berkel, A. J. Dirks, M. F. Debets, F. L. van Delft, J. J. L. M. Cornelissen, R. 
J. M. Nolte and F. P. J. T. Rutjes, ChemBioChem, 2007, 8, 1504-1508. 
21. X. Ning, J. Guo, M. A. Wolfert and G.-J. Boons, Angew. Chem. Int. Ed., 2008, 47, 
2253-2255. 
22. S. S. van Berkel, A. J. Dirks, S. A. Meeuwissen, D. L. L. Pingen, O. C. Boerman, P. 
Laverman, F. L. van Delft, J. J. L. M. Cornelissen and F. P. J. T. Rutjes, 
ChemBioChem, 2008, 9, 1805-1815. 
 74 Dibenzoazacyclooctynes: Synthesis and Bioconjugation 
 
23. P. Laverman, S. A. Meeuwissen, S. S. van Berkel, W. J. G. Oyen, F. L. van Delft, F. P. 
J. T. Rutjes and O. C. Boerman, Nucl. Med. Biol., 2009, 36, 749-757. 
24. S. T. Laughlin, J. M. Baskin, S. L. Amacher and C. R. Bertozzi, Science, 2008, 320, 
664-667. 
25. L. A. Canalle, S. S. van Berkel, L. T. de Haan and J. C. M. van Hest, Adv. Funct. 
Mater., 2009, 19, 3464-3470. 
26. F. M. Veronese and J. M. Harris, Adv. Drug Delivery Rev., 2008, 60, 1-2. 
27. G. Pasut, M. Morpurgo and F. M. Veronese, Imperial College Press, London, 2006, pp. 
85-110. 
28. G. Pasut, A. Mero, F. Caboi, S. Scaramuzza, L. Sollai and F. M. Veronese, 
Bioconjugate Chem., 2008, 19, 2427-2431. 
29. J. M. Harris and R. B. Chess, Nat. Rev. Drug Discov., 2003, 2, 214-221. 
30. F. M. Veronese, Biomaterials, 2001, 22, 405-417. 
31. W. H. Binder and R. Sachsenhofer, Macromol. Rapid Commun., 2007, 28, 15-54. 
32. A. J. Dirks, J. J. L. M. Cornelissen and R. J. M. Nolte, Bioconjugate Chem., 2009, 20, 
1129-1138. 
33. A. Deiters, T. A. Cropp, D. Summerer, M. Mukherji and P. G. Schultz, Bioorg. Med. 
Chem. Lett., 2004, 14, 5743-5745. 
34. E. M. Sletten and C. R. Bertozzi, Org. Lett., 2008, 10, 3097-3099. 
35. A. Elangovan, Y.-H. Wang and T.-I. Ho, Org. Lett., 2003, 5, 1841-1844. 
36. S. Schoffelen, M. H. L. Lambermon, M. B. van Eldijk and J. C. M. van Hest, 
Bioconjugate Chem., 2008, 19, 1127-1131. 
37. S. F. M. van Dongen, R. L. M. Teeuwen, M. Nallani, S. S. van Berkel, J. J. L. M. 
Cornelissen, R. J. M. Nolte and J. C. M. van Hest, Bioconjugate Chem., 2009, 20, 20-
23. 
38. L. S. Campbell-Verduyn, L. Mirfeizi, A. K. Schoonen, R. a. Dierckx, P. H. Elsinga and 
B. L. Feringa, Angew. Chem. Int. Ed., 2011, 50, 11117-11120. 
39. A. Kuzmin, A. A. Poloukhtine, M. A. Wolfert and V. V. Popik, Bioconjugate Chem., 
2010, 21, 2076-2085. 
40. J. Dommerholt, S. Schmidt, R. P. Temming, L. J. A. Hendriks, F. P. J. T. Rutjes, J. C. 
M. van Hest, D. J. Lefeber, P. Friedl and F. L. van Delft, Angew. Chem. Int. Ed., 2010, 
49, 9422-9425. 
41. J. C. Jewett, E. M. Sletten and C. R. Bertozzi, J. Am. Chem. Soc., 2010, 132, 3688-
3690. 
 
 
  
Part of this chapter will be published: 
Marjoke F. Debets, Jasper Prins, Donny W. Merkx,  
Jan C.M. van Hest and Floris P.J.T. Rutjes, in preparation 
In search for new cyclooctynes, with advantageous 
properties compared to previous cyclooctynes, a study 
towards DIBAC analogues was pursued. DIBAC, and late 
stage intermediates towards DIBAC could not be 
modified. Therefore, synthesis was performed with  
iodobenzyl alcohol analogues, which proceeded smoothly 
for all analogues up to the bromination of the double 
bond. Elimination proved to proceed more difficultly 
depending on the analogue. Chloro-, bromo-, and 
methoxy-substituted DIBACs could be synthesized in low 
yield, however in the elimination reaction with the 
nitro-, and disubstituted (Br and Cl) analogue, alkene 
was obtained instead of alkyne. Nonetheless, three 
analogues were successfully prepared showing rate 
constants in the SPAAC reaction between 0.45 and 0.9 M
-
1
s
-1
. An alternative route towards DIBAC analogues was 
successful using deprotection of a cyclopropenone. 
However, only one analogue was obtained in this manner 
displaying a rate constant of 0.62 M
-1
s
-1
. Lastly, a new 
BARAC analogue was prepared with a rate constant of 1.2 
M
-1
s
-1
.
 
 
 
   
3 
Synthesis of 
DIBAC analogues 
 76 Dibenzoazacyclooctynes: Synthesis and Bioconjugation 
 
3.1 Introduction 
Since the first application of the Strain-Promoted Azide Alkyne Cycloaddition 
(SPAAC) for biological system modification in 2004,
1
 many different cyclooctynes 
and dibenzocyclooctynes have been developed.
2, 3
 All cyclooctynes have their 
advantageous and disadvantageous properties, e.g. high water solubility but low 
reactivity,
4
 high reactivity but low selectivity,
5
 or good kinetics but low stability.
6
 
Improvement of the hydrophilicity, reactivity, stability, and functionalizability are of 
interest to increase the applicability of cyclooctynes in modification of different 
biological systems.  
Enhancement of the reactivity of cyclooctynes is likely to increase labeling 
efficiency and in vivo applicability, and reduce the concentration of reagent 
required. Enhancing hydrophilicity of cyclooctynes will enlarge water solubility, and 
reduce aspecific binding and cell permeability of the cyclooctynes.
7
 Apart from 
this, synthesis of multi-functionalizable cyclooctynes, thereby allowing for dual 
labeling or FRET studies, could be of interest. Lastly, a fluorogenic cyclooctyne 
would allow for direct visualization of conjugation products, eliminating the need to 
equip the cyclooctyne with a fluorescent dye. 
Each time a more hydrophilic, more reactive, or otherwise more favorable 
cyclooctyne is prepared, a new route is required, as the core cyclooctynes are 
hard to modify and routes are not versatile, requiring e.g. a specific starting 
material,
4, 8
 or electron-donating groups on the benzene rings.
9
 This makes 
development of new cyclooctynes and comparison of reactivity, selectivity and 
hydrophilicity extremely time consuming. 
We envisioned that the benzene rings of dibenzoazacyclooctyne (DIBAC, 1),
10
 
Chapter 2, could be modified because of the donating and directing effect of the 
amine moiety. Alternatively, the route developed towards DIBAC was envisioned 
to be highly versatile and applicable to different analogous starting materials.  
In this chapter, the synthesis of DIBAC analogues is described. First, the 
synthesis of DIBAC analogues using the route as described in Chapter 2 is 
described. Next, an alternative route is employed to prepare a DIBAC analogue. 
Lastly, attempts towards the synthesis of a fluorogenic dibenzoazacyclooctyne are 
described. 
 
3.2 Modifications based on DIBAC and intermediates 
In search for DIBAC analogues first modification of DIBAC (1) itself was 
attempted, as in this manner new dibenzoazacyclooctynes are obtained and no 
further synthesis is required after modification. However, it was also envisioned 
that the alkyne might be unstable, because of its high reactivity. Therefore, 
different modifications were also attempted at other stages of the DIBAC synthesis 
(2, 3, and 4). In all cases, the aniline moiety was expected to direct para-
modification relative to the amine. Nitration, sulfonylation, bromination, and 
Vilsmeier-Haack reactions were attempted on DIBAC and intermediates 
(compounds 1-4, Scheme 1). 
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Scheme 1. Modification of DIBAC (1) and DIBAC intermediates 2-4. 
The results of the different modifications are summarized in Table 1. For DIBAC, 
nitration, formylation, and bromination, showed multiple spots on TLC, and in 
addition, mass analysis did not show formation of the desired product. On the 
other hand, sulfonylation using chlorosulfonic acid, showed clean conversion on 
TLC, and mass analysis showed the presence of a product with the expected 
molecular weight. Strangely though, TLC did not show a high increase in polarity, 
on NMR still eight aromatic protons were observed, and the compound seemed to 
be susceptible to methanol addition. 
 
Scheme 2. Alcohol addition to β-sultone 14 
Based on 
13
C-NMR, it was concluded that a [2+2] cycloaddition had occurred 
between SO3 and DIBAC, forming sultone 14. This type of cycloaddition was 
shown to occur between alkenes and chlorosulfonic acids.
11, 12
 Also the addition of 
alcohols to the thus obtained sultones, resulting in opening of the ring (Scheme 2) 
was previously published.
13, 14
 Based on these results, we envisioned that 
cycloaddition of a strained alkyne with different sulfonic acids would be an 
interesting reaction. Unfortunately, upon addition of 3-methylbenzenesulfonic acid 
to 1, no cycloaddition did occur. Likely, substituted chlorosulfonic acids will give 
cycloaddition with 1, however, because of their instability in water they are no 
suitable candidates for our purposes. 
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Table 1. Results of different modifications for DIBAC (1) and DIBAC intermediates 2-4. 
Entry 
Start. 
Mat. 
Reaction Reagents Temp. 
Product  
(yield) 
Byproduct 
(yield) 
1 1 Nitration Cu(NO3)2·3H2O, 
Ac2O 
r.t. 5 (0%) n.d. 
2 1 Formylation POCl3, DMF 
125 ºC 
to r.t.
a 6 (0%) n.d. 
3 1 Sulfonylation ClSO3H, CH2Cl2 
-20 ºC 
to r.t. 
7 (0%) 14 (60%) 
4 1 Bromination NBS, THF 0 ºC 8 (0%) n.d.
b
 
5 2 Sulfonylation ClSO3H, CH2Cl2 
-40 ºC 
to r.t. 
9 (0%) 2 
6 3 Formylation POCl3, DMF 125 ºC 10 (0%) 3 
7 4 Nitration HNO3, AcOH 0 ºC 11 (0%) 
4 + 
unidentified 
8 4 Formylation POCl3, DMF 125 ºC 12 (0%) 15 (80%) 
9 4 Sulfonylation ClSO3H, CH2Cl2 
-40 ºC 
to r.t. 
13 (0%) 4 
a) Vilsmeier-Haack reagent was formed at 125 ºC, upon cooling 1 was added. 
b) According to low resolution mass analysis, multiple bromides were present in the obtained product 
 
Alternatively, we envisioned that modification of the benzene-ring could be 
performed on late-stage intermediates of the DIBAC synthesis (2-4). Sulfonylation 
was attempted on dibromo compound 2, yielding only starting material, also a 
Vilsmeier-Haack reaction on 3 gave no reaction. It was considered that the 
reactions did not proceed because of the reduced directing effect of the amide 
compared to an unprotected amine moiety. To that end, in spite of the unprotected 
nitrogen, reactions were also attempted on secondary amine 4. Unfortunately, also 
at this stage, for the nitration and sulfonylation mainly starting material was 
obtained. In case of the nitration reaction a new product was obtained, however, 
the structure could not be elucidated. The Vilsmeier-Haack reaction on the other 
hand, did appear to give the right product according to mass analysis, however 
again, the eight aromatic protons remained present. Apparently, formamide 15 
was formed instead of desired product 12. 
Due to the unsuccessful modification of DIBAC and its late-stage intermediates, 
focus was shifted towards the synthesis of analogues starting from modified 
starting materials. It was envisioned that by following the same route as described 
for DIBAC (Chapter 2) analogues could readily be obtained. 
 
3.3 DIBAC analogues from substituted iodobenzyl alcohols 
Synthesis of DIBAC started with a Sonogashira reaction of iodobenzyl alcohol 
and ortho-ethynylaniline. As substituted iodobenzyl alcohols or ethynylanilines are 
hardly commercially available, synthesis of iodobenzyl alcohol analogues from 
anthranilic acid analogues, was employed. Anthranilic acids, which are widely 
commercially available, can be converted into iodobenzyl alcohols by conversion 
of the amine into a diazonium salt, followed by substitution for an iodide (yielding 
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products 22-26). Subsequently, the acid can be reduced to the corresponding 
alcohol (27-31), shown in Scheme 3.  
As starting materials, chloro-, bromo- nitro- and methoxy-substituted anthranilic 
acids were chosen. 2-Chloro anthranilic acid (17) could also be brominated at the 
para-position using bromine in acetic acid. During this reaction, a mixture of two 
products was obtained which could not be separated until the formation of 
iodobenzyl alcohol 28.  
The amines of the five different anthranilic acids 17-21 were converted into the 
iodides in good yields. The acid of the crude product was directly reduced to the 
alcohol. First ethyl chloroformate was added to form the mixed anhydride which 
was then reduced to the corresponding alcohol using NaBH4. In this manner, 
iodobenzyl alcohols 27 to 31 were obtained in moderate to good yields. The 
results of these reactions are summarized in Table 2. 
The thus prepared iodobenzyl alcohols 27-31 were subsequently applied in a 
Sonogashira reaction with ethynylaniline, using identical reaction conditions as 
described for the synthesis of DIBAC (Scheme 3).
10
 All reactions proceeded 
smoothly in excellent yields (89-100%, as shown in Table 2). Notably, the 
Sonogashira reaction proved fully selective towards the iodide, and no reaction 
was observed with the chloride or bromide for compounds 27-29. 
 
Scheme 3. Synthesis of acetylenes 37-41. Reagents: (a) 1) 30% H2SO4, NaNO2, DMSO; 2) KI, 
H2O; (b) 1) ClCO2Et, NEt3, CH2Cl2; 2) NaBH4, H2O; (c) 2-ethynylaniline, PdCl2(PPh3)2, CuI, Et3N, 
THF, N2/H2-atmosphere; (d) Boc2O, THF, 70 ºC. 
Next, all obtained Sonogashira products were Boc-protected, yielding 
compounds 37-41, Scheme 3. Although this reaction proceeded smoothly for the 
synthesis of DIBAC (83%), it proved more troublesome depending on the 
substitution pattern of the analogues. From the results, as shown in Table 2, can 
be concluded that with highly electron-withdrawing groups on the benzene ring, 
Boc-protection proceeded more troublesome (entries 2 and 4). Fortunately, in all 
cases, only mono-Boc-protected compounds 37-41 and starting material were 
obtained, which could be adequately separated. 
With the Boc-protected alkynes in hand, we set out to partially reduce the 
alkyne, Scheme 4. Again, substituents on the benzene rings tended to influence 
the reduction. While 2 mol% of Pd on BaSO4 with 0.1 equivalent of quinoline solely 
yielded the alkene for chloro- and bromo-substituted compounds 37-39, reduction 
under these conditions of the methoxy- and nitro-substituted alkynes (40 and 41) 
gave a significant amount of alkane. Apparently, mesomeric electron-withdrawing 
and electron-donating groups highly influence the rate of reduction 
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Table 2. Results of the synthesis of Boc-protected intermediates 37-41. 
Entry 
Starting 
Material 
R
1
 R
2
 Step 1
a 
Step 2 Step 3 Product 
1 17 Cl H 22 (85%) 27 (88%) 32 (95%) 37 (81%) 
2 18 (82%)
b
 Cl Br 23 (124%)
 
28 (37%) 33 (94%) 38 (57%
c
) 
3 19 H Br 24 (95%) 29 (57%) 34 (100%) 39 (88%) 
4 20 H NO2 25 (120%) 30 (46%) 35 (89%) 40 (51%
c
) 
5 21 OMe H 26 (85%) 31 (63%) 36 (91%) 41 (80%) 
a)  crude yields are given. 
b)  18 was prepared from 17 using Br2 in AcOH, resulting in a mixture of two products, which could be 
separated at the iodobenzyl alcohol stage. 
c)  For 38, 87% b.r.s.m., for 40, 91% b.r.s.m. 
 
.  
 
Scheme 4. Partial reduction of alkynes 37-41 to alkenes 42-46. Reagents and conditions: (a) 10% 
Pd/BaSO4, quinoline, H2-gas, MeOH. 
For 40 and 41 it was required to increase catalyst poisoning by the addition of 
more quinoline, thereby reducing the rate of reduction. Nitro-compound 40 needed 
to be reduced in the presence of 0.5 equivalent quinoline to obtain clean 
conversion to the alkene; methoxy-compound 41 required 5 equivalents to obtain 
the alkene in good yield (Table 3). 
 
Table 3. Partial reduction of alkynes 37-41. 
Entry Starting Material R
1
 R
2
 Equiv. Quinoline Product 
1 37 Cl H 0.1 42 (97%) 
2 38 Cl Br 0.1 43 (100%) 
3 39 H Br 0.1 44 (90%) 
4 40 H NO2 0.5 45 (78%) 
5 41 OMe H 5 46 (90%) 
 
 
Scheme 5. Synthesis of dibenzodihydroazocines 52-56. Reagents: (a) Dess-Martin periodinane, 
NaHCO3, CH2Cl2; (b) 1) 2 M HCl in EtOAc; 2) NaBH4, H2O.  
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Next, compounds 42-46 were oxidized to the corresponding aldehydes, and 
subsequently ring-closing reductive amination yielded dibenzodihydroazocines 52-
56, Scheme 5.  
In general, the Dess-Martin oxidation proceeded smoothly for all analogues in 
good to excellent yields. Aldehyde 50 gave some isomerization of the double bond 
based on 
1
H-NMR. Probably, the electron-withdrawing nitro- and aldehyde-groups 
reduce the double bond character of the olefin, thereby inducing isomerization. 
Even so, the reductive amination of 50 yielded full conversion to compound 55. 
Also for compounds 47, 49, and 51 the reductive amination proceeded smoothly 
and in high yields. Reductive amination with aldehyde 48 proceeded more 
troublesome in only 50%. In this last case, it was the reduction of the imine that 
went more sluggishly and gave rise to side-product formation. 
 
Table 4. Results of Dess-Martin oxidation and ring-closing reductive amination. 
Entry Starting Material R
1
 R
2
 Intermediate Product 
Yield over 
7 steps 
1 42 Cl H 47 (94%) 52 (95%) 50% 
2 43 Cl Br 48 (88%) 53 (50%) 9%
a 
3 44 H Br 49 (86%) 54 (91%) 28% 
4 45 H NO2 50 (86%) 55 (100%) 17% 
5 46 OMe H 51 (78%) 56 (87%) 24% 
a) Yield over 8 steps. 
 
The overall yields towards dibenzodihydroazocine analogues 52-56 are 
summarized in Table 4. Although yields were significantly lower than for the 
synthesis of non-substituted dibenzodihydroazocine 4, the analogues were still 
obtained in moderate to good yield.  
Next steps in the synthesis of DIBAC analogues were introduction of the 
functionalizable linker and bromination of the double bond, as shown in Scheme 6. 
Linker attachment proceeded in good yields for 53, 54, and 56, Table 5. The low 
yielding formation of compound 57 was probably caused by impurities present in 
starting material 52. Linker attachment to compound 55 was troublesome and side 
products were formed, causing a relatively low yield. 
 
Scheme 6. Introduction of functionalizable linker (57-61) and bromination of the double bond (62-
66). Reagents: (a) ClCO2C3H6CO2Me, NEt3, CH2Cl2; (b) Br2, CH2Cl2. 
Bromination of compounds 57-61 proceeded readily and in good yields. Only 
bromination of methoxy-functionalized 61 resulted in sideproduct formation. 
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Apparently, the methoxy-group directs bromination of the benzene-ring, resulting 
not only in dibrominated desired compound 66, but also in the mono-, and tri-
brominated products.  
 
Table 5. Overview of synthesis of dibromo-compounds 65-69. 
Entry 
Starting  
material 
R
1
 R
2
 Intermediate Product 
Ratio of diastereo-
isomers (X (*) : Y (
O)
) 
1 52 Cl H 57 (46%) 62 (71%) 1:0.8 
2 53 Cl Br 58 (82%) 63 (96%) 0.32:1 
3 54 H Br 59 (90%) 64 (80%) 1:0.47 
4 55 H NO2 60 (37%) 65 (84%) 0.42:1 
5 56 OMe H 61 (76%) 66 (39%) 1:0.2 
 
3.4 Bromination yields anti- and syn-isomers 
The bromination reaction always yielded two diastereoisomers (X and Y), which 
could be separated by column chromatography and showed different shifts in 
NMR. This implied that not only the expected anti-isomers are formed, but also the 
syn-isomers. Notably, the ratio between the two isomers changed depending on 
the substituents on the benzene ring. The ratio of the two isomers could be 
determined by comparing the signal originating from one of the two benzylic 
protons (assigned with either * or 
o
, Figure 1). The ratio between both isomers for 
compound 2 (without any substituents) was 1:0.18. Electron-withdrawing groups 
on the benzene ring changed this ratio in favor of the minor isomer. Especially, for 
bromochloro-compound 63 and nitro-compound 65 isomer Y was obtained as the 
major isomer (Table 5, entries 2 and 4, and Figure 1). 
 
Figure 1. Diastereoisomers of dibromides 2 and 62-66. Not all spectra are representative for the 
ratio of obtained stereoisomers. 
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These surprising observations, which were not observed for other cyclooctyne 
syntheses involving bromination followed by elimination,
8, 15
 led us to assign the 
different isomers. In this investigation, we focused on the differences in NMR. The 
most notable dissimilarity is the difference in chemical shift of one of the benzylic 
protons (H
2
, * vs 
o
, Figure 1). This is probably caused by the shielding of H
2
 by 
one of the bromides. In addition, the coupling constants for H
3
 and H
4
 are different 
for the syn- and anti-isomers (J = 10 Hz (for X) vs. J = 9.4 Hz (for Y)), indicative of 
a difference in dihedral angle between the two protons.  
 
Figure 2. All diastereoisomers obtained during alkene bromination.  
To determine the distance between the bromides and H
2
 and the dihedral angle 
between H
3
 and H
4
, the anti- and syn-compounds were modeled using 
ChemBio3D with MOPAC interface. The results of these calculations are shown in 
Figure 3, which shows the two possible conformers of B and D (Figure 2). In all 
models, H
2
 and one bromide are highlighted in green. In both anti conformers, one 
bromide is close to H
2
 (2.8 Å), while in the possible syn conformers, equal in 
energy (-90 kCal/mol), a distance between the closest bromide and H
2
 of either 
4.4 Å or 2.8 Å exists. On average, the distance between bromide and H
2
 is smaller 
for the anti-isomer, suggesting that for this isomer H
2
 is more shielded, and hence 
shows a smaller chemical shift. This finding is indicative for X being the anti-
isomer. 
On the other hand, the dihedral angle between H
3
 and H
4
 for the syn-isomers 
(highlighted in yellow in Figure 3) is 113.2º, for the anti-isomers either 19º or 150º. 
As, according to the Karplus curve, coupling constants become larger the more 
the dihedral angle deviates from 90º, the anti-isomer is supposed to show a larger 
coupling constant. This again is indicative for X being the anti-isomer. 
 
Figure 3. Results of MOPAC energy minimization for compound 2 (isomers D and B). 
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The dihedral angle and the distance between H
2
 and bromide, both indicate that 
isomer X is the anti-isomer, and isomer Y is the syn-isomer. In addition to the 
calculated values, Y slowly isomerized to X in solution, which also indicated that X 
is the anti-isomer, as this is supposedly the thermodynamically most stable 
isomer. In conclusion, the anti-isomer is the main product for dibromides 2, 62, 64, 
and 66, while the syn-isomer is the main product for dibromides 63 and 65. 
The mechanism for the formation of the unexpected syn-isomer is likely to be 
caused by neighboring group participation.
16
 Scheme 7 depicts the possible 
resonance structures of bromonium ion I which are both stabilized by the benzene 
rings. However, with electron-withdrawing groups on one of the rings, a (partial) 
positive charge (II) is significantly destabilized, compared to III. Possibly, when 
structure III is favored, neighboring group attack is more likely compared to 
bromide attack, forming the structure (IV) as shown in Scheme 7. Attack of the 
bromide-anion on this intermediate structure would then lead to the syn-isomer 
(V). 
 
Scheme 7. Resonance structures of bromonium ion I and tentative mechanism for formation of the 
syn-isomer (V). 
 
3.5 Double bromide elimination 
The last step towards DIBAC analogues involved elimination of the two 
bromides. Base screen and optimization for DIBAC (1) showed that elimination 
proceeded smoothly using slightly more than two equivalents of commercially 
available 1M KO
t
Bu solution in THF. However, when this procedure was applied to 
compound 62, a mixture of desired alkyne 67 and alkene 57 (Scheme 8) was 
obtained.  
To investigate whether the elimination would proceed differently for the two 
stereoisomers of 62, elimination was performed with the anti-stereoisomers and 
compared to the outcome of the elimination of a 1:1 mixture (syn:anti). Upon 
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reaction with KO
t
Bu, the anti-isomer was successfully converted into alkyne 67 
with only 5% contamination of alkene 57 (yield 37%), whereas for the 1:1 mixture 
alkyne 67 was obtained with a 20% contamination of alkene 57. The latter 
indicated that the syn-isomer had yielded 24% of alkene and 76% of alkyne.  
As compounds 64 and 66 were also obtained with the anti-isomer as major 
isomer, elimination was also performed on the pure anti-isomers, yielding 69 and 
71 in moderate yields, with no to slight alkene contamination (4 and 0%, 
respectively).  
The elimination reaction of analogues 63 and 65 was performed on the mixture 
of diastereoisomers. Unfortunately, this resulted mainly in alkene formation, while 
no alkyne formation was observed, Table 6. In both cases, this surprising product 
was confirmed by mass analysis and 
1
H-NMR spectroscopy.  
 
Scheme 8. Elimination of bromides from 62-66, yielding alkynes 67-71 and/or side-products. 
Reagents: (a) 1M KO
t
Bu in THF, THF. 
Figure 4 shows the spectra of compounds 58, 63, and the elimination mixture. 
The peaks specific for the alkene are marked with *, peaks specific for the 
dibromide are marked with 
o
. In the spectrum of 63, no peaks corresponding to the 
alkene are present, while in the spectrum of the elimination mixture peaks specific 
for the alkene have reappeared. On the other hand, peaks specific for 63 have 
disappeared. 
 
Figure 4. Spectra of alkene 58, dibromide 63 and the elimination mixture. Peaks specific for 
alkene 58 are marked with *, peaks specific for dibromide 63 with 
o
. 
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Table 6. Products obtained from elimination reactions of compounds 62-66. 
Entry Starting material R
1
 R
2
 Product Side-product 
1 62 Cl H 67 (35%) 57 (2%) 
2 63 Cl Br 58 73 
3 64 H Br 69 (35%) 59 (2%) 
4 65 H NO2 60 - 
5 66 OMe H 71 (34%) - 
 
In literature, the removal of vicinal halogen atoms, forming the alkene has been 
observed for dihalides of stilbenes.
17
 In addition, when the acetylene is extremely 
hard to form by dibromide elimination, also alkene formation has been observed.
18, 
19
 In addition, a potential mechanism for alkyne formation using alkoxy-based 
bases was proposed by Ramazan and Osman in 2004.
20
 Translation of this 
mechanism to compound 65 is shown in Scheme 9. Although it seems unlikely that 
tert-butanol is eliminated in the final step instead of hydrogen bromide, removal of 
the proton at the tert-butoxide side is sterically disfavored. 
 
Scheme 9. Proposed mechanism for alkene formation. 
In conclusion, Cl-DIBAC (67), Br-DIBAC (69), and MeO-DIBAC (71) were 
obtained in moderate yields (6, 7, and 2.5%, respectively) over 10 steps, with no 
or only little contamination of the corresponding alkene. For the preparation of 
Br,Cl-DIBAC (68) and NO2-DIBAC (70) further optimization, by varying base, 
equivalents, temperature, and reaction time, is required. 
 
3.6 Base screen towards formation of 68 and 70 
The alkene formation after treatment of 63 and 65 with KO
t
Bu led us to 
investigate other bases to obtain alkyne instead of alkene. To this end, a base 
screen towards the elimination of the bromides of 63 was performed. Bases that 
were previously shown to be unsuccessful in elimination were LDA, aqueous 
NaOH (6M and 12M) and 
n
BuLi, see Chapter 2. The bases which were used in the 
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elimination reaction with 63 and the corresponding obtained products are 
summarized in Table 7.  
Based on the mechanism as proposed in literature, the use of different types of 
bases was pursued. Hydride bases, i.e. NaH and KH, Table 7 entries 2 and 3, 
were used as it was envisioned that the formation of hydrogen gas could drive the 
elimination to completion. However, both bases proved not strong enough, and 
only single eliminated product 73 was obtained. On the other hand, it was thought 
that non-ionic bases would not be able to give addition to the double bond as is 
the case for KO
t
Bu. DBU was not strong enough to eliminate the second bromide. 
As alternative, Verkade’s base, Table 7, entry 6, was considered. This is a really 
strong and effective base with a pKa of 32, and has been applied in many different 
reactions.
21
 Surprisingly, this was one of the most efficient bases to reform alkene 
58. In the end, NaHMDS was also used resulting in a mixture of alkene and 
alkyne. As this base was the first that gave a detectable amount of alkyne, further 
optimization of the conditions was pursued. 
 
Table 7. Bases for attempted bromide elimination and obtained products. 
Entry Base Equivalents Temperature Product 
1 KO
t
Bu 2 -40 ºC 58 + 73 
2 NaH 5 r.t. to 70 ºC 73 
3 KH 10 0 ºC to r.t. 73 
4 NaHMDS 2 -78 ºC 68 + 58 
5 DBU 10 r.t. 73 
6 
 
2.2 r.t. 58 
 
Dibromide 63 was treated with two or ten equivalents of NaHMDS and at 
different temperatures (-78, 0, 20 and 70 ºC). Unfortunately, the increase in 
equivalents of base and the increase in temperature resulted in less formation of 
desired alkyne 68, and therefore no significant conversion to desired product 68 
could be obtained with NaHMDS.  
Based on this base screen it was concluded that also non alkoxy-based bases 
give rise to alkene formation, which could indicate a different mechanism. Possible 
mechanisms are shown in Scheme 10. If formation occurs via mechanism A, 
formation of the alkene could be prevented by performing a stepwise elimination. 
First one bromide is selectively eliminated, then, upon addition of additional base, 
the second bromide is eliminated. To this end, 63 was first treated with one 
equivalent of KO
t
Bu, and upon formation of bromo-alkene 73, an excess of KO
t
Bu 
was added. However, this also resulted in alkene formation. Alternatively 
(mechanism B shown in Scheme 10), 73 is formed and subsequently the base 
picks up Br
+
. The vinylic anion could either pick up Br
+
, reforming 73, or H
+
, 
forming alkene 58. To investigate this mechanism, elimination towards 73 was 
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carried out using NaH. Subsequently, standard work-up was performed, and 73 
was subjected to elimination with KO
t
Bu, yielding a mixture of alkene 58 and 
alkyne 68. The formation of little alkyne could indicate that the reaction occurs via 
mechanism B, however the mechanism remains unclear. Overall, it can be 
concluded that formation of alkyne 68 is possible, but always as a mixture 
containing predominantly alkene 58. 
 
Scheme 10. Possible mechanistic explanations for formation of alkene 58. 
Elimination of the dibromide precursor of nitro-substituted 65 was not extensively 
optimized and yielded mainly alkene 60 upon treatment with KO
tBu or Verkade’s 
base. 
 
3.7 DIBAC analogue synthesis via cyclopropenone 
deprotection 
The results described above clearly demonstrate that alkyne formation is in 
general the most troublesome step in cyclooctyne formation. Apart from that, the 
route became rather long and low yielding. To prepare additional DIBAC 
analogues an alternative, shorter, strategy for alkyne formation was envisioned. 
Popik et al. already described a method to prepare dibenzocyclooctynes via the 
formation of a cyclopropenone ring, followed by UV irradiation.
9
 Disadvantage of 
this route is that electron-donating groups are required on the benzene rings to 
direct the Friedel-Craft alkylations. However, we envisioned that the methoxides 
could be transformed into e.g. alcohols, acetates, triflates, sulfates, or phosphates 
after formation of the cyclopropenone. 
It was shown by Pietzsch et al. that this method could be used to prepare 
DIBAC-analogue 77, Scheme 11.
22
 Disadvantage of this system is that with a rate 
constant of 0.8 × 10
-2
 M
-1
s
-1
 kinetics are almost a 100-fold lower than for DIBAC 
(1) itself. Probably, the low reactivity is mainly caused by the methoxy-group at the 
ortho-position relative to the alkyne, as these ortho-substitutions have been shown 
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to significantly decrease reactivity for other systems as well.
23
 In order to increase 
reactivity and to simplify modifications of the methoxy-groups, we aimed for 
synthesis of compound 78.  
 
Scheme 11. DIBAC analogue 77 as synthesized by Pietzsch et al. and synthetic target 78. 
Synthesis of 78 commenced with synthesizing the starting material for the 
Friedel-Crafts alkylation, 80, Scheme 12. First, a reductive amination was 
performed with 3-methoxyaniline and 3-methoxybenzaldehyde, yielding 79 in 98% 
yield. Next, a functionalizable linker was attached, giving rise to compound 80 in 
54% yield.  
 
Scheme 12: Synthesis of the starting material for the Friedel-Crafts alkylation (79). Reagents and 
conditions: (a) 1) dry MeOH, r.t., 1.5 h; 2) NaBH4, r.t., 30 min (98%); (b) ClCO2C3H6CO2Me, NEt3, 
CH2Cl2, 0 ºC, 1.5 h (54%); (c) 1) AlCl3, perchlorocycloprop-1-ene, CH2Cl2, -78 ºC to r.t., o.n.; 2) 1M 
HCl, r.t., 5 min; (30%) (d) MeCN, UV-light, r.t. 65 min (35%). 
Compound 80 was then subjected to a Friedel-Crafts alkylation (Scheme 12), 
yielding 81 in a moderate yield of 30%. The lower yield is mainly caused by the 
formation of side-products due to the lack of regioselectivity of the Friedel-Crafts 
alkylation.  
Ultimately, cyclopropenone 81 had to be irradiated with UV-light to form alkyne 
78, as depicted in Scheme 12. Irradiation was performed for 65 minutes using a 
Bluespot 2 Easycure whereupon cyclooctyne 78 was obtained in a moderate yield 
of 35%. Probably, a large part of the product was lost during column 
chromatography, as full conversion was observed on 
1
H-NMR. In literature 
precedents for this procedure, alkyne formation and cycloaddition are often 
performed in one pot.
9
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Having successfully synthesized dibenzoazacyclooctyne 78, we set out to 
deprotect the methoxy-groups. Upon treatment of 81 with BBr3, the main reaction 
was formation of the acid out of the ester. Furthermore, little methoxy deprotection 
was observed, however, in extremely low yield. Also with a different group 
(acryloyl) on the nitrogen, the demethylation did not give the desired result. Lastly, 
demethylation prior to formation of the cyclopropenone also failed. 
  
3.8 Towards a fluorogenic dibenzoazacyclooctyne 
The preparation of a cyclooctyne which turns fluorescent upon reaction with an 
azide could be of high impact. First of all, the problem of aspecific labeling is 
addressed since the cyclooctyne only turns fluorescent upon triazole formation; 
secondly, there is no need to functionalize the cyclooctyne with a fluorophore. The 
latter can also circumvent the synthetic challenges that are sometimes 
encountered when a functionalizable part has to be introduced. 
Due to the aromatic character of dibenzocyclooctynes, formation of a fluorogenic 
cyclooctyne is more likely to occur with one of these than with cyclooctynes. 
Especially since after formation of the triazole, a highly conjugated system is 
formed. Recently, a coumarin analogue, CoumBARAC, and a cyclopropenone-
containing analogue (see Chapter 1) were synthesized which turned fluorescent 
upon reaction with an azide.
24, 25
 However, these molecules showed fluorescence 
at a relatively low wavelength, rendering them less suitable for labeling in 
biological systems. 
It was previously reported that the preparation of a conjugated push-pull system 
leads to dyes emitting at higher wavelengths,
26-28
 we envisioned that creating a 
dibenzoazacyclooctyne containing an electron-withdrawing group on one site, and 
an electron-donating group on the other, might yield a fluorogenic cyclooctyne 
emitting at wavelengths more preferable for biological research. To this end, we 
designed BARAC analogue 82 depicted in Scheme 13. BARAC
29
 was chosen 
since it was shown that analogue synthesis could be achieved more easily,
23, 24
 
than for DIBAC analogues. 
 
Scheme 13. Retrosynthetic analysis  of Push-Pull BARAC analogue. 
Synthesis of 82 was envisioned to proceed similar to BARAC and analogues. 
Retrosynthetically (Scheme 13), the alkyne (82) can be formed via TMS-enol 
triflate elimination, commonly used in benzyne synthesis.
30
 The precursor for this 
elimination is TMS-ketone 83, which can be formed from 84 via protection of the 
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amine, silylation and ring-opening using mCPBA. Compound 84 can be prepared 
using a Fisher-indole synthesis starting from indanone 85 and hydrazine 86.   
In the forward synthesis, Fisher-indole formation from 85 and 86 yielded 84 in a 
yield of 21%. Subsequent methylation of the amine gave compound 87. 
Unfortunately, the introduction of TMS failed using different bases and 
temperatures. 
 
Scheme 14. Synthesis of indole 84, followed by methylation and attempted TMS-introduction. 
Reagents and conditions: (a) 1) EtOH, AcOH, 85 °C, 1.5 h; 2) iPrOH, H2SO4, 95 °C, 10 min, 21%; 
(b) iodomethane, NaOH, TBAI, toluene, r.t., 42 h, 33%; (c) TMSCl, different bases, 0 ºC to r.t. 
As the TMS-group is crucial for the synthesis of the alkyne in the end of the 
synthesis, a different strategy needed to be developed. It had previously been 
shown by Buchwald et al. that a chloride can be transformed into a nitro-group 
using a Pd-catalyzed reaction.
31
 Therefore, it was envisioned that BARAC 
analogue 93, Scheme 15, could be prepared, whereupon the nitro-group would be 
introduced after alkyne-formation or in late stage intermediates. 
 
Scheme 15. Synthesis of BARAC analogue 93. Reagents and conditions: (a) 1) EtOH, AcOH, 85 
°C, 15 min; 2) iPrOH, H2SO4, 95 °C, 18 h; (b) MeI, NaOH, TBAI, toluene, r.t., 2 h, 44% over two 
steps; (c) TMSCl, n-BuLi, Et2O, -78 °C to r.t., 20 min, 95% (d) mCPBA, NaHCO3, CH2Cl2, 0 °C to 
r.t., 2 h; (e) Tf2O, KHMDS, THF, -78 °C, 1 h; (f) TBAF, Et2O, r.t., 40 min, 20% over three steps. 
Formation of the indole (90) was directly followed by methylation, as during the 
Fisher-indole synthesis a mixture of two regioisomers was obtained. After 
introduction of the methyl-group, both isomers could be separated. Fortunately, 
continuing with the desired isomer 91, the TMS-group could be introduced in an 
excellent yield. The next steps in the synthesis were opening of the indole using 
mCPBA, formation of the triflate-protected enol ether, and elimination to the 
alkyne. Only when these last three steps were performed without intermediate 
purification, compound 93 was successfully obtained in 20% yield. Overall, 
BARAC 93 was prepared in 8% yield over six steps. 
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At this point, the chloride of compound 93 could be used in a Pd-catalyzed 
reaction to introduce the desired nitro-group and form 82, Scheme 16. 
Unfortunately, when the reaction was performed with 93 no anticipated product 
was obtained, and the starting material had decomposed. When compound 93 
was heated without reagents to the required 130 ºC, the same product was 
obtained. Probably the high temperature induced intermolecular [2+2]-
cycloaddition, as previously reported for a highly activated cyclooctyne,
6
 however, 
this was not further investigated. Alternatively, the nitro-introduction was 
attempted on intermediate 92 and on compound 94, containing a TBS-group 
instead of a TMS-group, shown in Scheme 16. However, both reactions did not 
give the desired product.  
Since the envisioned fluorogenic BARAC (82) could not be prepared directly, 
and also introduction of the nitro-group during the synthesis or after alkyne 
formation, had failed, this synthesis was not further pursued. Nonetheless, a novel 
BARAC was prepared and the effect of the substituents on the kinetics of BARAC 
were investigated.  
 
Scheme 16. Attempts to introduction of a nitro-group. Reagents and conditions: (a)
t
BuBrettPhos, 
Pd2(dba)3, tris(3,6-dioxaheptyl)amine, NaNO2, tBuOH, 130 °C, 24 h. 
 
3.9 Kinetics of synthesized dibenzoazacyclooctyne analogues 
In spite of the troublesome syntheses of dibenzoazacyclooctyne analogues, 
several new dibenzoazacyclooctynes were obtained as shown in Scheme 17. 
These cyclooctynes were all used for kinetic studies, using benzyl azide.  
Kinetic studies were performed as previously described in Chapter 2. For each 
experiment, stock solutions of the dibenzoazacyclooctyne and benzyl azide were 
used. Subsequently, the desired volumes of both solutions were mixed and NMR-
spectra were taken at preset time intervals. To increase the comparability of the 
kinetics for 67, 69, 71, and 78 for all experiments the same stock solution of 
benzyl azide was used. In addition, kinetic experiments using this benzyl azide 
stock solution were also performed with 1. All logarithmic plots obtained as 
described in Chapter 2, are shown in Figure 5.  
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Scheme 17. Newly synthesized dibenzoazacyclooctynes. 
 
Figure 5. Logarithmic plots of (A) DIBAC (1); (B) Cl-DIBAC (67), (C) Br-DIBAC (69); (D) MeO-
DIBAC (71); (E) (MeO)2-DIBAC (78) in reaction with benzylazide in CD3OD.     
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The slope of each graph is the rate constant for the 1,3-dipolar cycloaddition. 
These data are summarized in Figure 6 and Table 8. This figure shows that all 
substitutions do increase the rate constant compared to non-substituted DIBAC 
(1), which is in line with the observations for BARAC analogues.
23
 The electron-
withdrawing halogens (67 and 69), have, as expected, the highest effect on the 
rate of the cycloaddition. On the other hand, MeO-DIBAC (71) shows a rate 
constant comparable to DIBAC (1), while (MeO)2-DIBAC (78) again reacts 
significantly faster than DIBAC (1).  
The MeO-substituted DIBAC analogues give a first indication that meta-
substitution, compared to the alkyne, has less effect on the rate constant than 
para-substitution. Taking that into account, it also seems that Cl has a larger effect 
on the rate constant than Br. As chloride is more electron-withdrawing than 
bromide, this is also in line with the expectations. 
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Figure 6. Overview of rate constants for DIBAC-analogues using benzylazide in CD3OD. 
Table 8. Rate constants of DIBAC and analogues in reaction with benzylazide in CD3OD. 
Entry 
Rate constant 
(M
-1
s
-1
) 
DIBAC (1) 0.4 ± 0.1 
Cl-DIBAC (67) 0.9 ± 0.1 
Br-DIBAC (69) 0.80 ± 0.05 
MeO-DIBAC (71) 0.45 ± 0.06 
(MeO)2-DIBAC (78) 0.62 ± 0.05 
 
To investigate the effect of an electron-withdrawing group on one side, and an 
electron-donating group on the other side on the kinetics, we determined the rate 
constant of compound 93 with benzyl azide in a similar manner as described 
previously (Figure 7). The rate constant was determined to be 1.2 M
-1
s
-1
, which is 
an increase of 0.3 M
-1
s
-1
 compared to non-substituted BARAC, and an 0.1 M
-1
s
-1
 
increase compared to methoxy-substituted BARAC.
23
 Surprisingly, the chloride-
substituent on BARAC had less influence on the kinetics than was observed for Cl-
DIBAC (67). 
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Figure 7. Logarithmic plots of Cl,OMe-BARAC (93) in reaction with benzylazide in CD3OD. 
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3.10 Conclusions and outlook 
Modification of DIBAC (1), introducing an aldehyde, bromide, nitro-group, or 
sulfonic acid was not successful. Also modifications on late stage intermediates 
towards 1 (2, 3 or 4) were not fruitful, yielding mainly starting material. In 
retrospect, if these modifications had been successful, probably elimination of the 
bromides would have turned out to be troublesome for most analogues. 
As modification of DIBAC had failed, synthesis of DIBAC analogues was 
attempted using different iodobenzyl alcohol analogues as starting material. 
Iodobenzyl alcohols were prepared with chloro (27, 28), bromo (28, 29), nitro (30), 
and methoxy (31) substituents from the corresponding anthranilic acids 17-21. 
Subsequently, all these iodobenzyl alcohols were used in a Sonogashira reaction 
with ethynylaniline. The thus obtained alkynes 32-36 were then subjected to Boc-
protection, partial hydrogenation, Dess-Martin oxidation, and ring-closing reductive 
amination. This sequence yielded dibenzodihydroazocine analogues 52-56 in 
moderate yield.  
The dibenzodihydroazocines were equipped with a functionalizable linker, and 
the double bond was brominated. Until now, all synthetic steps had proceeded 
relatively smoothly, and analogous to synthesis of DIBAC. Notably, depending on 
the substitution pattern on the benzene-ring, not only the expected anti-isomer 
was obtained, but also the syn-isomer. To our surprise, elimination of the 
bromides did not yield the alkyne for all analogues. Compound 71 could be 
obtained in pure form, whereas compound 67 and 69 were obtained with a slight 
contamination of the corresponding alkene (57 and 59, respectively). On the other 
hand, elimination on 68 and 70 yielded only the corresponding alkene (58 and 60). 
Unfortunately, extensive optimization and base screen did not improve the results 
for 68 and 70. Cl-DIBAC (67), Br-DIBAC (69) and MeO-DIBAC (71) were obtained 
relatively pure, in a moderate yields of 6, 7, and 2.5%, respectively, over 10 steps. 
Rate constants of the 1,3-dipolar cycloaddition were determined for all three 
DIBACs (67, 69, and 71), and showed rate constants of 0.9, 0.8, and 0.45 M
-1
s
-1
, 
respectively, compared to DIBAC 1 (0.4 M
-1
s
-1
). 
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To avoid the troublesome bromide elimination, a different route towards DIBAC 
analogues was envisioned, forming the alkyne by UV-irradiation of its 
cyclopropenone analogue, which was published previously.
9
 In this manner, 
cyclooctyne 78 was prepared. However, removal of the methoxy-groups was 
unsuccessful. The rate constant of the reaction of cyclooctyne 78 with benzyl 
azide was shown to be 0.62 M
-1
s
-1
. 
Finally, we wanted to investigate whether forming a push-pull system would 
create a fluorogenic cyclooctyne and would influence reaction rate. Due to the 
troublesome synthesis of DIBAC analogues, we switched to BARAC.
29
 Our first 
aim, to directly synthesize nitro- and methoxy-substituted BARAC (82) failed. On 
the other hand, chloro- and methoxy-substituted BARAC (93) was successfully 
synthesized in a yield of 8% over 6 steps, and showed a rate constant 1.2 M
-1
s
-1
. 
Conversion of the chloride into a nitro-group, failed at different stages of the 
synthesis. 
Overall, five new dibenzoazacyclooctynes were prepared with rate constants 
varying between 0.45 and 1.2 M
-1
s
-1
.  
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3.12 Experimental Section 
3.12.1 General experimental 
See Section 2.7 
 
3.12.2 Synthesis 
methyl 5-(1,1-dioxidodibenzo [b,f] [1,2] oxathieto [4,3-d] azocin-7(8H)-yl) -5-
oxopentanoate (14) 
DIBAC 1 (20 mg, 0.06 mmol) was dissolved in CH2Cl2 (2 mL) and 
the reaction was cooled to -20 ºC. Chlorosulfonic acid (16 µl, 0.24 
mmol) was added and the mixture was slowly warmed to 0 ºC. 
After 1 hour the reaction was quenched with H2O (5 mL), and 
extracted with CH2Cl2 (3 × 10 mL). The organic layers were 
combined and washed with H2O (10 mL) and brine (10 mL) and 
subsequently dried over MgSO4. The solvents were evaporated 
under reduced pressure and the crude product was purified by 
column chromatography (EtOAc/n-heptane, 1:2) to obtain 14 as 
brownish solid (15 mg, 60%). RF = 0.3 (EtOAc/n-heptane, 1:2). 
1
H-NMR (400 MHz, CDCl3) 
δ: 7.85 (d, J = 7.9 Hz, 1H), 7.78 (d, J = 7.6 Hz, 1H), 7.67 (dd, J = 7.3, 1.8 Hz, 1H), 7.62 (t, 
J = 7.5 Hz, 1H), 7.54-7.38 (m, 3H), 7.31 (dd, J = 7.7, 1.3 Hz, 1H), 5.22 (d, J = 14.4 Hz, 
1H), 3.84 (d, J = 14.4 Hz, 1H), 3.56 (s, 3H), 2.56-2.31 (m, 1H), 2.14 (dt, J = 14.2, 3.9 Hz, 
1H), 2.07-1.94 (m, 2H), 1.85-1.68 (m, 2H). 
13
C-NMR (75 MHz, CDCl3) δ: 173.2, 172.2, 
151.5, 141.8, 139.5, 132.9 (2C), 129.6, 129.0, 128.5 (2C), 128.3, 127.7, 124.3, 123.1, 
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122.9, 55.0, 51.5, 33.6, 32.6, 20.5. . FT-IR νmax (cm
-1
): 2937, 1740, 1671, 1343, 1200, 
1152, 1009, 776, 633. HRMS (ESI+) m/z calcd for C21H20NO6S [M+H]
+
 414.1011, found 
414.1018. 
 
(Z)-dibenzo[b,f]azocine-5(6H)-carbaldehyde (15)  
Compound 4 (19 mg, 0.09 mmol) was dissolved in DMF (2 mL) and 
placed under an Ar-atmosphere in a flame-dried flask. Subsequently, 
POCl3 (17 µl, 0.18 mmol) was added. The reaction mixture was 
heated to 125 ºC and after 6 hours, H2O (2 mL) was added. The 
mixture was refluxed overnight and upon cooling neutralized with 2M 
aqueous NaOH. The H2O-layer was extracted with EtOAc (3 × 10 mL) and the combined 
organic layers were washed with H2O (2 × 10 mL), and brine (10 mL) and dried over 
MgSO4. The solvents were removed under reduced pressure and the crude product was 
purified by column chromatography (EtOAc/n-heptane, 1:4) to obtain 15 (17 mg, 79%). RF 
= 0.25 (EtOAc/n-heptane, 1:4). 
1
H-NMR (400 MHz, CDCl3) δ: 8.31 (s, 1H), 7.46 (dd, J = 
7.2, 1.7 Hz, 1H), 7.26-7.22 (m, 5H), 7.10-6.98 (m, 1H), 6.80 (d, J = 13.3 Hz, 1H), 6.66 (d, 
J = 13.2 Hz, 1H). 
13
C-NMR (75 MHz, CDCl3) δ: 162.7, 139.5, 137.6, 134.1, 133.4, 132.8, 
131.7, 131.3, 130.8, 129.3, 128.3, 127.8, 127.4, 127.2, 126.4, 51.7. FT-IR νmax (cm
-1
): 
3071, 2885, 1662, 1476, 1346, 1299, 1238, 806, 746. HRMS (ESI+) m/z calcd for 
C16H14NO [M+H]
+
 236.1075, found 236.1065. 
 
2-amino-4-bromo-5-chlorobenzoic acid (18) 
2-amino-4-chlorobenzoic acid (1.1 g, 6.4 mmol) was dissolved in acetic 
acid (8 mL) and Br2 (0.33 mL, 6.4 mmol) was added. The mixture was 
stirred at room temperature for 4 hours and subsequently poured into 
saturated aqueous NaHSO3 (50 mL). The H2O-layer was extracted with 
EtOAc (2 × 50 mL), and the combined organic layers were washed with 
water (2 × 50 mL), brine (50 mL), and subsequently dried over MgSO4. The solvents were 
evaporated under reduced pressure to obtain 18 as a mixture of two products. 18 was not 
further purified and used as a crude in the following reaction. 
1
H-NMR (400 MHz, CD3OD) 
δ: 8.00 (s, 1H), 6.92 (s, 1H).  
 
5-chloro-2-iodobenzoic acid (22)  
2-amino-4-chlorobenzoic acid (10.0 g, 58.2 mmol) was dissolved in 
DMSO (100 mL), and 30% H2SO4 was added (100 mL). The solution 
was cooled to 0 ºC, whereupon NaNO2 (8.8 g, 129 mmol) was added. 
The reaction was stirred for two hours at room temperature, after which 
a solution of KI (19.3 g, 106 mmol) in H2O (50 mL) was added. After one 
hour, an additional portion of KI (9.7 g, 58.2 mmol) in H2O (25 mL) was added. In addition, 
DMSO (50 mL) was added to keep the reaction mixture solubilized. After one additional 
hour, EtOAc (300 mL) was added, and the organic layer was washed with H2O (3 × 200 
mL) and brine (200 mL), and subsequently dried over MgSO4. The solvents were removed 
in vacuo to obtain crude 22 as white solid. 22 was not further purified and used as a crude 
in the following reaction. 
1
H-NMR (400 MHz, CD3OD) δ: 8.01 (d, J = 2.1 Hz, 1H), 7.76 (d, 
J = 8.4 Hz, 1H), 7.45 (dd, J = 8.4, 2.1 Hz, 1H). 
13
C-NMR (75 MHz, CD3OD) δ: 168.9, 
141.7, 138.6, 136.0, 132.7, 129.3, 95.0. HRMS (EI+) m/z calcd for C7H4O2ClI [M]
•+
 
281.8945, found 281.8936. 
 
4-bromo-5-chloro-2-iodobenzoic acid (23)  
Crude 2-amino-5-bromo-4-chlorobenzoic acid 18 (6.0 g, 24 mmol) was 
dissolved in DMSO (100 mL) and 30% H2SO4 (100 mL) and the 
resulting mixture was cooled to 0 ºC. NaNO2 (3.6 g, 53 mmol) was 
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added and the mixture was stirred for 2 hours at room temperature. Hereupon, a solution 
of KI (8.0 g, 48 mmol) in H2O (40 mL) was added. After one hour an additional portion of 
KI (4.0 g, 24 mmol) in H2O (20 mL) was added. After one more hour, EtOAc (200 mL) was 
added, and the organic layer was washed with H2O (2 × 200 mL) and brine (200 mL), and 
dried over MgSO4. The solvents were removed in vacuo to obtain 23 as a mixture of two 
products. 23 was used as a crude in the following reaction. 
1
H-NMR (400 MHz, CD3OD) δ: 
8.16 (s, 1H), 8.07 (s, 1H). 
 
5-bromo-2-iodobenzoic acid (24)  
2-amino-5-bromobenzoic acid (2.0 g, 9.2 mmol) was dissolved in 
DMSO (50 mL) and 30% H2SO4 (50 mL) and NaNO2 (0.89 g, 13 
mmol) were added. The reaction mixture was stirred for 1 hour at 
room temperature, whereupon a solution of KI (3.1 g, 19 mmol) in 
H2O (20 mL) was added and the reaction mixture was stirred for 
another hour. Next, another portion of KI (3.1 g, 19 mmol) in H2O (10 mL) was added and 
the reaction mixture was stirred for an additional hour. The reaction mixture was 
quenched with a saturated aqueous Na2SO3-solution (75 mL), EtOAc (100 mL) was added 
and the layers were separated. Hereupon, the H2O-layer was extracted with EtOAc (100 
mL). The combined organic layers were washed with H2O (2 × 100 mL) and brine (100 
mL). The organic layer was dried over MgSO4 and concentrated in vacuo to afford 
compound 24 as a yellow solid. 24 was not further purified and used as a crude in the 
following reaction. RF = 0.05 (EtOAc/n-heptane, 1:4). 
1
H-NMR (400 MHz, CDCl3) δ: 8.13 
(d, J = 2.4 Hz, 1H), 7.90 (d, J = 8.4 Hz, 1H), 7.33 (dd, J = 8.4, 2.4 Hz, 1H). 
 
2-iodo-5-nitrobenzoic acid (25)  
2-amino-5-nitrobenzoic acid (1.82 g, 10 mmol) was dissolved in DMSO 
(50 mL) and 30% H2SO4 (50 mL) was added. The resulting mixture 
was heated for two hours at 50 ºC. The reaction was cooled to 0 ºC 
and a solution of NaNO2 (970 mg, 14 mmol) in water (25 mL) was 
added. The mixture was stirred at 0 ºC for one hour, whereupon a 
solution of KI (5.0 g, 30 mmol) in H2O (10 mL) was added and the mixture was stirred for 
1 hour at room temperature. Next, another portion of KI (5 g, 30 mmol) in H2O (10 mL) 
was added and the mixture was stirred for an additional hour. EtOAc (100 mL) was added 
and the reaction was quenched with saturated aqueous NaHSO3 (100 mL). The organic 
layer was washed with water (2 × 100 mL) and brine (100 mL) and subsequently dried 
over MgSO4. The solvents were evaporated under reduced pressure and the crude 
product was obtained as yellow solid (12.0 g, 120%). 25 was not further purified and used 
as a crude in the following reaction. 
1
H-NMR (400 MHz, CD3OD) δ: 8.54 (d, J = 2.7 Hz, 
1H), 8.29 (d, J = 8.6 Hz, 1H), 8.01 (dd, J = 8.7, 2.7 Hz, 1H). 
13
C-NMR (75 MHz, CD3OD) 
δ: 168.0, 149.2, 144.1, 139.2, 127.1, 125.8, 103.0, 49.6, 49.3, 49.1, 48.8, 48.5. FT-IR νmax 
(cm
-1
): 2932, 1722, 1588, 151, 1342, 1295, 1022, 1234, 728. HRMS (EI+) m/z calcd for 
C7H4NO4I [M]
•+
 292.9185, found 292.9184. 
 
2-iodo-4-methoxy-benzoic acid (26)  
2-amino-4-methoxybenzoic acid (2.0 g, 12 mmol) was dissolved in 
DMSO (75 mL) whereupon 30% H2SO4 (75 mL) and NaNO2 (1.156 
g, 16.75 mmol) were added. The reaction mixture was stirred for 1 
hour at room temperature, before addition of KI (4.0 g, 24 mmol) in 
H2O (10 mL) and the reaction mixture was stirred for another hour. 
Next, another portion of KI (4.0 g, 24 mmol) in H2O (10 mL) was added and the reaction 
mixture was stirred for an additional hour. The reaction mixture was quenched with a 
saturated aqueous Na2SO3-solution (50 mL), EtOAc (100 mL) was added, and the layers 
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were separated. Hereupon, the H2O-layer was extracted with EtOAc (100 mL). The 
combined organic layers were washed with H2O (2 × 100 mL) and brine (100 mL). Next, 
the organic layers were dried over MgSO4 and concentrated in vacuo to afford compound 
26 as an orange solid. 26 was not further purified and used as a crude in the following 
reaction. RF = 0.20 (EtOAc/n-heptane, 1:1). 
1
H-NMR (400 MHz, CDCl3) δ: 8.02 (d, J = 8.8 
Hz, 1H), 7.58 (d, J = 2.5 Hz, 1H), 6.94 (dd, J = 8.8, 2.5 Hz, 1H), 3.86 (s, 3H). 
 
(4-chloro-2-iodophenyl)methanol (27)  
4-chloro-2-iodobenzoic acid 22 (15 g, 53 mmol) was dissolved in dry THF 
(250 mL) and the solution was cooled to 0 ºC. Hereupon, NEt3 (11 mL, 80 
mmol) and ethyl chloroformate (7.6 mL, 80 mmol) were added. The 
reaction was stirred for 1.5 hour and subsequently NaBH4 (8.0 g, 210 
mmol) was added in four portions. After 1.5 hour, additional NaBH4 (4.0 
g, 105 mmol) was added and the reaction was stirred for another hour. Hereupon, the 
reaction was quenched with H2O (100 mL) and EtOAc (200 mL) was added. The organic 
layer was washed with H2O (3 × 150 mL), brine (100 mL) and subsequently dried over 
MgSO4. The solvents were removed under reduced pressure and the crude product was 
obtained by gradient column chromatography (EtOAc/n-heptane, 1:9 to 1:6). Compound 
27 was obtained as white solid (8.4 g, 75% over 2 steps). 
1
H-NMR (400 MHz, CDCl3) δ: 
7.82 (s, 1H), 7.45–7.33 (m, 2H), 4.65 (d, J = 6.2 Hz, 2H), 1.94 (t, J = 6.2 Hz, 1H). 13C-
NMR (75 MHz, CDCl3) δ: 141.1, 138.3, 133.8, 128.8, 128.6, 96.9, 68.6. HRMS (EI+) m/z 
calcd for C7H6OClI [M]
•+
 267.9152, found 267.9160. 
 
(4-bromo-5-chloro-2-iodophenyl)methanol (28) 
Crude 5-bromo-4-chloro-2-iodobenzoic acid (23, 11 g, 30 mmol) was 
dissoled in dry THF (100 mL) and the solution was cooled to 0 ºC. Next, 
NEt3 (6.2 mL, 44 mmol) and ethyl chloroformate (4.3 mL, 44 mmol) were 
added. The reaction mixture was stirred for 1 hour and subsequently a 
solution of NaBH4 (2.24 g, 59 mmol) in H2O (10 mL) was added. The 
mixture was stirred another hour, prior to quenching with H2O (100 mL). The H2O-layer 
was extracted with EtOAc (2 × 100 mL), and the combined organic layers were washed 
with H2O (2 × 150 mL) and brine (150 mL). The organic layer was dried over MgSO4 and 
the solvents were removed under reduced pressure. The crude product was purified using 
column chromatography (EtOAc/n-heptane, 1:6) to obtain 28 as a white solid (3.84 g, 38% 
over 3 steps). 
1
H-NMR (400 MHz, CDCl3) δ: 7.88 (s, 1H), 7.72 (s, 1H), 4.62 (dd, J = 6.0, 
0.7 Hz, 2H), 1.96 (t, J = 6.1 Hz, 1H). 
13
C-NMR (75 MHz, CDCl3) δ: 142.8, 139.5, 139.2, 
135.7, 132.4, 122.9, 94.3, 68.0, 52.4. 
 
(5-bromo-2-iodophenyl)methanol (29)  
5-bromo-2-iodobenzoic acid (24) (750 mg, 2.3 mmol) was dissolved in 
dry THF (25 mL) and the reaction mixture was cooled to 0 ºC. NEt3 
(0.48 mL, 3.4 mmol) and ethyl chloroformate (0.33 mL, 3.4 mmol) 
were added and the reaction mixture was stirred for 1 hour. Next a 
solution of NaBH4 (130 mg, 3.4 mmol) in H2O (2 mL) was added and the mixture was 
stirred for 1.5 hour. The reaction was quenched with H2O (15 mL), whereupon CH2Cl2 (20 
mL) was added and the layers were separated. Hereupon, the H2O-layer was extracted 
with CH2Cl2 (20 mL). Subsequently, the combined organic layers were washed with H2O 
(25 mL) and brine (25 mL), dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by gradient column chromatography (n-heptane/EtOAc, 19:1 to 9:1) 
to obtain compound 29 as a white solid (410 mg, 54% over 2 steps). RF = 0.40 (EtOAc/n-
heptane, 1:4). 
1
H-NMR (400 MHz, CDCl3) δ: 7.65 (d, J = 8.3 Hz, 1H), 7.63 (d, J = 2.4 Hz, 
1H), 7.14 (dd, J = 8.3, 2.5 Hz, 1H), 4.64 (d, J = 6.1 Hz, 2H), 1.96 (t, J = 6.2 Hz, 1H). 
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(2-iodo-5-nitrophenyl)methanol (30)  
2-iodo-5-nitrobenzoic acid (25) (3.0 g, 10.2 mmol) was dissolved in dry 
THF (100 mL) and the reaction was cooled to 0 ºC. NEt3 (2.1 mL, 15.4 
mmol) and ethyl chloroformate (1.5 mL, 15.4 mmol) were added and the 
reaction was stirred for 1 hour. Next, a solution of NaBH4 (0.78 g, 20.5 
mmol) in H2O (5 mL) was added and the reaction was stirred for 1.5 
hour. Hereupon, an additional portion of NaBH4 (0.78 g, 20.5 mmol) in H2O (5 mL) was 
added and the reaction was stirred for an additional 30 minutes. The reaction was then 
quenched by the addition of H2O (20 mL). The reaction was diluted with EtOAc (150 mL) 
and the organic layer was washed with H2O (2 × 100 mL) and brine (100 mL) and 
subsequently dried over MgSO4. The solvents were removed in vacuo and the crude 
product was purified by gradient column chromatography (EtOAc/n-heptane, 1:9 to 1:3). 
Compound 30 was obtained as an orange solid (1.32 g, 55% over 2 steps). 
1
H-NMR (400 
MHz, CDCl3) δ: 8.36 (d, J = 2.8 Hz, 1H), 8.01 (d, J = 8.5 Hz, 1H), 7.85 (dd, J = 8.6, 2.8 
Hz, 1H), 4.75 (d, J = 3.4 Hz, 2H), 2.10 (t, J = 5.0 Hz, 1H). HRMS (EI+) m/z calcd for 
C7H6NO3I [M]
•+ 
278.9393, found 278.9396. 
 
(2-iodo-4-methoxyphenyl)methanol (31)  
2-iodo-4-methoxybenzoic acid (26) (3.7 g, 13.4 mmol) was dissolved 
in dry THF (75 mL) and the reaction mixture was cooled to 0 ºC. 
NEt3 (2.8 mL, 20 mmol) and ethyl chloroformate (1.9 mL, 20 mmol) 
were added and the reaction mixture was stirred for 1 hour. Next, NaBH4 (760 mg, 20 
mmol) in H2O (0.1 mL) was added and the mixture was stirred for 1.5 hour. The reaction 
was quenched with H2O (50 mL). CH2Cl2 (50 mL) was added, the layers were separated 
and hereupon the water layer was extracted with CH2Cl2 (50 mL). The combined organic 
layers were washed with H2O (50 mL) and brine (50 mL). Next, the organic layer was 
dried over MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography (EtOAc/n-heptane, 1:9) to obtain compound 31 as a colorless oil (2.3 g, 
54% over 2 steps). RF = 0.40 (EtOAc/n-heptane, 1:2). 
1
H-NMR (400 MHz, CDCl3) δ: 7.38 
(d, J = 2.6 Hz, 1H), 7.33 (d, J = 8.5 Hz, 1H), 6.91 (dd, J = 8.5, 2.6 Hz, 1H), 4.64 (d, J = 6.3 
Hz, 2H), 3.86 (s, 3H), 1.91 (t, J = 6.3 Hz, 1H). 
13
C-NMR (75 MHz, CDCl3) δ: 159.4, 135.0, 
129.4, 124.6, 114.2, 98.1, 68.8, 55.3. FT-IR νmax film (cm
-1
): 3395, 2833, 2362, 2336, 
1700, 1593, 1554, 1480, 1282, 1234, 1022, 914, 845, 811, 746, 616. HRMS (EI+) m/z 
calcd for C8H9O2I [M]
•+
 263.9648, found 263.9650. 
 
(2-((2-aminophenyl)ethynyl)-5-chlorophenyl)methanol (32)  
Compound 27 (8.5 g, 29.9 mmol), Pd(PPh3)2Cl2 (430 mg, 0.60 
mmol), and CuI (57 mg, 0.30 mmol) were added to a flame-dried 
flask. The flask was evacuated and refilled with an N2/H2-mixture 
(3:2) three times. THF (150 mL) and NEt3 (12.4 mL, 89 mmol) 
were bubbled through with an N2/H2-mixture (3/2) for 10 minutes 
and subsequently added to the reaction mixture. Hereupon, 2-
ethynylaniline (3.75 mL, 33 mmol) was added, and the mixture 
was stirred overnight under N2/H2-atmosphere.The reaction mixture was diluted with 
CH2Cl2 (250 mL) and the organic layer was washed with H2O (3 × 250 mL). The H2O-
layers were combined and back-extracted with CH2Cl2 (150 mL). The organic layers were 
combined and washed with brine (150 mL). The solvents were removed under reduced 
pressure and the crude product was purified by gradient column chromatography 
(EtOAc/n-heptane, 1:4 to 1:1) to obtain 32 as a yellow solid (7.3 g, 95%). 
1
H-NMR (400 
MHz, CDCl3) δ: 7.52 (d, J = 1.9 Hz, 1H), 7.35 (t, J = 8.7 Hz, 2H), 7.29 (dd, J = 8.2, 2.1 Hz, 
1H), 7.19-7.14 (m, 1H), 6.74-6.70 (m, 2H), 4.83 (d, J = 4.8 Hz, 2H), 4.41 (br s, 2H), 2.06 
(t, J = 5.6 Hz, 1H). 
13
C-NMR (75 MHz, CDCl3) δ: 148.34, 140.24, 133.36, 132.08, 131.58, 
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130.35, 128.92, 128.47, 123.70, 117.92, 114.53, 107.03, 92.26, 90.84, 63.69. HRMS 
(ESI+) m/z calcd for C15H13ClNO [M+H]
+
 258.0686, found 258.0677. 
 
(2-((2-aminophenyl)ethynyl)-5-bromo-4-chlorophenyl)methanol (33)  
Compound 28 (3 g, 8.6 mmol), Pd(PPh3)2Cl2 (0.121 g, 0.17 
mmol) and CuI (0.016 g, 0.086 mmol) were added to a flame-
dried Schlenk flask. The flask was subsequently evacuated and 
refilled with an N2/H2-mixture (3:2) three times. At the same 
time, dry THF (150 mL) and dry NEt3 (3.6 mL, 25.9 mmol) were 
bubbled with a N2/H2-mixture for 10 minutes. The bubbled 
solutions were subsequently added to the Schlenk flask. Next, 2-
ethynylaniline (1.08 mL, 9.5 mmol) was added and the mixture was stirred for 4 hours 
under N2/H2-atmosphere. Hereupon, CH2Cl2 (150 mL) was added and the organic layer 
was washed with H2O (3 × 100 mL). The H2O-layers were combined and back-extracted 
with CH2Cl2 (150 mL). The organic layers were combined and dried over MgSO4. The 
solvents were removed under reduced pressure and the crude product was purified by 
gradient column chromatography (EtOAc/n-heptane, 1:4 to 1:2). Compound 33 was 
obtained as a white solid (2.74 g, 94%). 
1
H-NMR (400 MHz, CDCl3) δ 7.78-7.69 (m, 1H), 
7.60 (s, 1H), 7.33 (dd, J = 8.0, 1.6 Hz, 1H), 7.18 (ddd, J = 8.2, 7.4, 1.6 Hz, 1H), 6.80-6.57 
(m, 2H), 4.83 (d, J = 5.7 Hz, 2H), 4.37 (br s, 2H), 2.01 (t, J = 6.2 Hz, 1H). 
13
C-NMR (75 
MHz, CD3OD) δ: 150.7, 144.3, 133.7 (2C), 133.2, 133.0, 131.4, 123.7, 122.9, 118.2, 
115.7, 107.8, 94.5, 90.5, 62.7. HRMS (ESI+) m/z calcd for C15H12BrClNO [M+H]
+
 
335.9791, found 335.9781. 
 
(2-((2-aminophenyl)ethynyl-5-bromophenyl)methanol (34)  
(5-bromo-2-iodophenyl)methanol (29) (106 mg, 0.34 mmol), 
Pd(PPh3)2Cl2 (7.0 mg, 0.01 mmol)  and CuI (1.2 mg, 6.3 µmol) 
were added to a flame-dried Schlenk flask. The flask was 
evacuated and refilled with an N2/H2-mixture (3:2) three times. 
Dry THF (3 mL) and dry NEt3 (71 μL, 0.51 mmol) were bubbled 
through with an N2/H2 mixture (3:2) for 10 minutes and 
subsequently added to the mixture. Hereupon, 2-ethynylaniline (0.060 mL, 0.58 mmol) 
was added and the mixture was stirred for 16 hours under an N2/H2-atmosphere. The 
reaction mixture was diluted with CH2Cl2 (5 mL) and the organic layer was washed with 
H2O (5 mL). The H2O-layer was then back-extracted with CH2Cl2 (2 × 5 mL). The 
combined organic layers were washed with H2O (15 mL) and brine (20 mL). Next, the 
organic layer was dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by gradient column chromatography (EtOAc/n-heptane, 1:6 to 1:2) to obtain 34 as 
a yellow solid (102 mg, 100%). RF = 0.40 (EtOAc/n-heptane, 1:2). 
1
H-NMR (300 MHz, 
CD3OD) δ: 7.68-7,67 (m, 1H), 7.43-7.42 (m, 2H), 7.28 (ddd, J = 7.7, 1.5, 0.4 Hz, 1H), 7.12 
(ddd, J = 7.3, 6.6, 1.6 Hz, 1H) 6.79-6.76 (m, 1H) 6.64 (td, J = 7.7, 1.1 Hz, 1H), 4.80 (d, J = 
0.6 Hz, 2H). 
13
C-NMR (75 MHz, CD3OD) δ: 148.6, 144.2, 132.4, 131.0, 129.4, 129.2, 
129.1, 121.4, 120.0, 116.5, 113.8, 106.5, 91.6, 89.8, 61.3. FT-IR νmax film (cm
-1
): 3360, 
2923, 2850, 2362, 2202, 1610, 1489, 1450, 815, 750. HRMS (ESI+) m/z calcd for 
C15H13BrNO [M+H]
+
 302.0181, found 302.0169. 
 
(2-((2-aminophenyl)ethynyl)-5-nitrophenyl)methanol (35)  
(2-iodo-5-nitrophenyl)methanol (30) (1.32 g, 4.73 mmol), 
Pd(PPh3)2Cl2 (66 mg, 0.095 mmol) and CuI (5 mg, 0.047 mmol) 
were added to a flame-dried flask. The flask was evacuated 
and refilled with an N2/H2-mixture (3/2). Dry THF (70 mL) and 
dry NEt3 (2.0 mL, 14 mmol) were bubbled through with an 
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N2/H2 mixture (3:2) for 10 minutes and subsequently added to the mixture. Hereupon, 2-
ethynylaniline (0.81 mL, 7.1 mmol) was added, and the mixture was stirred for 3 
hours.The reaction mixture was diluted with CH2Cl2 (100 mL) and washed with H2O (3 × 
100 mL). The H2O-layers were combined and back-extracted with CH2Cl2 (100 mL). The 
organic layers were combined and dried over MgSO4. The solvents were removed under 
reduced pressure and the crude product was purified by gradient column chromatography 
(EtOAc/n-heptane, 1:4 to 2:1). Compound 35 was obtained as a red solid (1.13 g, 89 % 
yield). 
1
H-NMR (400 MHz, CDCl3) δ: 8.38 (d, J = 2.0 Hz, 1H), 8.16 (dd, J = 8.5, 2.0 Hz, 
1H), 7.67 (d, J = 8.5 Hz, 1H), 7.50-7.32 (m, 1H), 7.24-7.16 (m, 1H), 6.87-6.53 (m, 2H), 
4.98 (d, J = 4.0 Hz, 2H), 4.44 (br s, 2H), 2.10 (t, J = 6.1 Hz, 1H). 
13
C-NMR (75 MHz, 
CDCl3) δ: 177.2, 165.2, 143.4, 132.5, 132.3, 131.1, 128.5, 127.9, 122.6, 122.3, 118.1, 
114.7, 96.7, 96.2, 63.4. HRMS (ESI+) m/z calcd for C15H13N2O3 [M+H]
+
 269.0926, found 
269.0916. 
 
(2-((2-aminophenyl)ethynyl)-4-methoxyphenyl)methanol (41)  
Compound 36 (100 mg, 0.40 mmol), Pd(PPh3)2Cl2 (5.3 mg, 7.6 
µmol)  and CuI (0,7 mg, 4 µmol) were added to a flame-dried 
Schlenk flask. The flask was evacuated and refilled with an 
N2/H2 mixture (3:2) three times. Dry THF (7 mL) and dry NEt3 
(84 µL, 0.61 mmol) were bubbled through with an N2/H2 
mixture (3:2) for 10 minutes and subsequently added to the 
mixture. Hereupon 2-ethynylaniline (47 μL, 0.42 mmol) was added and the mixture was 
stirred for 3 hours under an N2/H2-atmosphere. The reaction mixture was diluted with 
CH2Cl2 (10 mL) and washed with H2O (5 mL). The H2O-layer was extracted with CH2Cl2 (2 
× 10 mL). The combined organic layers were washed with H2O (10 mL) and brine (15 mL). 
Next, the organic layer was dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by gradient column chromatography (EtOAc/n-heptane, 1:4 to 1:2) to 
obtain compound 41 as a yellow solid (92 mg, 91%). RF = 0.20 (EtOAc/n-heptane, 1:2). 
1
H-NMR (400 MHz, CDCl3) δ: 7.36 (d, J = 7.7 Hz, 1H), 7.32 (d, J = 8.5 Hz, 1H), 7.16 (d, J 
= 7.4 Hz, 1H), 7.09 (d, J = 2.8 Hz, 1H), 6.88 (dd, J = 8.4, 2.9 Hz), 6.74 (s, 1H), 6.72 (s, 
1H), 4.81 (d, J = 6.2 Hz, 2H), 4.47 (s br., 2H), 3.84 (s, 3H), 1.86 (t, J = 6.2 Hz). 
13
C-NMR 
(75 MHz, CDCl3) δ: 159.0, 148.4, 134.4, 132.0, 130.1, 129.6, 123.6, 117.8, 116.8, 114.6, 
114.4, 107.4, 92.2, 90.8, 64.1, 55.5. FT-IR νmax film (cm
-1
): 3339, 2924, 2837, 2202, 1601, 
1576, 1489, 1450, 1303, 1225, 1087, 1040, 910, 745, 733. HRMS (ESI+) m/z calcd for 
C16H16NO2 [M+H]
+
 254.1181, found 254.1183. 
 
tert-butyl (2-((5-chloro-2-(hydroxymethyl) phenyl)ethynyl) phenyl) carbamate (37)  
Compound 32 (7.3 g, 28.4 mmol) was dissolved in THF (34 
mL) and Boc2O (7.4 g, 33.9 mmol) was added. The mixture 
was heated to 70 ºC and stirred for three days. The mixture 
was diluted with EtOAc (300 mL) and the organic layer was 
washed with H2O (3 × 200 mL), and brine (200 mL) and 
subsequently dried over MgSO4. The solvents were removed 
under reduced pressure and the thus obtained crude product 
was purified by gradient column chromatography (EtOAc/n-heptane, 1:7 to 1:4) yielding 
37 as a white solid (8.24 g, 81%). 
1
H-NMR (400 MHz, CDCl3) δ: 8.13 (br d, J = 7.0 Hz, 
1H), 7.83 (s, 1H), 7.56 (d, J = 2.0 Hz, 1H), 7.45 (dd, J = 7.7, 1.4 Hz, 1H), 7.39-7.31 (m, 
3H), 7.01 (t, J = 7.3 Hz, 1H), 4.88 (d, J = 4.5 Hz, 2H), 2.38 (br s, 1H), 1.57 (s, 9H). 
13
C-
NMR (75 MHz, CDCl3) δ: 152.6, 140.2, 139.8, 133.6, 131.8, 131.5, 130.2, 129.5, 128.8, 
123.6, 122.3, 118.1, 111.0, 92.6, 90.5, 81.3, 63.7, 28.3 (3C). HRMS (ESI+) m/z calcd 
[M+Na]
+
 for C20H20ClNNaO3 380.1029, found 380.1019.  
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tert-butyl (2- ((4- bromo-5-chloro-2-(hydroxymethyl) phenyl) ethynyl) phenyl) 
carbamate (38) 
Compound 33 (1.8 g, 5.35 mmol) was dissolved in THF (5.4 
mL) and Boc2O (1.17 g, 5.35 mmol) was added. The mixture 
was heated to 70 ºC and stirred overnight. The reaction 
mixture was diluted with EtOAc (100 mL) and the organic 
layer was washed with H2O (3 × 100 mL), and brine (100 mL), 
and was subsequently dried over MgSO4. The solvents were 
removed under reduced pressure and the crude product was 
purified by gradient column chromatography (EtOAc/n-heptane, 1:8 to 1:2). Compound 38 
was obtained as a white solid (1.34 g, 57%), also starting material 33 was re-obtained 
(540 mg, 30%). 
1
H-NMR (400 MHz, CDCl3) δ: 8.12 (d, J = 5.8 Hz, 1H), 7.74 (br s, 1H), 
7.72 (s, 1H), 7.63 (s, 1H), 7.44 (ddd, J = 7.7, 1.6, 0.5 Hz, 1H), 7.40 – 7.31 (m, 1H), 7.02 
(dt, J = 7.6, 1.1 Hz, 1H), 4.85 (d, J = 4.8 Hz, 2H), 2.43 (br s, 1H), 1.57 (s, 9H). 
13
C-NMR 
(75 MHz, CDCl) δ: 151.7, 141.2, 140.2, 133.8, 133.2, 133.1, 131.5, 130.4, 122.9, 122.3, 
118.2, 118.0, 110.7, 91.8, 91.3, 81.4, 63.1, 28.3 (3C). HRMS (ESI+) m/z calcd [M+H]
+
 for 
C20H20BrClNO3 436.0301, found 436.0315.  
 
tert-butyl 2-((4-bromo-2-hydroxymethyl)phenyl)ethynyl)phe-carbamate (39)  
Compound 34 (381 mg, 1.26 mmol) was dissolved in THF 
(1.2 mL) and Boc2O (275 mg, 1.26 mmol) was added. The 
reaction was stirred for two days at 70 ºC in a sealed tube. 
The reaction mixture was diluted with CH2Cl2 (10 mL) and the 
organic layer was washed with H2O (15 mL). The H2O-layer 
was extracted with CH2Cl2 (10 mL). The combined organic 
layers were washed with H2O (2 × 10 mL) and brine (10 mL). Next, the organic layer was 
dried over MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography (EtOAc/n-heptane, 1:4) to obtain compound 39 as a yellow oil (444 mg, 
87%). RF = 0.55 (EtOAc/n-heptane, 1:2). 
1
H-NMR (300 MHz, CD3OD) δ: 7.87 (d, J = 8.3 
Hz, 1H), 7.71 (m, 1H), 7.50-7.48 (m, 1H), 7.46-7.41 (m, 2H), 7.38-7.32 (m, 1H), 7.08 (td, J 
= 8.7, 1.2 Hz, 1H), 4.85 (s, 2H), 1.54 (s, 9H). 
13
C-NMR (75 MHz, CD3OD) δ: 154.9, 146.8, 
140.8, 134.4, 132.9, 131.3, 131.0, 130.7, 124.4, 124.1, 121.7, 121.0, 115.0, 92.9, 91.9, 
81.8, 63.2, 28.7 (3C). FT-IR νmax film (cm
-1
): 3395, 2976, 2928, 2366, 1735, 1519, 1498, 
1455, 1394, 1243, 1161, 1044, 746. HRMS (ESI+) m/z calcd for C20H20BrNNaO3 [M+Na]
+
 
424.0524, found 424.0513. 
 
tert-butyl (2-((2-(hydroxymethyl)-4-nitrophenyl) ethynyl) phenyl) carbamate (40)  
Compound 35 (100 mg, 0.37 mmol) was dissolved in THF 
(370 µL) and Boc2O (81 mg, 0.37 mmol) was added. The 
reaction was stirred in a sealed tube at 70 ºC overnight. The 
reaction mixture was diluted with CH2Cl2 (10 mL) and the 
organic layer was washed with H2O (3 × 10 mL) and brine 
(10 mL) and subsequently dried over MgSO4. The solvents 
were removed in vacuo and the crude product was purified 
by gradient column chromatography (EtOAc/n-heptane, 1:6 to 1:4). Compound 40 was 
obtained as red solid (70 mg, 51%). In addition 35 was reobtained (40 mg, 40%). 
1
H-NMR 
(400 MHz, CDCl3) δ: 8.36 (d, J = 1.6 Hz, 1H), 8.20 (dd, J = 8.5, 2.3 Hz, 1H), 8.15 (br s, 
1H), 7.80 (s, 1H), 7.71 (d, J = 8.5 Hz, 1H), 7.49 (d, J = 7.7 Hz, 1H), 7.40 (t, J = 7.9 Hz, 
1H), 7.04 (t, J = 7.6 Hz, 1H), 5.00 (d, J = 4.6 Hz, 2H), 2.59 (br s, 1H), 1.58 (s, 9H). 
13
C-
NMR (75 MHz, CDCl3) δ: 152.5, 147.1, 142.9, 140.5, 132.7, 131.8, 130.9, 123.1, 122.9, 
122.4, 118.3, 114.6, 110.4, 94.6, 92.3, 81.6, 63.5, 28.3 (3C). HRMS (ESI+) m/z calcd for 
C20H20N2NaO5 [M+Na]
+
 391.1270, found 391.1265. 
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tert-butyl 2-((2-(hydroxymethyl)-5-methoxyphenyl)ethynyl)-phenylcarbamate (41) 
Compound 36 (1.75 g, 6.9 mmol) was dissolved in THF (5 
mL) and Boc2O (1.5 g, 6.9 mmol) was added. The reaction 
was stirred for two days at 70 ºC in a sealed tube. The 
reaction mixture was diluted with CH2Cl2 (30 mL) and 
washed with H2O (15 mL). The H2O-layer was extracted 
with CH2Cl2 (15 mL). The combined organic layers were 
washed with H2O (2 × 15 mL) and brine (20 mL). Next, the organic layer was dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography (EtOAc/n-heptane, 1:9) to obtain compound 41 as an orange oil (1.94 g, 
80%). RF = 0.50 (EtOAc/n-heptane, 1:2). 
1
H-NMR (400 MHz, CDCl3) δ: 8.15 (br s, 1H), 
7.94 (br s., 1H), 7.46 (dd, J = 7.7, 1.6 Hz, 1H), 7.36-7.32 (m, 2H), 7.11 (d, J = 2.7 Hz, 1H), 
7.00 (td, J = 7.6, 1.1 Hz, 1H), 6.90 (dd, J = 8.4, 2.7 Hz, 1H), 4.85 (d, J = 4.3 Hz, 2H), 3.84 
(s, 3H), 1.56 (s, 9H). 
13
C-NMR (75 MHz, CDCl3) δ: 159.1, 152.6, 140.2, 133.9, 131.4, 
130.0, 129.8, 123.3, 122.2, 118.1, 117.0, 115.0, 111.3, 93.9, 89.1, 81.1, 63.9, 55.5, 28.3 
(3C). Ft-IR νmax film (cm
-1
): 3404, 2980, 2933, 2353, 1727, 1601, 1588, 1519, 1450, 1368, 
1303, 1230, 1152, 1053, 1022, 754. HRMS (ESI+) m/z calcd for C21H24NO4 [M+H]
+
 
354.1705, found 354.1715. 
 
(Z)-tert-butyl (2-(5-chloro-2-(hydroxymethyl) styryl) phenyl) carbamate (42)  
Compound 37 (8.24 g, 23.1 mmol) was dissolved in methanol 
(100 mL). After addition of quinoline (273 µl, 2.31 mmol) and 
10% Pd/BaSO4 (492 mg, 0.231 mmol), the reaction was 
stirred under H2-atmosphere for 2 hours. The reaction 
mixture was then filtered over celite and diluted with CH2Cl2 
(150 mL). The organic layer was washed with 2M aqueous HCl (2 × 100 mL), H2O (100 
mL), and brine (100 mL). The organic layer was dried over MgSO4 and the volatiles were 
removed under reduced pressure to obtain compound 42 (7.91 g, 95%). 
1
H-NMR (400 
MHz, CDCl3) δ: 7.26-7.18 (m, 2H), 7.14 (dd, J = 8.2, 1.9 Hz, 1H), 7.11 (s, 1H), 6.99 (t, J = 
7.4 Hz, 1H), 6.92 (s, 1H), 6.90 (d, J = 12.0 Hz, 1H), 6.69 (d, J = 12.0 Hz, 1H), 6.62 (br s, 
1H), 4.67 (d, J = 6.2 Hz, 2H), 1.43 (s, 9H). 
13
C-NMR (75 MHz, CDCl3) δ: 150.3, 137.2, 
137.0, 134.9, 133.3, 130.0, 129.8, 129.5, 129.3, 128.8, 128.4, 127.8 (2C), 125.8, 123.1, 
120.4, 81.0,  63.2, 28.2. HRMS (ESI+) m/z calcd for C20H23ClNO3 [M+H]
+
 360.1367, found 
360.1387. 
 
(Z)-tert-butyl(2-(4-bromo-5-chloro-2-(hydroxymethyl)styryl)phenyl)carbamate (43) 
Compound 38 (470 mg, 1.1 mmol) was dissolved in methanol 
(20 mL) and 10% Pd/BaSO4 (15 mg, 14 μmol) and quinoline 
(13 μl, 0.11 mmol) were added. The reaction was stirred 
under H2-atmosphere for two hours. Additional 10% 
Pd/BaSO4
 
(15 mg, 14 μmol) was added, and after 1 hour 
again 10% Pd/BaSO4 (15 mg, 14 μmol) was added. After 1 additional hour the reaction 
was completed and filtered over celite. The celite was washed with CH2Cl2 (50 mL), and 
the thus obtained organic layer was washed with 2M aqueous HCl (2 × 50 mL), H2O (50 
mL), and brine (50 mL) and subsequently dried over MgSO4. The solvents were removed 
under reduced pressure to obtain 43 as a single product (470 mg, 100%). 
1
H-NMR (400 
MHz, CDCl3) δ: 8.12 (d, J = 8.5 Hz, 1H), 7.74 (br s, 1H), 7.72 (m, 1H), 7.63 (s, 1H), 7.44 
(ddd, J = 7.7, 1.6, 0.5 Hz, 1H), 7.36 (dddd, J = 7.5, 1.6, 0.5 Hz, 8.5 Hz, 1H), 7.01 (dt, J = 
7.5, 1.1 Hz, 1H), 4.85 (d, J = 4.8 Hz, 2H), 2.45 (br s, 1H), 1.57 (s, 9H). 
13
C-NMR (75 MHz, 
CDCl3) δ: 152.8, 138.7, 135.9, 134.8, 133.3, 130.3, 129.2, 129.0, 128.6, 128.3 (2C), 
125.7, 123.4, 121.4, 120.8, 81.2, 62.5, 28.2 (3C). HRMS (ESI+) m/z calcd for 
C20H22BrClNO3 [M+H]
+
 438.0472, found 438.0495. 
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(Z)-tert-butyl2-(4-bromo-2-(hydroxymethyl)styryl)phenyl-carbamate (44)  
Compound 39 (720 mg, 1.8 mmol) was dissolved in methanol 
(12 mL) and 10% Pd/BaSO4 (35 mg, 33 µmol) and quinoline 
(21 μL, 0.18 mmol) were added. The reaction mixture was 
stirred under H2-atmosphere for 1.5 hour. Next, the mixture 
was filtered over celite and the solvents were removed under 
reduced pressure. The crude product was purified by column chromatography (EtOAc/n-
heptane, 1:9) to obtain compound 44 as an orange oil (650 mg, 90%). RF = 0.40 
(EtOAc/n-heptane, 1:2). 
1
H-NMR (400 MHz, CDCl3) δ: 7.48 (s, 1H), 7.21 (t, J = 7.5 Hz, 
1H), 7.14-7.12 (m, 2H), 6.99 (t, J = 7.3 Hz, 1H), 6.88 (d, J = 12.1 Hz, 1H), 6.81 (d, J = 7.6 
Hz, 1H), 6.64 (d, J = 11.9 Hz, 1H), 6.62 (s, 1H), 4.70 (d, J = 6.4 Hz, 2H), 1.43 (s, 9H). 
13
C-
NMR (75 MHz, CDCl3) δ: 152.6, 140.5, 134.8, 134.3, 131.3, 130.7, 130.5, 130.2, 129.4, 
128.3, 128.0, 127.3, 123.0, 121.7, 120.2, 81.2, 63.3, 28.2 (3C). FT-IR νmax film (cm
-1
): 
3421, 2976, 2933, 2362, 2327, 1705, 1576, 1519, 1472, 1446, 1398, 1364, 1308, 1230, 
1156, 1053, 1022, 767, 763. HRMS (ESI+) m/z calcd for C20H23BrNO3 [M+H]
+
 404.0861, 
found 404.0865. 
 
(Z)-tert-butyl (2-(2-(hydroxymethyl)-4-nitrostyryl)phenyl)carbamate (45)  
Compound 40 (70 mg, 0.19 mmol) was dissolved in methanol 
(10 mL) and quinoline (11 μL, 95 μmol) and 10% Pd/BaSO4 
(2.66 mg, 2 μmol) were added. The reaction was stirred 
under H2- atmosphere for 3 hours after which the mixture was 
filtered over celite. The celite was washed with CH2Cl2 (20 
mL) and the organic layer was washed with H2O (2 × 20 mL) and brine (20 mL) and 
subsequently dried over MgSO4. The solvents were removed under reduced pressure and 
the crude product was purified by column chromatography (EtOAc/n-heptane, 1:4) to 
obtain 45 as red solid (55 mg, 78%). 
1
H-NMR (300 MHz, CDCl3) δ: 8.24 (d, J = 2.4 Hz, 
1H), 7.84 (dd, J = 8.5, 2.4 Hz, 1H), 7.73 (br s, 1H), 7.26-7.18 (m, 1H), 7.10 (d, J = 8.5 Hz, 
1H)), 7.06 (s, 1H), 6.98 (d, J = 7.4 Hz, 1H), 6.93 (d, J = 12.0 Hz, 1H), 6.81 (d, J = 12.0 Hz, 
1H), 6.56 (s, 1H), 4.79 (s, 2H), 1.40 (s, 9H). 
13
C-NMR (75 MHz, CDCl3) δ: 152.6, 147.0, 
142.2, 140.3, 135.0, 129.9, 129.7, 129.3 (2C), 128.8, 125.7, 123.4, 123.1, 122.4, 120.8, 
81.3, 62.9, 28.13 (3C). HRMS (ESI+) m/z calcd for C20H2N2NaO5 [M+Na]
+
 393.14264, 
found 393.14315. 
 
(Z)-tert-butyl (2-(2-(hydroxymethyl)-5-methoxystyryl)phenylcarbamate (46)  
Compound 41 (1.72 g, 4.87 mmol) was dissolved in methanol 
(75 mL) and 10% Pd/BaSO4 (84 mg, 79 µmol) and quinoline 
(2.88 mL, 24.3 mmol) were added. The reaction mixture was 
stirred under H2-atmosphere for 1.5 hour. Next, the mixture 
was filtered over celite and washed with 2M aqueous HCl (50 
mL), saturated aqueous NaHCO3-solution (50 mL) and brine (50 mL). The organic layer 
was dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
gradient column chromatography (EtOAc/n-heptane, 1:9 to 1:4) to obtain compound 46 as 
a yellow oil (1.66 g, 96%). RF = 0.15 (EtOAc/n-heptane, 1:4). 
1
H-NMR (400 MHz, CDCl3) 
δ: 7.85 (br s, 1H), 7.22-7.18 (m, 3H), 7.03-6.98 (m, 2H), 6.74-6.66 (m, 3H), 6.48 (d, J = 
2.5 Hz, 1H), 4.68 (d, J = 5.2 Hz, 2H), 3.93 (s, 3H), 1.41 (s, 9H). 
13
C-NMR (75 MHz, CDCl3) 
δ: 158.9, 136.7, 135.0, 131.4, 130.9, 130.2, 129.3, 128.0, 126.8, 126.2, 122.8, 119.8, 
119.7, 114.6, 113.5, 80.8, 63.5, 54.9, 28.2 (3C). FT-IR νmax film (cm
-1
): 3417, 2976, 2928, 
1722, 1576, 1524, 1442, 1372, 1225, 1152, 1044, 1018, 754, 741, 573. HRMS (ESI+) m/z 
calcd for C21H26NO4 [M+H]
+
 356.1862, found 356.1860. 
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(Z)-tert-butyl (2-(5-chloro-2-formylstyryl)phenyl)carbamate (47)  
Compound 42 (7.91 g, 22 mmol) was dissolved in dry CH2Cl2 
(150 mL) under Ar-atmosphere in a flame-dried flask. Dess-
Martin periodinane (11.2 g, 26.4 mmol) and NaHCO3 (5.54 g, 
66 mmol) were added and the mixture was stirred for 45 
minutes. The reaction was quenched by the addition of 
saturated aqueous NaHSO3 (100 mL). The layers were 
separated and the H2O-layer was extracted with CH2Cl2 (100 mL). The organic layers 
were combined and washed with saturated aqueous NaHSO3 (200 mL), H2O (2 × 200 mL) 
and brine (200 mL) and then dried over MgSO4. The organic solvents were evaporated 
and the crude product was purified by column chromatography (EtOAc/n-heptane, 1:9). 
Compound 47 was obtained as a yellow solid (7.36 g, 95%). 
1
H-NMR (300 MHz, CDCl3) δ: 
10.13 (s, 1H), 7.87 (d, J = 8.2 Hz, 1H), 7.74 (d, J = 8.3 Hz, 1H), 7.33 (dd, J = 8.1, 1.9 Hz, 
1H), 7.25-7.18 (m, 1H), 7.16 (d, J = 12.0 Hz, 1H), 7.09 (d, J = 2.0 Hz, 1H), 7.00-6.87 (m, 
2H), 6.84 (d, J = 11.9 Hz, 1H), 6.44 (br s, 1H), 1.46 (s, 9H). 
13
C-NMR (75 MHz, CDCl3) δ: 
190.6, 152.4, 140.4, 140.0, 135.6, 132.3, 131.7, 130.3, 129.7, 129.5, 129.0, 128.9, 128.3, 
125.1, 123.1, 120.3, 80.5, 28.3 (3C). HRMS (ESI+) m/z calcd for C20H20ClNNaO3 [M+Na]
+
 
380.1029, found 380.1032. 
 
(Z)-tert-butyl (2-(4-bromo-5-chloro-2-formylstyryl)phenyl)carbamate (48)  
Compound 43 (1.17 g, 2.67 mmol) was dissolved in dry CH2Cl2 
(40 mL) under Ar-atmosphere in a flame-dried flask. NaHCO3 
(670 mg, 8.0 mmol) and Dess-Martin periodinane (1.47 g, 3.47 
mmol) were added and the reaction was stirred for 1 hour. 
Hereupon, the reaction was quenched with saturated aqueous 
NaHSO3 and diluted with CH2Cl2 (20 mL). The organic layer 
was washed with H2O (3 × 50 mL) and brine (50 mL) and subsequently dried over MgSO4. 
The solvents were removed under reduced pressure and the crude product was purified 
by column chromatography (EtOAc/n-heptane, 1:9). Compound 48 was obtained as a 
yellow solid (1.02 g, 89%). 
1
H-NMR (400 MHz, CDCl3) δ: 10.07 (s, 1H), 8.02 (s, 1H), 7.85 
(d, J = 8.2 Hz, 1H), 7.26-7.22 (m, 1H), 7.21 (s, 1H), 7.07 (d, J = 11.9 Hz, 1H), 6.98-6.90 
(m, 2H), 6.87 (d, J = 11.9 Hz, 1H), 6.39 (s, 1H), 1.47 (d, J = 1.0 Hz, 9H). 
13
C-NMR (75 
MHz, CDCl3) δ: 189.3, 152.4, 140.1, 138.8, 135.6 (2C), 132.7, 131.9, 130.5, 129.5, 129.1, 
127.6, 125.1, 123.4, 122.2, 120.7, 80.7, 28.3 (3C). HRMS (ESI+) m/z calcd for 
C20H19BrClNNaO3 [M+Na]
+ 
458.0135, found 458.0123. 
 
(Z)-tert-butyl 2-(4-bromo-2-formylstyryl)phenylcarbamate (49)  
Compound 44 (651 mg, 1.62 mmol) was dissolved in dry 
CH2Cl2 (15 mL) and placed under an Ar-atmosphere in a 
flame-dried flask. Subsequently, Dess-Martin periodinane (888 
mg, 2.09 mmol) and NaHCO3 (406 mg, 4.83 mmol) were added 
and the mixture was stirred for 40 minutes. The reaction was 
quenched with saturated aqueous Na2SO3 (15 mL). The 
mixture was diluted with CH2Cl2 (25 mL), washed with saturated aqueous NaHSO3 (15 
mL), H2O (15 mL) and brine (15 mL). Next, the organic layer was dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by column chromatography 
(EtOAc/n-heptane, 1:9) to obtain compound 49 as a yellow oil which solidified upon 
storage at -20 ºC (560 mg, 86%). RF = 0.40 (EtOAc/n-heptane, 1:4). 
1
H-NMR (400 MHz, 
CDCl3) δ: 10.16 (s, 1H), 7.93 (d, J = 2.2 Hz, 1H), 7.87 (d, J = 7.7 Hz, 1H), 7.43 (dd, J = 
8.3, 2.2 Hz, 1H), 7.23-7.19 (m, 1H), 7.17 (d, J = 12.0 Hz, 1H), 6.99-6.96 (m, 2H), 6.92 (d, 
J = 7.3 Hz, 1H), 6.82 (d, J = 11.9 Hz, 1H), 6.42, (br s, 1H), 1.45 (s, 9H). 
13
C-NMR (75 
MHz, CDCl3) δ: 190.4, 152.4, 137.5, 136.4, 135.5, 134.7, 133.8, 131.9, 129.6, 129.3, 
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129.2, 128.7, 125.5, 123.1, 122.0, 120.3, 80.6, 28.2 (3C). FT-IR νmax film (cm
-1
): 2982, 
1729, 1695, 1584, 1515, 1445, 1238, 1369, 1148, 1051, 1016, 780, 746. HRMS (ESI+) 
m/z calcd for C20H20BrNNaO3 [M+Na]
+
 424.0524, found 424.0516. 
 
(Z)-tert-butyl (2-(2-formyl-4-nitrostyryl)phenyl)carbamate (50)  
Compound 45 (170 mg, 0.46 mmol) was dissolved in dry 
CH2Cl2 (5 mL) under Ar-atmosphere in a flame-dried flask. 
Dess-Martin periodinane (234 mg, 0.55 mmol) and NaHCO3 
(116 mg, 1.38 mmol) were added. The reaction was stirred for 
30 minutes whereupon saturated aqueous NaHSO3 (10 mL) 
was added. The mixture was diluted with CH2Cl2 (15 mL) and 
the organic layer was washed with saturated aqueous NaHSO3 (30 mL), water (2 × 30 
mL) and brine (30 mL) before drying over MgSO4. The solvents were removed in vacuo 
and the crude product was purified by gradient column chromatography (EtOAc/n-
heptane, 1:19 to 1:6) to obtain 50 as a red solid (145 mg, 86%). 
1
H-NMR (400 MHz, 
CDCl3) δ: 10.27 (s, 1H), 8.66 (d, J = 2.4 Hz, 1H), 8.14 (dd, J = 8.5, 2.5 Hz, 1H), 7.82 (d, J 
= 8.3 Hz, 1H), 7.32 (d, J = 8.6 Hz, 1H), 7.25 (d, J = 11.8 Hz, 1H), 7.26-7.21 (m, 1H), 6.97 
(d, J = 11.9 Hz, 1H), 6.93-6.88 (m, 2H), 6.44-6.35 (br s, 1H), 1.45 (s, 9H). 
13
C-NMR (75 
MHz, CDCl3) δ: 189.7, 152.4, 144.8, 135.7, 134.1, 133.0, 131.9, 131.6, 129.6, 129.3, 
128.4, 127.4, 126.0, 125.4, 123.5, 121.0, 80.8, 28.3 (3C). HRMS (ESI+) m/z calcd for 
C20H20N2NaO5 [M+Na]
+
 391.1270, found 391.1259. 
 
(Z)-tert-butyl 2-(2-formyl-5-methoxystyryl)phenylcarbamate (51)  
Compound 46 (1.66 g, 4.67 mmol) was dissolved in dry CH2Cl2 
(75 mL) and placed under Ar-atmosphere in a flame-dried flask. 
Subsequently, Dess-Martin periodinane (2.57 g, 6.06 mmol) 
and NaHCO3 (1.18 g, 14.0 mmol) were added and the mixture 
was stirred for two hours. The reaction was quenched with a 
saturated aqueous Na2SO3-solution (50 mL). The mixture was 
diluted with CH2Cl2 (50 mL), washed with saturated aqueous NaHSO3 (50 mL), H2O (50 
mL), and brine (50 mL). Next, the organic layer was dried over MgSO4 and concentrated 
in vacuo. The crude product was purified by column chromatography (EtOAc/n-heptane, 
1:9) to obtain compound 51 as a yellow oil which solidified upon storage at -20 ºC (1.29 g, 
78%). RF = 0.30 (EtOAc/n-heptane, 1:4). 
1
H-NMR (400 MHz, CDCl3) δ: 10.09 (s, 1H), 7.89 
(d, J = 8.2 Hz, 1H), 7.74 (d, J = 8.6 Hz, 1H), 7.33 (d, J = 11.9 Hz, 1H), 7.21-7.17 (m, 1H), 
7.05 (d, J = 7.6 Hz, 1H), 6.92 (td, J = 7.6, 1.2 Hz, 1H), 6.84 (dd, J = 8.6, 2.6 Hz, 1H), 6.78 
(d, J = 11.9 Hz, 1H), 6.54 (d, J = 2.5 Hz, 1H), 6.52 (s, 1H), 3.52 (s, 3H), 1.43 (s, 9H). 
13
C-
NMR (75 MHz, CDCl3) δ: 190.5, 163.2, 152.4, 140.6, 135.4, 134.0, 130.8, 129.3, 128.3, 
128.1, 126.9, 125.8, 122.8, 119.8, 114.4 (2C), 80.1, 55.1, 28.1 (3C). FT-IR νmax film (cm
-
1
): 3356, 2971, 2933, 2855, 1722, 1684, 1588, 1515, 1446, 1234, 1156, 1022, 754. HRMS 
(ESI+) m/z calcd for C21H24NO4Na [M+Na]
+
 354.1705, found 354.1698. 
 
(Z)-9-chloro-5,6-dihydrodibenzo[b,f]azocine (52)  
Compound 47 (7.34 g, 20.6 mmol) was dissolved in 2M HCl in 
EtOAc (100 ml, 200.00 mmol) and the reaction was stirred for 1 
hour. Then, NaBH4 (3.11 g, 82.4 mmol) in H2O (10 mL) was 
added and the reaction was stirred overnight. As reduction of the 
imine was not completed yet, another portion of NaBH4 (2.25 g, 60 mmol) was added and 
the reaction was stirred for 1.5 hour. Hereupon, the reaction was quenched by the 
addition of H2O (50 mL) and the product was extracted with EtOAc (100 mL). The organic 
layer was washed with H2O (3 × 100 mL) and brine (100 mL) and subsequently dried over 
MgSO4. The solvents were removed under reduced pressure to obtain 52 as a yellow 
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solid (4.7 g, 95%). 
1
H-NMR (300 MHz, CDCl3) δ: 7.18-7.09 (m, 3H), 7.06-6.84 (m, 2H), 
6.69-6.60 (m, 1H), 6.58 (d, J = 13.2 Hz, 1H), 6.46 (dd, J = 8.1, 0.6 Hz, 1H), 6.27 (d, J = 
13.1 Hz, 1H), 4.55 (s, 2H), 4.22 (br s, 1H). 
13
C-NMR (75 MHz, CDCl3) δ: 146.8, 141.1, 
136.6, 134.7, 134.0, 133.3, 130.3, 129.7, 128.3, 127.3, 126.1, 121.3, 118.0, 117.9, 48.8. 
HRMS (ESI+) m/z calcd for C15H13ClN [M+H]
+
 242.0737, found 242.0726. 
 
(Z)-8-bromo-9-chloro-5,6-dihydrodibenzo[b,f]azocine (53)  
Compound 48 (920 mg, 2.1 mmol) was dissolved in 2M HCl in 
EtOAc (40 mL, 80 mmol). After 30 minutes, NaBH4 (240 mg, 6.3 
mmol) in H2O (2 mL) was added. After two hours another portion 
of NaBH4 (240 mg, 6.3 mmol) in H2O (2 mL) was added, followed 
by another portion of NaBH4 (80 mg, 2.1 mmol) in H2O (1 mL) after 1 hour. After an extra 
30 minutes, the reaction was quenched by the addition of H2O (40 mL). The layers were 
separated, and the H2O-layer was extracted with EtOAc (50 mL). The organic layers were 
combined and washed with H2O (2 × 100 mL), and brine (100 mL), and subsequently 
dried over MgSO4. The volatiles were removed under reduced pressure and the crude 
product was purified by column chromatography (EtOAc/n-heptane, 1:6). Compound 53 
was obtained as yellow solid (340 mg, 50%). 
1
H-NMR (300 MHz, CDCl3) δ: 7.44 (s, 1H), 
7.24 (s, 1H), 6.99-6.87 (m, 2H), 6.63 (dt, J = 7.7, 1.3 Hz, 1H), 6.59 (d, J = 13.0 Hz, 1H), 
6.47 (dd, J = 8.0, 1.2 Hz, 1H), 6.20 (d, J = 13.1 Hz, 1H), 4.52 (s), 4.24 (s). 
13
C-NMR (75 
MHz, CDCl3) δ: 146.6, 140.1, 138.4, 134.7, 134.4, 134.0, 133.4, 131.5, 128.5, 125.1, 
121.3, 120.1, 118.1, 118.0, 48.6. HRMS (ESI+) m/z calcd for C15H12BrClN [M+H]
+
 
319.9842, found 319.9825. 
 
(Z)-8-bromo-5,6-dihydrodibenzo[b,f]azocine (54)  
Compound 49 (560 mg, 1.4 mmol) was dissolved in 2M HCl in 
EtOAc (20 mL, 40 mmol) and stirred for 1.5 hour. Next, NaBH4 
(196 mg, 5.2 mmol) and a few drops of water were added. The 
reaction was stirred overnight whereupon an additional portion of 
NaBH4 (196 mg, 5.2 mmol) was added and, after an additional 90 
minutes, the reaction was quenched with H2O (15 mL). The H2O-layer was extracted with 
EtOAc (2 × 15 mL). The organic layers were combined and washed with 2M aqueous 
NaOH (2 × 20 mL), H2O (2 × 20 mL) and brine (20 mL). Next, the organic layer was dried 
over MgSO4 and concentrated in vacuo to obtain compound 54 as a yellow solid (360 mg, 
91%). RF = 0.55 (EtOAc/n-heptane, 1:2). 
1
H-NMR (400 MHz, CDCl3) δ: 7.36 (dd, J = 8.7, 
2.1 Hz, 1H), 7.34 (d, J = 2.1 Hz, 1H), 7.02 (d, J = 8.1 Hz, 1H), 6.96 (dd, J = 7.7, 1.7 Hz, 
1H), 6.90 (ddd, J = 7.2, 6.5, 1.6 Hz, 1H), 6.62 (ddd, J = 8.4, 7.2, 1.2 Hz, 1H), 6.55 (d, J = 
13.1 Hz, 1H), 6.47 (dd, J = 8.1, 1.2 Hz, 1H), 6.26 (d, J = 13.1 Hz, 1H), 4.54 (s, 2H). 
13
C-
NMR (75 MHz, CDCl3) δ: 146.3, 139.8, 137.7, 134.3, 132.9, 131.3 (2C), 130.2, 127.7, 
126.9, 125.8, 121.1, 119.8, 117.5, 48.7. FT-IR νmax film (cm
-1
): 3391, 3002, 2924, 2850, 
2362, 2098, 1593, 1485, 1325, 1269, 901, 828, 776, 750. HRMS (ESI+) m/z calcd for 
C15H13BrN [M+H]
+
 286.02314 found 286.0219. 
 
(Z)-8-nitro-5,6-dihydrodibenzo[b,f]azocine (55)  
Compound 50 (200 mg, 0.54 mmol) was dissolved in 2M HCl in 
EtOAc (10 mL, 20 mmol). After 30 minutes NaBH4 (470 mg, 
12.4 mmol) in water (1 mL) was added and after stirring 
overnight the reaction was quenched with H2O (10 mL). The 
H2O-layer was extracted with EtOAc (2 × 20 mL), and the combined organic layers were 
washed with H2O (3 × 20 mL), brine (20 mL) and subsequently dried over MgSO4. The 
solvents were removed in vacuo to obtain 55 as a red solid (140 mg, 100%) 
1
H-NMR (400 
MHz, CDCl3) δ: 8.11 (dd, J = 8.5, 2.4 Hz, 1H), 8.05 (d, J = 2.3 Hz, 1H), 7.29 (d, J = 8.6 
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Hz, 1H), 7.01 (d, J = 7.7 Hz, 1H), 6.97-6.91 (m, 1H), 6.71-6.62 (m, 2H), 6.51 (d, J = 8.1 
Hz, 1H), 6.36 (d, J = 13.4 Hz, 1H), 4.69 (s, 2H). 
13
C-NMR (75 MHz, CDCl3) δ: 147.3, 
146.7, 145.9, 139.5, 135.9, 135.4, 131.3, 128.8, 125.0, 124.1, 122.8, 121.2, 118.4, 118.0, 
49.6. HRMS (ESI+) m/z calcd for C15H13N2O2 [M+H]
+
 253.0977 found 253.0965. 
 
(Z)-9-methoxy-5,6-dihydrodibenzo[b,f]azocine (56)  
Compound 51 (122 mg, 0.35 mmol) was dissolved in 2M HCl in 
EtOAc (3 mL, 6 mmol) and the solution was stirred for 75 
minutes. Next, NaBH4 (39 mg, 1.0 mmol) and a drop of water 
were added. MeOH (2 mL) was added to keep the reactants in 
solution. After 75 minutes an additional portion of NaBH4 (39 
mg, 1.04 mmol) was added and after another hour, the reaction was quenched with H2O 
(10 mL). The H2O-layer was extracted with EtOAc (2 × 15 mL). The organic layers were 
combined and washed with 2M aqueous NaOH (2 × 20 mL), H2O (2 × 20 mL) and brine 
(20 mL). Next, the organic layer was dried over MgSO4 and concentrated in vacuo to 
obtain compound 56 as an orange solid (72 mg, 87%). RF = 0.55 (EtOAc/n-heptane, 1:2). 
1
H-NMR (400 MHz, CDCl3) δ: 7.12 (d, J = 8.2 Hz, 1H), 6.94 (dd, J = 7.8, 1.4 Hz, 1H), 6.88 
(td, J = 6.6, 1.6 Hz, 1H), 6.73 (dd, J = 8.2, 2.7 Hz, 1H), 6.69 (d, J = 2.7 Hz, 1H), 6.61-6.59 
(m, 1H), 6.55 (d, J = 12.8 Hz, 1H), 6.45 (d, J =8.1 Hz, 1H), 6.32 (d, J = 12.9 Hz, 1H), 4.53 
(s, 2H), 3.78 (s, 3H). 
13
C-NMR (75 MHz, CDCl3) δ: 158.9, 146.8, 140.5, 134.4, 133.0, 
130.6, 130.0, 127.9, 127.4, 121.3, 117.9, 117.4, 114.3, 113.4, 55.2, 48.5. FT-IR νmax film 
(cm
-1
): 3399, 2997, 2924, 2855, 1722, 1601, 1571, 1498, 1455, 1325, 1260, 1217, 1165, 
1109, 1035, 862, 746, 573. HRMS (ESI+) m/z calcd for C16H16NO [M+H]
+
 238.1232, found 
238.1229. 
 
(Z)-methyl 5- (9-chlorodibenzo [b,f] azocin-5(6H)-yl)-5-oxopentanoate (57)  
Compound 52 (3 g, 12.4 mmol) was dissolved in dry CH2Cl2 (100 
mL) and NEt3 (3.46 mL, 24.8 mmol) was added. After cooling the 
mixture to 0 ºC, methyl 5-chloro-5-oxopentanoate (2.13 mL, 15 
mmol) was added and the reaction was stirred overnight. 
Hereupon, the reaction was quenched with H2O (100 mL) and the 
layers were separated. The organic layer was washed with 2M 
aqueous NaOH (2 × 70 mL), water (2 × 70 mL) and brine (70 mL) 
and subsequently dried over MgSO4. The solvents were removed under reduced pressure 
and the crude product was purified by column chromatography (EtOAc/n-heptane, 1:2) to 
obtain 57 as a yellow solid (2.11 g, 46%). 
1
H-NMR (400 MHz, CDCl3) δ: 7.31-7.27 (m, 
3H), 7.23 (d, J = 8.8 Hz, 1H), 7.19-7.10 (m, 3H), 6.69 (d, J = 13.1 Hz, 1H), 6.62 (d, J = 
13.1 Hz, 1H), 5.43 (d, J = 14.9 Hz, 1H), 4.17 (d, J = 14.9 Hz, 1H), 3.59 (s, 3H), 2.25-2.03 
(m, 3H), 1.94-1.76 (m, 3H). 
13
C-NMR (75 MHz, CDCl3) δ: 173.5, 171.8, 140.8, 137.6, 
135.8, 133.3, 132.7, 131.7, 131.5, 131.4, 131.1, 128.7, 128.5, 128.1, 128.1, 127.3, 53.9, 
51.4, 33.5, 33.0, 20.4. HRMS (ESI+) m/z calcd for C21H21ClNO3 [M+H]
+
 370.1210, found 
370.1203. 
 
(Z)-methyl 5- (8-bromo-9-chlorodibenzo [b,f] azocin-5 (6H) -yl)-5-oxopentanoate (58) 
Compound 53 (200 mg, 0.62 mmol) was dissolved in dry CH2Cl2 
(15 mL) and the solution was cooled to 0 ºC. Subsequently, NEt3 
(174 μL, 1.25 mmol) and methyl 5-chloro-5-oxopentanoate (133 
μl, 0.94 mmol) were added. The reaction was stirred overnight 
and then quenched with H2O (10 mL). The layers were 
separated, and the H2O-layer was extracted with CH2Cl2 (20 mL). 
The organic layers were combined and washed with H2O (2 × 30 
mL), and brine (30 mL) and dried over MgSO4. The solvents were removed in vacuo and 
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the crude product was purified by column chromatography (EtOAc/n-heptane, 1:2). 
Compound 58 was obtained as yellow solid (230 mg, 82%). 
1
H-NMR (400 MHz, CDCl3) δ: 
7.53 (s, 1H), 7.34-7.29 (m, 3H), 7.22 (s, 1H), 7.18 (dd, J = 6.4, 2.6 Hz, 1H), 6.64 (d, J = 
13.3 Hz, 1H), 6.60 (d, J = 13.3 Hz, 1H), 5.45 (d, J = 15.2 Hz, 1H), 4.12 (d, J = 15.2 Hz, 
1H), 3.59 (s, 3H), 2.62-2.29 (m, 1H), 2.26-1.96 (m, 2H), 1.93-1.76 (m, 3H). 
13
C-NMR (75 
MHz, CDCl3) δ: 173.4, 171.8, 140.5, 136.2, 135.5, 135.0, 134.9, 133.2, 132.7, 131.4, 
130.0, 129.0, 128.7, 128.2, 128.1, 120.8, 53.4, 51.3, 33.3, 32.9, 20.3. HRMS (ESI+) m/z 
calcd for C21H20BrClNO3 [M+H]
+
 448.0321, found 448.0315. 
 
(Z)-methyl 5-(8-bromodibenzo[b,f]azocin-5(6H)-yl)-5-oxopentano-ate (59)  
Compound 54 (360 mg, 1.26 mmol) was dissolved in dry CH2Cl2 (8 mL) and NEt3 (351 μL, 
2.52 mmol) was added. The mixture was cooled to 0 ºC, whereupon methyl 5-chloro-5-
oxopentanoate (221 μL, 1.89 mmol) was added. The reaction was 
stirred for 90 minutes, after which it was quenched with H2O (5 
mL). The mixture was diluted with CH2Cl2 (10 mL) and washed 
with 2M aqueous NaOH (2 × 10 mL), 2M aqueous HCl (2 × 10 
mL), H2O (2 × 10 mL) and brine (10 mL). Next, the organic layer 
was dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by column chromatography (EtOAc/n-
heptane, 1:2) to obtain compound 59 as a yellow solid (466 mg, 90%). RF = 0.30 
(EtOAc/n-heptane, 1:2). 
1
H-NMR (400 MHz, CDCl3) δ: 7.42 (d, J = 2.1 Hz, 1H), 7.31-7.27 
(m, 4H), 7.19-7.15 (m, 1H), 7.00 (d, J = 8.3 Hz, 1H), 6.69 (d, J = 13.1 Hz, 1H), 6.59 (d, J = 
13.1 Hz, 1H), 5.49 (d, J = 15.2 Hz, 1H), 4.16 (d, J = 15.2 Hz, 1H), 3.59 (s, 3H), 2.22-2.17 
(m, 2H), 2.13-2.04 (m, 2H), 1.85-1.79 (m, 2H). 
13
C-NMR (75 MHz, CDCl3) δ: 173.5, 171.8, 
140.7, 136.9, 136.1, 134.5, 133.7, 132.9, 131.4, 131.1, 130.1, 128.8, 128.1 (2C), 127.6, 
121.2, 54.0, 51.4, 33.3, 33.1, 20.4. FT-IR νmax film (cm
-1
): 3473, 2947, 2868, 2150, 1874, 
1731, 1653, 1498, 1437, 1403, 1195, 1169, 1018, 832, 776. HRMS (ESI+) m/z calcd for 
C21H21BrNO3 [M+H]
+
 414.0705, found 414.0699. 
 
(Z)-methyl 5-(8-nitrodibenzo[b,f]azocin-5(6H)-yl)-5-oxopentanoate (60)  
Compound 55 (45 mg, 0.18 mmol) was dissolved in dry CH2Cl2 
(5 ml) and the solution was cooled to 0 ºC. Subsequently, NEt3 
(50 μL, 0.36 mmol) and methyl 5-chloro-5-oxopentanoate (37 μl, 
0.27 mmol) were added. The reaction was stirred overnight and 
quenched by the addition of 0.1 M aqueous NaOH (5 mL). The 
reaction was diluted with CH2Cl2 (10 mL) and the organic layer 
was washed with 2M aqueous NaOH (2 × 20 mL), H2O (20 mL) 
and brine (20 mL), and subsequently dried over MgSO4. The solvents were removed 
under reduced pressure and the crude product was purified by gradient column 
chromatography (EtOAc/n-heptane, 1:6 to 2:3). Compound 60 was obtained as a red solid 
(25 mg, 37%). 
1
H-NMR (300 MHz, CDCl3) δ: 8.20 (d, J = 2.4 Hz, 1H), 8.02 (dd, J = 8.5, 
2.4 Hz, 1H), 7.32 (dt, J = 11.5, 4.1 Hz, 5H), 7.24-7.17 (m, 1H), 6.81 (d, J = 13.4 Hz, 1H), 
6.73 (d, J = 13.3 Hz, 1H), 5.55 (d, J = 15.1 Hz, 1H), 4.23 (d, J = 15.0 Hz, 1H), 3.58 (s, 
3H), 2.25-2.08 (m, 2H), 2.06-1.91 (m, 2H), 1.86-1.66 (m, 2H). HRMS (ESI+) m/z calcd for 
C21H21N2O5 [M+H]
+
 381.1451, found 381.1446. 
 
(Z)-methyl 5-(9-methoxydibenzo [b,f] azocin-5 (6H) -yl)-5-oxopenta-noate (61) 
Compound 56 (75 mg, 0.46 mmol) was dissolved in dry CH2Cl2 
(4 mL) and NEt3 (85 µL, 0.61 mmol) was added. The mixture 
was cooled to 0 ºC, whereupon methyl 5-chloro-5-
oxopentanoate (53 µL, 0.46 mmol) was added. The reaction 
was stirred for 90 minutes and another portion of methyl 5-
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chloro-5-oxopentanoate (23 µL, 0.2 mmol) was added. After 45 minutes the reaction was 
quenched with H2O (5 mL). The mixture was diluted with CH2Cl2 (10 mL) and washed with 
2M aqueous NaOH (2 × 10 mL), 2M aqueous HCl (2 × 10 mL), H2O (2 × 10 mL) and brine 
(10 mL). Next, the organic layer was dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by gradient column chromatography (EtOAc/n-heptane, 1:4 to 
1:2) to obtain compound 61 as a yellow solid (84 mg, 76%). RF = 0.20 (EtOAc/n-heptane, 
1:2). 
1
H-NMR (400 MHz, CDCl3) δ: 7.25-7.21 (m, 3H), 7.17 (d, J = 8.4 Hz, 1H), 7.14-7.11 
(m, 1H), 6.74 (d, J = 12.9 Hz, 1H), 6.69 (dd, J = 8.4, 2.7 Hz, 1H), 6.64-6.58 (m, 1H), 5.38 
(d, J = 14.7 Hz, 1H), 4.19 (d, J = 14.7 Hz, 1H), 3.73 (s, 3H), 3.57 (s, 3H), 2.41 (q, J = 7.0 
Hz, 2H), 2.17 (q, J = 7.4 Hz, 2H), 1.84-1.79 (m, 2H). 
13
C-NMR (75 MHz, CDCl3) δ: 173.5, 
171.8, 158.2, 140.7, 137.3, 136.2, 132.5, 131.4, 130.9, 128.3, 128.1, 127.9, 127.7, 126.7, 
116.5, 112.7, 55.1, 53.8, 51.3, 33.5, 33.0, 20.4. FT-IR νmax film (cm
-1
): 2950, 2920, 2850, 
1731, 1658, 1606, 1576, 1493, 1442, 1403, 1521, 1204, 1169, 1040, 767. HRMS (ESI+) 
m/z calcd for C22H23NO4 [M+H]
+
 366.1705, found 366.1701. 
 
methyl 5-(11,12-dibromo-9-chloro-11,12-dihydrodibenzo [b,f] azocin-5(6H)-yl)-5-
oxopentanoate (62)  
Compound 57 (1 g, 2.7 mmol) was dissolved in CH2Cl2 (50 mL) 
and the solution was cooled to 0 ºC. A solution of Br2 (154 µl, 3 
mmol) in CH2Cl2 (5 mL) was added dropwise and after 2 hours at 
0 ºC additional Br2 (20 μL, 0.39 mmol) in CH2Cl2 (1 mL) was 
added. After 1 hour the reaction was quenched by addition of 
saturated aqueous NaHSO3 (50 mL), and layers were separated. 
The organic layer was washed with saturated aqueous NaHSO3-
solution (50 mL), water (2 × 50 mL) and brine (50 mL) and 
subsequently dried over MgSO4. The volatiles were removed under reduced pressure and 
the crude product was purified by gradient column chromatography (EtOAc/n-heptane, 1:4 
to 1:2) to obtain compound 62 (1.02 g, 71%) as mixture of two diastereoisomers 
(62X:62Y, 1:0.8). The isomers could be separated however due to slow isomerization of X 
to Y, no full analysis of 62Y was performed.Analytical data for 62X: RF = 0.30 (EtOAc/n-
heptane, 1:2). 
1
H-NMR (300 MHz, CDCl3) δ: 7.72 (d, J = 2.1 Hz, 1H), 7.28-7.15 (m, 2H), 
7.12-6.94 (m, 3H), 6.83 (d, J = 8.3 Hz, 1H), 5.85 (d, J = 9.9 Hz, 1H), 5.77 (d, J = 14.8 Hz, 
1H), 5.12 (d, J = 10.0 Hz, 1H), 4.14 (d, J = 14.8 Hz, 1H), 3.61 (s, 3H), 2.97-2.27 (m, 3H), 
2.27-2.13 (m, 1H), 2.08-1.92 (m, 2H). 
13
C-NMR (75 MHz, CDCl3) δ: 173.6, 172.7, 138.9, 
137.8, 137.0, 134.7, 131.5, 130.9 (2C), 130.7, 130.4, 129.6, 129.0, 128.9, 59.5, 54.5, 
51.8, 51.5, 34.8, 33.3, 20.3. HRMS (ESI+) m/z calcd for C21H21Br2ClNO3 [M+H]
+
 
527.9577, found 527.9564. 62Y: RF = 0.35 (EtOAc/n-heptane, 1:2). 
1
H-NMR (400 MHz, 
CDCl) δ 7.65 (dd, J = 7.8, 1.3 Hz, 1H), 7.25-6.98 (m, 4H), 6.88 – 6.78 (m, 2H), 5.71 (d, J = 
9.6 Hz, 1H), 5.14 (d, J = 9.6 Hz, 1H), 5.13 (d, J = 14.5 Hz, 1H), 4.95 (d, J = 14.0 Hz, 1H), 
3.63 (s, 3H), 2.48-2.31 (m, 3H), 2.26-2.05 (m, 1H), 2.04-1.80 (m, 2H). 
 
methyl 5-oxo-5-(8,11,12-tribromo-9-chloro-11,12-dihydrodibenzo[b,f]azocin-5(6H)-
yl)pentanoate (63)  
Compound 58 (100 mg, 0.22 mmol) was dissolved in CH2Cl2 (10 
mL) and the solution was cooled to 0 ºC. A solution of Br2 (11 μl, 
0.22 mmol) in CH2Cl2 (1 mL) was added dropwise and the 
reaction was stirred at 0 ºC. After 2 hours, the reaction was 
quenched with saturated aqueous NaHSO3 (10 mL). The layers 
were separated and the H2O-layer was extracted with CH2Cl2 (10 
mL). The combined organic layers were washed with saturated 
aqueous NaHSO3 (20 mL), water (2 × 20 mL) and brine (20 mL) 
and dried over MgSO4. The solvents were removed under reduced pressure to obtain 63 
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as white solid (130 mg, 96%). 63 was obtained as a mixture of two diastereoisomers 
(63X:63Y, 0.32:1). For the 
1
H-NMR signals from 63X are designated with *, signals from 
63Y with 
o
. In the 
13
C-NMR data, only peaks are given from major isomer 63X. 
1
H-NMR 
(400 MHz, CDCl3) δ 7.82* (s, 0.3H), 7.65
o
 (d, J = 7.7 Hz, 1H), 7.35
o
 (s, 1H), 7.32-7.08*
,o
 
(m, 3.4H), 7.02
o
 (s, 1H), 7.00* (s, 0.3H), 6.90
o
 (d, J = 7.8 Hz, 1H), 5.80* (d, J = 9.8 Hz, 
0.3H), 5.79* (d, J = 15.1 Hz, 0.3H), 5.69
o
 (d, J = 9.6 Hz, 1H), 5.12*
,o
 (d, J = 9.5 Hz, 1.3H), 
5.08
o
 (d, J = 14.6 Hz, 1H), 4.92
o
 (d, J = 14.3 Hz, 1H), 4.09* (d, J = 15.3 Hz, 0.3H), 3.63
o
 
(d, J = 0.7 Hz, 3H), 3.62* (s, 1H), 2.60-2.29*
,o
 (m, 4H), 2.21-2.02*
,o
 (m, 1.3H), 2.01-1.83*
,o
 
(m, 2.6H). 
13
C-NMR (75 MHz, CDCl3) δ: 173.6, 172.8, 137.9, 137.7, 136.8, 134.9, 134.2, 
133.2, 131.0 (2C), 130.8, 130.5, 130.0, 122.7, 59.1, 53.9, 51.5, 51.3, 34.7, 33.2, 20.3. 
HRMS (ESI+) m/z calcd for C21H20Br3ClNO3 [M+H]
+
 605.8682, found 605.8686. 
 
methyl 5-oxo-5-(8,11,12-tribromo-11,12-dihydrodibenzo[b,f]azo-cin-5(6H)-yl) 
pentanoate (64) 
Compound 59 (100 mg, 0.24 mmol) was dissolved in dry CH2Cl2 
(5 mL). The solution was cooled to 0 ºC and Br2 (13 µL, 0.24 
mmol) was added. After stirring for 1.5 hour, additional Br2 (13 
μL, 0.24 mmol) was added and the reaction was stirred for an 
additional hour. Hereupon, the reaction was quenched with 
saturated aqueous Na2SO3 (5 mL). The mixture was diluted with 
CH2Cl2 (10 mL) and washed with saturated aqueous Na2SO3 (2 × 
10 mL), H2O (2 × 10 mL) and brine (10 mL). Next, the organic 
layer was dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by gradient column chromatography (EtOAc/n-heptane, 1:4 to 
1:2) to obtain compound 64 as a white solid (111 mg, 80%). Compound 64 was obtained 
as mixture of diastereoisomers (64X : 64Y, 1:0.47). The major isomer (64X) could be 
obtained pure, due to slow isomerization of 64Y to 64X, no spectrum of pure 64Y was 
obtained. Analytical data for 64X: RF = 0.25 (EtOAc/n-heptane, 1:2). 
1
H-NMR (400 MHz, 
CDCl3) δ: 
1
H-NMR (400 MHz, CDCl3) δ: 7.61 (d, J = 8.4 Hz, 1H), 7.36 – 7.26 (m, 2H), 7.19 
(td, J = 7.6, 1.4 Hz, 1H), 7.11 – 7.03 (m, 2H), 7.00 (dd, J = 7.8, 1.4 Hz, 1H), 5.84 (d, J = 
10.0 Hz, 1H), 5.82 (d, J = 15.1 Hz, 1H), 5.12 (d, J = 10.0 Hz, 1H), 4.09 (d, J = 15.2 Hz, 
1H), 3.62 (s, 3H), 2.41-2.27 (m, 3H), 2.25 – 2.14 (m, 1H), 2.09 – 1.94 (m, 2H). 13C-NMR 
(75 MHz, CDCl3) δ: 173.6, 172.8, 137.8, 136.8, 136.1, 135.0, 132.2, 131.8, 130.8 (2C), 
130.5, 130.4, 129.7, 122.6, 59.4, 54.8, 51.9, 51.5, 34.7, 33.2, 20.3. FT-IR νmax film (cm
-1
): 
3453, 2953, 2367, 1734, 1660, 1593, 1484, 1441, 1398, 1254, 1203, 1179, 1152, 1015, 
875, 844, 801, 769. HRMS (ESI+) m/z calcd for C21H21Br3NO3 [M+H]
+
 571.9090, found 
571.9080. Analytical data for 64Y: 
1
H-NMR (400 MHz, CDCl3) δ: 7.68-7.61 (m, 1H), 7.38-
7.12 (m, 4H), 6.88 (dd, J = 7.7, 1.3 Hz, 1H), 6.79 (d, J = 8.2 Hz, 1H), 5.72 (d, J = 9.4 Hz, 
1H), 5.19 (d, J = 9.6 Hz, 1H), 5.09 (d, J = 14.7 Hz, 2H), 4.96 (d, J = 14.1 Hz, 1H), 3.63 (s, 
3H), 2.45 – 2.30 (m, 3H), 2.24 – 2.11 (m, 1H), 2.12 – 1.83 (m, 2H). 
 
methyl 5-(11,12-dibromo-8-nitro-11,12-dihydrodibenzo[b,f]azocin-5(6H)-yl)-5-
oxopentanoate (65)  
Compound 60 (25 mg, 66 μmol) was dissolved in CH2Cl2 (2 
mL) and the reaction was cooled to 0 ºC. A solution of Br2 (4.1 
µl, 79 μmol) in CH2Cl2 (2 mL) was added dropwise. The 
reaction was stirred at 0 ºC for 1 hour, and subsequently 
quenched with saturated aqueous NaHSO3 (10 mL) and diluted 
with CH2Cl2 (10 mL). The organic layer was washed with 
saturated aqueous NaHSO3 (10 mL), water (2 × 10 mL) and 
brine (10 mL) and dried over MgSO4. The solvents were 
evaporated under reduced pressure to obtain 65 as a red solid (30 mg, 84%). 65 was 
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obtained as a mixture of two diastereoisomers (65X:65Y, 0.42:1). For the 
1
H-NMR signals 
from 65X are designated with *, signals from 65Y with 
o
. 
1
H-NMR (400 MHz, CDCl3) δ: 
8.04* (dd, J = 8.6, 2.0 Hz, 0.43H), 7.99-7.90*
,o
 (m, 2.5H), 7.79* (d, J = 2.0 Hz, 0.4H), 
7.66
o
 (dd, J = 7.8, 1.4 Hz, 1H), 7.34-7.14*
,o
 (m, 3.1H), 7.12*
,o
 (d, J = 8.4 Hz, 1.2H), 7.09-
6.99
o
 (m, 1H), 6.91
o
 (dd, J = 7.8, 1.3 Hz, 1H), 5.93* (d, J = 11.6 Hz, 0.43H), 5.92* (d, J = 
13.7 Hz, 0.43H), 5.75
o
 (d, J = 9.5 Hz, 1H), 5.28
o
 (d, J = 9.6 Hz, 1H), 5.15* (d, J = 9.9 Hz, 
0.43H), 5.04
o
 (d, J = 14.3 Hz, 1H), 4.28* (d, J = 15.3 Hz, 0.43H), 3.63
o
 (s, 3H), 3.62* (s, 
1H), 2.48-2.39*
,o
 (m, 1.45H), 2.39-2.32*
,o
 (m, 3H), 2.17-2.05*
,o
 (m, 1.3H), 2.04-1.89*
,o
 (m, 
3.4H). HRMS (ESI+) m/z calcd for C21H21Br2N2O5 [M+H]
+
 538.9817, found 538.9822. 
 
methyl 5-(11,12-dibromo-9-methoxy-11,12-dihydrodibenzo[b,f]azocin-5(6H)-yl)-5-
oxopentanoate (66)  
Compound 61 (91 mg, 0.25 mmol) was dissolved in dry CH2Cl2 
(8 mL). The solution was cooled to 0 ºC and a solution of Br2 
(14 µL, 0.27 mmol) in CH2Cl2 (1 mL) was added. After stirring 
for 1.5 hour, another portion of Br2 (20 µL, 0.39 mmol) in 
CH2Cl2 (1 mL) was added. After stirring for 75 minutes an extra 
portion of Br2 (15 µL, 0.29 mmol) in CH2Cl2 (1 mL) was added. 
After stirring for another 75 minutes, the reaction was quenched 
with a saturated aqueous Na2SO3-solution (10 mL). The mixture 
was diluted with CH2Cl2 (25 mL) and washed with H2O (2 × 15 mL) and brine (15 mL). 
Next, the organic layer was dried over MgSO4 and concentrated in vacuo. The crude 
product (which was still a mixture of 66X and 66Y, 1:0.2) was purified by gradient column 
chromatography (EtOAc/n-heptane, 1:4 to 1:2) to obtain compound 66X as a white solid 
(50 mg, 39%). After column chromatography, 66 was obtained as a single diastereoisomer 
(66X). RF = 0.15 (EtOAc/n-heptane, 1:2). 
1
H-NMR (300 MHz, CDCl3) δ: δ 7.30-7.25 (m, 
1H), 7.22 (dd, J = 7.6, 1.6 Hz, 1H), 7.14 (td, J = 7.5, 1.3 Hz, 1H), 7.03 (dd, J = 7.7, 1.5 Hz, 
1H), 6.96 (dd, J = 7.7, 1.3 Hz, 1H), 6.78 (d, J = 8.3 Hz, 1H), 6.54 (dd, J = 8.4, 2.6 Hz, 1H), 
5.85 (d, J = 9.9 Hz, 1H), 5.71 (d, J = 14.7 Hz, 1H), 5.12 (d, J = 9.9 Hz, 1H), 4.12 (d, J = 
14.8 Hz, 1H), 3.60 (s, 3H), 2.45-2.24 (m, 3H), 2.24-2.11 (m, 1H), 2.07-1.89 (m, 2H). 
13
C-
NMR (75 MHz, CDCl3) δ: 173.6, 172.6, 159.8, 138.3, 138.1, 137.3, 130.9, 130.8, 130.5, 
130.4, 129.3, 124.8, 114.7, 113.7, 60.1, 55.7, 55.3, 51.8, 51.4, 34.9, 33.3, 20.4. FT-IR 
νmax film (cm
-1
): 2920, 2855, 1735, 1658, 1610, 1580, 1502, 1463, 1385, 1286, 1251, 
1200, 1096, 1040, 824, 772, 715, 672, 612. HRMS (ESI+) m/z calcd for C22H24Br2NO4 
[M+H]
+
 524.0072, found 524.0096. 
 
methyl 5- (9-chlorodidehydrodibenzo [b,f] azocin-5(6H)-yl)-5-oxopentanoate (67)  
Compound 62A (90 mg, 0.17 mmol) was dissolved in dry THF (3 
mL) under Ar-atmosphere in a flame-dried flask. The solution was 
cooled to -40 ºC and a KO
t
Bu-solution in THF (1M, 340 μL, 0.34 
mmol) was added dropwise. After stirring at -40 ºC for 1.5 hour, 
additional KO
t
Bu-solution in THF (1M, 50 μL, 0.05 mmol) was 
added. After 30 minutes, the reaction was quenched with H2O (5 
mL) and diluted with CH2Cl2 (10 mL). The layers were separated 
and the organic layer was washed with H2O (3 × 15 mL) and 
brine (15 mL) and subsequently dried over MgSO4. The solvents were removed under 
reduced pressure and the crude product was purified by column chromatography 
(EtOAc/n-heptane, 1:3). Compound 67 was obtained as a white solid (23 mg, 37%), with a 
5% contamination of compound 57. 
1
H-NMR (300 MHz, CDCl3) δ: 7.60 (d, J = 8.2 Hz, 1H), 
7.48-7.35 (m, 3H), 7.34-7.27 (m, 2H), 7.21 (d, J = 2.2 Hz, 1H), 5.11 (d, J = 13.8 Hz. 1H), 
3.59 (d, J = 13.9 Hz, 1H), 3.55 (s, 3H), 2.43-2.21 (m, 1H), 2.20-1.98 (m, 2H), 1.98-1.82 
(m, 1H), 1.82-1.64 (m, 2H). 
13
C-NMR (75 MHz, CDCl3) δ: 173.4, 172.5, 151.7, 146.2, 
 114 Dibenzoazacyclooctynes: Synthesis and Bioconjugation 
 
133.5, 133.3, 129.0, 128.7, 128.2, 128.1, 127.2, 125.4, 124.6, 122.0, 113.3, 109.2, 54.7, 
51.4, 33.6, 32.8, 20.5. HRMS (ESI+) m/z calcd for C21H19ClNO3 [M+H]
+
 368.1054, found 
368.1043. 
 
methyl 5- (8-bromodidehydrodibenzo [b,f] azocin-5(6H)-yl)-5-oxopentanoate (69)  
Compound 64A (75 mg, 0.13 mmol) was dissolved in dry THF in 
a flame-dried flask under Ar-atmosphere, and the solution was 
cooled to -40 ºC.  Next, a solution of KO
t
Bu in THF (1M, 260 μL, 
0.26 mmol) was added dropwise. After 2 hours, only one bromide 
was eliminated, whereupon additional KO
t
Bu (130 μL, 0.13 mmol) 
was added. After each subsequent hour an additional amount of 
KO
t
Bu (30 μL, 0.03 mmol) was added, while maintaining the 
reaction at -40 ºC. After 5.5 hours the reaction was completed and quenched by the 
addition of H2O (5 mL). The H2O-layer was extracted with EtOAc (3 × 10 mL). The 
combined organic layers were washed with H2O (20 mL), and brine (20 mL) and 
subsequently dried over MgSO4. The solvents were removed under reduced pressure and 
the crude product was purified by gradient column chromatography (EtOAc/n-heptane, 1:4 
to 1:2) to obtain compound 69 as a brown oil with a 2% contamination of 59 (20 mg, 37%). 
1
H-NMR (400 MHz, CDCl3) δ: 7.84 (d, J = 2.0 Hz, 1H), 7.44 (ddd, J = 8.1, 2.0, 0.4 Hz, 
1H), 7.42-7.36 (m, 3H), 7.35-7.30 (m, 1H), 7.10 (d, J = 7.6 Hz, 1H), 5.08 (d, J = 13.9 Hz, 
1H), 3.61 (d, J = 13.9 Hz, 1H), 3.56 (s, 3H), 2.36-2.24 (m, 1H), 2.21-2.05 (m, 2H), 1.97-
1.85 (m, 1H), 1.83-1.69 (m, 2H).
 13
C-NMR (75 MHz, CDCl3) δ: 173.4, 172.5, 151.5, 149.6, 
135.3, 131.0, 129.0, 128.6, 128.2, 127.1, 126.5, 122.5, 122.3, 122.0, 113.9, 108.8, 54.8, 
51.4, 33.6, 32.8, 20.5. HRMS (ESI+) m/z calcd for C21H18BrNNaO3 [M+Na]
+
 434.0368, 
found 434.0366. 
 
methyl 5- (9-methoxydidehydrodibenzo [b,f] azocin-5(6H)-yl)-5-oxopentanoate (71) 
Compound 66 (42 mg, 0.08 mmol) was dissolved in dry THF in 
a flame-dried flask under Ar-atmosphere, and the solution was 
cooled to -40 ºC. Next, a solution of KO
t
Bu in THF (1M, 160 μL, 
0.16 mmol) was added dropwise. After 2 hours, only one 
bromide was eliminated, whereupon additional KO
t
Bu (80 μL, 
0.08 mmol) was added. After each subsequent hour an 
additional amount of KO
tBu (40 μL, 0.04 mmol) was added, 
while maintaining the reaction at -40 ºC. After 5.5 hours the reaction was completed and 
quenched by the addition of H2O (5 mL). The H2O-layer was extracted with EtOAc (3 × 10 
mL). The combined organic layers were washed with H2O (20 mL), and brine (20 mL) and 
subsequently dried over MgSO4. The solvents were removed under reduced pressure and 
the crude product was purified by gradient column chromatography (EtOAc/n-heptane, 1:4 
to 1:2) to obtain compound 71 as a brown oil (10 mg, 34%). 
1
H-NMR (400 MHz, CDCl3) δ: 
7.59 (d, J = 8.5 Hz, 1H), 7.45-7.33 (m, 3H), 7.32-7.28 (m, 1H), 6.90 (dd, J = 8.5, 2.7 Hz, 
1H), 6.78 (d, J = 2.7 Hz, 1H), 5.11 (d, J = 13.9 Hz, 1H), 3.81 (s, 3H), 3.59 (d, J = 13.9 Hz, 
1H), 3.56 (s, 3H), 2.34-2.26 (m, 1H), 2.19-2.07 (m, 2H), 1.96-1.86 (m, 1H), 1.82-1.72 (m, 
2H).
 13
C-NMR (75 MHz, CDCl3) δ 173.1, 172.0, 158.5, 151.4, 140.0, 132.7, 128.5, 128.0, 
127.5, 126.7, 123.5, 122.0, 114.2, 113.5, 110.5, 107.5, 55.0, 54.3, 50.9, 33.3, 32.4, 20.6. 
HRMS (ESI+) m/z calcd for C22H21NNaO4 [M+Na]
+
 386.1368, found 368.1372. 
 
3-methoxy-N-(3-methoxybenzyl)aniline (79)  
To a solution of 3-methoxyaniline (615 μL, 5.5 mmol) in 
dry MeOH (50 mL), 3-methoxybenzaldehyde (608 μL, 5.0 
mmol) was added and the mixture was stirred for 1.5 hour. 
Next, NaBH4 (567 mg, 15.0 mmol) was added. After 
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stirring for 30 minutes, the reaction was quenched with H2O (25 mL). The H2O-layer was 
extracted with EtOAc (2 × 75 mL) and the organic layers were combined and washed with 
2M aqueous NaOH (50 mL), H2O (2 × 50 mL) and brine (50 mL). Next, the organic layer 
was dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
column chromatography (EtOAc/n-heptane 1:9) to obtain compound 79 as a yellow oil 
(1.19 g, 98%). RF = 0.30 (EtOAc/n-heptane, 1:4). 
1
H-NMR (400 MHz, CDCl3) δ: 7.25 (t, J 
= 7.9 Hz, 1H), 7.07 (t, J = 8.1 Hz, 1H), 6.95 (d, J = 7.5 Hz, 1H), 6.92 (m, 1H), 6.81 (dd, J = 
8.2, 2.6 Hz, 1H), 6.30-6.24 (m, 2H), 6.19 (t, J = 2.3 Hz, 1H), 4.29 (s, 2H), 3.79 (s, 3H), 
3.75 (s, 3H). 
13
C-NMR (75 MHz, CDCl3) δ: 160.7, 159.8, 149.5, 141.0, 129.9, 129.5, 
119.6, 112.9, 112.5, 105.9, 102.6, 98.8, 55.1, 54.9, 48.2. FT-IR νmax film (cm
-1
): 3412, 
3002, 2933, 2829, 1597, 1489, 1463, 1429, 1256, 1217, 1165, 1044, 983, 828, 759, 685, 
556, 452. HRMS (ESI+) m/z calcd for C15H18NO2 [M+H]
+
 244.1338, found 244.1341. 
 
Methyl 5-((3-methoxybenzyl) (3-methoxyphenyl) amino) -5-oxopentanoate (80)  
Compound 79 (652 mg, 2.7 mmol) was dissolved in CH2Cl2 
(20 mL). Then, NEt3 (750 µL, 5.4 mmol) was added. 
Subsequently, the mixture was cooled to 0 ºC and then 
methyl 5-chloro-5-oxopentanoate (354 µL, 2.56 mmol) was 
added. The reaction was stirred for 1.5 hour whereupon it 
was quenched with water (10 mL), diluted with CH2Cl2 (10 
mL) and washed with 2M NaOH (2 × 20 mL), 2M HCl (2 × 
20 mL), water (2 × 20 mL) and brine (20 mL). The organic 
layer was dried over MgSO4 and concentrated in vacuo. The product was purified by 
gradient column chromatography (EtOAc/n-heptane, 1:4 to 1:2). The product was 
obtained as a brown oil (510 mg, 54%). 
1
H-NMR (400 MHz, CDCl3) δ: 
1
H-NMR (400 MHz, 
CDCl3) δ: 7.22 (t, J = 8.0 Hz, 1H), 7.17 (t, J = 7.9 Hz, 1H), 6.85-6.82 (m, 1H), 6.80-6.76 
(m, 3H), 6.57 (d, J = 7.8 Hz, 1H), 6.50 (s br., 1H), 4.83 (s, 2H), 3.75 (s, 3H), 3.72 (s, 3H), 
3.60 (s, 3H), 2.32 (t, J = 7.3 Hz, 2H), 2.16 (t, J = 7.2 Hz, 2H), 1.97-1.90 (m, 2H). 
13
C-NMR 
(75 MHz, CDCl3) δ: 173.5, 171.9, 160.3, 159.6, 143.4, 139.1, 130.1, 129.3, 121.1, 120.5, 
114.1 (2C), 113.5, 113.0, 55.3, 55.2, 52.8, 51.4, 33.2 (2C), 20.7. FT-IR νmax film (cm
-1
): 
2946, 2842, 1735, 1653, 1597, 1489, 1433, 1394, 1260, 1191, 1152, 1044, 862, 785, 703, 
577, 556. HRMS (ESI+) m/z calcd for C21H26NO5 [M+H]
+
 372.1811, found 372.1804. 
 
Methyl 5-(4,9-dimethoxy-1-oxo-1H-dibenzo[b,f]cyclopropa[d]azocin-6(7H)-yl)-5-
oxopentanoate (81)  
A flame-dried flask under Ar-atmosphere was charged 
with aluminium chloride (144 mg, 1.08 mmol) in dry 
CH2Cl2 (3 mL) at -78 ºC. Perchlorocycloprop-1-ene (53 
μL, 0.43 mmol) was added dropwise and stirred for one 
hour. A solution of 80 (100 mg, 0.269 mmol) in dry 
CH2Cl2 (0.6 ml) was added dropwise at -78 ºC. The 
mixture was stirred for 2.5 hours at -78 ºC and then 
slowly warmed to room temperature and stirred for 16 
hours. Subsequently, the reaction was quenched by the 
addition of 1M aqueous HCl (5 mL). After stirring for 5 minutes, H2O (5 mL) was added 
and the layers were separated. The H2O-layer was extracted with CH2Cl2 (2 × 10 mL) and 
the organic layers were combined and washed with brine (20 mL). Next, the organic layer 
was dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
gradient column chromatography (EtOAc/n-heptane, 1:3 to 1:0) to obtain compound 81 as 
a green oil (34 mg, 81 μmol, 30%). RF = 0.35 (EtOAc). 
1
H-NMR (400 MHz, CDCl3) δ: 8.00 
(d, J = 8.6 Hz, 1H), 7.89 (d, J = 8.5 Hz, 1H), 7.25 (d, J = 2.5 Hz, 1H), 7.05 (dd, J = 8.6, 2.5 
Hz, 1H), 6.95 (dd, J = 8.5, 2.6 Hz, 1H), 6.89 (d, J = 2.5 Hz, 1H), 5.18 (d, J = 14.3 Hz, 1H), 
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4.09 (d, J = 14.3 Hz, 1H), 3.93 (s, 3H), 3.91 (s, 3H), 3.56 (s, 3H), 2.37-2.29 (m, 1H), 2.18-
2.10 (m, 1H), 2.04-1.89 (m, 2H), 1.82-1.66 (m, 2H). 
13
C-NMR (75 MHz, CDCl3) δ: 173.1, 
172.5, 162.9, 162.6, 152.4, 145.8, 143.1, 141.4, 138.9, 135.6, 135.1, 118.1, 115.4, 115.2, 
114.9, 113.7, 113.6, 56.0, 55.8, 55.5, 51.4, 33.4, 32.5, 20.5. FT-IR νmax film (cm
-1
): 3447, 
2941, 2837, 1848, 1740, 1662, 1601, 1558, 1429, 1364, 1286, 1256, 1022, 828, 733. 
HRMS (ESI+) m/z calcd for C24H23NO6Na [M+Na]
+
 444.1423, found 444.1435.  
 
methyl 5-(3,8-dimethoxydidehydrodibenzo[b,f]azocin-5(6H)-yl)-5-oxopentanoate (78) 
Compound 81 (100 mg, 0.237 mmol) was dissolved in 
acetonitrile (5 mL) and irradiated with UV-light using a 
Bluespot 2 Easycure for 65 minutes. After completion of 
the reaction, the solvent was removed under reduced 
pressure. The crude product was purified by gradient 
column chromatography (EtOAc/n-heptane, 1:4 to 1:2) to 
obtain compound 78 as an orange oil (33 mg, 0.084 
mmol, 35%). RF = 0.30 (EtOAc/n-heptane, 1:1). 
1
H-NMR 
(300 MHz, CDCl3) δ: 7.27 (d, J = 8.3 Hz, 1H), 7.23 (d, J = 2.6 Hz, 1H), 7.13 (d, J = 8.4 Hz, 
1H), 6.91-6.87 (m, 2H), 6.81 (dd, J = 8.5, 2.6 Hz, 1H), 5.06 (d, J = 13.8 Hz, 1H), 3.85 (s, 
6H), 3.69 (d, J = 13.7 Hz, 1H), 3.57 (s, 3H), 2.22-1.92 (m, 4H), 1.81-1.71 (m, 2H). 
13
C-
NMR (75 MHz, CDCl3) δ: 173.5, 172.6, 159.3 (2C), 152.4, 149.6, 127.2, 126.1, 118.3, 
115.8, 115.1, 114.9, 113.9, 113.3, 113.1, 106.5, 55.6 (2C), 55.3, 51.3, 33.6, 32.8, 20.6. 
FT-IR νmax film (cm
-1
): 2928, 2850, 2163, 1727, 1658, 1601, 1563, 1489, 1433, 1390, 
1286, 1264, 1230, 1195, 1174, 1035, 819, 750, 590, 504. HRMS (ESI+) m/z calcd for 
C23H24NO5 [M+H]
+
 394.16545, found 394.16571. 
 
3-Methoxy-7-nitro-5,10-dihydroindeno[1,2-b]indole (84)  
To a solution of 6-methoxy-2,3-dihydro-1H-inden-1-one 
(811 mg, 5 mmol) in EtOH (25 mL) was added (3-
nitrophenyl)hydrazine·HCl (951 mg, 5 mmol) followed by 
acetic acid (2 drops) at room temperature. While stirring, 
the yellow solution was heated to reflux for 65 minutes 
after which the solution had turned dark red. This solution was removed from the oil bath 
and allowed to cool to room temperature. Crystals precipitated and the solution was 
cooled to 0 ºC for 30 minutes. Subsequently the crystals were filtered via vacuum filtration 
and used without further purification. The crystals were dissolved in concentrated HCl (25 
mL). This solution was heated to reflux and vigorously stirred for 10 minutes. As the 
reaction proceeded the product began to precipitate. The solution was cooled to room 
temperature and poured into water (30 mL) and the product precipitated as a red solid. 
The solid was collected by vacuum filtration, azeotroped once with toluene and 
concentrated in vacuo to a red solid. This red solid was then dissolved in isopropanol (25 
mL) and concentrated sulfuric acid (0.5 mL) and warmed to reflux for 68 hours. The 
mixture was diluted with EtOAc (25 mL) and washed with water (2 × 25 mL); the organic 
layer was dried over MgSO4, filtered and concentrated in vacuo to an orange solid. The 
product was purified with gradient column chromatography (EtOAc/n-heptane, 1:10 to 
1:6). The product was obtained as an orange solid (291 mg, 21%). 
1
H-NMR (400 MHz, 
DMSO) δ 12.35 (s, 1H), 8.38 (d, J = 1.9 Hz, 1H), 7.92 (dd, J = 8.8, 2.2 Hz, 1H), 7.67 (d, J 
= 8.8 Hz, 1H), 7.49 (d, J = 8.2 Hz, 1H), 7.30 (d, J = 2.4 Hz, 1H), 6.88 (dd, J = 8.3, 2.5 Hz, 
1H), 3.82 (s, 3H), 3.69 (s, 2H). 
13
C-NMR (75 MHz, DMSO) δ 158.7, 150.0, 141.0, 140.2, 
138.9, 134.6, 128.5, 126.4, 121.7, 118.3, 114.9, 112.5, 109.1, 104.9, 55.3, 28.9. FT-IR 
νmax film (cm
-1
): 2353, 2334, 1520, 1345, 610, 461, 425, 412. HRMS (CI+) m/z calcd for 
C16H13N2O3 [M+H]
+
 281.0926, found 281.0906. 
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3-Methoxy-5-methyl-7-nitro-5,10-dihydroindeno[1,2-b]indole (87) 
To a solution of compound 84 (123 mg, 0.44 mmol) in 
toluene (2 mL) was added a catalytic amount of tetrabutyl 
ammonium iodide (10 mg, 0.027 mmol) and iodomethane 
(27 µL, 0.44 mmol). To this solution was added sodium 
hydroxide (1 mL, 50% in water) and the mixture was 
stirred vigorously at 35 ºC for 42 hours. The solution was diluted with toluene (5 mL) and 
the organic layer was separated from the aqueous layer. The aqueous layer was extracted 
with toluene (2 × 5 mL) and the organic layers were combined, dried over MgSO4, filtered 
and concentrated in vacuo to a brown solid. The product was purified with flash 
chromatography (EtOAc/n-heptane, 1:6). The product was obtained as a red solid (43 mg, 
33%). 
1
H-NMR (400 MHz, CDCl3) δ 8.36 (d, J = 2.0 Hz, 1H), 8.06 (dd, J = 8.8, 2.1 Hz, 
1H), 7.60 (d, J = 8.8 Hz, 1H), 7.48 (d, J = 8.7 Hz, 1H), 7.28 (d, J = 2.4 Hz, 1H), 6.88 (dd, J 
= 8.3, 2.4 Hz, 1H), 4.14 (s, 3H), 3.91 (s, 3H), 3.71 (s, 2H). 
13
C-NMR (75 MHz, CDCl3) δ 
159.09, 150.34, 140.71, 135.04, 129.36, 128.38, 126.36, 121.82, 120.72, 120.14, 118.35, 
115.62, 111.51, 106.93, 105.68, 55.70, 29.21. FT-IR νmax film (cm
-1
): 2920, 2353, 2332, 
1528, 1463, 1329, 599, 417, 413. HRMS (CI+) m/z calcd for C17H15N2O3 [M+H]
+
 295.1083, 
found 295.1076. 
 
7-Chloro-3-methoxy-5,10-dihydroindeno[1,2-b]indole (90)  
To a solution of 6-methoxy-2,3-dihydro-1H-inden-1-one 
(1.8 g, 11.3 mmol) and (3-chlorophenyl)hydrazine·HCl (2.0 
g, 11.3 mmol) in EtOH (20 mL) were added a few drops of 
acetic acid. Subsequently the reaction mixture was stirred 
at reflux for 15 minutes, after which the mixture was cooled 
to room temperature. EtOH was then removed whereupon the solid was dissolved in 
isopropanol (40 mL). Concentrated sulfuric acid (1.5 mL) was then added to the solution 
using a syringe. The solution was subsequently stirred at reflux for 18 hours. Upon cooling 
the solution to room temperature, some precipitate was formed, upon basifying the 
solution using an aqueous NaOH-solution (1M) to pH 10 additional precipitate formed. 
The solid was dissolved in CH2Cl2 (25 mL), after which H2O (25 mL) was added to wash 
the organic layer; the aqueous layer was extracted once with CH2Cl2 (25 mL). The organic 
layers were then combined, dried over MgSO4, filtered and concentrated in vacuo to yield 
a brown solid in 64% crude yield. The crude product was used without further purification. 
For analysis purposes the compound was purified using flash chromatography (EtOAc/n-
heptane, 1:10). 
1
H-NMR (400 MHz, CDCl3) δ 8.32 (s, 1H), 7.51 (d, J = 8.4 Hz, 1H), 7.41 
(d, J = 8.2 Hz, 1H), 7.41 (d, J = 1.9 Hz, 1H), 7.12 (dd, J = 8.4, 1.9 Hz, 1H), 7.02 (d, J = 2.4 
Hz, 1H), 6.77 (dd, J = 8.2, 2.4 Hz, 1H), 3.87 (s, 3H), 3.65 (s, 2H). 
13
C-NMR (75 MHz, 
CDCl3) δ 159.0, 143.8, 140.9, 139.7, 135.8, 125.8, 123.3, 122.9, 120.9, 120.0, 119.7, 
112.0, 110.3, 103.9, 55.6, 29.5. FT-IR νmax film (cm
-1
): 3378, 2937, 2353, 1623, 1537, 
1476, 1234, 1219, 806, 482. HRMS (ESI+) m/z calcd for C16H13ClNO [M+H]
+
 270.0686 , 
found 270.0688. 
 
7-Chloro-3-methoxy-5-methyl-5,10-dihydroindeno[1,2-b]indole (91)  
To a solution of compound 90 (3.04 g, 11.3 mmol) in 
toluene (35 mL) was added a catalytic amount of tetrabutyl 
ammonium iodide (154 mg, 0.42 mmol) and iodomethane 
(1.4 ml, 22.5 mmol). To this solution was added sodium 
hydroxide (2 mL, 50% in water) and the mixture was 
stirred vigorously at 35 ºC for two hours. The solution was diluted with toluene (50 mL) 
and the organic layer was separated from the aqueous layer. The aqueous layer was 
extracted with toluene (2 × 30 mL) and the organic layers were combined, dried over 
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MgSO4, filtered and concentrated in vacuo to obtain a brown solid. The product was 
purified by column chromatography (EtOAc/n-heptane, 1:10). The product was obtained 
as a yellow solid (1.42 g, 44% over two steps). 
1
H-NMR (400 MHz, CDCl3) δ 7.50 (d, J = 
8.4 Hz, 1H), 7.41 (d, J = 8.2 Hz, 1H), 7.35 (d, J = 1.7 Hz, 1H), 7.19 (d, J = 2.3 Hz, 1H), 
7.10 (dd, J = 8.4, 1.9 Hz, 1H), 6.77 (dd, J = 8.2, 2.4 Hz, 1H), 4.01 (s, 3H), 3.89 (s, 3H), 
3.63 (s, 2H). 
13
C-NMR (75 MHz, CDCl3) δ 159.2, 145.4, 142.5, 140.4, 136.5, 127.4, 126.2, 
123.0, 121.8, 120.5, 120.1, 110.2, 109.8, 105.1, 56.0, 31.5, 29.6. FT-IR νmax film (cm
-1
): 
2946, 2889, 2358, 1627, 1528, 1467, 1200, 1174, 1057, 798, 603, 421, 417. HRMS (ESI+) 
m/z calcd for C17H15ClNO [M+H]
+
 284.0842, found 284.0833. 
 
7-Chloro-3-methoxy-5-methyl-10-(trimethylsilyl)-5,10-dihydroindeno[1,2-b]indole 
(92) 
To a solution of crude compound 91 (284 mg, 1 mmol) in 
Et2O (6 mL) in a room temperature water bath was added 
n-BuLi (1.6 M in hexanes, 0.7 mL, 1.1 mmol) slowly while 
stirring. After two hours of stirring the solution was cooled 
to -78 ºC, and subsequently TMSCl (254 µL, 2 mmol) was 
added dropwise. The solution was immediately removed 
from the cold bath and allowed to warm to room temperature. After 20 minutes the white 
precipitate was filtered from the solution and rinsed with Et2O. Subsequently the solvent 
was removed and the product was purified using column chromatography (EtOAc/n-
heptane, 1:29). The product was isolated as a yellow solid (337 mg, 95%). 
1
H-NMR (400 
MHz, CDCl3) δ 7.53 (dd, J = 8.4, 0.4 Hz, 1H), 7.40 (dt, J = 8.5, 0.6 Hz, 1H), 7.36 (d, J = 
1.7 Hz, 1H), 7.26 (d, J = 2.3 Hz, 1H), 7.09 (dd, J = 8.5, 1.9 Hz, 1H), 6.80 (dd, J = 8.4, 2.5 
Hz, 1H), 4.04 (s, 3H), 3.90 (s, 3H), 3.65 (s, 1H), -0.04 (s, 9H). 
13
C-NMR (75 MHz, CDCl3) 
δ 157.9, 143.7, 142.3, 142.3, 134.2, 126.9, 124.9, 124.4, 122.1, 120.8, 119.6, 109.7, 
109.5, 103.8, 55.6, 35.8, 31.2, -2.38 (3C). FT-IR νmax film (cm
-1
): 2954, 2824, 1606, 1515, 
1463, 1243, 1195, 1057, 832, 798. HRMS (ESI+) m/z calcd for C20H23NOClSi [M+H]
+
 
356.1237, found 356.1237. 
 
3-chloro-8-methoxy-5-methyldidehydrobenzo[b,f]azocin-6(5H)-one (93)  
To a solution of compound 92 (150 mg, 0.42 mmol) in 
CH2Cl2 (15 mL) and a saturated aqueous NaHCO3-solution 
(2 mL) cooled to 0 ºC was added mCPBA (487 mg, 1.4 
mmol) portion wise over 5 minutes. After stirring for 20 
minutes at 0 ºC the solution was allowed to warm to room 
temperature for an additional 1.5 hours. The reaction was quenched with a solution of 1M 
NaOH (10 mL). The layers were separated and the aqueous layer was extracted with 
CH2Cl2 (2 × 15 mL) and EtOAc (15 mL). The organic layers were combined, washed with 
brine (15 mL) and subsequently dried over MgSO4, filtered and concentrated in vacuo to 
yield an oil that was used for triflation without further purification. The crude ketone was 
dissolved in anhydrous THF (5.5 mL) at -78 ºC; subsequently KHMDS (0.5 M in toluene, 
1.05 mL, 0.53 mmol) was added drop wise. The reaction mixture was then stirred at -78 
ºC for 40 minutes, after which triflic anhydride (96 µL, 0.57 mmol) was added quickly via a 
syringe. After 15 minutes stirring at -78 ºC the mixture was diluted with Et2O (22 mL) and 
tetrabutylammonium fluoride (1M in THF, 4.7 mL, 4.7 mmol) was added. The reaction was 
removed from the cold bath and warmed to room temperature over 40 minutes. The 
mixture was then quenched with saturated aqueous NaHCO3 (20 mL). The aqueous layer 
was subsequently extracted with EtOAc (2 × 30 mL) after which the organic layer was 
dried over MgSO4, filtered and concentrated in vacuo to an orange/brown oil. The product 
was then purified by gradient column chromatography (EtOAc/n-heptane, 1:10 to 1:6). The 
product was obtained as an orange solid (25.6 mg, 20%). 
1
H-NMR (400 MHz, CDCl3) δ 
 3 Synthesis of DIBAC analogues  119 
 
7.60 (d, J = 2.1 Hz, 1H), 7.36 (dd, J = 8.3, 2.1 Hz, 1H), 7.30 (d, J = 8.3 Hz, 1H), 7.29 (d, J 
= 8.6, 1H), 7.16 (d, J = 2.5 Hz, 1H), 6.97 (dd, J = 8.6, 2.6 Hz, 1H), 3.88 (s, 3H), 2.74 (s, 
3H). 
13
C-NMR (75 MHz, CDCl3) δ 176.0, 160.3, 156.6, 150.8, 134.7, 130.1, 128.4, 127.7, 
127.6, 121.3, 115.1, 113.6, 111.9, 110.8, 106.3, 55.7, 38.6. FT-IR νmax film (cm
-1
): 2928, 
2850, 2353, 2349, 1662, 1459, 1325, 1286, 1225, 1031, 824, 612. HRMS (ESI+) m/z 
calcd for C17H13ClNO2 [M+H]
+
 298.0635, found 298.0642, m/z calcd for C17H12ClNNaO2 
[M+Na]
+
 320.0454, found 320.0478. 
 
10-(Tert-butyldimethylsilyl)-7-chloro-3-methoxy-5-methyl-5,10-dihydroindeno[1,2-
b]indole (94)  
To a solution of compound 91 (750 mg, 2.6 mmol) in THF 
(2 mL) in a room temperature water bath n-BuLi (1.6 M in 
hexanes, 1.8 mL, 2.9 mmol) was added very slowly while 
stirring. After two hours of stirring the solution was cooled 
to -78 ºC, whereupon TBSCl (1M in THF) (5.3 mL, 5.3 
mmol) was added drop wise. The solution was then 
immediately removed from the cold bath and allowed to warm to room temperature. After 
two hours THF was removed, and the mixture was dissolved in Et2O (15 mL) in order for 
white precipitate to be formed. The precipitate was then filtered from solution and rinsed 
with Et2O; the solvent was removed in vacuo. The crude product was used for the next 
reaction. For analysis purposes the product was purified via flash chromatography 
(EtOAc/n-heptane, 1:19) resulting in a yellow solid. 
1
H NMR (400 MHz, CDCl3) δ 7.55 (d, J 
= 8.5 Hz, 1H), 7.44 (d, J = 8.4 Hz, 1H), 7.34 (d, J = 1.8 Hz, 1H), 7.24 (d, J = 2.5 Hz, 1H), 
7.08 (dd, J = 8.5, 1.9 Hz, 1H), 6.77 (dd, J = 8.4, 2.5 Hz, 1H), 4.00 (s, 3H), 3.90 (s, 3H), 
3.61 (s, 1H), 0.42 (s, 9H), 0.30 (s, 3H), 0.25 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 158.0, 
143.5, 142.9, 142.3, 134.4, 126.8, 125.4, 125.2, 122.4, 120.8, 119.6, 109.6, 109.4, 103.9, 
55.6, 35.0, 31.2, 26.9 (3C), 18.2, -3.8, -3.9. FT-IR νmax film (cm
-1
): 2915, 2846, 1606, 
1506, 1472, 1238, 1169, 966, 802, 737, 538. HRMS (ESI+) m/z calcd for C23H29ClNOSi 
[M+H]
+
 398.1707, found 398.1709. 
 
3.12.3 Kinetic experiments 
Kinetic experiments for 68, 70, 72, and 78 were performed similar as described in Section 
2.7.3. Due to increased reaction kinetics, 2.25 μmol alkyne was mixed with 2.25 μmol 
benzylazide in 0.5 mL CD3OD. The exact ratio between benzyl azide and alkyne was 
determined by comparison of the integrals of the aromatic signals and the benzyl ic 
protons of the alkyne. As the alkynes could not be obtained pure, the concentration of the 
benzyl azide was assumed to be accurate, and the alkyne concentration was adjusted 
using the ratio as determined in the NMR-spectrum. For 68, 70, 72, and 78, the rate 
constant was determined by comparing the signal from the methyl-ester of the starting 
material (δ: 3.52 ppm), to the signal from the methyl-ester of the product (δ: 3.60 ppm). 
Product formation was confirmed by mass spectrometry. For 68: HRMS (ESI+) m/z calcd 
for C28H26ClN4O3 [M+H]
+
 501.1693, found 501.1693. For 70: HRMS (ESI+) m/z calcd for 
C28H26BrN4O3 [M+H]
+
 545.1188, found 545.1189. For 72: HRMS (ESI+) m/z calcd for 
C29H29N4O4 [M+H]
+
 497.2189, found 497.2177. For 78: HRMS (ESI+) m/z calcd for 
C30H31N4O5 [M+H]
+
 527.2294, found 527.2280. 
For determination of the kinetics of 93 the following procedure was followed: 
A 5 mM solution of compound 93 and a 50 mM solution of benzyl azide were prepared in 
CD3CN. Next, 500 µL of BARAC solution and 50 µL benzylazide solution were added to 
an NMR tube. The conversion of the reaction was determined by comparing the signal 
from the methoxy-peak of the starting material (δ: 3.88 ppm), with the signal of the 
methoxy-peak of the product (δ: 3.78 and 3.79 ppm). 
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Heavy chain-only antibodies (VHHs) which can 
selectively target tumor cells and tumor vessels are 
of great interest for applications in the biomedical 
field. Here, we describe a method that allows site-
directed and controlled modification of a VHH (A12) 
against plexin D1, a transmembrane protein 
overexpressed on tumor vasculature. A12 was produced 
as an intein-fusion protein, which was subsequently 
subjected to expressed protein ligation (EPL) with 
different peptides. It was shown that this ligation 
did not affect the affinity of A12 towards its 
antigen. Using this strategy, A12 was equipped with 
both a carboxy-terminal cysteine and an azide. The 
free sulfhydryl group was subsequently used for thiol-
maleimide ligation with biotin and the azide was 
applied in a Strain Promoted Azide Alkyne 
Cycloaddition (SPAAC) with a fluorescent dye, thus 
yielding a dually labeled system. 
 
4 
Introducing functional handles to tumor-
targeting single domain antibody A12 
 
 122 Dibenzoazacyclooctynes: Synthesis and Bioconjugation 
 
4.1 Introduction 
Inhibition of angiogenesis is nowadays an established therapeutic concept in 
oncology for a number of tumor types. Unfortunately, with few exceptions the 
effects are generally limited and ultimately tumors escape these therapies.
1
 One of 
the possible explanations for this phenomenon is angiogenesis-independent 
growth which may occur in tissues with an intrinsically high density of blood 
vessels (e.g. brain, liver, lung).  
As in such cases angiogenesis inhibition alone does not suffice to deprive a 
tumor from blood, an interesting alternative has evolved by the targeting of 
existent blood vessels in tumors with the aim to induce tumor-specific 
coagulation.
2
 This coagulation would cause blood clogging specifically in tumor-
vessels and thereby cut-off the tumor from nutrients. In the last decade, different 
tumor vessel-targeting agents have been identified, e.g. the L19 single chain 
antibody
3
 and RGD peptides which interfere with the αvβ3-integrin function.
4
 
Radiolabeled RGD peptides have successfully been used for tumor imaging and 
radiotherapy.
5, 6
 
Another interesting tumor vessel target which was identified previously is Plexin 
D1.
7
 This is a single pass transmembrane protein expressed by tumor vasculature 
and tumor cells.
2, 7, 8
 Two llama heavy chain-only antibodies (VHH) against Plexin 
D1 were previously isolated via a phage display screening approach, i.e. A12 and 
F8.  
VHHs are 15-18 kDa recombinant antigen binding domains of IgG2 and IgG3 
heavy chain antibodies, which are found in cameloids.
9
 These nanobodies can be 
readily produced in cheap bacterial or yeast expression systems and show a 
number of advantages compared to conventional antibodies.
10
 The lack of 
hydrophobic domains makes them highly soluble; also their small size (one tenth 
the size of conventional antibodies) allows better penetration into tumors than 
conventional antibodies.
11
 The VHHs A12 and F8 specifically recognize tumor 
vasculature and tumor cells, and no healthy vasculature or cells.
8
    
In order to be able to use VHHs for imaging or therapy, efficient labeling 
strategies are required. Although many bioconjugation methods have been 
described for proteins,
12, 13
 VHH modification must meet special criteria. To date, 
reports on VHH conjugation are limited to NHS-ester or NCS-chemistry,
14-16
 SATA 
modification,
17
 and modification via a hexahistidine tag.
14
 Disadvantages of these 
methods are that they either require a very specific labeling agent, in case of the 
hexahistidine tag, or that potential complementarity determining regions (CDRs) 
are modified, thereby causing a loss of affinity. This risk is especially prominent 
since VHHs are small proteins, composed mostly of antigen binding sites. At-
random modification strategies (labeling of amine groups via diazo-transfer 
reactions
18, 19
 and NHS-ester chemistry)
20, 21
 are therefore likely to cause loss of 
functional characteristics. Also, labeling of the cysteine side chain using a thiol-
maleimide ligation
22, 23
 is not preferable as the two cysteines present in the VHH 
framework are involved in a disulfide bridge. Disruption of this intramolecular bond 
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will probably affect the VHH’s tertiary structure and affinity. Alternatively, azide 
handles can be introduced by expressing the VHH in auxotrophic bacteria where 
azidohomoalanine is built in instead of methionine.
24
 Again, this procedure may 
also influence the affinity, especially after ligation. Taking these limitations into 
account, labeling at the carboxy terminus, distant from the CDRs, is an attractive 
alternative. One of the more efficient methods to introduce a functional handle at 
the C-terminus is via Expressed Protein Ligation (EPL).
25-27
  
EPL can be used for the conjugation of proteins and peptides to the C-terminus 
of a target protein. To this end, the target protein is produced as a fusion protein, 
containing a C-terminal intein and chitin binding domain (CBD). Upon treatment 
with a thiol, followed by a N-terminal cysteine reagent, labeled proteins are formed 
(for a more detailed explanation, see Section 1.2.4). Performing EPL with a 
peptide containing a functional handle would introduce this moiety at a non-crucial 
site of the VHH, which then allows for the introduction of any label via a 
bioorthogonal ligation strategy.
28
 Furthermore, upon reaction, the thiol moiety of 
the N-terminal cysteine is retained, as shown in Scheme 1. EPL therefore allows 
for the introduction of two functional handles in one step at an innocuous site of 
the protein. Until now, to the best of our knowledge, this specific feature of EPL 
has not been explored. 
 
Scheme 1. Expressed Protein Ligation with a fusion protein of A12 to introduce two functional 
handles, i.e. a thiol and an azide. 
In the last decade, the azide moiety has become a well-studied functional 
handle,
29
 since it is relatively stable and small and is highly reactive in different 
bioorthogonal reactions, e.g. the Staudinger ligation, the Cu(I)-catalyzed Azide 
Alkyne Cycloaddition (CuAAC), and the Strain Promoted Azide Alkyne 
Cycloaddition (SPAAC)
30, 31
 It has been shown that azides can be introduced via 
Native Chemical Ligation,
32-34
 e.g. via a cysteine equipped with an azide,
34
 which 
was subsequently used in CuAAC. The disadvantage of using this reaction, 
however, is that it requires Cu(I), which is toxic to cells, affects protein activity, and 
highly limits in vivo applications. The SPAAC reaction, which proceeds 
spontaneously between cyclooctynes and azides
35-39
 is therefore a more attractive 
alternative for modification of VHHs.  
Using a thiol-maleimide ligation and a SPAAC reaction on VHH 2 (Scheme 1) 
allows us to combine different functional properties (e.g. improved circulation time 
by PEGylation, diagnostic moieties, therapeutic moieties) into one targeting 
construct. Ultimately, this can be applied for equipping the VHH with an imaging 
probe and a cargo-carrier, e.g. a polymersome, resulting in theragnostic targeting 
compounds, which will be discussed in Chapter 5.  
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In this chapter we describe the optimized procedure for the modification of an 
anti-plexin D1 VHH with different peptides using EPL, without loss of affinity for its 
antigen. We show that in this way a free thiol and an azide are introduced, which 
both can be used for labeling.  
 
4.2 Expressed Protein Ligation 
The A12 fusion protein was produced using the Intein-Mediated Purification with 
an Affinity Chitin-binding Tag (IMPACT) kit, thereby forming A12-Intein-Chitin 
Binding Domain (CBD) protein. The A12-part of the fusion protein furthermore 
contained a VSV-tag, which enables detection with specific antibodies and a His-
tag which allows for affinity purification.  
With the fusion protein in hand we first set out to investigate the cleavage of the 
protein from the intein with different thiol-containing probes. To that end, we 
treated the fusion protein (23 μM) with either 25 mM dithiothreitol (DTT), 50 mM 
sodium 2-sulfanylethanesulfonate (MESNA) (room temperature and 4 ºC) or 50 
mM of peptide 1. For DTT and MESNA this would result in the formation of 
thioester-functional A12, cleavage with peptide 1 would lead directly to the desired 
product. As can be seen in Figure 1 cleavage with DTT (lanes 1 and 2) or MESNA 
(lanes 5 and 6) proceeded smoothly at room temperature, and after one night full 
cleavage was observed. At 4 ºC cleavage proceeded significantly less efficient, as 
after 48 hours still no full conversion was obtained (lane 8). Incubation with 
peptide 1 unfortunately did not result in any cleavage (lanes 3 and 4, Figure 1), 
implying that cleavage with a small thiol-reagent is required prior to addition of the 
peptide. 
 
Figure 1. Cleavage of A12-Intein-CBD using different conditions; the green signal is related to 
A12, the red signal is related to the CBD. Lane 1: 25 mM DTT for 24 hours at r.t.; Lane 2: 50 mM 
DTT for 48 hours at r.t.; Lane 3: 50 mM peptide 1 for 24 hours at r.t.; Lane 4: 50 mM peptide 1 for 
48 hours at r.t.; Lane 5: 50 mM MESNA for 24 hours at r.t.; Lane 6: 50 mM MESNA for 48 hours at 
r.t.; Lane 7: 50 mM MESNA for 24 hours at 4 ºC; Lane 8: 50 mM MESNA for 48 hours at 4 ºC; 
Lane 9: A12-Intein-CBD. 
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Scheme 2. Cleavage of the intein using MESNA and thiophenol, followed by introduction of a 
biotin label, an azide functionality or an amine. A12-N3 is subsequently reacted with DIBAC-PEG44-
OMe yielding 7. 
For further optimization of the procedure we used commercially available peptide 
4, Scheme 2, as the biotin present in peptide 4 can easily be visualized on 
Western Blot. When peptide 4 was added to the reactive thio-ester without the 
addition of other reagents, two bands around 16 kDa were observed by Western 
Blot Analysis followed by imaging with Streptavidin-680 (Figure 2, lane 2). The 
upper band showed both the expected biotin-related (Figure 2B, red) and VSV-
related signals (Figure 2A, green, merge of A and B is shown in Figure 2C)), the 
lower one showed only a VSV-related signal. The lower band therefore represents 
VHH in which hydrolysis of the thioester has taken place prior to reaction with 
peptide 4 (see Scheme 2). To test whether the ligation efficiency could be 
increased, thiophenol was added (Figure 2, lanes 3 and 4).
40, 41
 Optimal formation 
of 5 (about 50%) was observed for a combination of 50 mM MESNA, 50 mM 
thiophenol and a 100-fold excess of peptide 4 (lane 3, Figure 2). Using more 
thiophenol probably either resulted in degradation of the VHH or significantly 
increased the rate of hydrolysis of the thioester, as both the overall intensity of the 
signal and the ratio between A12 and A12-biotin (5) decreased (Figure 2). 
 
Figure 2. Western Blot of A12 fusion protein and subsequent EPL reactions. A12 is visualized via 
staining with Rabbit-anti-VSV, followed by Goat-Anti-Rabbit-Alexa800 (A); the biotin label is 
visualized via staining with Avidin-Alexa680 (B). C) Shows the merged pictures. Lane 1: A12-
Intein-CBD; Lanes 2, 3, 4: Chitin beads with A12-Intein-CBD treated with 50 mM MESNA and 100 
equiv. of peptide 4 for 16 h with 0 mM (lane 2), 50 mM (lane 3) or 100 mM (lane 4) thiophenol. 
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Using these optimized conditions we prepared A12-N3 (2) by adding peptide 1, 
which was made via solid phase peptide synthesis. To determine the ligation 
efficiency, we purified VHH 2 by size exclusion chromatography and subsequently 
reacted A12-N3 with DIBAC-PEG44-OMe (6), Scheme 2, as we previously showed 
that this reaction proceeds quantitatively with azide-functional proteins (see 
Chapter 2).
39
 On SDS-PAGE gel we observed a conversion of 50%, Figure 3A, 
lane 2. Maldi-TOF analysis of the reaction mixture (Figure 3C) also showed two 
peaks in approximately equal ratio. The lower molecular weight peak orginated 
from the starting material, whereas the higher molecular weight signal was shifted 
2.2 kDa compared to the spectrum of A12-N3 (Figure 3B), indicating successful 
PEGylation. From these data, we concluded that the efficiency of the EPL was 
50%, which was also in line with the previous analysis of VHH 5 (lane 3, Figure 2). 
Maldi-TOF analysis of A12-N3 (Figure 3B), although the spectrum is of poor 
quality, seems to show multiple peaks of equal intensity around 17 kDa, indicating 
that A12-N3 also contains non-modified A12.
42
 The moderate conversion is 
probably caused by slow reaction of the tetrapeptide with the formed thio-ester 
which results in hydrolysis, resulting in non-functionalized VHH. One explanation 
could be that the tetrapeptides are dimerized by formation of a disulfide-bridge 
thereby inactivating the thiol-groups. Normally, this is circumvented by the addition 
of TCEP; however, as TCEP reduces azides, this cannot be used in this case.
43
  
 
Figure 3. (A) Silver-stained SDS-PAGE gel, showing PEGylation of A12-N3. Lane 1: A12-N3; Lane 
2: A12-N3 reacted with 10 equivalents of DIBAC-PEG44-OMe. (B) Maldi-TOF spectrum of A12-N3; 
(C) Maldi-TOF spectrum of A12-N3 reacted with 10 equivalents of DIBAC-PEG44-OMe. 
A final attempt to further optimize the conversion was made by altering the pH, of 
which the results are shown in Figure 4. It is clear that pH 5-7 gives less labeling 
than pH 8 and 9 (based on intensity of the red signal, Figure 4B). The smearing in 
lanes 4 and 5 (Figure 4B) is mainly caused by the intensity of scanning which was 
required to see the biotin-related signal in lanes 1-3. As in Figure 4A it seemed 
that the lower band (corresponding to non-modified A12) was less intense in lane 
4 than lane 5, it was concluded that the previously used pH 8 was optimal for the 
EPL procedure.  
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Figure 4. Western Blot Analysis of EPL performed with peptide 4 at different pHs; pH 5 (lane 1), 
pH 6 (lane 2), pH 7 (lane 3), pH 8 (lane 4), pH 9 (lane 5). VSV-related signal (A), biotin-related 
signal (B), A and B combined (C). 
 
4.3 Affinity studies 
To check whether the affinity of the VHH for plexin D1 was retained after the 
EPL, VHH 5 was used in immunohistochemical analyses. To this end, first the 
excess of peptide was removed with size exclusion chromatography, whereupon 
immunohistochemical analyses with purified VHH 5 were performed on sections of 
mammacarcinoma.
8
 Figure 5 shows that A12-biotin (5) stained tumor cells (arrow 
in Figure 5A) and tumor vessels (arrow in Figure 5B) in mammacarcinoma tissue 
in a pattern which is comparable to conventional immunohistochemical staining 
with unmodified A12, (Figure 5C).
8
 Figure 5D shows a negative control staining 
with only the secondary antibody. As the stainings observed for A12-Biotin and for 
A12 are comparable, it can be concluded that the affinity for the tumor t issue is not 
lost during the EPL.  
 
Figure 5. Immunohistochemical staining on ductal mamma carcinoma using A12-biotin 5 (A and 
B), A12 (C) or without VHH (D). 
To further substantiate the affinity of A12-N3 for Plexin D1, an ELISA essay was 
performed. To this end, a 96-wells plate was coated with neutravidin, wherupon it 
was incubated with a biotinylated plexin D1 peptide. The coated plate was then 
incubated with A12-N3 and with A1, a VHH that does not target Plexin D1-peptide 
but does contain a VSV-tag. The binding of A12-N3 2 and A1 was tested using 
different amounts of antibody, i.e. 0, 1 or 5 equivalents compared to the amount of 
Plexin D1 peptide. After incubation with the VHH followed by extensive washing, 
the VSV-tags were targeted using mouse-anti-VSV, followed by HRP-conjugated 
rabbit anti-mouse. After treatment with 3,3',5,5'-tetramethylbenzidine (TMB), the 
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plate was scanned at 450 nm. The experiment was performed in triplicate, the 
average of these three measurements is shown in Figure 6. 
From these data it can be concluded that A12-N3 specifically targets the peptide. 
For 2, an increase in absorption was observed upon the addition of 1 and 5 
equivalents. On the other hand, for negative control protein A1, no increase in 
absorption was observed, indicating that binding to Plexin D1 is specific.  
As second control experiment, neutravidin-coated wells were treated with PBS 
instead of biotinylated Plexin D1 peptide. Again, different amounts of A12 and A1 
were added to the wells, and treated as mentioned earlier. This resulted in 
extinction values as shown in Figure 6. From these data it can be concluded that 
addition of 1 equivalent of A12, did not result in any aspecific binding (Figure 6). 
On the other hand, addition of 5 equivalents A12-N3 to the non-Plexin D1 coated 
wells did give rise to some aspecific binding of the VHH, however still, significantly 
less than observed for the Plexin D1 coated wells (Figure 6). A1 gave no aspecific 
binding to the plate, as was already expected from the results with the Plexin D1 
functionalized wells. 
 
Figure 6. ELISA assay, measuring the TMB extinction at λ = 450 nm, after subsequent incubation 
with mouse anti-VSV, HRP conjugated rabbit anti-mouse and TMB. Plates are either modified with 
PLexinD1 or incubated with PBS (negative control).  
In conclusion, the immunohistochemical staining and the ELISA-assay both 
show that affinity for Plexin D1 is retained upon modification of A12 using EPL. 
 
4.4 Dual-labeling using SPAAC and thiol-maleimide ligation 
Having established that the VHH can be modified by EPL and that the affinity is 
retained after modification we set out to generate a dual labeling tumor-vessel 
targeting VHH by modification of A12-N3 (2). After removal of residual peptide 1 by 
size exclusion chromatography, we first reacted A12-N3 with DIBAC-Dye560 (8), 
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Scheme 3. Subsequently, the thiol of the introduced cysteine residue was labeled 
using commercially available maleimide-biotin (9). Thus, a dually labeled A12 (10) 
was formed, as shown in Scheme 3. The successful introduction of the fluorescent 
dye was confirmed by fluorescence imaging (Figure 7D, lane 1), the biotinylation 
of this VHH was confirmed on Western Blot using Streptavidin-680 (Figure 7B, 
lane 1). To check for the bioorthogonality of the SPAAC-reaction, we also 
prepared A12-NH2 (11), by performing the EPL with 12, Scheme 2, followed by 
treatment of the thus formed VHH with 8 and 9, which should only label the thiol 
and form A12-Biotin(SH)-NH2 (13). In all cases the VHHs were purified by size 
exclusion chromatography or affinity-based purification using Ni
2+
-beads as it was 
observed that residual reagents resulted in troublesome analysis. Western Blot 
analysis of VHH 10 and VHH 13 showed similar VHH-related signals (Figure 7A) 
and showed that in both cases the VHH was successfully labeled with maleimide-
biotin (9), as depicted in Figure 7B. Consistent with the absence of an N3-group in 
VHH 11, no fluorescent signal was observed after reaction of this VHH with 
DIBAC-Dye560 (Figure 7D, lane 2). These data indicate that SPAAC was selective 
for the azide-containing VHH, as expected.  
 
Scheme 3. Dual labeling of A12-N3 using a SPAAC reaction and a thiol-maleimide ligation, 
introducing a fluorescent dye and a biotin label respectively. 
 
Figure 7. Western Blot of A12-N3 (lane 1) and A12-NH2 (lane 2) after reaction with DIBAC-Dye560 
and maleimide-biotin followed by purification on Ni
2+
-beads. Blots are stained with Rabbit-anti-
VSV, followed by Goat-Anti-Rabbit-Alexa800 and Avidin-Alexa680 (panels A and B respectively, 
panel C shows the merged picture); fluorescence imaging to detect the presence of Dye560 is 
shown in panel D. 
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4.5 Conclusions 
Anti-plexin D1 VHH A12, a small antibody fragment with tumor targeting 
properties, was successfully dually labeled using a combination of EPL and 
bioorthogonal conjugation techniques. This was accomplished by producing the 
fusion protein A12-Intein-CBD, which underwent EPL with a biotin-containing 
peptide (4) and an azide-containing peptide (1). Unfortunately, in spite of 
optimizations, only a 50% conversion could be obtained. Nevertheless, A12-biotin 
(5) was used to investigate whether the affinity for tumor tissue was retained after 
EPL by immunohistochemical analysis. From this analysis it was observed that 
affinity of the VHH was not lost during modification as the signals from A12-Biotin 
and normal A12 were comparable. In addition, an ELISA test with A12-N3 showed 
that affinity for the Plexin D1 recognition peptide was retained. These data implied 
that after EPL the affinity of the VHH for its antigen was retained.  
A12-N3 (2) was subsequently used for the preparation of a dually-labeled VHH 
by using a strain-promoted 1,3-dipolar cycloaddition with DIBAC-Dye560 (8) and a 
thiol-maleimide ligation with maleimide-biotin (10). In this manner, a dually labeled 
VHH was formed, containing both a fluorescent dye and a biotin. Also, it was 
shown that the SPAAC reaction was selective for the azide-containing VHH as it 
did not proceed with amine-functional VHH 13. 
A dual-labeled A12 was thus successfully and selectively prepared. Application 
of this methodology will be described in Chapter 5, where A12-N3 is conjugated to 
cyclooctyne-containing polymersomes, in order to construct a drug carrier system 
with tumor-targeting properties. 
 
4.6 Acknowledgements 
Kiek Verrijp and Dr. William P. J. Leenders are greatly acknowledged for 
experimental contributions, discussions and collaboration. Mark B. van Eldijk is 
gratefully acknowledged for useful discussions and help with mass spectrometry. 
Marleen Zonjee is kindly acknowledged for performing the pH optimization 
experiment. Dr. Ilse Roodink is kindly acknowledged for useful advice. Dr. Luiz A. 
Canalle is kindly acknowledged for synthesis of azido-L-norleucine. P. Hans H. M. 
Adams is kindly acknowledged for synthesis of peptides 1 and 12. 
 
4.7 Experimental Section 
4.7.1 General experimental 
General experimental on synthesis, see Section 2.7.  
For modification of A12, unless stated otherwise, experiments were performed in TS-
buffer containing 20 mM Tris and 0.5 M NaCl at pH 8.0. Peptide 4 was purchased from 
Genscript, Piscataway, NJ, USA. Maleimide-biotin (9) was purchased from Pierce Protein 
Biology Products, Rockford, IL, USA. All SDS-PAGE analyses were done with 15% SDS-
PAGE gels. Unless stated otherwise, the Western Blots were blocked with 5% Elk in PBS 
and subsequently developed using rabbit anti-VSV-G antiserum (Sigma-Aldrich Chemie 
B.V., Zwijndrecht, The Netherlands) followed by Goat-Anti-Rabbit-IRDye800 (Rockland, 
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Gilbertsville, PA) for detection of the VHHs, and Streptavidin-680 (LI-COR, Westburg, 
Leusden) for detection of biotin groups.  The blots were subsequently imaged with a LI-
COR ODYSSEE scanner. Thus, in all blots shown, unless stated otherwise, a red color  
corresponds to a biotinylated protein, a green color corresponds to a protein containing a 
VSV-tag (characteristic for the nanobody used), a yellow/orange color corresponds to a 
mixture of both previously mentioned signals. Matrix-assisted laser desorption/ionisation 
time-of-flight (MALDI-ToF) mass spectra were recorded on a Bruker Biflex III 
spectrometer. Samples were prepared by mixing the solutions of the matrix α-cyano-4-
hydroxycinnamic acid (20 mg/mL, MeCN/H2O, 1:1 + 0.1 % TFA, 20 μL) with protein 
sample (5 μL). Spots of 0.3, 0.6 and 0.9 μL were placed on the MALDI sample plate and 
air-dried before analysis. 
 
4.7.2 Synthesis 
(Z)-2,5-dioxopyrrolidin-1-yl-(didehydrodibenzo[b,f]azocin-5(6H)-yl)-5-oxopentanoate 
(14) 
DIBAC
39
 (400 mg, 1.25 mmol) was dissolved in dry CH2-
Cl2
 
(15 mL). Subsequently EDC (776 mg, 5 mmol), 
DMAP (306 mg, 2.5 mmol) and N-hydroxysuccinimide 
(288 mg, 2.5 mmol) were added. The reaction was 
stirred overnight and subsequently quenched with H2O 
(5 mL). The H2O-layer was extracted with CH2Cl2 (2 × 
10 mL). The organic layers were combined and washed 
with 0.1 M NaOH (2 × 15 mL), 2 M HCl (3 × 20 mL), H2O (2 × 20 mL) and brine (30 mL)) 
and subsequently dried over MgSO4. The solvent was removed under reduced pressure to 
obtain compound 14 (370 mg, 70%). 
1
H-NMR (400 MHz, CDCl3) δ: 7.69 (d, J = 8.4 Hz, 
1H), 7.43-7.26 (m, 7H), 5.16 (d, J = 13.8 Hz, 1H), 3.67 (d, J = 13.8 Hz, 1H), 2.80 (br s, 
4H), 2.52 (td, J = 16.5, 7.2 Hz, 1H), 2.46-2.35 (m, 2H), 1.98-1.78 (m, 3H). 
13
C-NMR (75 
MHz, CDCl3) δ(ppm): 171.9, 168.9 (2C), 168.2, 151.4, 148.0, 132.2, 129.9, 128.5, 128.3, 
128.1, 127.8, 127.1, 125.5, 122.9, 122.6, 115.0, 107.7, 55.4, 33.1, 29.9 (2C), 25.5, 20.1. 
FT-IR νmax film: 2915, 2854, 1745, 1523, 1454, 1260, 1204, 1053. HRMS (ESI+) m/z calcd 
for C24H21N2O5 [M+H]
+
 417.1451, found 417.1442. 
 
(Z)-N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-5-(didehydrodibenzo[b,f]azocin-5(6H)-yl)-5-
oxopentanamide (15)  
Compound 14 (300 mg, 0.72 mmol) 
was dissolved in dry CH2Cl2 (10 mL) 
and 1,8-diamino-3,6-dioxaoctane (842 
μL, 5.77 mmol) was added. The 
reaction was stirred for 2 hours and 
the mixture was diluted with CH2Cl2 
(20 mL). The organic layer was 
washed with H2O (3 × 30 mL) and brine (30 mL) and subsequently dried over MgSO4. The 
solvents were removed under reduced pressure and the thus obtained crude product was 
purified by column chromatography (CH2Cl2/MeOH/7M NH3 in MeOH, 90:9:1) to obtain 
compound 15 as a yellow oil (180 mg, 56%). 
1
H-NMR (CDCl3, 400 MHz), δ: 7.70 (d, J = 
7.5 Hz, 1H), 7.42-7.26 (m, 7H), 6.18 (br s, 1H), 5.15 (d, J = 13.9 Hz, 1H), 3.67 (d, J = 13.8 
Hz, 1H), 3.62-3.58 (m, 4H), 3.53-3.48 (m, 4H), 3.42-3.30 (m, 2H), 2.85 (t, J = 5.7 Hz, 2H), 
2.28 (td, J = 13.7, 6.6 Hz, 1H), 1.99-1.84 (m, 3H), 1.73 (dt, J = 14.3, 6.8 Hz, 2H). 
13
C-NMR 
(CD3OD, 75 MHz), δ: 175.3, 174.8, 152.9, 149.5, 133.5, 130.4, 130.0, 129.7, 129.3, 
128.9, 128.1, 126.5, 124.3, 123.7, 115.7, 108.8, 72.8, 71.3 (2C), 70.6, 56.7, 41.9, 40.2, 
36.0, 35.0, 22.8. FT-IR νmax film: 2967, 2923, 2850, 1658, 1558, 1260, 1113, 1009, 806. 
HRMS (ESI+) m/z calcd for C26H32N3O4 [M+H]
+
 450.2392, found 450.2379. 
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(Z)-9-(4-(N-(1-(didehydrodibenzo[b,f] azocin-5(6H) -yl)-1, 5, 16 -trioxo-9, 12- dioxa- 6, 
15- diazahenicosan- 21-yl) sulfamoyl) -2-methylphenyl) -3,6-bis (diethylamino) -4a, 
9a-dihydroxanthylium (8)  
DY-560-NHS ester
44
 (0.2 mg, 
0.26 μmol) was dissolved in 
dry CH2Cl2 (1 mL), 
whereupon compound 15 
(0.23 mg, 0.52 μmol) was 
added. After 1 hour little 
product formation was 
observed according to mass 
analysis and Et3N (0.1 μL, 
0.52 μmol) was added. After 
2 hours the reaction was 
completed as indicated by 
mass analysis and the 
solvent was evaporated. The 
crude product was purified by column chromatography (CH2Cl2/MeOH, 9:1). No yield 
could be determined. HRMS (ESI+) m/z calcd for C59H71N6O11S2 [M+H]
+
 1103.4622, found 
1103.4646. 
 
Fmoc--azido-L-norleucine (16)
45
  
9-Fluorenylmethyloxycarbonyl-L-lysine(tert-butoxycarbonyl) (Fmoc-L-
lysine(Boc), 3.0 g, 6.40 mmol) was dissolved in a solution of HCl in 
EtOAc (2 M, 150 mL) and stirred at room temperature for 2 hours. 
The white precipitate that formed was isolated by filtration and dried 
in vacuo overnight to afford Fmoc-lysine as a white solid (2.13 g, 
90%), which was used without further purification. Fmoc-lysine (2.03 
g, 5.51 mmol), CuSO4 (88 mg, 0.35 mmol) and K2CO3 (2.46 g, 17.83 
mmol) were dissolved in MeOH (70 mL). Imidazole-1-sulfonyl azide 
hydrochloride (1.40 g, 6.70 mmol) was added in small portions and the suspension was 
stirred overnight at room temperature. The solvent was evaporated in vacuo, and the 
residue was redissolved in CH2Cl2 (50 mL). The solution was washed with aqueous HCl (1 
M, 50 mL), and the aqueous phase was extracted with CH2Cl2 (3 × 50mL). The crude 
mixture was purified using gradient column chromatography (CH2Cl2/MeOH/AcOH from 
96.5%/3%/0.5% to 93.5%/6%/0.5%) and lyophilized from dioxane, resulting in a colourless 
oil (1.94 g, 89%). In accordance with literature: 
1
H-NMR (400 MHz, CDCl3) δ: 7.76 (d, J = 
7.5 Hz, 2H), 7.59 (d, J = 6.9 Hz, 2H), 7.40 (t, J = 7.5 Hz, 2H), 7.31 (t, J = 7.5 Hz, 2H), 5.34 
(d, J = 7.8 Hz, 1H), 4.54 (br s, 1H), 4.43 (d, J = 6.6 Hz, 2H), 4.22 (t, J = 6.6 Hz, 1H), 3.27 
(t, J = 6.6 Hz, 2H), 1.3-2.0 (m, 2H). HRMS (ESI+) m/z calcd. for C21H23N4O8 [M+H]
+ 
395.1719, found 395.1718. 
 
4.7.3 Antibody modification 
Constructs and protein expression  
The cDNA encoding the mature sequence of VHH A12 (containing a 8×His-VSV tag at its 
carboxyl terminus) was PCR cloned from vector pHENIX-A12(7) in vector pTXB1 
(IMPACT kit, NEB, Ippswich, MA) as NdeI-SapI fragment as described by the 
manufacturer. Primers used were GGTGGTCATATGGCCCAGGTGCAG (NdeI-fw) and 
GGTGGTTGCTCTTCCGCATGCGGCCCCCTTTCC (SapI-rev). The resultant plasmid 
pTXb1-VHH A12 was transformed in ER2566 E. coli cells and expression was induced in 
logarithmically growing cultures by addition of 1 mM Isopropyl-thiogalactopyranoside 
(IPTG). Cultures were harvested after 3 hours induction at 30 ºC and VHH-intein-Chitin-
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binding domain (CBD) fusion proteins were isolated from the cytoplasm by five freeze-
thaw cycles followed by centrifugation at 14,000 g at 4 ºC to clarify the lysate. 
 
Cleavage of the intein using different reagents 
16 μL of A12-Intein-CBD was diluted with 64 μL of TS-buffer (20 mM Tris, 0.5 M NaCl, 1 
mM EDTA, pH 8.5) and divided into 4 equal portions to which reagents were added as 
follows: 
1) 20 μL of DTT-solution (50 mM in H2O) 
2) 20 μL of a solution of peptide 1 (100 mM in H2O, pretreated with solid-bound 
TCEP for 30 minutes) 
3) 20 μL of MESNA-solution (100 mM in H2O) 
4) 20 μL of MESNA-solution (100 mM in H2O) 
Sample 1, 2 and 3 were incubated at room temperature, sample 4 was incubated at 4 ºC.  
For each reaction a sample of 20 μL was taken after 24 hours and another sample was 
taken after 48 hours. All samples were analysed by SDS-PAGE followed by Western 
Blotting. The Western Blot was stained with mouse anti-VSV-G antiserum (Sigma-Aldrich 
Chemie B.V., Zwijndrecht, The Netherlands) followed by Goat-Anti-mouse-IRDye800 
(Rockland, Gilbertsville, PA) for detection of the VHHs (green signal), and Rabbit-Anti-
CBD (NEB, Ippswich, MA) followed by Goat-Anti-Rabbit-IRDye680 (Rockland, 
Gilbertsville, PA) for detection of the CBD (red signal). 
 
Optimization of EPL using biotinylated peptide 4  
0.5 mL of Chitin-beads (NEB) were washed and subsequently incubated for 20 minutes at 
room temperature with 1 ml of 0.2 mg/ml A12-Intein-CBD in TS-buffer (20 mM Tris, 0.5 M 
NaCl, pH 8.0) containing Complete protease inhibitors (50×) (Roche, Almere, The 
Netherlands). After washing with TS buffer for five times the beads were split into 3 equal 
portions in different eppendorf tubes. To each portion of beads was added 200 μL splicing 
buffer. The final solution contained 50 mM MESNA and 0, 50, or 100 mM thiophenol and a 
100-fold excess of peptide 4 (Genscript, Piscataway, NJ). The mixtures were incubated 
overnight at room temperature. After centrifugation, the supernatants containing spliced 
A12 were collected. All supernatants were analyzed by SDS-PAGE analysis followed by 
Western Blotting. 
 
Optimization of pH during EPL 
0.5 mL of Chitin-beads (50%, 1 mL slurry) was washed and subsequently incubated for 20 
minutes at room temperature with 0.2 mL A12-Intein-CBD in TS buffer (0.8 mL) containing 
Complete protease inhibitors (50×). After washing with TS buffer for three times, the 
solution was split in five equal aliquots and washed twice with TS buffer at pH 5, 6, 7, 8, 
or 9. Splicing buffer was added to a final volume of 200 μL. The final solution contained 
50 mM MESNA, 50 mM thiophenol and a 100-fold molar excess of peptide 4 was added to 
a total volume of 200 µL. The mixtures were incubated at room temperature. After 24 
hours 100 µL aliquots were taken, centrifuged and the supernatants containing spliced 
A12 taken for analysis. After 48 hours, the remaining mixtures were centrifuged and the 
supernatants were taken for analysis with SDS-PAGE followed by Western Blot. 
 
Expressed Protein Ligation with peptides 1, 4, and 12  
2 mL (0.2 mg/mL) A12-int-CBD was immobilized on 1 ml packed volume Chitin-beads. 
After washing with TS-buffer (20 mM Tris-Cl, 500 mM NaCl pH 8.0), the bead-protein 
complexes were incubated with TS buffer containing 50 mM MESNA, 50 mM thiophenol, 
protease inhibitors and a 100-fold molar excess of peptide 1 (50 μL, 10 mg/mL), 4 
(Genscript) or H2N-Cys-Gly-Gly-Lys-OH (12) (50 μL, 10 mg/mL). TS-buffer was added to a 
final volume of 2 mL. Splicing was allowed while leaving the samples overnight at room-
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temperature. The supernatant containing the modified A12 (A12-N3 (2), A12-Biotin (5) or 
A12-NH2 (11)) was collected and purified from unreacted peptides over a prepacked PD10 
sephadex size exclusion column using TS-buffer or phosphate buffered saline (PBS) as 
elution buffer. Fractions containing VHH were pooled and, unless used directly for further 
experiments, frozen in 20% (v/v) glycerol at -20 ºC. 
 
Immunohistochemistry  
Purified A12-Biotin (5) was used for immunohistochemistry on 4 µm sections of formalin-
fixed and paraffin-embedded ductal mammacarcinoma, using unmodified A12 as positive 
control. In short, tissue sections were subjected to pronase treatment for antigen retrieval
8
 
and subsequently blocked in 20% normal horse serum. Sections were incubated overnight 
at 4 ºC with similar concentrations of unmodified A12 or A12-biotin (5) in 1% bovine serum 
albumin (BSA) in PBS. Detection of A12 was performed by sequential incubation steps 
with mouse anti-VSV antibody,
8
 followed by biotinylated horse-anti-mouse antibodies 
(Vector). In both cases, biotin was visualized by incubation with an avidin-biotin-
peroxidase complex (Vector, Burlingham, CA). Detection was carried out with amino-
ethylcarbazole (AEC, Skytec, Utah) as substrate.
8
 As negative control a section of 
formalin-fixed and paraffin-embedded ductal mammacarcinoma was subjected to the 
same protocol but without the VHH incubation. 
 
Binding assay of A12 analogues for Plexin D1 peptide 
A 96-wells plate was coated with 100 μL of a 10 μg/mL neutravidin solution in 50 mM 
Na2CO3 buffer per well. The plate was coated overnight at 4 ºC, followed by washing with 
PBS at room temperature (3 × 5 min incubation). To prevent aspecific binding the plate 
was blocked using a solution of 1% gelatin in PBS for 1 h at room temperature. Unbound 
gelatin was washed away using PBS at room temperature (3 × 5 min incubation). 
Subsequently, a 100 μL solution of 0.6 μg/mL biotin functionalized plexin D1 peptide in 
PBS was added and allowed to bind to neutravidin for 1 h at room temperature. 
Alternatively, only PBS was added to the wells. The unbound peptide was removed by 
washing with PBS at room temperature (3 × 5 min incubation). The plate was 
subsequently blocked using 5% marvel in PBS for 1 h at room temperature, after which 
the plate was washed with PBS at room temperature (3 × 5 min incubation). Next, A12 (0, 
3, or 15 μL, 117 μg/mL) or A1 (0, 0.3, 1.5 μg) was added to the wells and incubated for 2 
hours at room temperature. After washing, A12 was visualized using mouse anti-VSV in 
PBS (1:5000) incubated overnight at 4 ºC. Unbound antibody was removed by washing 
with PBS at room temperature (3 × 5 min incubation) followed by incubation with HRP-
conjugated rabbit anti-mouse in PBS (1:5000) for 1 h at room temperature. Hereupon the 
plate was again washed with PBS at room temperature (3 × 5 min incubation). The 
staining was performed by addition of 100 μL TMB solution (1 μL H2O2 and 10 μL of 10 
mg/mL TMB in DMSO in 1 mL TMB buffer) per well. When the solution in the wells turned 
yellow, the reaction was stopped by the addition of 100 μL of 2M H2SO4. The extinction 
was determined at λ=450 nm. The reaction was performed in triplicate and the average 
value was taken.  
 
PEGylation of A12-N3 using SPAAC  
To 100 μL (0.13 nmol) of A12-N3 (2) in TS-buffer, 2 μL of protease inhibitors (50×) and 
12.8 μL of dibenzoazacyclooctyne-poly(ethylene glycol)44-OMe (DIBAC-PEG44-OMe)
39
 (6, 
1 mM in H2O, 10 equivalents) was added. The reaction was allowed to proceed in the dark 
for 2 hours and the formation of nanobody 7 was subsequently analyzed by SDS-PAGE 
(15%). The gel was silver stained using standard protocols.  
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Labeling of A12-N3 (2) and A12-NH2 (11) 
To 450 μL of A12-N3 (2) (6.1 μM, 2.75 nmol) or 475 μL A12-NH2 (11) (5.8 μM, 2.75 nmol) 
solution in TS-buffer, 20 μL of protease inhibitors (50×) was added. 55 μL of DIBAC-
Dye560 (8) (0.5 mM in DMSO/H2O, 1:1) was added and the reaction was allowed to 
proceed for 2 hours in the dark. Then, 27.5 μL of maleimide-biotin (Thermo, 9, 1 mM in 
H2O) was added. After reacting for 2 hours in the dark both VHHs were purified by affinity 
purification using Ni
2+
-beads with 250 mM imidazole in TS-buffer as elution buffer. The 
purified VHHs were analyzed by SDS-PAGE (15%) followed by Western Blot analysis 
using Rabbit anti-VSV-G antiserum (Sigma-Aldrich Chemie B.V., Zwijndrecht, The 
Netherlands) followed by Goat-Anti-Rabbit-IRDye800 (Rockland, Gilbertsville, PA) for 
detection of the VHHs, and Streptavidin-680 (LI-COR, Westburg, Leusden) for detection 
of biotin groups. Blots were scanned with the LI-COR ODYSSEE near infrared scanner. 
Fluorescence imaging was performed using a Fujifilm FLA-5100 scanner with 532 nm 
laser.  
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Targeted carrier systems (e.g. liposomes or 
nanoparticles)  are used to specifically deliver drugs 
to the site of interest. Site-direction can be achieved 
by attachment of targeting molecules, such as peptides, 
DNA/RNA, or antibodies, to the surface of the carrier. 
Here, we describe the formation of polymersomes with 
tumor-targeting potential. The modified A12 nanobodies, 
containing a free thiol and a biotin or azide (as 
described in Chapter 4), were charged to maleimide- or 
BCN-functionalized polymersomes, respectively. Retained 
affinity for tumor tissue was confirmed by an ELISA-
assay, using a Plexin D1-peptide as target. However, in 
vivo studies showed no specific tumor uptake, and 
further optimization is thus required. 
 
 
  
5 
Biodistribution studies with  
tumor-targeting polymersomes 
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5.1 Introduction 
Cancer is one of the leading causes of death worldwide. Major problems with 
cancer treatment include drugs being not effective enough in killing tumor cells 
and causing significant side effects. In order to improve both the selectivity and 
efficiency of tumor therapies many investigations have been performed to create 
targeted carrier systems, which transport and release the drugs at the desired 
tumor site and prevent exposure to healthy tissue.
1, 2
 Undoubtedly, the carrier 
system needs to be stable and able to carry a large amount of active molecules, 
which are thus shielded from the environment. Also, the carrier system should not 
show unspecific binding to proteins or cells, as this can cause clearance from the 
blood.
2, 3
  
In general, three types of carriers are used, liposomes, micelles and 
nanoparticles. An interesting new class of carrier systems is formed by polymer 
vesicles, or polymersomes. They resemble liposomes in their architecture,
3
 but 
have some additional features, which make them attractive from a drug carrier 
point of view. Polymersomes are robust structures, and the presence of both a 
lumen and a large hydrophobic bilayer membrane makes them more suitable for 
transport of large amounts of hydrophilic and apolar drugs than liposomes and 
micelles.
2, 4
 In addition, when using polymersomes formed from a PEG-containing 
block copolymer, stealth behavior is introduced and thereby circulation time is 
increased.
5
  
Targeting of polymersomes towards tumor tissue can be passive or active. 
Particles ranging from 10 to 100 nm can be taken up passively by tumors because 
of their leaky blood vessels.
6
 This phenomenon is called the enhanced 
permeability and retention effect (EPR) and was first introduced as such by 
Matsumura et al.
7
 In vivo studies of the EPR effect of passive carrier systems, 
however, often showed only a slight improvement of uptake compared to control 
experiments.
1
 Active uptake by tumor tissue is achieved by targeting receptors 
that are significantly more abundant on the surface of cancer cells and/or cancer 
vasculature, and not on healthy cells/tissue. Targeting molecules currently used 
for that purpose are antibodies or fragments thereof, peptides, and DNA/RNA 
aptamers.
8
 
Since antibodies bind in a strong and specific manner to proteins and haptens, 
they constitute promising candidates for the formation of targeted carrier systems.
9
 
Normal antibodies consist of a recognition domain (the Fv-region) and a Fc-region 
(the part that activates the immune system). For targeting purposes, clearly, only 
the Fv-region is required, and to that end, single domain Llama antibodies (so-
called VHHs) have been developed, which only consist of the heavy chain of the 
recognition domain.  
Advantages of using VHHs instead of antibodies, are the ease of production in 
cheap bacterial or yeast expression systems, lack of hydrophobic domains and 
therefore better water-solubility, efficient refolding after denaturation,
10, 11
 and a 
small size allowing for better penetration into tumor tissue.
11, 12
 Additionally, VHHs, 
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in general show similar affinity and specificity compared to the full antibodies.
8, 13
 A 
disadvantage of VHHs includes rather short in vivo circulation times due to their 
small size, which can be improved by the addition of PEG-tails.
13
  
Alternatively, conjugation of a VHH to a suitable carrier is likely to increase 
circulation time. However, to the best of our knowledge, no examples of 
conjugation of a VHH to polymersomes are known, and only one example of 
conjugation of a VHH to micelles was published.
14
 However, the VHH used in this 
case had no significant function, targeting glutathione S-transferase, and nothing 
was enclosed in the micelles. 
A number of strategies have been reported to conjugate functional proteins, such 
as enzymes and antibodies, to polymersomes. Biotinylated antibodies were 
connected to biotinylated polymersomes mediated by the addition of streptavidin 
or neutravidin.
3, 15, 16 
Disadvantage, however, is the use of a protein as linker which 
is almost as big as the targeting agent introduced, e.g. ICAM-1, a 90-110 kDa 
antibody.
15, 16
 In addition, this method gives rise to problems with in vivo 
applications due to human intolerance towards streptavidin.
9
  
Conjugation of functional proteins to polymersomes using a small linker has up 
to now only been performed by modification of lysines. In these cases, lysines 
have mostly been equipped with a functional handle (e.g. a free thiol via SATA 
modification,
17, 18
 an alkyne,
19, 20
 or a hydrazone
9
) using NHS-based ligation; 
subsequently, this handle is reacted with the corresponding counterpart. 
Alternatively, a diazo-transfer reaction can be performed on lysines,
21, 22
 thereby 
introducing an azide moiety, which is a small and stable functional handle that 
reacts rapidly and selectively in cycloaddition reactions with alkynes and in the 
Staudinger ligation.
23
  
An attractive site for modification of VHHs is the C-terminus, as this terminus is 
rarely involved in binding. One of the more efficient methods to introduce a peptide 
or protein at the C-terminus is via Expressed Protein Ligation (EPL),
24-26
 which 
was also previously used by Merkx et al. for modification of a VHH.
14
 We already 
showed that different peptides containing an N-terminal cysteine could be 
introduced to tumor-vessel targeting single-domain antibody A12 without loss of 
affinity (see Chapter 4). Also, we showed that an azide-containing peptide could 
be introduced and that the azide and the thiol from the newly introduced cysteine 
could both be used for labeling. 
In order to prepare targeted polymersomes, a logical counterpart for the 
prepared A12s containing a free thiol and/or an azide, would be cyclooctyne- or 
maleimide-functionalized polymersomes. Cyclooctyne-functionalized 
polyethyleneglycol-b-polystyrene (PEG-b-PS) polymersomes have previously been 
prepared by our group,
27
 and also maleimide-functionalized polyethyleneglycol-b-
polybutadiene (PEG-b-PB) polymersomes have already been published.
18
 
Advantage of PEG-b-PS polymersomes is that they can easily be imaged using 
EM methods and that solid polymersomes are formed. Disadvantage of the system 
is that the size of the polymersomes is more difficult to control. On the contrary, 
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PEG-b-PB polymersomes are highly flexible, and can be prepared in different 
sizes in a controlled manner.  
For PEG-b-PB polymersomes it was previously shown that the size of the 
polymersomes has a large influence on circulation time in mice.
28
 Polymersomes 
with a diameter of 90 nm proved to have a significantly improved circulation time 
over polymersomes with a diameter of 120 nm. Since our ultimate goal was to test 
these targeted polymersomes in mice, preparation of PEG-b-PB polymersomes 
with a diameter of less than 100 nm, would be highly advantageous for this 
purpose. 
In this chapter, first a proof of concept for the functionalization of polymersomes 
with A12-N3 is given, using BCN-functionalized PEG-b-PS polymersomes.
27
 Next, 
an ELISA assay was used to test whether the targeted polymersomes had affinity 
for Plexin D1. Subsequently, PEG-b-PB polymersomes equipped with maleimide 
moieties were prepared, and ligated to A12-biotin. Ultimately, these targeted 
polymersomes were used for biodistribution studies in mice. 
 
5.2 Preparation of targeting PEG-b-PS polymersomes 
 
Scheme 1. Labeling of A12-N3 and A12-NH2 with maleimide-biotin followed by a SPAAC 
reaction with BCN-functionalized polymersomes to form VHH containing polymersomes. 
A method to functionalize polymersomes with cyclooctynes for the SPAAC 
reaction was previously reported.
27
 In short, PEG-b-PS polymersomes with a 
diameter of around 100 nm were formed by mixing MeO-PEG22-b-PS160 with 10 
mol% of H2N-PEG66-b-PS255. The polymersomes were loaded with 
indocyanogreen-labeled BSA for visualization purposes. Subsequently, the amine-
groups of the thus formed polymersomes were functionalized by reaction with 
BCN-NHS.
29
  
Prior to ligation of A12-N3 to the BCN-functionalized polymersomes, the VHH 
was subjected to a thiol-maleimide ligation, thereby introducing a biotin group (4, 
Scheme 1). The thus obtained A12 was analyzed by Western Blot, using 
streptavidin-680 for imaging, confirming the introduction of the peptide, Figure 1, 
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lane 2. In addition, we aimed to show that ligation of A12-N3 to the polymersomes 
was specific. Therefore, also A12-NH2 (2) was prepared and reacted with 
maleimide-biotin, to confirm introduction of the peptide, Figure 1, lane 4. 
 
Figure 1. Western Blot analysis of maleimide-biotin ligation with A12-N3 (1) and A12-NH2 (2). 
The biotin label is identified via staining with Avidin-Alexa680 (red signal, A); A12 is visualized 
via staining with Rabbit-anti-VSV, followed by Goat-Anti-Rabbit-Alexa800 (green signal, B); C 
shows the merged picture. Lane 1: A12-N3 (1); Lane 2: A12-Biotin(SH)-N3 (4) Lane 3: A12-NH2 
(2); Lane 4: A12-Biotin(SH)-NH2 (5). 
Biotinylated A12-N3 and A12-NH2 (4 and 5, respectively) were then mixed with 
cyclooctyne-functionalized polymersomes 6, Scheme 1. An equimolar amount of 
VHH compared to the molar amount of functional groups theoretically present on 
the polymersome surface was used. The VHH and polymersomes were shaken 
overnight, whereupon residual VHH was removed by spin filtration.  
The A12-functionalized polymersomes, 8, were subsequently analyzed by 
Immuno Electron Microscopy (ImmunoEM). Prior to this procedure, the remaining 
unreacted BCN on the polymersomes was quenched with MeO-PEG44-N3 to avoid 
aspecific binding. EM grids containing VHH-polymersomes were incubated with 
mouse anti-VSV followed by gold (10 nm)-labeled goat anti-mouse IgG. Figure 2A 
shows that a significant amount of gold particles are attached to polymersomes 
functionalized with A12-N3 (8). The immunoEM picture obtained from 
polymersomes which were treated with A12-NH2 showed hardly any gold 
nanoparticles, as can be seen in Figure 2B. Although there seem to be few gold 
nanoparticles present on the surface of the polymersomes in Figure 2A, this is 
plausible as the VSV tag is hard to reach for the antibody, since it is located close 
to the C-terminus, and therewith close to the polymersome. This could cause 
inaccessibility of the tag, especially when the surface of the polymersome is 
coated with VHH.  
 
Figure 2. Immuno EM analysis of BCN-functionalized polymersomes reacted with A12-N3 (A) 
and A12-NH2 (B). Grids were incubated with mouse-anti-VSV antibodies, followed by gold 
nanoparticles (10 nm) with affinity for mouse antibodies, thereby targeting A12.  
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To estimate the functionalization degree of the polymersomes, a separate 
experiment was performed in which A12-N3 (2) was labeled with a Ru
2+
-complex 
and after purification subjected to reaction with BCN-functionalized polymersomes. 
According to ICPMS around 10% of the VHH was attached to the surface of the 
polymersomes. Taking into consideration that only 50% of the added VHH was 
functionalized, 20% of the functionalized VHHs were attached to the polymersome 
surface. Roughly, this corresponds to one VHH per 100 polymers located in the 
outer part of the bilayer of the polymersome. 
 
5.3 Affinity experiments with A12-functionalized polymersomes 
A12-containing polymersomes were anticipated to show affinity for their target, 
i.e. Plexin D1, as the polymersomes were site-specifically ligated to the C-
terminus of the VHH, and it was already demonstrated that affinity of A12 was 
retained after performing EPL, both by immunohistochemical analysis of tumor 
tissue and an ELISA assay (Chapter 4). We aimed to test the affinity of A12-
functionalized polymersomes (7) for Plexin D1 using an identical ELISA test.  
Polymersomes were modified by reaction with either VHH 1 or 2 instead of their 
biotinylated variants 4 and 5, as the biotin was expected to give rise to undesired 
binding to the neutravidin-coated plates used in the ELISA assay.  
To each well, A12-N3, A12-polymersomes (7), or polymersomes which were 
incubated with A12-NH2 were added. Scanning of the 96-wells plate after 
treatment with mouse-anti-VSV, HRP-functionalized rabbit-anti-mouse and 
3,3’,5,5’-tetramethylbenzidine (TMB), resulted in extinction values as displayed in 
Figure 3. Due to limited availability of material, measurements were only 
performed in duplicate and Figure 3 shows the average of the two measurements. 
Unfortunately, as can be seen from the error bars, the two data points for the A12-
polymersome contrast were not consistent with each other and further research is 
required. Nonetheless, on average, the results looked promising. 
The wells which were not modified with Plexin D1 showed that both A12-N3 as 
well as both polymersome-containing samples gave a background extinction 
between 0.09 and 0.12 (Figure 3). As observed in Chapter 4, A12-N3 specifically 
bound to the Plexin D1 peptide (Figure 3). On average, A12-functionalized 
polymersomes yielded a 1.5-fold higher extinction compared to uncoupled A12-N3 
and a 3-fold increase compared to the A12-polymersomes added to the uncoated 
wells. On the other hand, polymersomes treated with A12-NH2 showed only a 
negligible increase of signal compared to the wells containing no peptide (Figure 
3). It must, however, be noted that the average number given for the A12-
polymersomes construct is based on measurements of two data points which were 
not consistent with each other. 
The data in Figure 3 give a preliminary indication that polymersome construct 7 
still has affinity for the target of A12, i.e. Plexin D1. Aspecific binding is excluded 
by the incubation experiments of Plexin D1 coated wells with non-functionalized 
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polymersomes, as well as by incubation of non-coated wells with both A12-
functionalized and non-functionalized polymersomes.  
 
Figure 3. ELISA test with A12-N3, A12-polymersomes and A12-NH2 incubated polymersomes. 
In conclusion, PEG-b-PS polymersomes can be equipped with tumor-vessel 
targeting VHH A12. After modification, these polymersomes appear to show 
affinity for Plexin D1, the target of A12, however further research is required. 
 
5.4 Preparation of targeting PEG-b-PB polymersomes 
Although PEG-b-PS polymersomes are highly stable and easy to analyze and 
visualize, their size is hard to control which is a disadvantage for in vivo 
applications. It was previously shown that biodistribution studies require the 
polymersomes to have a diameter below 100 nm.
28
 Polymersomes of 250 or 120 
nm in diameter were cleared from the blood almost completely within 4 hours, 
while polymersomes with a diameter of 90 nm were still circulating 24 hours post 
injection. This circulation time proved to be virtually independent on the size of the 
PEG part of the block copolymer.
28
 
In order to prepare a system suitable for in vivo studies, we therefore switched to 
PEG-b-PB polymersomes. It was already shown that maleimide-functionalized 
PEG-b-PB (10) polymersomes can be prepared, and used for functionalization of 
the polymersomes with an antibody.
18
 Therefore, we decided not to functionalize 
PEG-b-PB polymersomes with a cyclooctyne, but instead, use the avalaible 
maleimide-functionalized PEG-b-PB. As in this case only a free thiol is required 
and no azide-functionality, not A12-N3 was used, but A12-biotin (9) to functionalize 
the polymersomes. The introduction of an additional cysteine can easily be 
confirmed by Western Blot for A12-biotin, due to the simultaneous introduction of a 
biotin-handle. 
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Figure 4. Thiol-maleimide ligation with A12-biotin and maleimide-functionalized polymersomes.  
First, we set out to prepare maleimide-functionalized polymersomes with a 
diameter of less than 100 nm. To this end, MeO-PEG-b-PB was mixed with Mal-
PEG-b-PB, such that 10% of the surface would contain a maleimide-moiety. 
Polymersomes were formed by the slow addition of PBS to a solution of the 
polymer mixture in THF, in a solvent ratio of 2:1. 
In this manner, polymersomes with a diameter of around 1 μm were formed. As 
was previously reported,
28
 upon treatment with ultrasound the polymersomes were 
shrunk to obtain polymersomes with an average diameter of 70 nm, Figure 5. In 
this procedure, the solvent ratio was crucial in order to obtain polymersomes of the 
right size. 
 
Figure 5. DLS measurement in triplicate of maleimide-functionalized PEG-b-PB polymersomes 
(10) after sonication in a solvent mixture of PBS:THF (2:1). 
A12-biotin was now ligated to the thus obtained maleimide-functionalized 
polymersomes. Since PEG-b-PB polymersomes are hard to image using EM 
methods, immunoEM could not be used to analyze A12-functionalized 
polymersomes 11. ICPMS-measurements of the construct were performed, as 
described earlier, and showed a functionalization between 10 and 15% compared 
to the amount of added VHH. Taken into account that only 50% of the VHH-
mixture did actually contain the free cysteine, 20-30% of the A12-biotin present 
was ligated to the polymersome surface, roughly corresponding to 1 VHH per 100 
polymers located on the outer part of the polymersome bilayer. This proved highly 
comparable to the experiments as performed with A12-N3 and cyclooctyne-
functionalized polymersomes. 
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5.5 Affinity studies of A12-functionalized PEG-b-PB 
polymersomes 
The PEG-b-PB polymersomes conjugated to A12 were now used for affinity and, 
ultimately, biodistribution studies. For imaging purposes, polymersomes were 
prepared containing 10% maleimide-functionalized PEG-b-PB and 1% DTPA-
functionalized PEG-b-PB. After polymersome formation, the DTPA was labeled 
with 
111
In, whereupon the indium-labeled polymersomes were mixed with A12-
biotin. Due to a limited availability of A12-biotin, a ratio of maleimide to A12 of 15:1 
was used. After overnight incubation and removal of residual A12, the construct 
was used in an ELISA test and for biodistribution studies.  
 
Scheme 2. SATA-modification on lysozyme, followed by polymersome conjugation using a thiol-
maleimide ligation. 
As negative control, lysozyme-polymersome conjugates 14 were prepared, 
Scheme 2. For the introduction of functionalizable thiol-groups to lysozyme, a 
SATA-modification was applied. In this manner, multiple (1-3) acetyl-protected 
sulfur groups were introduced (forming 12 as confirmed by mass spectrometry, 
Figure 6) which were deprotected just before ligation to the polymersomes. For the 
ligation, the same polymersome batch and identical procedure was used as for the 
formation of the A12-polymersome construct. 
 
Figure 6. Mass spectra of lysozyme (A) and lysozyme modified by SATA-modification (12) (B). 
The prepared polymersomes 11 and 14 were injected into nude BALB/c mice 
containing OVCAR-3 tumors. OVCAR-3 tumor cells express Plexin D1, and are 
therefore recognized by A12. After 24 hours, mice were sacrificed and the 
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radioactivity of the organs was determined. Thus, the biodistribution of the A12-
polymersomes 11 and lysozyme-polymersomes 14 was investigated. The 
functionalized polymersomes (both 11 and 14) showed excellent circulation times, 
which can be observed from the significant amount of material still present in the 
blood of the mice after 24 hours. This observation is in line with previously 
reported experiments.
28
 Unfortunately, no tumor-specific uptake was observed, as 
can be seen in Figure 7. 
 
Figure 7. Biodistribution of A12-polymersomes and lysozyme-polymersomes in mice. 
The lack of labeling can be caused by little attachment of A12 to the 
polymersome surface due to the limited material available. Another possible 
explanation for the lack of tumor labeling can be saturation. This phenomenon can 
occur when too much material is injected. In this case, binding locations are 
mainly occupied by unlabeled constructs, and labeled constructs can no longer 
bind. To investigate whether this effect occurs, or to identify other causes 
responsible for the lack of labeling, a more elaborate study is required. For 
example, a more detailed affinity study of the A12-polymersome (11) construct 
towards Plexin D1, a dose-finding study with unmodified A12, and a more detailed 
in vivo study with the A12-polymersome construct would be required.  
 
5.6 Conclusions and outlook 
In this chapter, it was shown that A12-N3 could selectively be attached to BCN-
functionalized PEG-b-PS polymersomes. The successful and selective attachment 
of A12 to the polymersomes was confirmed by immunoEM. In this experiment, the 
A12-polymersome conjugates 7 were incubated with mouse-anti-VSV, followed by 
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gold-labeled goat-anti-mouse IgG. In the EM-pictures it was observed that gold 
nanoparticles were attached to the A12-polymersome conjugate, whereas the 
negative control (in which A12-NH2 was reacted with BCN-polymersomes) showed 
hardly any gold nanoparticle attachment. 
To investigate whether the affinity for Plexin D1 was retained an ELISA test was 
performed. In this test, a first indication that the A12-polymersome construct 7 still 
showed tumor-affinity was obtained, however, further research is required. 
In line with these experiments, also maleimide-functionalized PEG-b-PB 
polymersomes 10 were prepared. For these polymersomes it was possible to 
obtain high control over the size of the polymersomes, which is an essential factor 
in circulation time during in vivo studies. The PEG-b-PB-polymersomes were 
labeled with A12-biotin, which contains a free cysteine, and can therefore be used 
for thiol-maleimide ligation. The thus obtained polymersomes (11) were used in an 
ELISA assay to determine affinity for Plexin D1 and for biodistribution studies in 
mice. Unfortunately, the ELISA assay and in vivo studies with these constructs 
gave no results so that further research is required. 
To establish the viability of the A12-polymersomes several experiments are 
required in future research. First of all, the ELISA test with 
111
In-labeled A12-
containing PEG-b-PB polymersomes should be repeated with more material to 
obtain reliable results. For biodistribution studies, a dose-dependency study 
should be performed with A12, to determine the amount of material required to 
obtain good labeling. Only after these experiments are successfully performed, 
biodistribution studies with A12-polymersome conjugates can reliably be 
performed.  
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5.8 Experimental Section 
5.8.1 General experimental 
General experimental for the preparation of A12 analogues can be found in Section 4.7. 
Specific techniques used in this chapter are described below. 
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Materials Goat anti-mouse gold nanoparticles of 10 nm were purchased from Aurion 
Immuno Gold Reagents and Accessories (Wageningen, the Netherlands). BCN-OSu was 
purchased from SynAffix BV (Nijmegen, the Netherlands). H2N-PEG66-b-PS255, MeO-
PEG22-b-PS160 and MeO-PEG44-N3 were prepared according to literature.
27, 30
  
 
Instrumentation Regular TEM was performed on a JEOL JEM 1010 microscope with an 
acceleration voltage of 60 kV equipped with a charge-coupled device (CCD) camera. 
Samples were prepared by placing a drop of aqueous polymersome solution on an EM 
science carbon-coated copper grid (200 mesh). ImmunoEM was performed using a JEOL 
1200 EX/II Microscope with an acceleration voltage of 60 kV. The polymersome solution 
was disposed on a carbon-coated copper grid (120 mesh) and allowed to dry for 45 
minutes. DLS measurements were recorded on a ZetaSizer Nano-S. Infrared analyses of 
the encapsulated BSA-ICG in polymersomes were performed using GBOX Chemi IR6 
F1.4 with LY800 filter. Protein concentrations were determined using BCA Protein Assay 
Reagent kit (Pierce Protein Biology Products, Rockford, USA). Absorption of the protein 
samples at 562 nm was measured using a Wallac Multilabel Counter 1420 (Perkin Elmer). 
Inductively coupled plasma-mass spectrometry (ICP‐MS) measurements were performed 
on a Thermo Fisher Scientific Xseries I quadrupole machine using 5.0 mL samples 
containing 0.97 mg/L InCl3 solutions as internal standard. 
 
5.8.2 Protein modifications 
Formation of A12-N3, A12-NH2 and A12-biotin 
A12-N3, A12-NH2 and A12-biotin were prepared as described in Section 4.7.  
 
Formation of A12-Biotin(SH)-NH2 and A12-Biotin(SH)-N3  
To 400 μL of A12-N3 (1) or 400 μL A12-NH2 (2) solution in Tris-buffer (7.5 μM for both), 
8.6 μL of protease inhibitors (50×) was added. 30 μL of maleimide-biotin (3) solution (1 
mM in H2O) was added and the mixture was reacted for 2 hours in the dark.  
 
Preparation of Lysozyme-SAc 
Lysozyme (3.8 mg, 0.27 μmol) was dissolved in PBS (pH 7.8) and N-succinimidyl S-
acetylthioacetate (SATA, 50 μL, 17 mg/mL, 3.7 μmol) was added and the mixture was 
shaken for 4 hours. The non-reacted SATA was removed by size exclusion 
chromatography using a PD10 desalting column in PBS. The final concentration of 
lysozyme-SAc was 1.75 mg/ml. To confirm the introduction of protected thiol-groups, 10 
μL of the lysozyme-SAc solution was desalted over an Amicon Ultra filter with a 3 kDa cut-
off and analyzed by mass spectrometry. This indicated that on average two protected 
thiol-groups per lysozyme were introduced (see Figure 6). 
 
Preparation of Lysozyme-SH 
Lysozyme-SAc (500 µL of 1.75 mg/mL) in PBS was charged with deacetylation buffer (100 
µL of 50 mM PBS supplemented with 0.50 M hydroxylamine and 20 mM tris(2-
carboxyethyl)phosphine) (TCEP) at pH 7.4) and the solution was agitated for 90 min. The 
white precipitate that was formed during deacetylation was packed into a pellet by 
centrifugation (10,000 rpm, 5 min) and the enzyme-containing solution was pipetted off. 
Lysozyme-SH was subsequently dialyzed against PBS buffer (pH 7.4) by centrifugation 
over an Amicon Ultra filter with a 3 kDa cut-off. 
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5.8.3 Polymersome functionalization 
Synthesis of BSA-ICG 
A solution of ICG in DMSO (13 mM, 97 µL, 1.25 µmol) was added to a solution of BSA in 
water (0.14 mM, 838 µL, 0.125 µmol) and incubated overnight at room temperature. The 
crude protein was purified from the unbound ICG over a G50 Sephadex size exclusion 
column.  
 
BSA-ICG encapsulation in PS-PEG polymersomes 
Prepared according to a modified literature procedure.
31, 32
 MeO-PEG22-b-PS160 (10.0 mg, 
588 nmol) and 10 mol% of H2N-PEG66-b-PS255 (2.0 mg, 64 nmol) were dissolved in 
distilled THF (2.0 mL). This solution was added dropwise to a solution of BSA-ICG in 
MilliQ (0.8 mg, 12 nmol, 246 μL of 3 mg/mL solution). This mixture was allowed to stand 
for 30 minutes at room temperature. The suspension was transferred to a dialysis 
membrane (SpectraPor, molecular weight cut off at 12000-14000 Da, width of 25 mm) and 
dialyzed against MilliQ (800 mL) overnight, replenishing the MilliQ after 1 hour.  
The polymersomes were separated from the free BSA-ICG over a G150 Sephadex size 
exclusion column eluted with MilliQ. The encapsulation of BSA-ICG was confirmed by 
tracing the fluorescence of ICG in the fractions containing polymersomes. The fractions 
were pooled and concentrated using centrifugation (5 min, 3000 rpm) over a 100 nm pore 
size filter (Amicon UltraFree MC, polycarbonate membrane, diameter of 19 mm). The 
sample was obtained at a concentration of 3.0 mg polymer per mL.  
 
Functionalizing PS-PEG polymersomes with BCN 
Modified literature procedure:
27
 To the H2N-functionalized polymersome solution (940 μL, 
20 nmol theoretically available NH2-groups) was added phosphate buffer (80 mM, 0.33 
mL, pH 7.8) and little NaOH (0.1 M) to bring the pH to 7.8. A solution of BCN-OSu in DMF 
(2.5 mM, 200 µL, 500 nmol) was added and incubated overnight at room temperature. The 
unreacted BCN-OSu was removed by washing six times with PBS buffer over a 100 nm 
pore size filter (Amicon UltraFree MC, polycarbonate membrane, diameter of 19 mm) 
using centrifugation (5 min, 3000 rpm). The solution was obtained at a concentration of 
1.3 mg polymer per mL PBS. 
 
Reacting A12-biotin(SH)-N3 (4) and A12-biotin(SH)-NH2 (5) with BCN-containing 
polymersomes (6)  
A12-biotin(SH)-N3 (4) or A12-biotin(SH)-NH2 (5) in PBS-buffer (438 μL, 6.8 μM, 3 nmol) 
was added, without further purification, to a suspension of bicyclo[6.1.0]nonyne (BCN)-
functionalized polymersomes (6, 0.4 mL, 3 nmol theoretically available BCN-groups). The 
reaction was allowed to shake at 4 ºC overnight. The unreacted unmodified A12 and A12-
biotin(SH)-N3 (4 or A12-biotin(SH)-NH2 (5) were removed by repeated (6×) centrifugation 
with PBS buffer over a 100 nm pore size filter (Amicon UltraFree MC, polycarbonate 
membrane, diameter of 19 mm).  
 
ImmunoEM analyses  
The VHH-conjugated polymersomes prepared as mentioned above (12 μL, 72 pmol 
theoretical BCN-groups) were first treated with 1.4 μL MeO-PEG44-N3-solution (1 mg/mL, 
720 pmol) for 2 hours at room temperature to block unreacted BCN. The thus obtained 
polymersome solutions were placed on EM grids and about 50% of the water was allowed 
to evaporate; the remaining liquid was subsequently removed to prevent osmotic pressure 
to build up. Next, the grids were incubated with mouse anti-VSV (1:50) in PBS buffer with 
1% BSA for 1 hour at room temperature, after which the grids were washed three times by 
placing a drop of PBS buffer on the surface, incubating for 5 minutes and subsequent 
removal of the PBS. Subsequently, the grids were incubated for 1 hour at room 
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temperature with 10 nm gold-labeled goat anti-mouse IgG (Aurion, Wageningen, The 
Netherlands) in PBS containing 1% BSA. The grids were washed twice by placing a drop 
of PBS buffer on the surface, incubating for 5 minutes and subsequent removal of the 
PBS and subsequently the grids were washed twice in a similar manner using MilliQ. The 
grids were allowed to dry and the polymersomes were analyzed with TEM. 
 
Formation of maleimide-functionalized PEG-b-PB polymersomes 
Maleimide-PEG22-PB66 (1 mg, 0.2 μmol) was dissolved in THF (200 μL) and added to 
MeO-PEG22-PB66 (9 mg, 2 μmol). The solution was thoroughly mixed by vortexing. 
Subsequently PBS (600 μL) was added dropwise. The thus obtained particles were 
subjected to ultrasonic waves (48 kHz, 200 W) for 30 min at 35 ºC. As particles  had not 
yet reached the desired diameter, THF (40 μL) was added and the particles were again 
subjected to ultrasonic sound waves (48 kHz, 200 W) for 30 min at 35 ºC. Still, not the 
desired diameter was reached, and again THF (60 μL) was added, followed by sonication 
for 30 min at 35 ºC. Subsequently, THF was removed and samples were washed with 
PBS using 100 kDa membrane Amicon Ultra centrifugal filters. 
 
Preparation of DTPA-labeled maleimide-functionalized polymersomes 
Prior to the self-assembly procedure, MilliQ, THF 
and all buffers were treated with Chelex (2 g/L 
solution) for 20 h to remove any residual heavy 
metals. Then, PEG22-b-PB66, (9.0 mg, 1.9 µmol), 
maleimide-PEG22-b-PB66 (1.0 mg, 0.21 mmol), and 
diethylenetriaminepentaacetic acid (DPTA)-PEG22-
b-PB66 (0.10 mg, 0.021 mmol) were dissolved in 
THF (200 µL). Self-assembly was induced by drop 
wise addition of MilliQ (400 µL), whereupon the 
polymersomes were resized by sonification (48 
kHz, 200 W) for 30 min (2×) at 35 °C. The vesicular 
diameter and accompanying size distribution were verified by dynamic light scattering 
(DLS), and were determined as 73 nm (based on intensity-average) and 0.25, 
respectively. Next, the polymersome solution was diluted with MilliQ (400 µL) and the 
dispersion was concentrated by centrifugation using Amicon Ultra filters with a cut-off of 
100 kDa (4000 rpm, 5 min). The suspension was replenished with 4-
morpholineethanesulfonic acid (MES) buffer (pH 5.5, 400 µL) and subsequently 
concentrated by centrifugation (4000 rpm, 5 min). After performing another four washing 
steps, the polymersomes were resuspended in a total volume of 500 µL MES buffer.  
 
111
Indium labeling of DTPA-labeled maleimide-functionalized polymersomes 
To the polymersome mixture (250 µL) in MES buffer (pH 5.5), 50 MBq 
111
InCl3 in MES 
buffer (pH 5.5) (80 µL) was added. The labeling solution was incubated for 30 min at room 
temperature and subsequently charged with PBS buffer supplemented with 
ethylenediaminetetraacetic acid (EDTA) (0.1 M buffer with 0.1 M EDTA at pH 7.4, 33 µL). 
The sample was purified from EDTA-In complex using a PD10 desalting column that was 
eluted with PBS buffer. The turbid fractions (in total 1.0 mL, 33 MBq) were combined and 
immediately used for the immobilization of A12 or lysozyme. 
 
Conjugation of A12-Biotin or lysozyme-SH on 
111
In-polymersomes 
A12-Biotin was prepared as described in Section 4.7. A12-biotin (100 µg in 380 μL, 5.9 
nmol) or lysozyme-SH (83 μg in 380 μL, 5.9 nmol) was immobilized on maleimide-
displaying 
111
In-labeled polymersomes (2 × 250 µL, 2 × 7.4 MBq, in PBS buffer) by mixing 
and reacting the components for 16 h at 4 ºC. The unbound A12-Biotin or lysozyme-SH 
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was washed away by centrifugation using Amicon Ultra filters with a cut-off of 100 kDa 
(4000 rpm, 5 min). The remaining suspension was replenished with PBS buffer (pH 7.4, 
400 µL) and concentrated by centrifugation (4000 rpm, 5 min), followed by another four 
washing steps. Finally, the A12- and lysozyme-polymersomes (160 µL of each, both 
containing 3.0 MBq of radio-activity) were resuspended in aqueous NaCl solution (0.9%, 
1320 µL). The quality of the 
111
In-labelling was checked by radio TLC. Hereto, 5 µL of the 
polymersome samples was spotted on an ITLC-SG strip. The strips were developed in 0.1 
M ammonium acetate (pH 5.5):0.1 M EDTA (1:1, v:v) as the eluent, whereupon the strips 
were air-dried and read in a radiochromatograph scanner (AmRay Medical, Drogheda, Co. 
Louth, Ireland). The effective 
111
In-labeling of the polymersomes was determined to be 
quantitative. 
 
5.8.4 ICMPS measurements 
Labeling of A12-N3 and A12-biotin with Ru
2+
 
A12-N3 and A12-biotin were prepared as described in Section 4.7. After removal of 
residual peptide and thiol-reagents using size-exclusion chromatography in PBS, for both 
VHHs 2 mL was obtained with a concentration of 0.13 mg/mL as determined by BCA 
analysis. The pH of the VHH solution (15 nmol protein, 150 nmol NH2-groups) was 
adjusted to 10.5 by the addition of 0.1 M aqueous NaOH. Hereupon Bis(2,2′-bipyridine)-
(5-isothiocyanato-phenanthroline)ruthenium bis(hexafluorophosphate) (200 μL, 1 mg/mL 
in MQ containing 10% DMSO, 210 nmol) was added. The mixture was shaken for 3 hours, 
whereupon residual reagent was removed using a 10 kDa membrane Amicon Ultra 
centrifugal filter. After extensive washing against PBS, the Ru-labeled VHH was taken up 
in 1 mL of PBS. 
 
Functionalization of BCN-polymersomes with A12-N3 
Ru-labeled A12-N3 or A12-biotin (286 μL, 0.13 mg/mL, 2 nmol) was added to 250 μL of 
polymersome solution (containing 2.1 nmol of BCN-functionalized polymer). The mixture 
was shaken at 4 ºC overnight and subsequently washed extensively with PBS using 
centrifugation (5 min, 3000 rpm) over a 100 nm pore size filter (Amicon UltraFree MC, 
polycarbonate membrane, diameter of 19 mm).  
 
ICPMS analysis of A12-polymersome conjugate 
Ru-labeled A12-N3, A12-biotin and the A12-N3 or A12-biotin functionalized polymersome 
suspensions were lyophilized and subsequently destructed for 3 h in nitric acid (65%, 0.50 
mL) at 80 ºC. After cooling the samples to room temperature, the samples were filtered 
over cotton, which was subsequently washed with MilliQ. An internal standard of InCl3 
(1.50 mL of 0.97 mg/L) was added. The total volume of each sample was adjusted to 5.00 
mL with MilliQ. The functionalization percentages were obtained by comparing the results 
obtained for A12-N3 to the results obtained for the A12-functionalized polymersomes. 
 
5.8.5 ELISA assay for affinity testing 
Binding assay of A12-polymersomes for Plexin D1 peptide 
A 96-wells plate was coated with 100 μL of a 10 μg/mL neutravidin solution in 50 mM 
Na2CO3 buffer per well. The plate was coated overnight at 4 ºC, followed by washing with 
PBS at room temperature (3 × 5 min incubation). Subsequently, a 50 μL solution of 0.6 
μg/mL biotin-functionalized Plexin D1 peptide in PBS was added and allowed to bind to 
neutravidin for 1 hour at room temperature. Alternatively, only PBS was added to the 
wells. The unbound peptide was removed by washing with PBS at room temperature (3 × 
5 min incubation). The plate was subsequently blocked using 5% marvel  powder in PBS 
for 1 h at room temperature, after which the plate was washed with PBS at room 
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temperature (3 × 5 min incubation). Three equivalents of A12-N3 (1, 72 μL, 1.5 nmol), 
A12-polymersomes (7, 160 μL, 1.5 nmol), and BCN-polymersomes (6) that were reacted 
with A12-NH2 (2) (160 μL, 1.5 nmol) were then diluted five times with PBS and 
subsequently added to the wells (100 μL/well). The wells were incubated for 2 hours at 
room temperature. After extensive washing, A12 was visualized using mouse anti -VSV in 
PBS (1:2000, 100 μL/well) which was incubated for 1 hour at room temperature. Unbound 
antibody was removed by washing with PBS at room temperature (3 × 5 min incubation) 
followed by HRP conjugated rabbit anti-mouse in PBS (1:5000, 1 mL/well) incubated for 1 
hour at room temperature, after which the plate was again washed with PBS at room 
temperature (3 × 5 min incubation). The staining was performed by addition of 100 μL 
TMB solution (1 μL H2O2 and 10 μL of 10 mg/mL TMB in DMSO in 1 mL TMB buffer) per 
well. When the solution in the wells turned yellow, the reaction was stopped by the 
addition of 100 μL of 2M H2SO4. The extinction was determined at λ = 450 nm. The 
reaction was performed in duplicate and the average value was taken.  
 
5.8.6 Biodistribution studies 
 
In vivo biodistribution studies 
The in vivo behavior of the A12-
111
In-polymersomes and Lys-
111
In-polymersomes was 
evaluated in 10 nude BALB/c mice (6-8 weeks, 20-25 grams) bearing s.c. OVCAR-3 
tumors. The mice were divided in two groups: 5 animals were injected in their tail vein with 
0.4 MBq (200 µL) A12-labeled polymersome solution, the other 5 animals received 0.4 
MBq (200 µL) of Lys-labeled polymersomes. All animals were sacrificed by CO2/O2 
asphyxation 24 h post-injection. Then, blood, muscle, tumor, lung, spleen, kidney, liver, 
stomach and intestine were collected, weighed and counted in a well-type γ-counter 
(Wizard, Perkin-Elmer, Waltham, MA). The percentage injected dose per gram (%ID/g) 
was calculated for each tissue. The animal experiments were approved by the local 
animal welfare committee and performed according to national regulations. 
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Efficient enantioselective synthesis of organic 
compounds is of high importance for the fine chemical 
and pharmaceutical industries. One of the most 
efficient manners to induce enantioselectivity is by 
using the chiral environment of an enzyme. In this 
chapter, a non-selective metal catalyst complex was 
positioned in close proximity of the active site of the  
lipase CalB via Strain-Promoted Azide Alkyne 
Cycloaddition (SPAAC). Preliminary investigations were 
performed to assess if both catalytic systems (metal 
and enzyme) still showed activity.  
 
 
  6 
Formation of an enzyme-metal catalyst 
hybrid system using Strain-Promoted 
Azide Alkyne Cycloaddition 
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6.1 Introduction 
The chiral nature of all living organisms and the high selectivity these organisms 
display for chiral substrates, e.g. in pharmaceuticals, makes the synthesis of 
enantiomerically pure substrates of great interest.
1
 Generally spoken, synthetic 
catalysts, enzymes, or a combination of the two can be employed to produce 
enantiopure compounds. In addition, certain methods are known to selectively 
obtain one enantiomer out of a racemic mixture. Synthetic catalysts (e.g. metal 
catalysts or proline-based catalysts) are known for their broad reaction scope and 
substrate tolerance. Enzymes, on the other hand, show excellent efficiency and 
enantioselectivity, however, substrate tolerance and reaction scope is generally 
limited. Combination of a synthetic catalyst and an enzyme would then ideally 
combine the enantioselectivity of enzymes and the broad reaction scope of 
synthetic catalysts. 
In industry, several ways are used to obtain enantiomerically pure substrates like 
amino acids, alcohols and epoxides. For example, enantiopure compounds are 
obtained via extraction of natural substances, racemic synthesis followed by 
conversion into enantiomerically pure substrates by biocatalytic methods, or by 
using fermentation (for natural amino acids) or biotransformations (for non-natural 
amino acids). Another method for enantioselective synthesis employed is by using 
racemate resolution (or so-called kinetic resolution, KR). In this procedure, 
racemic precursors are converted to an enantiomerically pure compound by 
different selective enzymes. Apart from these enzyme based procedures, other 
processes used for enantiomerically pure substrate synthesis are crystallization 
with chiral substances (e.g. carboxylic acids or phosphoric acid esters), and 
enantioselective reduction, hydrogenation, or epoxide opening.
2
 
KR presents a fast entry to enantiopure substrates. A disadvantage of this 
method is that a maximal yield of 50% can be obtained. An interesting addition to 
KR is dynamic kinetic resolution (DKR). In this process, enrichment occurs 
identical to KR, but now, in addition, simultaneous isomerization by a metal 
catalyst or base constantly isomerizes the starting material. This ultimately leads 
(theoretically) to 100% of the desired enantiomer.
1
 DKR has found numerous 
applications, for example for the conversion of cyclic racemic allylic acetates to 
enantiomerically pure allylic alcohols.
3
 Several groups also employed DKR for the 
preparation of enantiomerically pure esters from secondary alcohols. In these 
cases, the secondary alcohols are isomerized by a metal-induced reaction. CalB, 
or another stable lipase, subsequently selectively esterifies one of the alcohols 
into the corresponding acetate.
4-6
  
Apart from DKR, the combination of an enzyme and a metal-catalyst has also 
been employed in one-pot two-step reactions. For example, glucose was 
converted into mannitol by combining an isomerase and a copper-catalyzed 
hydrogenation.
7
 Reek et al. showed that amine acylation by CalB can be combined 
with a Buchwald-Hartwig coupling, a Suzuki coupling, or a Sonogashira reaction.
8
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Notably, not only could these reactions be performed in one-pot, the CalB-
mediated acylation also improved the rate of the metal-catalyzed reaction. 
An alternative for the above described procedure is the linkage of  a metal 
catalyst to an enzyme, creating metallo-enzymes. In this manner, the chiral 
environment of the enzyme can induce enantioselectivity in the metal-catalyzed 
reaction. The first to describe this effect was the group of Whitesides.
9
 They 
reported the attachment of a biotin-containing rhodium-catalyst to BSA using the 
biotin-avidin interaction. This resulted in improved reaction rates and improved 
enantioselectivity, whereas no enantioselectivity was observed when simply 
mixing BSA (or lysozyme or carbonic anhydrase) with the rhodium-catalyst. Later 
work by different groups showed that modifications of an enzyme via directed 
evolution can increase and/or invert the enantioselectivity of the catalyst.
10
 It was 
also found that the tertiary conformation of the avidin cavity may significantly 
influence enantioselectivity.
11
 Metallo-enzymes created via the biotin-avidin 
interaction have been used for the hydrogenation of dehydroamino acids, transfer 
hydrogenation of ketones and allylic alkylation of 1,3-diphenylallylacetate.
12
  
The use of the (strept)avidin-biotin binding for formation of metalloenzymes 
poses high limitations to labeling. Either (strept)avidin is to be equipped with a 
metal-complex, or a large (strept)avidin moiety has to be used for linkage. To 
circumvent this, it was shown that metal catalysts can be covalently bound to the 
active site of an enzyme. Reetz et al. demonstrated that the cysteine in the active 
site of tHisF, an enzyme subunit which catalyzes the formation of imidazole 
glycerol phosphate in histidine biosynthesis, could be equipped with ligands and 
metal catalysts via thiol-maleimide ligation.
13, 14
 However, in these cases the 
catalytic activity of the metal-complex was not investigated. Laan and co-workers 
showed that the thiol in the active site of photoactive yellow protein (PYP) reacted 
with phosphine-metal complexes containing imidazolides, forming thio-ester 
linkages.
15
 In this case, catalytic activity was observed, however, no 
enantioselectivity was obtained. 
Van Koten et al. showed that active site inhibitors can also be used for the 
installation of a metal-catalyst in the active site of cutinase. A pincer-palladium 
complex was equipped with a p-nitrophenol phosphonate, which reacts selectively 
with the lysine in the active site of cutinase.
16
 Later, it was shown that the same 
technique can also be used for installing pincer platinum complexes.
17
 However, in 
both cases no catalytic studies were performed. Recently, Hirota et al. 
demonstrated that using the same strategy, a Hoveyda-Grubbs catalyst can be 
installed in the active site of α-chymotrypsin. This metalloenzyme still proved 
effective in ring-closing metathesis.
18
 Disadvantage of all cases described above 
is that the activity of the active site is blocked (or not investigated). 
In order to combine the activity of the metal catalyst and the enzyme, ideally also 
inducing enantioselectivity in the former, linkage at an innocuous amino acid 
residue in close proximity of the active site is required. Previously, a CalB mutant 
was developed in our group which contains an azide-handle close to the active 
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site of CalB.
19
 This modified lipase (147CalB-N3) mutant was prepared by mutating 
Leu147 into methionine. By subsequently expressing the protein in methionine-
auxotrophic bacteria in medium containing azidohomoalanine instead of 
methionine, the azide was introduced at position 147. Furthermore, the methionine 
residue in close proximity of the N-terminus was mutated into a glycine to prevent 
undesired side reactions at that position.
19
  
 
Scheme 1. Formation of a hybrid enzyme using SPAAC. 
Aim of the research described in this chapter was to attach a metal-catalyst to 
the azide of 147CalB-N3 close to the active site by using SPAAC (Scheme 1), in 
order to optimally profit from the chiral environment created by the enzyme. This 
hybrid catalytic system would still have enzymatic activity and would hopefully 
install enantioselective properties on the metal catalyst complex. As a result , a 
double enantioselective hybrid catalyst should be obtained.  
In first instance, the bioconjugation was performed with a DIBAC-functionalized 
metal catalyst. However, due to the apparent incompatibility of strained alkyne and 
the palladium used for formation of the metal-complex, this approach was not 
successful. Therefore an alternative strategy was followed, in which the azide of 
147CalB-N3 was first reacted with dibenzocyclooctadiyne (DIBODY, 1),
20
 thereby 
introducing a strained alkyne to CalB. This strained alkyne could then be reacted 
with an azide-containing metal-catalyst, also shown in Scheme 1. 
 
6.2 A hybrid catalyst using DIBAC-pincer: attempts to 
conjugate Pincer-ligands to CalB 
Search for a suitable metal-catalyzed reaction for the construction of a hybrid 
catalyst was guided by stability of the catalyst, turn-over number of the reaction, 
and potential to form a compound which can be used for two consecutive 
reactions, i.e. a metal-catalyzed reaction and a CalB-catalyzed reaction. Solvent 
choice and temperature are of less importance since CalB is a highly stable lipase, 
tolerating a wide range of solvents and temperatures. CalB can either form or 
hydrolyze esters, hence a metal-catalyzed reaction tolerating or forming ester, 
acid, or alcohol substrates was pursued.  
Bearing these requirements in mind, the [2,6-(ECH2)2C6H3]
-
 (ECE)-pincer metal 
complex (Scheme 2) was chosen as complex of interest, as these complexes 
show a high chemical and thermal stability due to the stable metal-carbon bond.
16, 
21
 In addition, several reactions catalyzed by this complex form ester- or alcohol-
  6  Formation of a hybrid catalyst using SPAAC  159  
 
containing compounds, which can subsequently react with CalB. Alternatively, the 
starting material for the metal-catalyzed reaction can be prepared by the CalB-
mediated reaction. 
As model reaction, the Heck reaction was chosen. This reaction is shown to 
proceed well with allylic esters, and several pincer-complexes have a high turn-
over number in catalysis of the Heck reaction.
21
 The general structure of a pincer 
complex is shown in Scheme 2, where E represents a two-electron donor (NR2, 
SR, OR, or PR2).
21
 Due to the stability displayed by NCN-pincer palladium 
complexes, combined with the possibility for para-substitution,
22, 23
 NCN-pincer 
complex 4 was chosen as catalyst of interest. 
First, a non-modified pincer complex was prepared, as depicted in Scheme 2. To 
this end, 2-bromo-1,3-dimethylbenzene was first dibrominated using NBS and 
AIBN, yielding 2. In this reaction, a mixture of mono-, di-, and tribrominated 
product was obtained. However, fortunately, the desired compound was the major 
product. Next, bromides were substituted using dimethylamine (yielding 3), and 
lastly, the palladium-complex (4) was formed. 
 
Scheme 2. Pincer ligand synthesis. Reagents and conditions: (a) NBS (2 equiv), AIBN, CCl4, 
reflux, o.n., 52%; (b) HNMe2, toluene, 5 ºC to r.t., 3 h, 88%; (c) 1) Pd2(dba)3, toluene, r.t., o.n; 2) 
THF, 1 h, r.t, 56%. 
With the catalyst in hand, the Heck reaction, Scheme 3, was explored with 
different percentages of catalyst and in different solvents. Using 1% of catalyst 4 
in methanol gave the best conversion to 5, however, also transesterification of 
ethyl acrylate to methyl acrylate was observed.  
 
Scheme 3. Heck reaction catalyzed by Pd-pincer complex 4. 
Having shown that complex 4 indeed catalyzes a Heck reaction between 
iodobenzene and ethyl acrylate, a pincer-ligand which can be bound to CalB had 
to be synthesized. To this end, a DIBAC-functionalized pincer-ligand was 
prepared, as shown in Scheme 4. Preparation of amine-functionalized pincer 
complex 7 was achieved via nitration (yielding 6), followed by reduction of the nitro 
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group.
23
 Unfortunately, direct acylation of the amine group with DIBAC was 
unsuccessful, likely due to the lower reactivity of the aniline moiety. Therefore, first 
a small spacer was introduced by reacting 7 with acid chloride 8. Subsequent 
deprotection of the Cbz-group and introduction of DIBAC, resulted in Pincer-ligand 
12 (Scheme 4). 
 
Scheme 4. Preparation of DIBAC-functionalized pincer-ligand 12. Reagents and conditions: (a) 
H2SO4, HNO3, 0 ºC, 3 h, 72%; (b) N2H4·H2O, 10% Pt/C, 50 ºC, o.n., 56%; (c) C2O2Cl2, CH2Cl2, 0 ºC 
to r.t., 4 h (d) 8, NEt3, CH2Cl2, 0 ºC to r.t., 1.5 h; 78%; (e) HBr in AcOH (33 wt%), r.t. 5 min, 84%; (f) 
DIBAC-NHS, NEt3, DMF, r.t., 2h, 92%. 
The DIBAC-functionalized pincer ligand 12 was added to 147CalB-N3. After 
overnight ligation, full conversion to the ligand-functionalized CalB was obtained, 
as was confirmed by mass spectrometry.
19
 Unfortunately, complexation of the 
ligand attached to CalB with Pd was unsuccessful. Instead, it was attempted to 
form the Pd-complex first from ligand 12. However, the desired complex could not 
be formed. In addition the characteristic DIBAC-signals had changed, suggesting 
that the Pd(OAc)2 had reacted with the strained alkyne. 
 
6.3 A hybrid catalyst via the dibenzocyclooctadiyne approach: 
Cyclooctyne introduction in CalB 
As formation of the CalB-pincer palladium complex, using a DIBAC-
functionalized pincer ligand was troublesome, the possibility of preparing an azide-
functionalized metal complex was investigated. This also required formation of a 
strained-alkyne functionalized CalB. To switch the reactivity of 147CalB-N3 from 
azide to strained alkyne, the azide could be reacted with a DIBAC dimer (13, 
Figure 1), which was previously used in dimerization of CalB.
19
 Disadvantage of 
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this approach is that the linker between both DIBAC molecules is relatively large, 
thereby probably placing the second DIBAC-moiety far away from the active site. 
In this case, the metal catalyst would be far from the active site, thereby reducing 
the potential proximity effect of active site and metal catalyst. An alternative for the 
DIBAC dimer is DIBODY 1 (Figure 1). In solution 1 always yields the ditriazole 
upon reaction with azides, however, Hosoya et al. showed that when applied in 
protein modification, dialkyne 1 only gives a single cycloaddition, thereby leaving 
one strained alkyne intact.
20
 Based on this observation, DIBODY seemed a 
suitable candidate to convert the azide functionality in CalB to a strained alkyne 
without the drawback of introducing a spacer.  
 
Figure 1. DIBODY (1) and DIBAC-dimer 13.  
DIBODY was prepared according to a literature procedure (Scheme 5).
24
 A 
single bromide was attached to the methyl group of ortho-tolunitrile using NBS and 
AIBN, yielding 14. This bromide was subsequently substituted using 
benzenesulfinic acid, forming sulfone 15. Reduction of the nitrile to the aldehyde 
with DIBAL-H proceeded more troublesome, and gave 16 in only 26% yield, 
probably due to overreduction.  
Two molecules of 16 were then fused, leading to the formation of DIBODY, in a 
one-pot three-step procedure. First, a Horner-Wadsworth-Emmons (HWE) reagent 
was formed at the benzylic position of 16. Two subsequent HWE-reactions (first 
intermolecular, then intramolecular) yielded the eight-membered ring, which upon 
LDA-induced elimination of the sulfone groups yielded dialkyne 1.  
 
Scheme 5. Synthesis of dibenzocyclooctadiyne. Reagents and conditions: (a) NBS (1.05 equiv), 
AIBN, CCl4, 90 ºC, 2 h, 71%; (b) PhSO2Na, DMF, 80 ºC, 2 h, 84%; (c) DIBAL-H, CH2Cl2, -78 ºC, 2 
h, 26%; (d) 1) ClPO(OEt)2, LiHMDS, -78 ºC, 30 min, r.t. 2 h; 2) LDA, -78 ºC, 2 h, 40%. 
To obtain optimal protein labeling, the ligation of an azide-containing protein with 
DIBODY was first optimized. Since 147CalB-N3 was relatively scarce, optimization 
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was first performed on a model elastin-like polypeptide (ELP90)
25
 which was 
equipped with a single azide using a diazotransfer reaction.
26
  
 
Scheme 6. Protein labeling using DIBODY (1). 
The first aim was to optimize the reaction time of the azido-protein with DIBODY. 
Therefore, ELP90-N3 and DIBODY were mixed in PBS/DMSO at room 
temperature, and samples were taken at different time points. The alkyne-
containing ELP90 was subsequently labeled by the addition of a large excess of 
azidocoumarin (17, Figure 2). The labeling process is schematically shown in 
Scheme 6. In addition, all remaining DIBODY was quenched as well in this latter 
step. In the same experiment, the orthogonality of DIBODY was also investigated 
by treating non-modified ELP90 with DIBODY and azidocoumarin 17. 
 
Figure 2. Dyes used for protein modification. 
The results from these experiments are shown in Figure 3; panel A shows the 
fluorescence image, panel B shows the coomassie stain. Figure 3A shows that 
already after 5 minutes labeling is obtained. Prolonged reaction times seem to 
increase labeling only slightly. The lack of fluorescence in lane 7 of Figure 3A 
shows that labeling is selective for azide-functionalized protein. 
 
Figure 3. SDS-PAGE gel analysis of ELP-90-N3 reacted with 1 for different amounts of time, 
followed by N3-coumarin (17), visualized by fluorescence imaging (A) and coomassie stain (B). 
Lane 1: 5 min; Lane 2: 10 min; Lane 3: 20 min; Lane 4: 30 min; Lane 5: 60 min; Lane 6: 120 min; 
Lane 7: ELP-90, 120 min. 
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However, when these experiments were repeated, the negative control 
experiment showed higher fluorescent labeling than obtained for ELP90-N3. To 
investigate whether this was caused by aspecificity of 1, ELP90 and azido-
functionalized ELP90 were reacted with 1 or 13 followed by azidocoumarin 17. 
Figure 4 shows that labeling of ELP90-N3 with DIBODY or DIBAC2 resulted in 
fluorescently labeled ELP (Figure 4A, lanes 1 and 3 respectively). However, 
fluorescence for the negative control experiments (lanes 2 and 4) was in both 
cases higher than observed for ELP90-N3. 
 
Figure 4. SDS-PAGE gel analysis of ELP90-N3 and ELP90 reacted with 1 or 13, followed by N3-
coumarin (17), visualized by fluorescence imaging (A) and coomassie staining (B). Lane 1: ELP90-
N3 with 1; Lane 2: ELP90 with 1; Lane 3: ELP90-N3 with 13; Lane 4: ELP90 with 13. 
It was already shown in different labeling studies that DIBAC reacts selectively 
with azide-functionalized proteins (see Chapters 4 and 7). Since the results as 
shown in Figure 4 were not in line with this observation, it was tested whether the 
aspecific signal originated from the azidocoumarin. To this end, fluorescein was 
equipped with an azide functionality, yielding azidofluorescein (18, Figure 2). 
ELP90 and ELP90-N3 were first treated with DIBODY for one hour, followed by 
labeling with azidofluorescein 18. Now, as can be observed in Figure 5A, ELP-N3 
(lane 2) gave a clear fluorescent signal. Fortunately, ELP (lane 1) showed hardly 
any fluorescence, which was reproducible through several experiments. This 
indicated that azidocoumarin 17 caused problems with aspecific labeling, and not 
the DIBODY.  
 
Figure 5. SDS-PAGE gel analysis of ELP90-N3 and ELP90 reacted with 1, followed by N3-
fluorescein, visualized by fluorescence imaging (A) and coomassie staining (B). Lane 1: ELP90; 
Lane 2: ELP90-N3. 
Now that labeling of ELP-N3 using DIBODY was reproducible and selective, 
labeling of 147CalB-N3 was performed using the exact same procedure. Wildtype 
CalB (Figure 6A, lane 1) showed no fluorescent labeling. On the other hand, 
147CalB-N3 was successfully fluorescently labeled (Figure 6A, lane 2). 
Surprisingly, not only labeled CalB was observed, but also multimer formation in 
fluorescence imaging (Figure 6A) and by coomassie stain (Figure 6B).  
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Figure 6. SDS-PAGE gel analysis of CalB and CalB-AHA reacted with 1, followed by N3-
fluorescein (18), visualized by fluorescence imaging (A) and coomassie stain (B). Lane 1: CalB; 
Lane 2: CalB-AHA. 
Multimer formation can be explained by reaction of 147CalB-N3 with a 
cyclooctyne-functionalized 147CalB-N3. However, Hosoya et al. showed that 
dimerization does not occur.
20
 Also, it was previously shown that dimer formation 
of 147CalB-N3 was troublesome.
19
 Therefore, it was considered that aggregation 
had occurred due to the high DMSO content in the reaction mixture (50%), as 
DMSO-mediated aggregation was already previously published.
27
  
To investigate whether DMSO content and concentration would influence 
multimer formation and/or aggregation, labeling was performed at three different 
concentrations (1, 0.5 and 0.1 mg/mL) and at three different DMSO percentages 
(50, 25 and 10%). The results of this investigation are displayed in Figure 7. It 
shows that multimer formation increased upon increasing concentration 
independent of the DMSO content (compare for example lanes 2, 5, and 8 in 
Figure 7B). Also the DMSO content does influence dimer formation, which can be 
observed by comparing lanes 8 to 10 in Figure 7B. At 1 mg/mL and 50% DMSO 
content (lane 8), almost no 147CalB-N3 was observed, and only dimer and trimer 
were detected. When ligation was performed with either 25 or 10% DMSO at 
identical concentration, the main signal corresponded to fluorescein-labeled 
147CalB-N3. 
 
Figure 7. SDS-PAGE gel analysis of 147CalB-N3 labeled with 20 equiv of 1, followed by 50 equiv 
N3-fluorescein at different concentrations and varying DMSO percentages, visualized by 
fluorescence imaging (A) and coomassie staining (B). Lane 1: 147CalB-N3; Lane 2: 0.1 mg/mL, 
50% DMSO; Lane 3: 0.1 mg/mL, 25% DMSO; Lane 4: 0.1 mg/mL, 10% DMSO; Lane 5: 0.5 
mg/mL, 50% DMSO; Lane 6: 0.5 mg/mL, 25% DMSO; Lane 7: 0.5 mg/mL, 10% DMSO; Lane 8: 1 
mg/mL, 50% DMSO; Lane 9: 1 mg/mL, 25% DMSO; Lane 10: 1 mg/mL, 10% DMSO. 
Also, fluorescent labeling was influenced by concentration and DMSO content. 
As can be observed in Figure 7A, with 50% DMSO hardly any protein labeling was 
observed. A clear fluorescent signal was detected when 25 or 10% of DMSO was 
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used. The successful and quantitative labeling of 147CalB-N3 with 
azidofluorescein was confirmed by mass spectrometry (Figure 8), showing mono- 
and difunctionalized 147CalB-N3 (34996 and 35804 respectively) and 147CalB, 
containing methionine instead of azidohomoalanine (34213). The occurrence of 
147CalB without azide can be explained by incorporation of methionine instead of 
azidohomoalanine during the production process, which is a common observation 
using this technique.
28
 
 
Figure 8. Mass spectrometry analysis of fluorescein-labeled 147CalB-N3 showing the mass of 
147CalB without azide (34213), 147CalB-N3 labeled with one fluorescein (34996), and 147CalB-N3 
with two fluorescein groups (35804). 
 
6.4 A hybrid catalyst via the dibenzocyclooctadiyne approach: 
N3-catalysts 
Now that labeling of 147CalB-N3 with DIBODY (1) was shown to be quantitative, 
the next step was the preparation of an azido-functionalized pincer complex. 
Amine-functionalized pincer ligand 7 was successfully converted to azide-
functionalized pincer ligand 19 via a diazonium salt. However, complexation of 19 
with Pd (forming 20) was unsuccessful. 
 
Scheme 7. Preparation of azide-functionalized pincer ligand and attempted complexation. 
Reagents and conditions: (a) 1) NaNO2, HCl, EtOH, 0 ºC, 30 min; 2) NaN3, H2O, 0 ºC, 3 h, 50%; 
(b) 1) Pd2(dba)3, toluene, r.t., o.n; 2) THF, 1 h, r.t. 
Due to the troublesome formation of the pincer complex, the use of a different 
metal-complex was considered. Ir-catalyst 21 is known to catalyze the reduction of 
aldehydes to alcohols in the presence of a hydrogen source in water. As azide-
functionalized Ir-catalyst 21 was available, this appeared a suitable candidate for 
the formation of a hybrid system.  
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Scheme 8. Labeling of 147CalB-N3 using DIBODY (1) and N3-functionalized Ir-cat (21). 
Formation of this CalB-iridium construct was performed identical to the labeling 
of 147CalB-N3 with fluorescein. Unfortunately, until now, no mass spectrum could 
be obtained of the CalB-iridium construct. Nonetheless, based on the similarity of 
this reaction compared to the fluorescein labeling, it was assumed in further 
studies, that the iridium catalyst was successfully attached to CalB. 
  
6.5 Catalysis with the hybrid system 
To investigate the catalytic potential of the CalB-iridium construct, the reduction 
of benzaldehyde to benzyl alcohol was investigated as shown in Scheme 9. In 
addition, two different negative control constructs were used. The first was 
prepared by treatment of wildtype CalB (wtCalB) with DIBODY and iridium catalyst 
21, the second by mixing 147CalB-N3 with iridium catalyst 21 (without the addition 
of DIBODY). All thus obtained constructs were purified in exactly the same 
manner, by dialyzing against 250 mM imidazole in phosphate buffer, followed by 
spin-concentration against MilliQ and sodium citrate buffer. Dialysis against 250 
mM imidazole was performed to ensure that iridium that potentially had bound to 
the His-tag was removed.  
 
Scheme 9. Iridium-catalyzed reduction of aldehyde to alcohol. 
Reduction of benzylaldehyde to benzylalcohol (Scheme 9) was subsequently 
performed using the CalB-catalyst construct. The ratio between catalyst construct 
and benzylaldehyde was 1:500. Formation of benzyl alcohol during the iridium-
mediated reduction was followed by HPLC. The formation over time is shown in 
Figure 9. Comparing the CalB-iridium construct (graph 1) with the negative control 
experiments (graphs 2 and 3), the conversion was two-fold higher for the CalB-
iridium complex than for the negative control experiments. As positive control 
experiment, the reaction was also performed with Ir-catalyst 21 (4). In this 
experiment, about 22% conversion was observed (three times higher than for the 
CalB-iridium construct). It must, however, be noted that the amount of Ir-catalyst 
used in experiment 4, was based on the theoretical amount of catalyst present in 
the construct. As, in general, protein and iridium are lost during purification, the 
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amount of CalB-iridium construct actually present is probably significantly lower 
than theoretically assumed. Ideally, protein concentration and iridium-content 
would have been determined. However, only little protein material was available, 
making extensive analysis hard to achieve.  
 
Figure 9. Benzyl alcohol formation catalyzed by Ir-complexes. (1) 147CalB-N3-CO-Cat; (2) 
147CalB-N3 + Cat; (3) CalB + CO + Cat; (4) Ir-cat. 
Apart from the catalytic activity of the iridium catalyst, the activity of CalB 
towards ester hydrolysis was investigated. The main concern in this case was 
whether the reagents used for the iridium-catalyzed reaction would block CalB 
activity, as it is known that proteins can be modified by the iridium catalyst 
together with an aldehyde in a reductive amination type reaction.
29
 Therefore, the 
CalB-iridium construct was, after being exposed to the reductive conditions, used 
in a fluorescence assay. In this assay, DiFMU octanoate, which is only slightly 
fluorescent, is hydrolyzed to highly fluorescent DiFMU, shown in Scheme 10. By 
measuring fluorescence, and thus the formation of DiFMU, it was determined 
whether CalB was still active.  
 
Scheme 10. CalB-mediated hydrolysis of DiFMU octanoate. 
Hydrolysis of DiFMU octanoate was performed with the CalB-iridium construct 
(1) and also with CalB from the negative control experiments as described above 
(2 and 3). Lastly, hydrolysis of DiFMU without CalB, but with Ir-catalyst, HCO2K, 
and benzaldehyde was also performed (4). 
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Figure 10. CalB-mediated ester hydrolysis of DiFMU octanoate. (1) 147CalB-N3-CO-Cat; (2) 
147CalB-N3+ Cat; (3) CalB + CO + Cat; (4) Ir-cat. 
Figure 10 shows that without CalB no hydrolysis of DifMU was observed. All 
hydrolysis observed in other samples was therefore caused by CalB. All samples 
containing CalB showed efficient hydrolysis of DiFMU octanoate. This indicates 
that the reaction conditions used for the reduction of the aldehyde to the alcohol 
do not inhibit CalB. Figure 10 shows the hydrolysis of DiFMU by CalB after the 
enzyme was exposed to the benzaldehyde reduction conditions at 37 ºC for 86 
hours; the same experiment was performed after 45 hours of reduction, with no 
difference in hydrolysis rate. 
As mentioned earlier, probably protein material was lost during purification. 
Therefore, it is hard to tell whether the negative controls contained an identical 
amount of protein compared to the CalB-iridium construct. An indication can be 
obtained from the rate of hydrolysis of CalB in these samples. Comparing lines 1 
and 2 in Figure 10, corresponding to 147CalB-N3 with (1) or without DIBODY (2) 
with iridium catalyst shows that both samples hydrolyze DiFMU octanoate with a 
similar rate. This indicates that a similar amount of protein was present in both 
samples. On the other hand, the CalB-iridium construct showed a slightly higher 
aldehyde reduction (1, Figure 9), compared to the negative control experiment (2, 
Figure 9). 
Obviously, the CalB activity essay is not conclusive about the amount of protein 
present, and therefore no clean comparison of the iridium catalyzed reactions can 
be made. Nonetheless, the combination of both experiments looks promising and 
gives a preliminary indication that the iridium catalyst was attached to 147CalB-N3. 
It was demonstrated that the iridium-catalyzed aldehyde reduction and CalB-
mediated ester hydrolysis are compatible, and can be performed in one pot. 
Especially promising was the observation that the conditions used for the aldehyde 
reduction did not inhibit CalB. 
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6.6 Conclusions and outlook 
Towards the development of a hybrid catalyst, consisting of a metal catalyst and 
an enzyme, two different routes were investigated. At first, a DIBAC-functionalized 
pincer was prepared and ligated to CalB. Unfortunately, complexation of the pincer 
complex was unsuccessful prior to and after ligation to the enzyme. Alternatively, 
the azide-functionality of the 147CalB-N3 was used to introduce a strained alkyne 
using DIBODY, and subsequently introduction of an azide-functionalized catalyst 
was pursued. 
Towards the first approach, NCN-pincer palladium complex was chosen as 
catalyst of interest, due to its stability and functionalizability. After showing that the 
unfunctionalized palladium complex was able to catalyze a Heck reaction, a 
DIBAC-functionalized NCN-pincer ligand was prepared. This ligand was 
successfully and quantitatively introduced to CalB, however, complexation of the 
ligand was not possible. In addition, complexation of the DIBAC-containing pincer-
ligand failed as well, probably due to incompatibility of DIBAC to the excess of 
palladium. 
To avoid the strained-alkyne/palladium combination, an alternative strategy was 
envisioned using an azide-functionalized catalyst and a dibenzocyclooctadiyne to 
introduce a strained alkyne to 147CalB-N3. After optimization, it was shown that 
fully labeled 147CalB-N3 can be obtained, using DIBODY and azidofluorescein.  
As azide-functionalized catalyst, an Iridium catalyst was used, since the azide-
functionalized NCN-pincer complex could not be formed. This iridium-catalyst was 
attached to CalB applying the same procedure as for the fluorescent labeling of 
CalB. 
Initial experiments showed that the thus formed CalB-iridium construct catalyzed 
aldehyde reduction to a higher extent than the control experiments. In addition, 
during this reduction CalB remained active. However, further research is required 
to confirm the formation of the conjugate of CalB and iridium catalyst. 
Furthermore, further research is required to prove the viability of this hybrid 
catalyst. To this end, a substrate which can undergo a reaction with CalB on one 
side of the molecule and a metal catalyst-mediated reaction on the other side 
could be designed. An example of a suitable substrate is 22 (Scheme 11). Upon 
hydrolysis by CalB and reduction by the iridium catalyst 23 would be formed. 
 
Scheme 11. Hydrolysis and reduction of substrate 22 by the CalB-iridium construct. 
Ideally, a rate increase of the metal-catalyzed reaction would be observed due to 
substrate enrichment by the active site of CalB. In addition, when racemic ester 
substrates, e.g. 24 (Scheme 12), would be used, chiral selection could occur, 
forming 23 and 25. 
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Scheme 12. Chiral selection by CalB-iridium catalyst. 
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6.8 Experimental Section 
6.8.1 General experimental 
General experimental on synthesis, see Section 2.7. 
ELP90 was prepared according to a literature procedure.
25
 ELP precipitation was 
performed by heating the samples to at least 40 ºC, and subsequent centrifugation at 40 
ºC (10 min, 4.5k × g). 147CalB-N3 was prepared according to an earlier described 
procedure.
19
 wtCalB was purchased from Sigma-Aldrich. N3-coumarin was prepared 
according to a literature procedure.
30
 Citrate buffer contained 25 mM citrate (0.96 g citric 
acid and 2.33 g C3H5(CO2)3Na3∙2H2O) in 0.5 L MilliQ, pH 5. Elution buffer contained 50 
mM NaH2PO4, 300 mM NaCl, and 250 mM imidazole, the pH was adjusted to pH 8.0 using 
an aqueous NaOH-solution. Analysis of protein modification was performed using 12% 
SDS-PAGE gels. All gels were imaged using GBOX Chemi IR6 F1.4 with UV filter, and 
stained with Coomassie stain. 
  
6.8.2 Synthesis 
2-bromo-1,3-bis(bromomethyl)benzene (2)  
2-Bromo-1,3-dimethylbenzene (1.1 g, 5.9 mmol) was dissolved in CCl4 
(100 mL) in a flame-dried flask under Ar-atmosphere. Next, AIBN (49.2 mg, 
0.30 mmol) and NBS (2.1 g, 12 mmol) were added and product formation 
was followed by TLC. After completion, the mixture was filtered over celite 
and washed with CH2Cl2 (150 mL). The solvents were removed in vacuo and the thus 
obtained crude product was purified by column chromatography (n-heptane). Compound 2 
was obtained as a white solid (1.05 g, 52%). RF = 0.25 (n-heptane). 
1
H-NMR (400 MHz, 
CDCl3) δ: 7.42 (d, J = 7.6 Hz, 2H), 7.29 (dd, J = 8.1, 7.1 Hz, 1H), 4.65 (s, 4H). 
 
1,1'-(2-bromo-1,3-phenylene) bis(N,N-dimethylmethanamine) (3)  
Compound 2 (0.50 g, 1.5 mmol) was dissolved in dry toluene (20 
mL) in a flame-dried flask under Ar-atmosphere. Upon cooling to 0 
ºC, a HNMe2-solution in toluene (2M, 7.5 mL, 15 mmol) was added 
drop wise. The reaction was stirred at 0 ºC for 3 hours whereupon 
the mixture was filtered over celite and washed with EtOAc (100 mL). The solvents were 
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removed under reduced pressure and the crude product was purified by column 
chromatography (EtOAc/NEt3, 99.5:0.5). Compound 3 was obtained as a yellow oil (350 
mg, 88%). 
1
H NMR (400 MHz, CDCl3) δ: 7.33 (d, J = 7.2 Hz, 2H), 7.25 (dd, J = 8.4, 6.5 
Hz, 1H), 3.55 (s, 4H), 2.31 (s, 12H). 
 
NCN-Pincer palladium complex (4)  
Compound 3 (27 mg, 0.1 mmol) and tris(benzylideneacetone)dipalladium 
(92 mg, 0.1 mmol) were stirred overnight in toluene (20 mL). The next day 
THF (2 mL) was added and the reaction was stirred for an additional 2 
hours. Hereupon, more THF (5 mL) was added and stirring was continued 
for 1 hour. All volatiles were evaporated in vacuo and the residue was 
diluted in CH2Cl2 (30 mL), filtered over celite and washed with CH2Cl2 (30 
mL). The product was precipitated using isopropylether resulting in a brown solid (21 mg, 
55.6%). 
1
H-NMR (300 MHz, CDCl3) δ: 2.98 (s, 12H), 4.00 (s, 4H), 6.78 (d, J = 7.5 Hz, 2H), 
6.99 (t, J = 7.7 Hz, 1H). 
 
1,1'-(2-bromo-5-nitro-1,3-phenylene)bis(N,N-dimethylmethanamine) (6)  
Compound 3 (350 mg, 1.3 mmol) was dissolved in H2SO4 (1.8 mL) 
at 0 ºC. Subsequently, HNO3 (346 μL, 7.7 mmol) was added slowly 
while cooling and the resulting solution was stirred at 0 ºC for 3 
hours. The mixture was poured into cold H2O (50 mL) and 
neutralized by the addition of 1M aqueous NaOH. The H2O-layer 
was extracted with CH2Cl2 (3 × 100 mL) and the combined organic 
layers were dried over MgSO4. After removal of the solvents in vacuo, the crude product 
was purified by column chromatography (EtOAc/n-heptane/NEt3, 1:1:0.005) to obtain 6 as 
yellow solid (295 mg, 72%). 
1
H-NMR (300 MHz, CDCl3) δ: 2.35 (s, 12H), 3.61 (s, 4H), 8.25 
(s, 2H). 
 
1,1'-(5-amino-2-bromo-1,3-phenylene)bis(N,N-dimethylmethanamine) (7)  
Compound 6 (50 mg, 0.16 mmol) was dissolved in EtOH (1.5 mL). 
10% Pt/C (3 mg, 1.6 μmol) was added upon which the mixture was 
heated to 50 ºC. At this temperature, hydrazine monohydrate (98 
μL, 0.64 mmol) was added drop wise, after which the reaction was 
left to reflux for an additional 3 hours. The reaction mixture was 
filtered over celite and washed with EtOH (20 mL). The filtrate was 
concentrated in vacuo and subsequently dissolved in CH2Cl2 (10 mL) and washed with 
H2O (3 × 10 mL) and brine (10 mL). The organic layer was dried over MgSO4 and 
concentrated in vacuo. The crude product was purified using gradient column 
chromatography (EtOAc/n-heptane/NEt3 50:1:0.25 to CH2Cl2:MeOH/NEt3 9:1:0.5) and 7 
was obtained as a yellow solid (38 mg, 85%). 
1
H-NMR (400 MHz, CDCl3) δ: 6.74 (s, 2H), 
3.64 (br s, 2H), 3.50 (s, 4H), 2.32 (s, 12H). 
 
benzyl 3-chloro-3-oxopropylcarbamate (8)  
3-(benzyloxycarbonyl amino) propanoic acid (150 mg, 0.67 mmol) was 
dissolved in dry CH2Cl2 (7 mL) and oxalyl chloride (575 μL, 6.7 mmol) 
was added. This mixture was stirred at room temperature for 4 hours. 
All solvents were evaporated and 8 was obtained as a yellow oil and used without further 
purification. 
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benzyl3-(4-bromo-3,5-bis((dimethylamino)methyl)phenylamino)-3-
oxopropylcarbamate (9) 
 Compound 7 (30 mg, 0.11 mmol) was dissolved in dry 
CH2Cl2 (5 mL) and NEt3 (21 mg, 0.21 mmol) was added upon 
which the reaction mixture was cooled to 0 ºC. Compound 8 
(38 mg, 0.16 mmol) was added and the reaction was stirred 
for 3 hours while slowly warming to room temperature. The 
reaction was quenched with H2O (10 mL) and diluted with 
CH2Cl2 (10 mL). The layers were separated and the organic 
layer was washed with 2M aqueous NaOH (2 × 10 mL), H2O (2 × 10 mL) and brine (10 
mL). The organic layer was dried over MgSO4 and concentrated in vacuo. The crude 
product was purified using gradient column chromatography (DCM:MeOH:NEt3 199:6.5:1 
to 199:20:1), yielding 9 as a yellow solid with some impurities (42 mg, 78%). 
1
H-NMR (400 
MHz, CDCl3) δ: 8.57 (br s, 1H), 7.67 (s, 2H), 7.29-7.34 (m, 5H), 5.09 (s, 2H), 3.62 (s, 4H), 
3.55 (q, 2H), 2.61 (t, J = 5.6 Hz, 2H), 2.36 (s, 12H). 
 
3-amino-N-(4-bromo-3,5-bis((dimethylamino)methyl)phenyl)propanamide (10)  
Compound 9 (32 mg, 65 μmol) was dissolved in HBr in AcOH 
(33wt%, 30 mL). This mixture was stirred for 5 minutes 
whereupon the solvents were removed in vacuo. Compound 10 
was obtained as a brown solid (16 mg, 69%) and was used 
crude in the next reaction. 
1
H-NMR (400 MHz, D2O) δ: 7.91 (s 
2H), 4.62 (s, 4H), 3.38 (t, J = 6.8 Hz, 2H), 2.99 (s, 12H), 2.94 (t, 
J = 6.5 Hz, 2H). 
13
C-NMR (75 MHz, D2O) δ: 170.5, 137.1, 131.4, 
126.4, 122.9, 60.6, 42.4, 34.8, 32.2 
 
(Z)-N-(3-((4-bromo-3,5-bis((dimethylamino)methyl)phenyl)amino)-3-oxopropyl)-5-
(didehydrodibenzo[b,f]azocin-5(6H)-yl)-5-oxopentanamide (12)  
Compound 10 (16 mg, 0.045 mmol) was dissolved in dry 
DMF (2 mL) under N2-atmosphere. Subsequently, a solution 
of DIBAC-NHS (11, 22 mg, 0.054 mmol) in dry CH2Cl2 (0.5 
mL) and NEt3 (12 μL, 0.09 mmol) were added. The reaction 
was stirred for 1 hour whereupon the mixture was diluted 
with CH2Cl2 (5 mL) and washed with 2M aqueous NaOH (2 × 
10 mL), H2O (10 mL) and brine (10 mL). The organic layer 
was dried over MgSO4 whereupon all solvents were removed 
under reduced pressure. Compound 12 was obtained as a 
yellow solid (27 mg, 92%). 
1
H-NMR (400 MHz, D2O) δ: 8.46 
(br s, 1H), 7.65 (d, J = 6.6 Hz, 2H), 7.42-7.27 (m, 7H), 7.23-
7.02 (m, 1H), 6.13 (br s, 1H), 5.15 (d, J = 13.9 Hz, 1H), 3.67 
(d, J = 13.9 Hz, 1H), 3.58 (d, J = 3.1 Hz, 4H), 2.33 (s, 12H), 
2.13-1.80 (m, 4H), 1.78-1.63 (m, 2H).
 13
C-NMR (75 MHz, 
D2O) δ: 173.8, 172.2, 170.5, 152.3, 151.6, 138.3, 136.8, 128.1 (2C), 127.0 (2C), 123.5 
(2C), 121.7, 121.5, 120.9, 119.6, 115.8, 109.2, 62.4, 48.4, 45.8, 37.0, 36.1, 34.5, 29.7, 
21.5 HRMS (ESI+) m/z calcd for C35H40BrN5NaO3 [M+Na]
+
 680.2205, found 680.2212. 
 
2-(bromomethyl)benzonitrile (14)  
Ortho-tolunitrile (2.37 mL, 20 mmol) was dissolved in CCl4 (30 mL) and 
AIBN (328 mg, 2 mmol) and NBS (3.74 g, 21 mmol) were added. The 
reaction was heated to 90 ºC and stirred for 2 hours. Upon cooling to room 
temperature, the mixture was filtered and diluted with CH2Cl2 (30 mL). The 
filtrate was washed with saturated aqueous NaHCO3 (50 mL) and H2O (50 
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mL) and the organic layer was dried over MgSO4. The solvents were removed under 
reduced pressure and the crude product was purified by column chromatography 
(EtOAc/n-heptane, 1:9). Compound 14 was obtained as white solid (2.75 g, 71%). 
1
H-
NMR (300 MHz, CDCl3) δ: 7.67 (d, J = 7.6 Hz, 1H), 7.64-7.52 (m, 2H), 7.41 (ddd, J = 7.7, 
6.9, 1.9 Hz, 1H), 4.64 (s, 2H). 
 
2-((phenylsulfonyl)methyl)benzonitrile (15)  
Compound 14 (2.75 g, 14.1 mmol) was dissolved in DMF (30 mL) 
and benzene sulfinic acid (2.77 g, 16.9 mmol) was added. The 
mixture was heated to 80 ºC for 2 hours and subsequently cooled to 
room temperature. After dilution with EtOAc (50 mL), the organic 
layer was washed with H2O (3 × 100 mL) and brine (100 mL) and dried over MgSO4. The 
solvents were removed under reduced pressure and the crude product was crystallized 
from EtOAc/n-heptane yielding 15 as colorless needles (3.04 g, 84%). 
1
H-NMR (400 MHz, 
CDCl3) δ: 7.72 (d, J = 8.4 Hz, 2H), 7.69-7.60 (m, 3H), 7.58-7.42 (m, 4H), 4.57 (s, 2H). 
 
2-((phenylsulfonyl)methyl)benzaldehyde (16)  
Compound 15 (514 mg, 2 mmol) was dissolved in dry CH2Cl2 (30 mL) 
in a flame-dried flask under Ar-atmosphere. The solution was cooled 
to -78 ºC, whereupon DIBAL-H in hexanes (1M, 4.6 mL, 4.6 mmol) 
was added. After stirring for 2 hours at -78 ºC, the reaction was 
quenched by the addition of saturated aqueous NH4Cl (20 mL). The 
resulting mixture was diluted with CH2Cl2 (20 mL) and the layers were separated. The 
organic layer was washed with 1M aqueous HCl (2 × 30 mL) and H2O (30 mL) and dried 
over MgSO4. The solvents were removed under reduced pressure and the crude product 
was redissolved in little CH2Cl2 (2 mL) and filtered over silica, eluting with CH2Cl2 (50 mL). 
The solvents were removed under reduced pressure and the crude product was 
crystallized from CH2Cl2/n-heptane to obtain 16 as white solid (135 mg, 26%). 
1
H-NMR 
(400 MHz, CDCl3) δ: 9.83 (s, 1H), 7.79-7.72 (m, 1H), 7.72-7.67 (m, 2H), 7.62-7.56 (m, 
3H), 7.50-7.42 (m, 3H), 5.03 (s, 2H). 
 
dibenzo[a,e]cycloocta-1,5-diyne (1)  
Compound 16 (50 mg, 0.2 mmol) was dissolved in dry THF (5 mL) in 
a flame-dried flask under Ar-atmosphere. The solution was cooled to -
78 ºC and diethyl phosphorochloridate (35 μL, 0.24 mmol) and 
LiHMDS in toluene (1M, 0.4 mL, 0,4 mmol) were added. Upon 
addition the solution immediately changed color from yellow to dark red. The reaction 
mixture was stirred at -78 ºC for 30 minutes, and for 1.5 hours at room-temperature. In the 
meantime diisopropylamine (140 μL, 1 mmol) was dissolved in dry THF in a flame-dried 
flask under Ar-atmosphere. This solution was cooled to -30 ºC and n-BuLi in hexanes 
(1.6M, 675 μL, 1,1 mmol) was added. The reaction was stirred for 1 hour at room  
temperature, whereupon the thus obtained LDA-solution was added drop wise to the 
reaction mixture. The reaction was stirred for 2 hours at -78 ºC and subsequently poured 
into saturated aqueous NH4Cl (10 mL). The aqueous layer was extracted with EtOAc (2 × 
10 mL) and the combined organic layers were washed with H2O (2 × 20 mL) and brine (20 
mL). The organic layer was then dried over MgSO4 and the solvents were removed under 
reduced pressure. The crude product was purified by column chromatography (CH2Cl2/n-
heptane, 3:2) to obtain 1 as a brown solid (8 mg, 40%). 
1
H-NMR (300 MHz, CDCl3) δ: 6.92 
(dd, J = 5.6, 3.3 Hz, 4H), 6.74 (dd, J = 5.5, 3.4 Hz, 4H). 
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1,1'-(5-azido-2-bromo-1,3-phenylene)bis(N,N-dimethylmethanamine) (19)  
Compound 7 (20 mg, 0.07 mmol) was dissolved in EtOH (1 mL) and 
concentrated aqueous HCl (0.1 mL) was added. The solution was 
cooled to 0 ºC and a solution of NaNO2 (11 mg, 0.15 mmol) in H2O 
(1 mL) was added. The mixture was stirred for 30 minutes at 0 ºC, 
whereupon NaN3 (10 mg, 0.15 mmol) in H2O (1 mL) was added. 
After stirring for 3 hours at 0 ºC, the mixture was diluted with H2O 
(10 mL) and quenched with saturated aqueous NaHCO3 (10 mL). The product was 
extracted with Et2O (3 × 10 mL), and the combined organic layers were washed with 
saturated aqueous NaHCO3 (2 × 20 mL) and brine (20 mL). After drying over MgSO4, the 
solvents were removed under reduced pressure and the crude product was purified by 
gradient column chromatography (DCM:MeOH:NEt3 199:6.5:1 to 199:20:1) yielding 19 (10 
mg, 46%).
 1
H-NMR (300 MHz, CDCl3) δ 7.07 (s, 2H), 3.51 (s, 4H), 2.30 (s, 12H).
 13
C-NMR 
(75 MHz, CDCl3) δ: 140.5, 139.1, 121.8, 119.6, 63.7, 45.7. FT-IR νmax film (cm
-1
): 2767, 
2128, 1679, 1588, 1389, 1247, 616. HRMS (ESI+) m/z calcd for C12H19BrN5 [M+H]
+
 
312.0824, found 312.0807. 
 
1-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-3-(3',6'-dihydroxy-2,3-
dihydrospiro[indene-1,9'-xanthen]-5-yl)thiourea (18)  
Fluorescein-NCS (100 mg, 0.26 mmol) was 
dissolved in dry CH2Cl2 (5 mL) and NEt3 (142 
μL, 1.03 mmol) and 2- (2- (2- (2-azidoethoxy) 
ethoxy) ethoxy)ethanamine (101 μL, 0.51 
mmol) were added. The reaction was followed 
by LR-MS and upon completion solvents were 
removed under reduced pressure. The crude 
product was purified by column 
chromatography (CH2Cl2/MeOH, 9:1). 
Compound 18 was obtained as an orange solid (40 mg, 26%). 
1
H-NMR (400 MHz, 
CD3OD) δ: 7.19 (d, J = 8.3 Hz, 1H), 6.76-6.53 (m, 8H), 3.81-3.54 (m, 16H). LR-MS (ESI+) 
m/z [M+H]
+
 calcd for C29H30N5O8S 608.2, found 608.2. 
 
ethyl 4-(4-formylphenyl)butanoate (22)  
Ethyl 4-phenylbutanoate (384 mg, 2 mmol) was dissolved in TFA (5 mL) and 
hexamethylenetetramine (308 mg, 2.2 mmol) was added. 
The reaction was heated to 80 ºC overnight, whereupon the 
TFA was evaporated. Saturated aqueous NaHCO3 (20 mL) 
was added and the aqueous layer was extracted with Et2O (3 
× 30 mL). The organic layers were combined, washed with 
water (50 mL) and brine (50 mL) and dried over MgSO4. The solvents were removed 
under reduced pressure and the crude product was purified by column chromatography 
(EtOAc/n-heptane, 1:9). Compound 22 was obtained as an oil which solidified at -20 ºC 
(115 mg, 26%). 
1
H-NMR (400 MHz, CDCl3) δ: 9.98 (s, 1H), 7.81 (d, J = 8.1 Hz, 2H), 7.35 
(d, J = 8.1 Hz, 2H), 4.13 (q, J = 7.1 Hz, 2H), 2.74 (t, J = 8.0 Hz, 2H), 2.33 (t, J = 7.4 Hz, 
2H), 2.13-1.88 (m, 2H), 1.26 (t, J = 7.1 Hz, 3H). 
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6.8.3 Protein labeling 
Preparation of ELP90-N3 
ELP90 (5 mg/mL, 210 μL) was mixed with diazotransfer reagent (9 μL, 
0.26 mg 1H-imidazole-1-sulfonyl azide in MilliQ (13 μL) with 1M aqueous 
NaOH (1.3 μL), pH 7) and 990 μL of 30 mM diethanol amine  at pH 8.5. 
The reaction was shaken overnight at room temperature, whereupon 
ELP90-N3 was precipitated. The precipitate was washed twice with PBS by 
subsequently dissolving and precipitating. The remaining precipitate was 
taken up in PBS. The formation of ELP90-N3 was confirmed by mass 
spectrometry. 
 
ELP90-N3 labeling with DIBODY and N3-coumarin  
To ELP90-N3 (480 μg, 96 μL) was added DIBODY (1.6 μL, 3 mg/mL in DMSO) and the 
mixture was shaken at room temperature. After 5, 10, 20, 30, 60, and 120 minutes a 15 μL 
sample was taken and N3-coumarin (2 μL, 2 mg/mL DMSO) was added. ELP90 was 
treated similarly as ELP-N3. In this case a sample was only taken after 2 hours. Samples 
were purified by precipitation and subsequently analyzed by SDS-PAGE gel. 
 
ELP90-N3 labeling with DIBODY or DIBAC2 followed by N3-coumarin 
To ELP and ELP-N3 (20 μL, 5 mg/mL) was added DIBODY 1(0.33 μL, 3 mg/mL) or 
DIBAC2 13 (1.88 μL, 5 mg/mL). The samples were shaken for 1 hour whereupon N3-
coumarin (1.25 μL for DIBODY and 5 μL for DIBAC2, 12 mg/mL) was added. After 
overnight reaction, samples were purified by precipitation and analyzed by SDS-PAGE gel 
analysis. 
 
Labeling of ELP90-N3 and 147CalB-N3 with N3-fluorescein 
To ELP-N3, ELP, wtCalB, and 147CalB-N3 (20 μL, 5 mg/mL for ELP; 50 μL, 2 mg/mL for 
CalB) was added DIBODY (50 μL, 0.12 μg/mL in DMSO). After 1 hour N3-fluorescein (50 
μL/sample, 3 mg/mL in DMSO) was added and reacted overnight. Samples were analyzed 
by SDS-PAGE gel analysis. In addition, modified 147CalB-N3 was analyzed by mass 
spectrometry (see section 6.3). 
 
Effect of DMSO and concentration on 147CalB-N3 labeling 
Samples were prepared as shown in Table 1. After shaking for 2 hours with DIBODY, to 
each sample N3-fluorescein (1 μL, 8.8 mg/mL in DMSO) was added. Samples were 
analyzed by SDS-PAGE analysis. 
Table 1. Sample preparation for DMSO and concentration screen. 
Entry 147CalB-N3
a 
PBS DMSO DIBODY
b Percentage 
DMSO 
Final  
concentration 
1 5 μL 45 μL 49 μL 1 μL  50% 0.1 mg/mL 
2 5 μL 70 μL 24 μL 1 μL  25% 0.1 mg/mL 
3 5 μL 85 μL 9 μL 1 μL  10% 0.1 mg/mL 
4 5 μL 5 μL 9 μL 1 μL  50% 0.5 mg/mL 
5 5 μL 10 μL 4 μL 1 μL  25% 0.5 mg/mL 
6 5 μL 13 μL 1 μL 1 μL  10% 0.5 mg/mL 
7 5 μL 0 μL 4 μL 1 μL  50% 1.0 mg/mL 
8 5 μL 2.5 μL 1.5 μL 1 μL  25% 1.0 mg/mL 
9 5 μL 4 μL 0 μL 1 μL  10% 1.0 mg/mL 
a 
147CalB-N3 was a 2 mg/mL solution in PBS. 
b 
DIBODY was a solution of 1.2 mg/mL in DMSO. 
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Preparation of CalB-iridium catalyst complex 
To 147CalB-N3 (25 μL, 2 mg/mL) and wtCalB (25 μL, 10 mg/mL
31
) was added PBS (25 
μL) and DIBODY (25 μL, 1.2 mg/mL in DMSO). After 2 hours, iridium catalyst 21 (25 μL, 
1.54 mg/mL in MilliQ) was added and the reaction was shaken overnight. In addition, 
147CalB-N3 (25 μL, 2 mg/mL) was directly mixed with iridium catalyst 21 (25 μL, 1.54 
mg/mL in MilliQ) and shaken overnight. All proteins were dialyzed against elution buffer (2 
× 1 hour, r.t.), MilliQ (1 × 1 hour, r.t., 1 × o.n., 4 ºC) and citrate buffer (2 × 1 hour, r.t.). 
 
Reduction by CalB-Ir complex  
The different CalB samples prepared as described above were mixed with benzaldehyde 
(2 μL, 5.5 μL/mL in citrate buffer) and KCO2H (2 μL, 11.3 mg/mL in citrate buffer). As 
positive control, Ir-catalyst 21 (20 μL, 23 μg/mL in citrate buffer) was mixed with 
benzaldehyde (2 μL, 5.5 μL/mL in citrate buffer) and HCO2K (2 μL, 11.3 mg/mL in citrate 
buffer). All samples were shaken at 37 ºC, and a sample for HPLC analysis was taken 
after 2 and 4 days. 
 
Hydrolysis of DiFMU octanoate by CalB 
To each sample used for HPLC analysis (2 × 5 μL) was added 90 μL PBS and DiFMU 
octanoate (5 μL, 1M in DMSO). Fluorescence was measured over a 1 hour time span (λex 
= 355 nm, λem = 460 nm). 
 
6.9 References 
1. B. Martín-Matute and J.-E. Bäckvall, Curr. Opin. Chem. Biol., 2007, 11, 226-232. 
2. M. Breuer, K. Ditrich, T. Habicher, B. Hauer, M. Keßeler, R. Stürmer and T. Zelinski, 
Angew. Chem. Int. Ed., 2004, 43, 788-824. 
3. J. V. Allen and J. M. J. Williams, Tetrahedron Lett., 1996, 37, 1859-1862. 
4. A. L. E. Larsson, B. A. Persson and J.-E. Bäckvall, Angew. Chem. Int. Ed., 1997, 36, 
1211-1212. 
5. B. Martín-Matute, M. Edin, K. Bogár and J.-E. Bäckvall, Angew. Chem. Int. Ed., 2004, 
43, 6535-6539. 
6. B. Martín-Matute, M. Edin, K. Bogár, F. B. Kaynak and J.-E. Bäckvall, J. Am. Chem. 
Soc., 2005, 127, 8817-8825. 
7. M. Makkee, A. P. G. Kieboom and H. van Bekkum, Carbohydr. Res., 1985, 138, 237-
245. 
8. A. Caiazzo, P. M. L. Garcia, R. Wever, J. C. M. van Hest, A. E. Rowan and J. N. H. 
Reek, Org. Biomol. Chem., 2009, 7, 2926-2932. 
9. M. E. Wilson and G. M. Whitesides, J. Am. Chem. Soc., 1978, 100, 306-307. 
10. M. T. Reetz, J. J.-P. Peyralans, A. Maichele, Y. Fu and M. Maywald, Chem. Commun., 
2006, 4318-4320. 
11. C.-C. Lin, C.-W. Lin and A. S. C. Chan, Tetrahedron: Asymmetry, 1999, 10, 1887-
1893. 
12. T. Heinisch and T. R. Ward, Curr. Opin. Chem. Biol., 2010, 14, 184-199. 
13. M. T. Reetz, M. Rentzsch, A. Pletsch, M. Maywald, P. Maiwald, J. J.-P. Peyralans, A. 
Maichele, Y. Fu, N. Jiao, F. Hollmann, R. Mondière and A. Taglieber, Tetrahedron, 
2007, 63, 6404-6414. 
14. M. T. Reetz, M. Rentzsch, A. Pletsch, A. Taglieber, F. Hollmann, R. J. G. Mondiere, N. 
Dickmann, B. Hocker, S. Cerrone, M. C. Haeger and R. Sterner, ChemBioChem, 2008, 
9, 552-564. 
15. W. Laan, B. K. Munoz, R. den Heeten and P. C. J. Kamer, ChemBioChem, 2010, 11, 
1236-1239. 
16. C. A. Kruithof, M. A. Casado, G. Guillena, M. R. Egmond, A. van der Kerk-van Hoof, A. 
J. R. Heck, R. J. M. Klein Gebbink and G. van Koten, Chem. Eur. J., 2005, 11, 6869-
6877. 
17. B. Wieczorek, D. J. M. Snelders, H. P. Dijkstra, K. Versluis, M. Lutz, A. L. Spek, M. R. 
Egmond, R. J. M. Gebbink and G. van Koten, Organometallics, 2012, 31, 2810-2820. 
  6  Formation of a hybrid catalyst using SPAAC  177  
 
18. T. Matsuo, C. Imai, T. Yoshida, T. Saito, T. Hayashi and S. Hirota, Chem. Commun., 
2012, 48, 1662-1664. 
19. S. Schoffelen, Well-defined Enzyme Architectures, 2011, Radboud University 
Nijmegen. 
20. I. Kii, A. Shiraishi, T. Hiramatsu, T. Matsushita, H. Uekusa, S. Yoshida, M. Yamamoto, 
A. Kudo, M. Hagiwara and T. Hosoya, Org. Biomol. Chem., 2010, 8. 
21. M. Albrecht and G. van Koten, Angew. Chem. Int. Ed., 2001, 40, 3750-3781. 
22. H. P. Dijkstra, M. Q. Slagt, A. McDonald, C. A. Kruithof, R. Kreiter, A. M. Mills, M. Lutz, 
A. L. Spek, W. Klopper, G. P. M. Klink and G. Van Koten, Eur. J. Inorg. Chem., 2003, 
830-838. 
23. M. Q. Slagt, G. Rodríguez, M. M. P. Grutters, R. J. M. Klein Gebbink, W. Klopper, L. 
W. Jenneskens, M. Lutz, A. L. Spek and G. van Koten, Chem. Eur. J., 2004, 10, 1331-
1344. 
24. A. Orita, D. Hasegawa, T. Nakano and J. Otera, Chem. Eur. J., 2002, 8, 2000-2004. 
25. R. L. M. Teeuwen, F. A. de Wolf, H. Zuilhof and J. C. M. van Hest, Soft Matter, 2009, 
5, 4305-4310. 
26. S. Schoffelen, M. B. van Eldijk, B. Rooijakkers, R. Raijmakers, A. J. R. Heck and J. C. 
M. van Hest, Chem. Sci., 2011, 2, 701. 
27. A. Tjernberg, N. Markova, W. J. Griffiths and D. Hallen, J. Biomol. Screen., 2006, 11, 
131-137. 
28. S. Schoffelen, M. H. L. Lambermon, M. B. van Eldijk and J. C. M. van Hest, 
Bioconjugate Chem., 2008, 19, 1127-1131. 
29. J. M. McFarland and M. B. Francis, J. Am. Chem. Soc., 2005, 127, 13490-13491. 
30. J. C. Morris, J. C. McMurtrie, S. E. Bottle and K. E. Fairfull -Smith, J. Org. Chem., 
2011, 76, 4964-4972. 
31. wtCalB from Sigma-Aldrich contained a lot of impurities. 10 mg/mL is the concentration 
crude material. 
 
 
 
 
  
 
Identification of new glycoproteins and elucidation of 
protein structure and glycosylation sites are likely to 
increase insight in many biological processes and 
diseases. A class of complex glycoproteins highly 
associated with many forms of cancer is formed by 
mucin-type glycoproteins. The weight of these proteins 
is for 50-85% caused by glycans. Deglycosylation of 
these glycoproteins was envisioned to improve 
detectability by mass spectrometry by increasing 
detection.  
To this end, a method was developed to label and 
enrich for glycoproteins and remove glycans from a 
complex glycoprotein mixture. To enrich for 
glycoproteins from cell lysate mixtures, live cells 
were equipped with biotin-tags. After cell lysis and 
enrichment, deglycosylation would give information on 
the glycoproteins. 
 
 
  7 
Towards identification of 
glycosylation sites on  
mucin-type glycoproteins 
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7.1 Introduction 
During protein synthesis in cells, proteins are often modified post-translationally 
by e.g. phosphorylation, lipidation, acetylation or glycosylation. Of the more than 
100 types of post-translational modifications known, glycosylation is the most 
common one, occurring in over 50% of all proteins.
1
 Glycosylation can occur on 
the asparagine residue (so-called N-linked glycosylation) or on the serine or 
threonine residues (O-linked glycosylation). Monosaccharides are attached to the 
protein by glycosyltransferases. These enzymes can form a glycosidic linkage 
between two monosaccharides (nine different types in mammals). In the formation 
of this linkage, two different stereoisomers can be formed at the anomeric carbon 
(α and β), and attachment can occur at different hydroxyl-groups of the sugar, 
forming different regioisomers. This process allows for the formation of a myriad of 
different glycans.
2
 
A change in the glycosylation pattern, for example altered branching, altered 
expression of glycans, or changes in the occurrence of terminal sialylation, are 
highly associated with many types of cancer.
2
 For example, tumor formation 
increases with the increased expression of GlcNAc-TV, a glycosyltransferase that 
introduces N-acetyl glucosamine (GlcNAc) on N-linked glycans, and metastasis is 
promoted by the formation of altered mucins and by an increased level of sialic 
acids.
3, 4
  
Although the importance of glycans, and their role in several diseases are widely 
acknowledged, research has proceeded slowly compared to studies on other 
biomolecules, e.g. DNA and proteins.
4
 One of the main issues in studying 
glycoproteins is that the biosynthetic pathway is not template-based, leading to 
formation of a diverse array of glycans.  
A class of glycoproteins of high interest is formed by the mucin-type 
glycoproteins. This type of glycoprotein is often found to have an altered 
expression in many types of epithelial cancer,
5
 and mucins are used as diagnostic 
markers of cancer.
4
 In addition, mucins might be used by cancer cells to control its 
microenvironment during invasion and metastasis, and tumor-associated mucins 
are hypothesized to disrupt existing interactions between opposing cells, while 
establishing new ligands for interaction with adjoining cells.
3
 One of the main 
problems in the analysis of mucins is that they are heavily O-glycosylated (50-85% 
of the total molecular weight) thereby complicating structure elucidation. 
In the elucidation of glycoprotein structures, the first step is often the 
determination of the glycosylation sites by a mass spectrometry-based protocol.
6-9
 
A challenge in the analysis of these glycoproteins by mass spectrometry is that 
glycopeptides (obtained by tryptic digest of glycoproteins) have a reduced 
detectability because of a lower ionization efficiency.
10
 This, in combination with 
the fact that the concentration of serum proteins varies within 10 orders of 
magnitude,
8
 makes it hard to detect low abundant glycoproteins. 
To improve the detectability of low abundant and/or poorly ionizing peptides, 
different techniques can be used. By metabolically incorporating different 
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isotopically labeled monosaccharides, glycans with a distinct labeling pattern are 
obtained.
9
 For example, using a mixture of different isotopically labeled GlcNAc 
(containing no isotopic label, two 
13
C-atoms, or three 
13
C-atoms and one 
15
N-atom 
in a 1:2:1 ratio), a distinctive triplet pattern was detected by mass spectrometry 
which could be related back with high sensitivity to the corresponding 
glycoproteins by applying a computational pattern-searching algorithm.
11, 12
 Other 
methods that have been developed to enrich glycoproteins or glycopeptides, 
include lectin affinity chromatography for O-GlcNAc peptides
10
 or mucin-type O-
linked glycopeptides.
1
 Alternatively, glycans can be equipped with a 
monosaccharide containing a ketone moiety
13
 or an azide
6
 using a mutant 
galactosyltransferase. Reaction with an aminooxy-biotin or alkyne-biotin, 
respectively, yields biotinylated glycans, which can be enriched by using 
streptavidin beads.  
An interesting alternative to this chemoenzymatic strategy is the metabolic 
incorporation of azido-sugars in glycans, thereby partially substituting the natural 
sugar for a labeled analogue, as was first published by Bertozzi et al.
14
 They 
showed that N-azidoacetylglucosamine (GlcNAz) is accepted by the hexosamine 
salvage enzymes and successfully incorporated in living cells. Subsequently, the 
azides can be labeled with either the Staudinger ligation,
15
 or a Strain-Promoted 
Azide Alkyne Cycloaddition (SPAAC).
16-18
 Using this strategy, it was recently 
shown that azide-containing live cells can be equipped with a FLAG-tag, allowing 
enrichment for glycoproteins by immunoprecipitation.
19
 These proteins were then 
subjected to in-gel digestion and identified by LC-MS/MS. However, following this 
methodology, the glycan still remains attached to the peptide, potentially reducing 
the detection of these glycopeptides by mass spectrometry. 
To improve this, and potentially detect more proteins, we envisioned that a 
similar strategy as described above, followed by removal of the glycan after 
enrichment, could improve LC-MS/MS analysis. In addition, glycosylation sites can 
be determined if a small residue (e.g. one sugar-moiety) would remain on the 
amino acid after deglycosylation. Deglycosylation of N-linked glycans is commonly 
achieved by the use of enzymes.
4, 8
 On the contrary, global deglycosylation of O-
glycosylation cannot be achieved enzymatically and has to be performed 
chemically. The most suitable method for deglycosylation depends on the type of 
linkage to be cleaved. For deglycosylation of O-linked GlcNAc-containing 
glycoproteins, β-elimination20 and NaIO4-oxidation followed by elimination
9, 21, 22
 
are the best studied methods. On the other hand, for other O-linker sugars and 
mucins, the most extensively studied method is the deglycosylation using 
trifluoromethanesulfonic acid (TFMSA), which is shown to remove all glycans, 
apart from the N-linked GlcNAc.
23-25
 However, this method has until now not been 
applied on complex mixtures, i.e. cell lysates. 
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Scheme 1. Schematic outline of the project. 
The aim of the research described in this chapter was to identify mucin-type O-
linked glycoproteins and possibly identify glycosylation sites. To this purpose, 
reducing complexity of the protein mixtures (i.e. cell lysates) and increasing 
detectability is required to allow for mass spectrometry analysis. To address the 
first issue, labeling of the cell lysates with an enrichment probe ( i.e. biotin) 
followed by enrichment for glycoproteins can be performed. Subsequently 
deglycosylation of the thus obtained glycoproteins followed by tryptic digest would 
yield peptides which could have an improved detectability. An overview of the 
method is summarized in Scheme 1. First, cells are grown in N-azidoacetyl 
galactosamine (GalNAz) containing medium. The thus obtained azide-containing 
live cells are labeled with a biotin-probe using the Staudinger ligation or SPAAC. 
Next, cell lysis followed by enrichment for the labeled glycoproteins using 
streptavidin-beads, yields the glycoproteins on the beads. Subsequent 
deglycosylation of the proteins should at the same time elute the proteins from the 
beads. Ultimately, the proteins could then be subjected to tryptic digest and mass 
spectrometry. 
 
7.2 Deglycosylation of glycoproteins 
There are many deglycosylation methods reported in the literature, each differing 
in efficiency, selectivity, and protein degradation. To test which method worked 
best in our hands, we attempted a range of conditions on a model protein (fetuin), 
schematically shown in Scheme 2. Fetuin was used because it contains both N-
linked and O-linked glycans and is fairly glycosylated (12% of the molecular weight 
is formed by glycans). As a control, bovine serum albumin (BSA), which is not 
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glycosylated, was subjected to equivalent reaction conditions to assess the effect 
on protein degradation. 
 
Scheme 2. Deglycosylation of a single protein. 
In Figure 1 the results of the different conditions are shown. Figure 1A (odd 
lanes for BSA, even lanes for fetuin) shows the results for different β-elimination 
procedures, in which the linkage between sugar and amino acid side chain is 
cleaved by an elimination-type reaction. The conditions employed are the 
commercially available β-elimination kit (lanes 2 and 3), NaIO4 oxidation followed 
by β-elimination (lanes 4 and 5),21 and β-elimination with HNMe2 (lanes 6 and 7).
20
 
Figure 1B shows the results obtained with TFMSA at either 4 ºC or room 
temperature (lanes 10 and 11, respectively, for fetuin; lanes 12 and 13 for BSA).
24
 
Anisole was added as a scavenger to keep the side chains of the amino acids 
intact.
26
 
 
Figure 1. SDS-PAGE analysis of different deglycosylation conditions. A: (1) Fetuin; (2) Fetuin, β-
elimination kit; (3) BSA, β-elimination kit; (4) Fetuin, NaIO4 o.n., 4 h pH 10.5; (5) BSA, NaIO4 o.n., 
4 h pH 10.5; (6) Fetuin, HNMe2, 55 ºC, 6 h; (7) BSA, HNMe2, 55 ºC, 6 h; (8) BSA. B: (9) Fetuin; 
(10) Fetuin, TFMSA/anisole (3/2), 1 h, 4 ºC; (11) Fetuin, TFMSA/anisole (3/2), 1 h, r.t.; (12) BSA, 
(13) BSA, TFMSA/anisole (3/2), 1 h, 4 ºC; (14) BSA, TFMSA/anisole (3/2), 1 h, r.t. 
In short, the β-elimination kit gave hardly any deglycosylation, and showed some 
degradation of both fetuin and BSA; β-elimination using HNMe2 showed complete 
protein loss for fetuin and heavy protein backbone degradation for BSA. On the 
other hand, NaIO4 oxidation, followed by β-elimination, showed no protein 
degradation, but also incomplete deglycosylation of fetuin, as indicated by the 
broad band in Figure 1A, lane 4. Likely, the last procedure only removed the O-
linked glycans, while keeping the N-linked glycans intact. 
TFMSA did lead to complete deglycosylation at 4 ºC, as can be observed in 
Figure 1B, lane 10, and did not give rise to protein degradation for BSA. On the 
 184  Dibenzoazacyclooctynes: Synthesis and Bioconjugation 
 
 
other hand, applying the same procedure at room temperature resulted in loss of 
material for fetuin, although no protein degradation was observed for BSA. 
From the condition screen, it was concluded that TFMSA was the best 
deglycosylation agent for our purposes, and further optimization of this reaction 
was performed. First, the optimal ratio between TFMSA and anisole was 
determined to be 4:1. Next, fetuin was treated with this mixture at different 
temperatures (-20 ºC, 4 ºC and room temperature) for different periods of time. A 
summary of this condition screen is shown in Figure 2. Lanes 2 and 5 show that 
no deglycosylation occurred at -20 ºC. On the other hand, deglycosylation at 4 ºC 
was complete within 1 hour (lane 3); treatment for 4 hours gave rise to only little 
backbone degradation, indicated by the small band below the band corresponding 
to deglycosylated fetuin (lane 6). Deglycosylation at room temperature was 
completed within 1 hour, with little protein degradation (lane 4); however 
prolonged reaction times gave complete degradation of the protein (lane 7). 
 
Figure 2. SDS-PAGE analysis of fetuin deglycosylation using TFMSA/anisole (4/1) at different 
temperatures. (1) fetuin; (2) -20 ºC, 1 h; (3) 4 ºC, 1 h; (4) r.t., 1 h; (5) -20 ºC, 4 h; (6) 4 ºC, 4 h; (7) 
r.t., 4 h. 
Notably, lanes 3 and 6 in Figure 2 seemed to indicate that after 4 hours more 
fetuin was obtained than after 1 hour. As both samples were obtained by taking an 
identical amount from the same reaction, the work-up procedure apparently did not 
give reproducible results.  
Optimization of the work-up procedure showed that addition of three equivalents 
of a 60% pyridine solution is needed to neutralize TFMSA. Also addition was 
performed at -78 ºC as the reaction is highly exothermic. Further work-up was 
performed by dialysis of the protein against 250 mM NH4HCO3. 
With the optimized procedure for fetuin in hand, the next aim was to test the 
same conditions for other glycoproteins. Therefore, one lightly glycosylated protein 
(lactoperoxidase) and one heavily glycosylated protein (alpha acid) were chosen. 
With this protein mixture a time screen was performed, using the same volume of 
TFMSA per mg of protein. 
Figure 3 shows that lactoperoxidase is rapidly deglycosylated (lanes 1-4, Figure 
3), with complete conversion after 1 hour (lane 2). Notably, the protein did not 
seem to degrade during prolonged exposure to TFMSA. On the other hand, alpha 
acid showed only poor deglycosylation after 1 hour (lane 6, Figure 3), indicated by 
the broad band in SDS-PAGE analysis. Also after 2 or 3 hours, fully 
deglycosylated alpha acid was not observed (lanes 7 and 8, respectively). Only 
after 4 hours, most of the alpha acid was fully deglycosylated (lane 9). 
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Figure 3. Deglycosylation of lactoperoxidase (lanes 1-4) and alpha acid (lanes 5-9) with 
TFMSA/anisole (4/1) at 4 ºC. (1) 0 h; (2) 1 h; (3) 2 h; (4); 3 h; (5) 0 h; (6) 1 h; (7) 2 h, (8) 3 h; (9) 4 
h. 
To investigate how the deglycosylation would proceed in a protein mixture, equal 
amounts of fetuin, alpha acid and lactoperoxidase were mixed, lyophilized and 
then treated with TFMSA for different amounts of time. The results of this reaction 
are shown in Figure 4. Lane 2 shows the mixture after 30 minutes, where only 
lactoperoxidase was fully deglycosylated, while alpha acid was still obtained with a 
broad mass range. After 1 hour (lane 3), only alpha acid remained partially 
deglycosylated, and after 3-4 hours all proteins were completely deglycosylated. 
Remarkably, deglycosylation of alpha acid was now achieved faster than for the 
single protein experiment (Figure 3). This was probably because a larger amount 
of TFMSA was used compared to the amount of alpha acid (the volume of TFMSA 
was determined based on the amount of total protein).  
In conclusion, the time required to reach full deglycosylation depends on the 
degree of glycosylation of a protein. Also, the amount of TFMSA/anisole used, 
compared to the amount of saccharides, seemed to influence the reaction time 
required. In protein mixtures a large variety of lightly and heavily glycosylated 
proteins is present, making it hard to determine a molar ratio between saccharide 
and TFMSA. By performing several experiments with different protein mixtures the 
amount of TFMSA/anisole mixture was determined to be optimal at 0.5 mL per mg 
of protein. 
 
Figure 4. SDS-PAGE analysis of deglycosylation of a protein mixture of alpha acid, 
lactoperoxidase, and fetuin with TFMSA/anisole (4/1) at 4 ºC. (1) 0 h; (2) 30 min; (3) 1 h; (4) 2 h; 
(5) 3 h; (6) 4 h; (7) 5 h; (8) 6 h. 
Having shown that deglycosylation can be achieved in a protein mixture using 
TFMSA at 4 ºC, the focus shifted towards cell lysates. To avoid loss of material 
after lysate deglycosylation, different work-up conditions were attempted on cell 
lysates. 
As shown in Figure 5, dialysis against either 250 mM NH4HCO3 (which was used 
for the previous experiments) or Tris-buffer (20 mM Tris, 150 mM NaCl, 4% SDS) 
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gave a reasonable recovery of cell lysate (lanes 2 and 3), whereas purification 
using Zeba Spin Desalting Columns
27
 against the same buffers gave no results 
(lanes 4 and 5). Alternatively, precipitation is a common purification method for 
cell lysates. Precipitation in acetone gave hardly any recovery (lane 6); on the 
other hand, precipitation in CHCl3/MeOH
28
 gave good lysate recovery in all mass 
ranges (lane 7). 
 
Figure 5. Work-up conditions on cell lysate. (1) Cell lysate; (2) Dialysis with 250 mM NH4HCO3; (3) 
Dialysis with 20 mM Tris, 150 mM NaCl, 4% SDS; (4) Zeba Gel Filtration against 250 mM 
NH4HCO3; (5) Zeba Gel Filtration against 20 mM Tris, 150 mM NaCl, 4% SDS; (6) Precipitation in 
acetone; (7) Precipitation in CHCl3/MeOH. 
As final test towards lysate deglycosylation, the procedure was performed in the 
presence of different salts. Up to now, proteins were always prepared by 
dissolving the commercially available glycoproteins in water, followed by 
lyophilization. However, cell lysates are commonly prepared in buffered solutions. 
To investigate the compatibility of the deglycosylation method with these buffer 
salts, fetuin was dissolved in different buffers including PBS, 250 mM NH4HCO3, 
Tris buffer (50 mM Tris, 1 mM β-mercaptoethanol, 0.32 M sucrose, 1 mM EDTA, 
pH 8), 6M Urea and HEPES-buffer (20 mM HEPES, 1% SDS, pH 8)), followed by 
lyophilization and TFMSA treatment. 
 
Figure 6. Deglycosylation of fetuin in different cell lysate buffers, followed by lyophilization and 
treatment with TFMSA/anisole (4:1), for 4 hours. (1) Fetuin; (2) PBS; (3) 250 mM NH4HCO3; (3) 
Tris-buffer; (5) 6M Urea; (6) HEPES-buffer, pH 7.9; (7) MilliQ. 
Results of this experiment are shown in Figure 6, which shows that almost all 
buffers are compatible with TFMSA, resulting in full deglycosylation after 4 hours. 
6M Urea (lane 6) is not suitable for deglycosylation because after 4 hours 
deglycosylation was still incomplete.  
In conclusion, optimal deglycosylation without significant protein degradation 
was achieved using the following reaction conditions: a mixture of TFMSA and 
anisole (ratio 4:1) at 4 ºC for 4 to 6 hours with 0.5 mL per mg of protein. The 
reaction was quenched with 3 volumes of 60% pyridine and extracted with Et2O, 
followed by dialysis of the aqueous phase against 250 mM NH4HCO3 for simple 
protein mixtures, or precipitation in CHCl3/MeOH for cell lysates.  
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7.3 Cell Labeling studies 
To obtain as many glycoproteins as possible after enrichment, it is important that 
glycan labeling is a highly efficient process. In general, live cell labeling studies 
have looked at the overall amount of labeling obtained, instead of at the range of 
proteins labeled, or at which cellular compartments contain the labeled 
glycoproteins.
17, 29, 30
 To investigate which conditions are best to label the largest 
range of glycoproteins, whether only the cell membrane is labeled or also other 
cellular compartments,
31
 and which azide-reactive probe would be best for 
introduction of an enrichment probe, we introduced GalNAz to the glycoproteins of 
Jurkat cells and subsequently labeled the azides with a biotin, using either the 
Staudinger ligation of SPAAC, shown in Scheme 3. In our optimization efforts we 
applied a wide range of cyclooctynes and one Staudinger reagent. Also, the 
concentration of reagent and reaction time were optimized. 
 
Scheme 3. Schematic representation of cell surface labeling using SPAAC, with biotinylated 
probes. 
First, we investigated which probe would be the most suitable for our purposes. 
To this end, 7 different probes were used for labeling, i.e. PHOS-Biotin (1),
15
 
DIMAC-Biotin (2),
32
 MOFO-Biotin (3),
17
 DIBO-Biotin (4),
33
 DIBAC-Biotin (5),
34
 
DIFO-Biotin (6),
35
 and BARAC-Biotin (7),
29
 all shown in Figure 7. To check for the 
selectivity of the reaction, GalNAz-fed cells were compared to DMSO-treated cells. 
As the Staudinger ligation with PHOS-Biotin (1), and SPAAC with DIMAC-Biotin 
(2) or MOFO-Biotin (3) are known to be relatively slow, these probes were used in 
a higher concentration (250 μM) compared to the other probes (10  μM). With each 
probe, the labeling reaction was performed for 2.5 hours at room temperature. 
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Figure 7. Azide reactive probes used for glycoprotein labeling. 
Figure 8 shows the Western Blot from the lysates obtained after live cell labeling 
followed by cell lysis. The Western Blot was developed by incubating with anti-
biotin HRP, followed by development with chemiluminescence. The odd lanes 
show the results obtained with GalNAz labeled cells, the even lanes show the 
negative control experiments. Comparing the probes used at 250 μM (lanes 1-6), it 
is clear that the Staudinger ligation (lane 1) outperformed SPAAC with DIMAC 
(lane 3) or MOFO (lane 5). For the faster probes (lanes 7-14), there seemed to be 
less difference between the probes, although DIBAC (5, lane 9) and BARAC (7, 
lane 13) showed a slightly more intense labeling and a wider range of protein 
labeling compared to the other probes. This was in line with the expectations, as 
these two are the fastest probes known. At this stage, no comparison could be 
made between the Staudinger ligation and SPAAC with DIBAC and BARAC as the 
latter two were used in a 25-fold lower concentration. Much to our delight, all 
negative controls (even lanes in Figure 8) showed no labeling of the live cells, 
indicating that only azidated glycans are labeled. 
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Figure 8. Live cell labeling with GalNAz (odd lanes) or GalNAc (even lanes) containing cells using 
the Staudinger ligation and SPAAC. Labeling performed for 2.5 hours at room temperature. Lanes 
1 and 2: PHOS-biotin (1); Lanes 3 and 4: DIMAC-biotin (2); Lanes 5 and 6: MOFO-biotin (3); 
Lanes 7 and 8: DIBO-Biotin (4); Lanes 9 and 10: DIBAC-Biotin (5); Lanes 11 and 12: DIFO-Biotin 
(6); Lanes 13 and 14: BARAC-biotin (7): Lanes 15 and 16: no probe. 
To fairly compare the labeling efficiency of the Staudinger ligation with SPAAC 
using DIBAC, a concentration screen was performed using DIBAC-Biotin (lanes 1-
4) and PHOS-Biotin (lanes 5-10). With 50 μM of PHOS-Biotin (lane 9), little 
labeling was observed, whereas for 10 and 50 μM of DIBAC-Biotin (lanes 1 and 3 
respectively) already a significant amount of labeling was detected. Interestingly, 
increasing the concentration of PHOS-Biotin to 125 μM and 250 μM gave rise to 
labeling of a wider range of proteins compared to the labeling obtained for DIBAC. 
Also, different proteins seemed to be labeled. However, higher concentrations of 
DIBAC-Biotin or prolonged reaction times could possibly lead to the same degree 
and range of labeling. 
 
Figure 9. Live cell labeling with GalNAz (odd lanes) or GalNAc (even lanes) containing cells using 
SPAAC (lanes 1-4) or Staudinger ligation (lanes 5-10). Labeling performed for 2.5 hours at room 
temperature. Lanes 1 and 2: 10 μM DIBAC-Biotin (5); Lanes 3 and 4: 50 μM DIBAC-Biotin (5); 
Lanes 5 and 6: 250 μM PHOS-Biotin (1); Lanes 7 and 8: 125 μM PHOS-Biotin (1); Lanes 9 and 10: 
50 μM PHOS-Biotin (1); Lane 11: no probe. 
To investigate whether this was actually the case, cell labeling was performed 
with different concentrations of DIBAC-Biotin (from 5 μM to 100 μM). Figure 10 
shows the results obtained after 2.5 hours of labeling. While 5 μM (lane 1) gave 
poor labeling, 50 μM and 100 μM (lanes 9 and 11) seemed to label a significant 
range of proteins. 
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Figure 10. Live cell labeling (2.5 h reaction time) with GalNAz (odd lanes) or GalNAc (even lanes) 
containing cells using DIBAC-Biotin (5). Lanes 1 and 2: 5 μM DIBAC; Lanes 3 and 4: 10 μM 
DIBAC; Lanes 5 and 6: 15 μM DIBAC; Lanes 7 and 8: 20 μM DIBAC; Lanes 9 and 10: 50 μM 
DIBAC; Lanes 11 and 12: 100 μM DIBAC. 
As 50 μM of DIBAC-Biotin already resulted in a rather broad range of labeling 
after 2.5 hours, the time screen (30 minutes to 5 hours) was performed with 20 μM 
DIBAC-Biotin. From Figure 11 can be concluded that most labeling occurred within 
the first two hours (compare lanes 1, 3 and 5). After these two hours, labeling still 
increased, but there seemed to be no further improvement in the number of 
different proteins labeled. For comparison of the labeling with 50 μM DIBAC-Biotin 
after 2.5 hours and the labeling obtained in the time course experiment, see lane 
13 (Figure 11). The difference in labeling intensity between Figure 10 and Figure 
11 is caused by a difference in exposure time of the blot. 
 
Figure 11.Time course experiment of live cell labeling with GalNAz (odd lanes) or GalNAc (even 
lanes) containing cells using 20 μM DIBAC-Biotin (5). Lanes 1 and 2: 30 minutes; Lanes 3 and 4: 1 
hour; Lanes 5 and 6: 2 hours; Lanes 7 and 8: 3 hours; Lanes 9 and 10: 4 hours, Lanes 11 and 12: 
5 hours; Lanes 13 and 14: 2.5 hours with 50 μM of DIBAC-Biotin (5). 
From these experiments it was concluded that DIBAC-Biotin is a good candidate 
for live cell labeling, showing no aspecific binding and giving good labeling of a 
wide range of glycoproteins. The best conditions seemed to be 50 μM for 2.5 
hours or 20 μM for 5 hours. The Staudinger ligation, using 250 μM of PHOS-Biotin, 
seemed a good alternative, potentially leading to the labeling of different proteins 
compared to those obtained with labeling using SPAAC. 
An alternative for live cell labeling would be to perform the labeling on cell 
lysates. To test whether this would result in good glycan labeling, GalNAz-
containing cells were lysed and reacted with all available probes (1-8), again the 
relatively slow probes (1-3) were used at 250 μM concentration while the fast 
probes (4-8) were used at 10 μM (results shown in odd lanes, Figure 12). In 
addition to the probes used in live cell labeling, BCN
30
-biotin (8) was employed in 
lysate labeling. A negative control experiment was performed for all probes, by 
adding the probes to cell lysates that did not contain GalNAz (even lanes, Figure 
12).  
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Surprisingly, the probes did not perform as well as expected based on the live 
cell labeling experiments. The slow probes (lanes 1-6) performed reasonably well, 
with only little aspecific labeling. Interestingly, now DIMAC and MOFO showed 
comparable labeling compared to the Staudinger ligation, whereas in live cell 
labeling PHOS-Biotin significantly outperformed the other two azide-reactive 
probes. Of the fast probes (lanes 7-16), DIBO and BARAC gave only little labeling. 
DIFO, on the other hand, seemed to lead to efficient labeling, but also showed a 
large amount of aspecific reactions. Probably, this is caused by Michael addition of 
thiols to the alkyne, resulting in the elimination of one of the fluorides. Lastly, BCN 
and DIBAC gave good and selective labeling of cell lysates. Of these two probes, 
DIBAC gave the better results (lane 9). 
 
Figure 12. Lysate labeling containing GalNAz (odd lanes) or GalNAc (even lanes) with Staudinger 
ligation or SPAAC. Lanes 1 and 2: PHOS-Biotin (1); Lanes 3 and 4: DIMAC-biotin (2); Lanes 5 and 
6: MOFO-biotin (3); Lanes 7 and 8: DIBO-Biotin (4); Lanes 9 and 10: DIBAC-Biotin (5); Lanes 11 
and 12: DIFO-Biotin (6); Lanes 13 and 14: BARAC-biotin (7): Lanes 15 and 16: BCN-Biotin (8); 
Lanes 17 and 18: no probe. 
Overall, cell lysate labeling gives rise to more unspecific interactions, compared 
to live cell labeling. However, from the Western Blots it could not be concluded 
whether the same range of proteins were labeled, or if lysate labeling resulted in 
different biotinylated proteins than obtained in live cell labeling. Therefore, it might 
be interesting to compare both labeled lysates in a mass spectrometry experiment. 
 
7.4 Lysate enrichment and deglycosylation 
With the biotinylated glycans in hand, the optimized deglycosylation procedure 
was now applied to these glycoproteins. The lysate was first lyophilized and 
subsequently treated with a TFMSA/anisole (4:1) mixture. The progress of 
deglycosylation was easily followed by disappearance of the biotin-signal in 
Western Blot (Figure 13A). The Western Blot was also stained with Indian ink 
(Figure 13B), thereby staining all proteins present. In this manner, the loading and 
potential protein loss was examined. 
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Figure 13. Western Blot analysis of deglycosylation of biotin-labeled cell lysates, imaged with anti-
biotin HRP followed by H2O2 and luminol (A) or stained with Indian ink (B). Lane 1: labeled cell 
lysate; Lane 2: 1 hour TFMSA/anisole; Lane 3: 2 hours TFMSA/anisole; Lane 4: 4 hours 
TFMSA/anisole; Lane 5: 6 hours TFMSA/anisole. 
Figure 13A shows a decrease of biotin signal over time; already after 1 hour a 
significant amount of biotin had disappeared (compare lanes 1 and 2), and after 4 
hours hardly any biotin could be detected anymore. Although it has to be noted 
that also some protein is lost during the procedure (compare lanes 1 and 2 in 
Figure 13B), based on this Western Blot it can be concluded that the cell lysate 
was successfully deglycosylated, removing the biotin-label. 
These promising results prompted us to perform an enrichment experiment using 
neutravidin beads, followed by lyophilization of the beads and subsequent 
treatment with TFMSA. Unfortunately, as can be seen in Figure 14, only little 
biotinylated protein was bound to the beads (lane 1 shows the original lysate, lane 
2 shows the flow-through, and lane 3 shows the beads after boiling in loading 
buffer). Still, as some glycoproteins were bound to the beads, we proceeded with 
the experiment. To test the effect of lyophilization and to make sure protein was 
not released from the beads during this procedure, the beads were washed after 
lyophilization with 4% SDS in PBS, and this wash-fraction and the remaining 
beads were analyzed by Western Blot (lanes 5 and 6, Figure 14A). Fortunately, no 
biotinylated proteins were found in the wash-fraction, and all had remained on the 
beads.  
Ultimately, the beads were treated with TFMSA for 6 hours, and subsequent ly 
the supernatant was quenched by the addition of 60% pyridine, washed with Et2O, 
and the aqueous phase subjected to CHCl3/MeOH precipitation. The obtained 
precipitate was then taken up in sample buffer and analyzed by Western Blot 
(Figure 14, lane 8). Also the beads were boiled in sample buffer and analyzed 
(lane 9). Much to our delight, both lanes 8 and 9 did not show any biotin-signal at 
the height where signals were observed before. The biotin-related signals 
observed in lane 8 are probably caused by release of biotin-containing neutravidin 
from the beads. Furthermore, the ink-stain analysis (Figure 14B, lane 8) showed 
the presence of proteins at the expected molecular weight. This could indicate that 
the enriched sample was successfully deglycosylated and therewith released from 
the beads. However, further research is required to confirm these results. 
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Figure 14. Enrichment of biotinylated lysate followed by deglycosylation. Lane 1: Biotinylated 
lysate; Lane 2: Flow-through of beads; Lane 3: Beads boiled in sample buffer; Lane 4: Lyophilized 
beads washed with 4% SDS; Lane 5: Washed beads boiled in sample buffer; Lane 6: Supernatant 
from beads treated with TFMSA for 5 seconds; Lane 7: 5 seconds TFMSA-treated beads boiled in 
sample buffer; Lane 8: Supernatant from beads treated with TFMSA for 6 hours; Lane 9: Beads 
boiled in sample buffer after treatment with TFMSA for 6 hours. 
 
7.5 Conclusions and outlook 
In this chapter, the efforts towards the development of methodology to improve 
detection of glycoproteins in cell lysates are described. To this end, biotinylated 
cell lysates were created followed by enrichment for the biotin-containing proteins. 
Also, a procedure for deglycosylation to remove glycans and biotin from the 
glycoproteins was optimized.  
Optimal conditions for the deglycosylation of different glycoproteins were 
investigated. Of all the reagents tested, only TFMSA showed full deglycosylation 
of the glycoproteins studied. After optimization of the reaction time, temperature, 
volume, and work-up conditions, it was shown that the reaction proceeded best 
with a mixture of TFMSA/anisole (4:1), 0.5 mL/mg protein, at 4 ºC. The reaction 
time depended on the degree of deglycosylation of the protein, and 4 to 6 hours 
proved sufficient for all proteins and protein mixtures. Concerning work-up, for 
single proteins and simple protein mixtures, dialysis against 250 mM NH4HCO 
resulted in the most reproducible outcome, for cell lysates CHCl3/MeOH 
precipitation gave the best results.  
As second part of this investigation the goal was to obtain a cell lysate 
containing a wide range of biotin-labeled proteins. To prepare these cell lysates, 
GalNAz-labeled cells were reacted with different biotinylated azide-reactive 
probes, and the conditions were extensively optimized. Of all available azide-
reactive probes tested, PHOS-Biotin (1), DIBAC-Biotin (5), and BARAC-Biotin (7) 
gave the best results. When PHOS-Biotin (1) and DIBAC-Biotin (5) were used in 
the same concentration, DIBAC-Biotin showed a higher labeling, as expected. But, 
although DIBAC-Biotin (5) gave more efficient labeling, different proteins appeared 
to be labeled using PHOS-Biotin (1) compared to DIBAC-Biotin (5) and it is 
probably worth considering using both probes independently and comparing the 
results.  
Finally, biotinylated cell lysates were treated with TFMSA/anisole (4:1) for 6 
hours, which showed a significant loss of biotin, indicating that deglycosylation 
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was successful. Attempts to enrich the biotinylated lysate using neutravidin-coated 
beads showed only little binding, and most biotinylated proteins remained in the 
flow-through. However, deglycosylation on the beads seemed to proceed as all 
biotin-related signals had disappeared after treatment with TFMSA, whereas some 
released protein could be detected.  
Overall, the envisioned strategy looks promising. However, further optimization 
of especially the enrichment step is required. Possibly, using different beads or a 
different tag (e.g. FLAG-tag) would lead to an increase in enrichment for the 
biotinylated proteins. Ultimately, deglycosylation followed by mass spectrometry 
should show the viability of this method, and whether more or different proteins 
are identified compared to a method where the sugar-chains are retained.  
A topic which was not yet addressed in this research is the identification of 
glycosylation sites. To achieve this, a specific tag (e.g. one sugar moiety, or small 
label) should remain or be introduced to the side chain of the deglycosylated 
amino acid residue. According to literature, when TFMSA is used as 
deglycosylation agent one sugar-residue is retained for the N-linked saccharides, 
and all O-linked sugars are removed. The observation that intact amino acid side 
chains of serine and threonine are obtained, makes it impossible to identify O-
glycosylation sites. Further development of a deglycosylation method which would 
allow for the identification of these glycosylation sites would be highly 
advantageous in the elucidation of glycoprotein structures.  
We did not yet perform mass spectrometric analyses on the deglycosylated 
proteins; therefore it is not investigated yet whether for our proteins (single) sugar 
moieties were retained during deglycosylation. To address this, a mass 
spectrometry method needs to be applied which does not remove sugars 
(especially O-linked sugars) during the ionization process.  
In short, future research should not only comprise of improving the enrichment 
for biotinylated proteins and analysis by mass spectrometry, but also the 
development of other deglycosylation methods.  
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7.7 Experimental Section 
7.7.1 General experimental 
General synthetic experimental 
All reagents were purchased from Sigma-Aldrich, and used without further purification. 
BCN-OSu was purchased from SynAffix. DIBAC-OSu was synthesized as described in 
Chapter 4. Other biotinylated azide-reactive probes were obtained from Dr. Ellen M. 
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Sletten. Reactions were performed at room temperature and under normal atmosphere 
unless stated otherwise. Thin layer chromatography was performed with EMD 60 Å silica 
gel plates. Flash chromatography was performed using Silicycle 60 Å 230-400 mesh 
silica. All 
1
H and 
13
C spectra were reported in ppm and referenced to solvent peaks 
(CDCl3, δ: 7.29 (
1
H) and 77.0 (
13
C). Spectra were obtained on Bruker AVQ-400, AVB-400 
(
1
H), AV-600 (
13
C) instruments. Electrospray ionization (ESI) mass spectra were obtained 
from the UC Berkeley Mass Spectrometry Facility.   
 
General deglycosylation experimental 
All proteins were purchased from Sigma-Aldrich. Stock-solutions of the proteins were 
made for each reaction and the desired amount was lyophilized in a glass vial. Spin 
filtration was performed with Amicon 10 MWCO filters. Dialysis was performed using 10 
kDa MWCO dialysis cartridges (Piercenet, Rockford, USA). All protein samples were 
prepared by the addition of SDS-PAGE loading buffer and subsequently loaded on SDS-
PAGE gels, (4-12% Bis-Tris, Bio Rad). Gels were stained with coomassie blue. 
 
General cell culture procedures 
Jurkat cells (human T-cell lymphoma) were maintained in RPMI-1640 media (Invitrogen 
Life Technologies) supplemented with 10% fetal calf serum (FCS), penicillin (100 
units/mL), and streptomycin and penicillin (0.1 mg/mL) in a 5% CO2 water-saturated 
atmosphere. Cells were counted using a Reichert Bright-line hemacytometer (Hausser 
Scientific). Cell lysates were prepared by resuspending the cells in lysis buffer (20 mM 
Tris; 150 mM NaCl, 1% Triton, PI (1:100) followed by sonication (5 sec on, 5 sec off, for 2 
minutes, 0.5 W). Protein concentrations were determined using a BCA protein assay kit 
(Pierce Protein Biology Products). Western blots were developed by blocking with 5% 
BSA in TBST-buffer (50 mM Tris, 150 mM NaCl, 0.05% Tween 20) for 30 minutes at room 
temperature. Anti-biotin HRP in TBST (1:100000) was added for 30 minutes at room 
temperature. The blots were washed with H2O (5 × 5 sec) and TBST (3 × 10 min). 
Detection was performed by chemiluminescence using Pierce SuperSignal West Pico 
Chemiluminescent Substrate (Pierce Biotechnology). Films for Western blot image 
exposure were obtained from Kodak and developed using a Kodak X-OMAT 5000RA 
processor.   
 
7.7.2 Synthesis of biotinylated cyclooctynes 
DIBAC-Biotin (5)  
DIBAC-NHS (20 mg, 0.05 mmol) was added to a flask 
under N2-atmosphere. Dry DMF (3 mL) was added and 
the suspension was heated slightly to dissolve DIBAC-
NHS. Next, NEt3 (13 μL, 0.1 mmol) and Biotin-NH2 (21 
mg, 0.05 mmol) were added and the mixture was stirred 
overnight. DMF was evaporated and the crude product 
was purified by gradient column chromatography 
(CH2Cl2/MeOH, 1:0 to 9:1) to obtain compound 5 as a 
white solid. 
1
H-NMR (400 MHz, CDCl3): δ 7.67 (d, J = 7.3 
Hz, 1H), 7.52-7.08 (m, 7H), 6.75 (br s, 1H), 6.40-6.27 (m, 
1H), 6.21 (d, J = 7.8 Hz, 1H), 5.55 (d, J = 11.5 Hz, 1H), 
5.14 (d, J = 13.8 Hz, 1H), 4.64-4.41 (m, 1H), 4.29-4.26 (m, 
1H), 3.73-3.44 (m, 12H), 3.38-3.05 (m, 4H), 2.86 (td, J = 
12.3, 4.9 Hz, 1H), 2.69 (dd, J = 23.2, 12.7 Hz, 1H), 2.33-
2.09 (m, 4H), 2.03-1.84 (m, 3H), 1.81-1.58 (m, 11H), 1.53-
1.36 (m, 2H).
 13
C-NMR (151 MHz, CDCl3) δ 173.1, 172.9, 172.5, 163.6, 151.6, 148.1, 
132.3, 129.0, 128.6, 128.2, 128.1, 127.7, 127.1, 125.4, 123.0, 122.4, 114.8, 108.0, 70.4 
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(2C), 70.0, 69.9, 69.4, 61.8, 60.1, 55.6, 55.4 (2C), 40.5, 37.7, 37.2, 35.9, 35.5, 35.4, 33.8, 
29.2, 28.9, 28.1, 28.0, 25.6, 21.6. HRMS (ESI+) m/z calcd for C40H54N5O7S [M+H]
+
 
748.3744, found 748.3764. 
 
BCN-Biotin (8)  
Biotin-NH2 (60 mg, 0.137 mmol) was dissolved in 
dry DMF (5 mL) under N2-atmosphere. BCN-NHS 
(40 mg, 0.137 mmol) and NEt3 (38 μL, 0.27 
mmol) were added and the reaction was stirred 
overnight. DMF was removed under reduced 
pressure and the crude product was purified by 
gradient column chromatography (CH2Cl2/MeOH, 
1:0 to 9:1) to obtain 8 as a white solid (30 mg, 
35%) 
13
C-NMR (101 MHz, CDCl3) δ 173.2, 164.0, 
156.8, 98.8 (2C), 70.4, 70.4, 70.1, 69.9, 69.8, 69.3, 62.5, 61.7, 60.1, 55.6, 45.5, 40.5, 
38.8, 37.6, 35.9, 29.5, 29.0 (3C), 28.9, 28.2, 28.0, 25.6, 21.4 (2C), 20.0 (2C), 17.7. HRMS 
(ESI+) m/z calcd for C31H51N4O7S [M+H]
+
 623.3478, found 623.3494. 
 
7.7.3 Deglycosylation protocols 
Deglycosylation using β-elimination kit  
The β-elimination mixture was prepared by mixing 37.6 μL of β-elimination reagent and 
2.4 μL of 5M aqueous NaOH-solution. Subsequently 20 μL of this mixture was added to 
100 μL of a fetuin/BSA stock solution (1 mg/mL in MQ). The mixture was shaken overnight 
and subsequently neutralized using 1M aqueous HCl-solution. The protein was purified 
using spin concentration filters, washing with 10 mM NaHCO3 (5 × 1 mL). 
 
Deglycosylation using NaIO4-oxidation 
A fetuin/BSA solution (100 μL, 2 mg/mL in 0.33 M aqueous NaCl) was mixed with 0.2 M 
aqueous sodium acetate (100 μL, pH 4.5) and 200 mM aqueous NaIO4 (200 μL). The 
mixtures were shaken overnight, whereupon the mixtures were quenched by the addition 
of 200 μL aqueous solution containing 400 mM Na2S2O3, 100 mM KI, and 100 mM 
NaHCO3. Next, the pH was adjusted to 10.5 by the addition of 1M aqueous NaOH-solution 
(about 20 μL), and an aqueous dimethyl aminoethanethiol-solution (1M, 6 μL) was added. 
The mixture was allowed standing for 5 hours, whereupon the protein was purified using 
spin concentration filters, washing with 10 mM NaHCO3. 
 
Deglycosylation by β-elimination with HNMe2 
Fetuin (190 μg) or BSA (231 μg) was dissolved in 40% HNMe2 in H2O (190 μL for fetuin, 
231 μL for BSA) and shaken for 6 hours at 55 ºC. Hereupon, the mixture was dialyzed 
against 10 mM NaHCO3. 
 
General procedure for deglycosylation for single proteins using TFMSA 
A stock solution of the desired protein was made in H2O and the required amount of 
solution was lyophilized in a glass vial. A mixture of TFMSA/anisole (4:1) was prepared in 
a dry vial which was placed under N2-atmosphere. The TFMSA/anisole mixture was added 
to the protein (0.5 mL/mg of lyophilized protein) at -78 ºC, whereupon the reaction was 
allowed standing at the desired temperature for a certain amount of time. Hereupon, 3 
volumes of Et2O were added, the mixture was cooled to -78 ºC and 60% pyridine in H2O 
(3 volumes) was added. Subsequently the mixture was washed by the addition of Et2O (3 
× 3 volumes). Ultimately the pyridine layer was purified using dialysis against 250 mM 
NH4HCO3 or spin concentration for buffer exchange.  
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Deglycosylation in lysate buffers 
A fetuin stock solution (100 μL/vial, 1 mg/mL) was mixed with 8.6 μL of different buffers 
(DPBS, 250 mM NH4HCO3, Tris-buffer (50 mM Tris, 1 mM β-mercaptoethanol, 0.32 M 
sucrose, and 1 mM EDTA), 6M Urea, or HEPES-buffer (20 mM HEPES, 1% SDS) and to 
the Tris-buffer and HEPES-buffer was added 0.1 μL of protease inhibitors. Subsequently, 
the samples were lyophilized. To each sample was added 30 μL of TFMSA/anisole (4/1) 
at -78 ºC. The mixture was kept at 4 ºC for 4 hours, whereupon it was cooled to -78 ºC. 
Et2O (100 μL) and pyridine (60%, 100 μL) were added, and the mixture was washed with 
Et2O (3 × 100 μL). The pyridine-layer was then spin concentrated against 250 mM 
NH4HCO3 (5 × 500 μL). Finally, the samples were taken up in 300 μL of buffer. 
 
Deglycosylation of labeled cell lysates 
The lysate of live cells labeled with DIBAC-Biotin (400 μg) was lyophilized. Subsequently, 
TFMSA/anisole (4:1, 200 μL) was added at -78 ºC and the mixture was kept at 4 ºC. At 
preset time points (1, 2, 4, and 6 hours) a sample (50 μL) was taken and cooled to -78 ºC. 
After the addition of 60% pyridine (150 μL) the lysate was purified by a CHCl3/MeOH 
precipitation. Samples were analyzed by Western Blot. 
 
Enrichment followed by deglycosylation 
Neutravidin-beads (750 μL, 50% slurry) were equilibrated with Tris-buffer (20 mM Tris, 
150 mM NaCl, 1 mM EDTA) by washing (3 × 1 mL). Next, cell lysate solution obtained 
from live cell labeling with DIBAC-Biotin (5) (200 μL) was added and the suspension was 
rotated overnight. Subsequently, the beads were spun down, and washed by rotating for 5 
minutes and spinning down (2 min, 800 × g). Washing was performed with 1% SDS in 
PBS (2 × 5 mL), 6 M Urea (2 × 5 mL), 2 M NaCl (2 × 5 mL), and 100 mM NH4HCO3 in 
PBS (2 × 5 mL). After washing, the beads were split into 4 equal portions. Portion 1 was 
taken up in loading buffer and boiled for 10 minutes; the supernatant was analyzed by 
Western Blot. Portion 2-4 were lyophilized overnight. Portion 2 was washed with 4% SDS 
in PBS (250 μL) and the supernatant was analyzed by Western Blot.  To the lyophilized 
beads from portion 3 TFMSA/anisole (4:1, 125 μL) was added at -78 ºC. The mixture was 
kept at room temperature for 5 seconds, subsequently cooled to -78 ºC and quenched by 
the addition of 60% pyridine (375 μL). The supernatant was purified by CHCl3/MeOH 
precipitation. Lastly, to the lyophilized beads from portion 4, TFMSA/anisole (4:1, 125 μL) 
was added and the mixture was kept at 4 ºC for 6 hours. After cooling to -78 ºC, the 
reaction was quenched by the addition of 60% pyridine (375 μL) and the supernatant was 
purified using a CHCl3/MeOH precipitation. The remaining beads from portions 2, 3, and 4 
were suspended in loading buffer and boiled for 10 minutes; the supernatants were also 
analyzed by Western Blot. 
 
7.7.4 Purification protocols 
Zeba gel filtration 
The Zeba Spin Desalting Column (7k MWCO) was spun down to remove the storage 
buffer (2 min, 1000 rpm). Next, the column was equilibrated by the addition of 100 mM 
NH4HCO3 (3 × 1 mL) followed by centrifugation (2 min, 1000 rpm). Hereupon, the sample 
was loaded together with 45 μL of NH4HCO3 and the column was spun down (2 min, 1000 
rpm). The filtrate contained the protein. 
 
Acetone precipitation 
A cell lysate solution (80 μL) was mixed with acetone (720 μL) and the mixture was stored 
at -78 ºC for 1 hour. The suspension was spun down (20 min, 15k rpm), and the 
supernatant was removed. The pellet was taken up in the desired buffer. 
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CHCl3/MeOH precipitation 
A cell lysate solution (80 μL) was mixed with MeOH (600 μL) and briefly vortexed. Next 
CHCl3 (150 μL) was added and the mixture was again briefly vortexed. Finally, MilliQ (400 
μL) was added, and again the mixture was vortexed briefly. The solvent mixture was 
centrifuged (5 min, 15k × g) and the upper (aqueous) layer was removed. The interface 
was left untouched as the lysate precipitate floats at the interface. To precipitate the 
lysate, MeOH (450 μL) was added and the mixture was briefly vortexed. After 
centrifugation (5 min, 15k × g) a white precipitate was formed on the bottom of the 
eppendorf tube and the supernatant was removed. The pellet was then dissolved in the 
desired buffer. 
 
7.7.5 Live cell and lysate labeling protocols 
General procedure for live cell labeling 
Two flasks were filled with 65 million cells in cell culture medium (175 mL). To flask 1, 
GalNAz (100 mM in DMSO, 87.5 μL) was added, to flask 2 DMSO (87.5 μL) was added, 
and the cells were grown for three days. The cells were spun down and combined into 
one 50 mL falcon tube each using FACS-buffer (1% FBS in PBS). The cells were spun 
down, and subsequently washed with FACS-buffer (2 × 45 mL). The cells were 
resuspended in FACS buffer (16 mL) and split in twelve portions of 1 mL and one of 4 mL 
(used for lysate labeling). The desired biotinylated probes (1-7) were added from stock 
solutions in DMF/PBS (3:7) such that the desired concentration was reached. After the 
desired amount of time, the cells were spun down (3 min, 1300 rpm, 4 ºC) and washed 
with PBS (3 × 1 mL). After removal of the PBS after the last washing step, the cells were 
taken up in lysis buffer and lysed by sonication. The resulting cell lysate was spun down 
(20 min, 16k rpm), and the supernatant was taken. All lysate concentrations were 
determined using a BCA analysis. All samples were analyzed by Western Blot (10 μg 
protein/lane). 
 
Lysate labeling 
Suspensions of GalNAz labeled cells (4 mL) and unlabeled cells (4 mL), prepared 
described as above, were spun down (3 min, 1300 rpm, 4 ºC) and washed with PBS (2 × 
12 mL). The cells were then resuspended in 1 mL of PBS and transferred to an eppendorf 
tube. After spinning down (3 min, 1300 rpm, 4 ºC), the PBS was removed and cells were 
resuspended in Tris-buffer (500 μL). Subsequently, the cell suspensions were  sonicated 
(5 sec on, 5 sec off, 2 minutes, 0.5 W) and the resulting solution was spun down (20 min, 
16k rpm). The supernatant was then taken and the protein concentration of the lysate was 
determined using a BCA analysis. Next, reagents were added to eppendorf tubes 
containing 100 μg (10 μL) of either GalNAz-labeled or non-labeled lysate according to 
Table 1. The mixtures were shaken for 2.5 hours, whereupon 190 μL of PBS was added. 
The lysates were purified using CHCl3/MeOH precipitation. The samples were 
subsequently analyzed by Western Blot (10 μg protein/lane). 
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Table 1. Addition of reagents for cell lysate labeling 
Reagent 
2.5 mM stock-
solution 
100 μM stock 
solution 
DMF/PBS (3:7) 
PHOS-Biotin (1) 1 μL 0 μL 0 μL 
DIMAC-Biotin (2) 1 μL 0 μL 0 μL 
MOFO-Biotin (3) 1 μL 0 μL 0 μL 
DIBO-Biotin (4) 0 μL 1 μL 0 μL 
DIBAC-Biotin (5) 0 μL 1 μL 0 μL 
DIFO-Biotin (6) 0 μL 1 μL 0 μL 
BARAC-Biotin (7) 0 μL 1 μL 0 μL 
BCN-Biotin (8) 0 μL 1 μL 0 μL 
No probe 0 μL 0 μL 1 μL 
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In the last two decades many new reactions have been 
developed for the modification of biological systems 
and these reactions found application in for example 
protein modification, cell surface labeling, and in 
vivo studies. 
 Although most of these reactions proceed in water, 
are selective, and show no toxicity or interference 
with biological processes, advances can still be made 
in the development of reactions that involve small 
reaction partners or allow for spatial and/or temporal 
control.  
In recent years, many biological applications of 
these reactions have already been published. Likely, 
applying bioorthogonal ligation strategies to more 
areas of biological research will lead to new 
insights. 
8 
Conclusions and 
Perspective 
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8.1 Bioorthogonal ligation reactions 
In the past two decades, enormous advances have been made in the field of 
chemical biology, both in the development of new bioorthogonal ligation reactions 
and applications of these reactions in biological research. Until the 1990s, 
chemical modification of biomolecules was limited to the functionalization of 
natural amino acids. In the late 90s, apart from research efforts with fluorescent 
proteins like GFP for biological research, methods have evolved which allow for 
more selective and controlled chemical modification of proteins. First of all, efforts 
have been made to more selectively modify natural amino acids, e.g. by modifying 
low abundant amino acids like tyrosine, selective labeling of the N-terminus, and 
the development of thiol-reagents which retain the dithiol-bridge structure. On the 
other hand, researchers became inspired by nature’s toolbox, resulting in the 
development of enzyme-mediated modifications, EPL, and tag-based ligations. 
Finally, investigations were pursued towards the development of new reactions 
which were suitable to selectively label biomolecules.  
These so-called bioorthogonal ligation reactions need to occur in water, at low 
concentration, and with a high reaction rate. Also, the reaction partners need to 
react selectively with each other and show no cross-reactivity with functional 
handles present in biological systems (e.g. free amines or thiols). Obviously, the 
reactants should not be toxic to living systems or influence the cellular behaviour 
(e.g. by altering cell proliferation).  
In this class of labeling tools, many novel reactions have been developed. The 
most prominent reactions are ketone-mediated ligations,
1
 the Staudinger ligation,
2
 
and cycloadditions with azides,
3
 nitrones,
4
 nitrile-oxides,
5
 tetrazines,
6
 and nitrile-
imines (formed by UV irradiation of tetrazoles).
7
 Especially, ligation reactions with 
azides have received much attention. On the one hand, azides can be readily 
introduced into proteins and cell surfaces, in vitro and in vivo, on the other hand 
azides react fast and selectively in a Staudinger ligation, CuAAC, and SPAAC. For 
this last reaction, many different strained alkynes, with increased ring strain and 
reactivity, have been developed.  
Although much progress has been made in the development of more reactive 
cyclooctynes, these improvements often came with a price. Some of the faster 
cyclooctynes are not shelf-stable (BCN
8
), or show significant cross-reactivity with 
thiols (BARAC,
9
 DIFO
10
). Also, most cyclooctynes are highly hydrophobic (see 
Chapter 1, Figure 3), and need to be prepared via lengthy and/or low yielding 
synthetic routes (Chapter 1, Table 2). Lastly, as was experienced during the work 
described in Chapter 3, the crucial step in all cyclooctyne synthesis is the last, 
alkyne-forming step, which is the most troublesome step. This renders cyclooctyne 
synthesis a cumbersome and time-consuming process. 
Due to the price that needs to be paid for increasing reactivity, ultimately leading 
to unstable or less selective probes which are hard to synthesize, the development 
of new cyclooctynes will probably cease and the development of new and 
improvement of other bioorthogonal ligations are likely to attain more attention. 
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One of the most promising reaction partners for further improvement is the 
tetrazine moiety. Research from the 1960s and 1970s already showed the high 
reactivity of tetrazines towards several reaction partners. With the recent 
development of functionalizable probes (e.g. trans-cyclooctenes
6
 and 
cyclopropenes
11
), and the possibility to selectively introduce tetrazines and their 
reactive counterparts to proteins (via the amber stop codon)
12
 and cell surfaces 
(via the metabolic pathway of sugars),
13
 these ligations are likely to be optimized 
further in coming years. 
The high kinetics of the tetrazine-based ligations, and more in particular the 
ligation with trans-cyclooctenes, allow for new possibilities which are not possible 
with slower bioorthogonal ligation reactions. For example, Rossin et al. showed 
that tumors can be pre-targeted in vivo with trans-cyclooctene containing 
antibodies, followed by labeling with a tetrazine containing radio-label.
14
 Further 
development and application of this methodology will allow for the use of less 
stable radio-isotopes, as the lag time between injection and detection of the radio-
label can be significantly reduced, due to fast secretion of the small tetrazine-
containing label. Another interesting study could involve the labeling of short living 
biological intermediates in living systems. These studies might help to further 
understand biological processes like cell-cell interactions, neuron-signaling, or cell 
membrane transport. 
 
8.2 New bioorthogonal reactions and reactive probes 
In the development for new bioorthogonal reactions and/or reactive probes, a 
few highly interesting improvements can be made. On the one hand, the 
development of fluorogenic probes,
15-17
 which after reaction show an emission-
excitation pattern which is suitable for biological research, will prove valuable in 
research. Using these probes would avoid the introduction of often highly 
hydrophobic dyes, reduce risks of quenching, eliminate the problem of aspecific 
labeling, and will reduce synthetic challenges often encountered when preparing a 
probe suitable for labeling. 
On the other hand, tunable probes are likely to prove valuable in biological 
research, allowing for spacial and temporal control. The tetrazole-based ligation,
7
 
and cyclopropene-protected dibenzocyclooctyne
18
 are already examples in this 
direction. However, both require irradiation with UV-light, which makes them less 
suitable for biological studies. Possibly, different types of probes can be developed 
which become reactive upon irradiation with for example α-particles, X-rays, or by 
drug interaction. An interesting other option for spatial control, would be the use of 
probes that become highly reactive after reaction with a specific enzyme or upon 
encountering a specific biological condition. By development of such probes 
different conditions can be thought of, for example the change in pH in certain 
tissues (like tumor tissue) or the reductive conditions within cells cleaving S-S 
bridges. Also, reaction of the probe with certain enzymes (e.g. sulfatases, 
phosphorylases, and glycosyltransferases), could lead to the activation (or 
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deactivation) of a reactive probe. These pro-reactive reaction partners could, for 
example, be used in studies towards enzyme activity, cell-membrane permeability, 
and tumor labeling. 
Lastly, the fastest bioorthogonal ligations involve relatively large reactive groups. 
The larger the molecules, the bigger the chances that e.g. biological processes, 
epitope affinity, or enzyme functioning are influenced. To circumvent this, a 
challenge lies within the development of two small reactive partners which react in 
a fast and selective manner with each other. A promising advance in this field was 
recently made by the development of a tetrazine-cyclopropene
11
 and tetrazole-
cyclopropene
19
 cycloaddition. 
 
8.3 Outlook for biological research 
Apart from the development of new probes and new ligation reactions, a great 
potential has been displayed by the currently known and developed reactions. 
However, at the moment, research has mainly been limited to chemistry-oriented 
laboratories, since this is where the reactions were developed. Most probably, a 
great potential lies within the application of the bioorthogonal ligation reactions in 
many biological research areas, which are, unfortunately, often unaware of the 
possibilities chemical reactions have to offer.  
Research at the interface of chemistry and biology, forming the new field of 
chemical biology, holds considerable promise in further unraveling biological 
processes and developing new imaging, diagnostic, and therapeutic agents. To 
that end, it is important that chemists and biologists realize that only in joint 
efforts, where synergy between the two disciplines is reached, such challenging 
research problems can be solved. 
In the near future, it should be the task of chemists and biologists to look across 
the borders of their own field, communicate, and thus attempt to learn from each 
other. If chemists and biologists succeed in trusting their mutual research as much 
as they trust their own and look at this research with an open mind, a wide range 
of problems are likely to be addressed. As long as chemists and biologists 
collaborate, a bright future will lie ahead for the field of chemical biology. 
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Summary 
Labeling and modification of biomolecules have become of large interest in 
studying biological processes, molecular mechanisms of disease, and drug 
delivery. Obtaining a broader insight by e.g. protein or cell surface labeling can 
help to improve diagnosis and treatment. In the last two decades, many 
approaches to modify biomolecules have been published. In these labeling 
methods, two separate reaction classes can be distinguished in the myriad of 
strategies known, i.e. reactions that involve functional groups present in 
biomolecules (e.g. amines, thiols, free acids, Figure 1, right), and reactions that 
use functional handles which do not occur in biological systems (e.g. azides, 
tetrazines, nitrile oxides, Figure 1, left). The last class, the so-called bioorthogonal 
ligation reactions, has been given large attention in the last decade. Due to the 
orthogonal character of the reactions, it allows for selective labeling of for example 
proteins, cell surfaces, and fatty acids. An overview of all methods currently known 
in the field of bioconjugation is provided in Chapter 1.  
 
Figure 1. Protein ligation using either naturally occurring reactive groups (right) or bioorthogonal 
functional handles (left). 
The most prominent bioorthogonal handle currently used is the azide, which is 
small, inert, and relatively easy to introduce. The azide can react in a Staudinger 
ligation, a Cu(I)-catalyzed azide alkyne cycloaddition (CuAAC), and a Strain-
Promoted Azide Alkyne Cycloaddition (SPAAC). The latter involves the reaction 
between an azide and a strained alkyne (generally a cyclooctyne) and is of 
specific interest since this reaction proceeds fast, at low concentration, and 
without catalyst requirements.  
Chapter 2 describes the development of a new cyclooctyne, i.e. 
dibenzoazacyclooctyne (DIBAC (13), Figure 2). DIBAC was prepared in nine steps 
in an excellent overall yield of 41%. In reaction with benzyl azide, DIBAC showed 
an outstanding rate constant of 0.4 M
-1
s
-1
 which still is the second fastest rate 
constant of a cyclooctyne in reaction with an azide. In addition, DIBAC was highly 
stable and could be stored for years as a solid and for months in stock solutions. 
To demonstrate the superior properties of SPAAC with DIBAC over CuAAC, 
DIBAC-PEG44 was used for the PEGylation of azide-containing CalB. Only five 
equivalents of DIBAC-PEG44 were sufficient to achieve almost full double 
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PEGylation of CalB. For comparison, twenty equivalents of PEG-reagent in 
CuAAC resulted in only 50% conversion to single PEGylated CalB. 
With the aim to improve the DIBAC system, and prepare more reactive, more 
hydrophilic, or dually labeled DIBACs, synthesis of DIBAC analogues was 
pursued, as described in Chapter 3. In the research described in this chapter, 
preparation of analogues was performed following the identical route as reported 
for DIBAC. Up to the synthesis of alkenes 2-6 (Figure 2), the route proved highly 
versatile and all analogues could be prepared yielding comparable results as 
obtained for 1. From this point, double bromination followed by elimination was 
anticipated to yield the desired alkynes. Bromination proceeded in good yield for 
almost all analogues yielding dibromides 8-12. Surprisingly, in this reaction not 
only the expected trans-isomers, but also the syn-isomers were obtained. 
Especially when strongly electron-withdrawing groups were present on the 
benzene ring, the syn-isomer was the predominant product. In the final 
elimination, success appeared highly dependent on the substitution pattern on the 
benzene ring. Elimination towards Cl-DIBAC (14), Br-DIBAC (15), and MeO-
DIBAC (16) was successful, although in moderate yield. However, elimination of 
dibromides with multiple or more strongly electron-withdrawing substituents (i.e. 9 
and 11) was not possible and resulted in reformation of alkenes 3 and 5, 
respectively, instead.  
 
Figure 2. Dibromination of alkenes 1-6, followed by elimination of dibromides 7-12, yielding 
DIBAC-analogues 13-16. Double elimination of dibromides 9 and 11 was unsuccessful and yielded 
alkenes 3 and 5 respectively. 
To avoid the cumbersome bromide elimination, alternative methods were 
attempted to form other dibenzoazacyclooctynes. Cyclopropenone deprotection of 
17 resulted in (MeO)2-DIBAC 18 (Figure 3), alkyne formation via fluoride-mediated 
TMS-removal followed by triflate elimination on 19 successfully yielded Cl,MeO-
BARAC 20 (Figure 4). Unfortunately the formation of cyclopropenone 17 posed 
stringent limitations on the possible starting materials, allowing only for highly 
electron-donating groups on the para-position. In addition, attempts to further 
modify 17 and 20 by methoxy-deprotection or conversion of the chloride into a 
nitro group were unsuccessful. All dibenzoazacyclooctynes prepared (i.e. DIBAC 
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14-16, and 18 and BARAC 20) showed excellent rate constants between 0.45 and 
1.2 M
-1
s
-1
 in reaction with benzyl azide. It was observed that especially electron-
withdrawing groups on DIBAC have a large effect on the rate constant.  
 
Figure 3. UV-mediated cyclopropenone deprotection yielding DIBAC 18. 
 
Figure 4. Alkyne formation via TMS removal and triflate elimination. 
After successful synthesis of DIBAC and analogues as described in Chapters 2 
and 3, we aimed for application of these and other cyclooctynes in protein and cell 
surface modification which is described in Chapters 4-7.  
In Chapter 4 the dual labeling of tumor-vessel targeting single domain antibody 
A12 is reported. To achieve this, A12 first needed to be equipped with an azide 
and a free thiol. To this end, A12 was cloned as a fusion protein (A12-Intein-CBD), 
and subjected to Expressed Protein Ligation with a small peptide containing an 
azide and a free thiol. The azide was then used in SPAAC with a DIBAC equipped 
with a fluorescent dye; the thiol was functionalized with biotin via a thiol-maleimide 
ligation. It was demonstrated that A12 was successfully equipped with an azide 
and a free thiol, which could both be functionalized. Having established the 
preparation of A12 containing an azide and a thiol, the aim was to prepare 
targeting polymersomes, as proof of concept for a potential drug delivery system, 
which is described in Chapter 5. PEG-b-PS polymersomes charged with a 
cyclooctyne (BCN) were prepared and subsequently reacted with A12-N3. 
Formation of the nanobody-polymersome conjugate was confirmed by immunoEM 
and ICPMS. Studies towards the binding affinity of the construct indicated that the 
affinity for the Plexin D1 (the target of A12) was retained. Comparable 
polymersome-nanobody constructs were prepared to perform in vivo studies, 
however, no tumor-specific uptake was observed. 
In Chapter 6 the efforts towards the preparation of an enzyme-metal catalyst 
hybrid system are described. In this research, the aim was to prepare a construct 
that would combine the advantageous properties of enzyme-mediated and metal-
catalyzed reactions. Initially, it was tried to prepare a DIBAC-containing metal 
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catalyst and conjugate this to azide-functionalized CalB. However, formation of the 
cyclooctyne-containing metal catalyst was not possible in our hands. Therefore, a 
dibenzocyclooctadiyne was prepared and used to convert the azide of CalB into a 
cyclooctyne. Subsequently an azide-functionalized metal-catalyst was ligated to 
CalB-N3. Unfortunately, no direct evidence of successful formation of the enzyme 
metal-catalyst hybrid system could be obtained as mass spectrometry was not 
successful. Initial kinetic experiments on enzyme and metal-catalyst looked 
promising; however, further research is required to determine the efficiency of 
formation of the hybrid system, its catalytic properties, and whether there is a 
cooperative effect between enzyme and metal catalyst. 
Lastly, Chapter 7 describes research towards the improvement of the 
detectability of mucin-type glycoproteins by glycoprotein enrichment followed by 
removal of the glycans. To this end, first, conditions for the removal of O-linked 
glycans were optimized. Full deglycosylation of proteins without protein 
degradation was observed when using trifluoromethanesulfonic acid at 0 ºC. Next, 
modification of glycoproteins by live cell labeling with a biotin probe using SPAAC 
and the Staudinger ligation was optimized. Various azide-reactive probes were 
tested at different temperatures, concentrations and time intervals, to obtain the 
highest number of labeled proteins. This was achieved by treating the cells with 
either 20 μM of DIBAC-Biotin or 250 μM of PHOS-Biotin for 5 hours. After cell 
lysis, the biotin labels were successfully removed by deglycosylation. Further 
research towards enrichment for labeled proteins followed by on-bead 
deglycosylation still needs to be performed. 
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Samenvatting 
In hedendaags chemisch biologisch onderzoek is er grote interesse voor het 
labelen en modificeren van biomoleculen in studies naar biologische processen, 
ziektes, en medicijn afgifte. Het verkrijgen van een fundamenteel inzicht hierin 
door het labelen van bijvoorbeeld eiwitten of celoppervlakken kan helpen bij het 
verbeteren van diagnoses en therapieën. In de afgelopen twee decennia zijn veel 
verschillende methoden ontwikkeld om biomoleculen te modificeren. Hierin kan 
een duidelijk onderscheid gemaakt worden tussen twee verschillende 
reactiecategorieën, namelijk reacties die plaatsvinden met functionele groepen die 
van nature in biomoleculen aanwezig zijn (bijvoorbeeld aminen, thiolen en vrije 
zuren, Figuur 1 rechts) en reacties die gebruik maken van functionele groepen die 
niet voorkomen in biologische systemen (bijvoorbeeld aziden, tetrazinen en 
nitriloxiden, Figuur 1 links). Deze laatste klasse, de zogenaamde bioorthogonale 
ligatiereacties, hebben in het laatste decennium veel aandacht gekregen. Door het 
orthogonale karakter van deze reacties kunnen onder meer eiwitten, 
celoppervlakken en vetzuren selectief gefunctionaliseerd worden. Hoofdstuk 1 
geeft een overzicht van alle methoden die momenteel bekend zijn op het gebied 
van bioconjugatie. 
 
Figuur 1. Eiwitligatie gebruik makend van in de natuur voorkomende functionele groepen (rechts) 
en bioorthogonale functionele groepen (links). 
De functionele groep die momenteel het meest gebruikt wordt, is het azide 
aangezien deze klein en inert is en relatief gemakkelijk te introduceren. Een azide 
kan reageren in een Staudinger ligatie, een Cu(I)-gekatalyseerde azide-alkyn 
cycloadditie (CuAAC) en een strain-promoted azide-alkyn cycloadditie (SPAAC). 
Deze laatste behelst een reactie tussen een azide en een ringgespannen alkyn 
(over het algemeen een cyclooctyn) en is vooral interessant omdat deze reactie 
erg snel is, en plaatsvindt bij lage concentratie zonder dat een katalysator vereist 
is.  
Hoofdstuk 2 beschrijft de ontwikkeling van een nieuw cyclooctyn, 
dibenzoazacyclooctyn (DIBAC (13), Figuur 2). DIBAC werd gesynthetiseerd in 
negen stappen in een excellente opbrengst van 41%. DIBAC bleek met een 
uitstekende snelheidsconstante van 0,4 M
-1
s
-1
 met benzylazide te reageren. Deze 
snelheidsconstante is nog steeds de op-één-na-hoogste voor de reactie van een 
cyclooctyn met een azide. Daarnaast bleek DIBAC erg stabiel, het kon gedurende 
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meerdere jaren als vaste stof en zelfs diverse maanden in stockoplossing worden 
bewaard zonder aantoonbare decompositie. Om de superieure eigenschappen 
van SPAAC met DIBAC in verhouding tot CuAAC te demonstreren werd DIBAC 
uitgerust met een PEG44-staart en vervolgens gebruikt voor het PEGyleren van 
azide-gefunctionaliseerd CalB. Slechts vijf equivalenten DIBAC-PEG44 waren 
afdoende om bijna volledig dubbele PEGylering van CalB te realiseren. Ter 
vergelijking, voor CuAAC met azide-gefunctionaliseerd CalB waren twintig 
equivalenten PEG-alkyn nodig om slechts 50% conversie te krijgen naar het enkel 
gePEGyleerde product. 
Om het DIBAC systeem reactiever en/of hydrofieler te maken, zijn verschillende 
DIBAC analoga gesynthetiseerd zoals beschreven is in Hoofdstuk 3. Hiervoor is 
aanvankelijk een strategie gekozen die identiek was aan de syntheseroute naar 
DIBAC. Tot aan de synthese van alkenen 2-6 (Figuur 2) bleek de route algemeen 
toepasbaar en konden alle intermediairen met vergelijkbare resultaten worden 
verkregen als voor 1. Vervolgens was de verwachting dat dibromering, gevolgd 
door dubbele eliminatie, de gewenste alkynen zou opleveren. De dibromering 
verliep in goede opbrengsten voor vrijwel alle tussenproducten 8-12. Verrassend 
genoeg werden in deze reactie niet alleen de verwachte trans-isomeren, maar ook 
de syn-isomeren verkregen. Vooral met sterk elektronenzuigende groepen op de 
benzeenring, waren de syn-isomeren de voornaamste producten. Succes in de 
uiteindelijke eliminatie bleek erg afhankelijk van het substitutiepatroon op de 
benzeenring. Zo verliep eliminatie resulterend in Cl-DIBAC(14), Br-DIBAC (15) en 
MeO-DIBAC (16) succesvol, weliswaar in matige opbrengst. Echter, dubbele HBr 
eliminatie in aanwezigheid van meerdere of sterk elektronenzuigende 
substituenten (verbindingen 9 en 11) was niet mogelijk en resulteerde in het 
terugvormen van respectievelijk alkenen 3 en 5. 
 
Figuur 2. Dibromering van alkenen 1-6, gevolgd door eliminatie van de bromiden 7-12, 
resulteerde in DIBAC-analoga 13-16. Dubbele eliminatie van dibromiden 9 en 11 verliep zonder 
succes en resulteerde in het terugvormen van respectievelijk alkenen 3 en 5.  
Om de problematische bromide eliminatie te vermijden, werden alternatieve 
methoden geprobeerd om dibenzoazacyclooctynen te vormen. De ontscherming 
van cyclopropenon 17 resulteerde in (MeO)2-DIBAC 18 (Figuur 3), fluoride-
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gemedieerde TMS-ontscherming, gevolgd door triflaateliminatie van 19 leverde 
Cl,MeO-BARAC (20, Figuur 4) opleverde. Helaas zijn er strenge vereisten aan het 
startmateriaal om cyclopropenon 17 te kunnen vormen aangezien alleen sterk 
elektron-donerende groepen op de para-positie resulteren in het gewenste 
product. Ook pogingen om 17 en 20 verder te modificeren door 
methoxyontscherming of omzetting van het chloride in een nitrogroep waren niet 
succesvol. Alle gesynthetiseerde dibenzoazacyclooctynen (DIBAC 14-16 en 18, en 
BARAC 20) vertoonden excellente snelheidsconstanten uiteenlopend van 0,45  
M
-1
s
-1
 tot 1,2 M
-1
s
-1
 in reactie met benzylazide. Vooral elektronenzuigende 
groepen lieten een erg groot effect op de snelheidsconstante zien. 
 
Figuur 3. UV-licht-geïnitieerde cyclopropenon ontscherming leidend tot alkyn 18. 
 
Figuur 4. Alkynvorming via TMS ontscherming en triflaat eliminatie.  
Na de succesvolle synthese van DIBAC en analoga, was het doel om deze en 
andere cyclooctynen toe te passen in eiwit- en celoppervlakmodificatie, hetgeen 
beschreven is in Hoofdstukken 4-7. 
In Hoofdstuk 4 wordt de dubbele labeling van tumor-bloedvat labelend Single-
Domain Antibody A12 beschreven. Om dit te bereiken werd A12 uitgerust met een 
azide en een vrij thiol. Dit werd gedaan door A12 eerst te kloneren als fusie-eiwit 
(A12-inteine-CBD), en vervolgens te functionaliseren via Expressed Protein 
Ligation met een klein azide- en thiol-bevattend peptide. Het azide werd 
vervolgens toegepast in SPAAC met fluorescent gelabeld DIBAC; het thiol was 
gefunctionaliseerd met biotine, gebruik makend van een thiol-maleimide ligatie.  
Nadat vastgesteld was dat A12 uitgerust kon worden met een azide en een thiol, 
was het doel om targeting polymeersomen te maken, als een proof of concept 
voor een potentieel medicijnafgiftesysteem, zoals beschreven in Hoofdstuk 5. 
A12-N3 werd daartoe gereageerd met PEG-b-PS polymeersomen uitgerust met 
een cyclooctyn (BCN). De vorming van het nanobody-polymeersoom conjugaat 
was bevestigd met immunoEM en ICPMS. Studies naar de bindingsaffiniteit van 
de gevormde constructen gaven een indicatie dat de affiniteit voor Plexine D1 (het 
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target van A12) behouden was gebleven. Vergelijkbare nanobody-polymeersoom 
constructen werden gemaakt om in vivo onderzoek te kunnen doen, maar helaas 
werd hierbij geen tumorspecifieke opname gemeten. 
In Hoofdstuk 6 wordt de synthese van een hybride enzym-metaalkatalysator 
beschreven. In dit onderzoek was het doel om een construct te maken, dat de 
gunstige eigenschappen van enzym-gemedieerde en metaal-gekatalyseerde 
reacties zou combineren. In eerste instantie was geprobeerd om een DIBAC-
bevattende metaalkatalysator te synthetiseren en deze te conjugeren aan azide-
gefunctionaliseerd CalB. Echter, de beoogde cyclooctyn-bevattende 
metaalkatalysator kon niet worden gemaakt. In plaats daarvan werd een 
dibenzocyclooctadiyn gesynthetiseerd om het azide van CalB om te zetten in een 
cyclooctyn. Vervolgens werd een azide-gefunctionaliseerde metaal katalysator 
geligeerd aan CalB. Helaas kon geen direct bewijs geleverd worden van de 
succesvolle vorming van het hybride enzym-metaalkatalysator systeem. Eerste 
kinetiekexperimenten met enzym en metaalkatalysator lijken desondanks 
veelbelovend. Verder onderzoek is echter nodig om de efficiëntie van de vorming 
van het hybride systeem, de katalytische eigenschappen, en een mogelijk 
coöperatief effect te bepalen. 
Tot slot beschrijft Hoofdstuk 7 onderzoek naar het verbeteren van de 
detecteerbaarheid van glycoeiwitten van het mucin-type door middel van verrijking 
van de glycoeiwitten, gevolgd door het verwijderen van de glycanen. Om dit te 
realiseren zijn eerst de condities voor het verwijderen van O-geligeerde glycanen 
geoptimaliseerd. Volledige deglycosylering zonder eiwit degradatie kon worden 
bereikt wanneer trifluoromethaansulfonzuur gebruikt werd bij 0 ºC. Na deze 
optimalisatie zijn de condities voor het biotinyleren van levende cellen door middel 
van SPAAC en de Staudinger ligatie geoptimaliseerd. Om een zo groot mogelijk 
aantal eiwitten te labelen, zijn diverse azide-reactieve moleculen getest bij 
verschillende temperaturen en concentraties gedurende verschillende 
tijdsintervallen. Optimale biotinylering werd bereikt door de cellen gedurende vijf 
uur te behandelen met ofwel 20 μM DIBAC-biotin, danwel 250 μM PHOS-biotin. 
Na het lyseren van de cellen konden de biotinelabels met succes worden 
verwijderd door middel van deglycosylering. Verder onderzoek naar de verrijking 
van gelabelde eiwitten, gevolgd door deglycosylering op een vast dragermateriaal 
moet nog worden uitgevoerd. 
 
 
  
Claudia de Breij – Leven te Kort 
 
Geef me er één waarin ik vrij ben 
altijd vrij ben, de hele dag 
één leven waarin ik nooit moet werken 
nooit moet werken, maar altijd mag 
één zonder deadlines 
één zonder klok 
één waarin ik op mijn 35ste nok 
één met ambitie, mijn naam op een bord 
één waar ik me vol op op mijn werk stort 
geef me, de tijd waar het nu aan schort 
geef me een leven 
waarin het nooit later wordt 
ik kom een leven te kort 
kom aan dit leven, leven te kort 
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Later als ik groot ben, word ik... Vraag het een kind van 10 en het antwoord is astronaut, 
zuster, juffrouw of brandweerman. Nog nooit heb ik gehoord dat een kind antwoordde 
chemicus, onderzoeker, of promovendus. Mijn antwoord was het in ieder geval niet. Dat ik 
uiteindelijk toch scheikunde gestudeerd heb, ben gaan promoveren, en er nu een 
proefschrift ligt, is dankzij een heleboel mensen, en daarvoor dit dankwoord. 
Mijn voorliefde voor scheikunde is begonnen op de middelbare school. Esther, jij hebt mij 
enthousiast gemaakt voor de scheikunde. Jouw altijd heldere en motiverende lessen 
hebben zeker bijgedragen aan mijn studiekeuze. Ik heb er nooit één seconde spijt van 
gehad.  
Tijdens mijn master werd ik echt enthousiast voor het onderzoek en besloot ik dat ik wilde 
promoveren. Sander, je kennis, maar vooral je werkhouding en (soms) wilde ideeën zijn 
voor mij een grote inspiratiebron geweest. Ik wil je dan ook bedanken voor het vele 
samenwerken.  
Na mijn master begon het 4-jarige traject dat heeft geleid tot dit proefschrift. Allereerst wil 
ik Floris en Jan bedanken voor het vertrouwen in mij, de mogelijkheden die jullie mij 
gegeven hebben en alles wat ik van jullie heb mogen leren. Floris, je kennis van de 
chemie is ongeëvenaard en met opmerkingen als “maar is dat niet een...”, en “maar hoe 
zit het dan met ...” wist je me altijd weer aan het denken te zetten, met soms verrassende 
conclusies (zo blijkt uit hoofdstuk 3). Jan, de tijd die jij vrij weet te maken voor je aio’s en 
PostDocs en je grote interesse voor ongeveer alle takken van de organische chemie, 
maakten dat ik me nooit bezwaard voelde om bij je aan te kloppen, voor ieder stukje 
onderzoek. Dank jullie wel! Tot slot wil ik jullie beiden heel erg bedanken voor de 
mogelijkheid om naar Berkeley te gaan, dat was een fantastische ervaring die zonder 
jullie steun niet mogelijk geweest was.  
Floris van Delft, ook jou wil ik bedanken voor je inspirerende enthousiasme voor de 
“chemical biology”. Samen hebben we dan ook vier mooie publicaties behaald (tot nu toe).  
Een promotie zou onmogelijk te volbrengen zijn zonder de hulp van vast personeel, en 
hen ben ik dan ook veel dank verschuldigd. In het bijzonder wil ik Jacky en Marieke 
bedanken voor alle hulp met afspraken plannen, formulieren en alle ontelbare andere 
dingen die jullie gedaan hebben. Een bedankje voor Peter en Jan, zonder wie het een 
chemicalie- en glaswerk-loos lab zou zijn geweest, en voor Peter, Ad, en Paul, voor het 
laten functioneren van NMR en massa, en hulp bij de analyses, mag ook niet ontbreken. 
Hans Adams, bedankt voor de synthese van peptides, en je labmanagement. En last-but-
not-least, René Aben, niet alleen bedankt voor het repareren van pompen en advies bij 
reacties, maar ook zeker voor de vroege goedemorgens!  
Bijna mijn gehele promotie heb ik studenten (bachelor en master) mogen begeleiden. Ook 
al is hun bijdrage niet altijd in dit proefschrift beland, ik wil ze hierbij allemaal bedanken 
voor hun bijdrage. Jasper, al snel bleek dat onderzoek niet jouw ding is, gelukk ig heb je je 
wel helemaal gevonden in het onderwijs (en is er toch nog resultaat gekomen uit het 
onderzoek). Nanda, ondanks dat je wat synthese ervaring miste, heeft je zelfstandigheid, 
inzet, en intelligentie tot een mooi stukje onderzoek geleid. Moniek, soms zit het mee en 
soms zit het tegen in onderzoek... Ondanks de vele tegenslagen, heb je toch veel geleerd 
en ook zeker aan mijn onderzoek bijgedragen. Marleen, ook al zat je in het begin niet echt 
op je plek, volgens mij hebben we uiteindelijk jouw ding wel gevonden en heb je erg 
mooie resultaten weten te behalen! Donny, je was zeker een gezellige toevoeging op het 
lab, en die BARAC heb je toch maar mooi gemaakt! Lianne, ook bij jou compenseerde je 
inzet en wilskracht voor je mindere synthetische ervaring. Jammer dat we het niet hebben 
kunnen afronden, maar toch een mooi stuk werk waar je trots op mag zijn! Tot slot wil ik 
ook Jolanda nog bedanken, niet alleen voor de grote schaal DIBAC synthese, die zeer 
van pas gekomen is, maar ook voor het uitwisselen van praktische kennis en ervaringen. 
Het leuke aan mijn project was dat ik veel kon samenwerken met verschillende 
afdelingen. In het bijzonder wil ik Kiek bedanken, zonder jou was het mij nooit gelukt! 
William, bedankt voor de ideeën en het samenwerken. Peter Laverman, bedankt voor de 
goede samenwerking en vooral je altijd stimulerende enthousiasme en interesse. 
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The most special collaboration I was allowed to pursue during my PhD was the one in the 
Bertozzi Lab, and I want to thank everybody in the lab for giving me such a great time and 
sharing all your knowledge and experiences with me. Carolyn, thank you so much for 
allowing me to stay in your lab, I had the most amazing time and am looking so much 
forward to joining your lab again! Asia, I guess none of this would have been possible 
without your efforts, thank you! Special thanks to Kanna for supervising me, I’m glad I was 
assigned to you, you taught me so much! (Also opening doors using an elbow still turns 
out to be a useful trick) A big thank you also goes to the “slow-to-react” team and my 
running mates for keeping me in shape (and good times). Ellen, thank you for being such 
a great colleague and for sharing your wide knowledge with me. And finally, Chelsea, you 
were and still are a great friend! Thank you for taking me out on so many occasions, I 
can’t wait to see you again! 
De afgelopen 4 jaar waren een stuk minder succesvol, maar vooral minder leuk, geweest 
zonder alle collega’s en studenten. Dus allereerst wil ik (zonder uitzondering), alle (oud -) 
studenten en (oud-)collega’s uit de Nolte, Rowan, Huck, van Hest en Rutjes groep 
bedanken. Een paar mensen wil ik echter in het bijzonder bedanken. Allereerst mijn twee 
trouwe labgenoten, Jorgen en Henri, bedankt voor alle hulp, adviezen, gezelligheid, 
slechte muzieksmaak (Jorgen dan), en alle kennis over fietsen (ooit komt het vast van 
pas)! Mark, bedankt voor de hulp met bio-dingetjes, je enthousiaste idee’tjes en je 
gezelligheid! Angelique, bedankt voor alle koffie(thee…)-pauzes, etentjes en uitstapjes! 
SF marathon, here we come! 
Twee collega’s wil ik nog speciaal noemen, mijn paranimfen Nanda en Silvie. Nanda, niet 
alleen bedankt voor je bijdrage aan dit proefschrift, maar ook voor je vrolijkheid, 
oprechtheid en vriendschap! Ik ben blij dat ik jou als student heb mogen begeleiden, en 
dankbaar voor de vriendschap die daaruit voortgekomen is! Silvie, samen studeren, 
masterstage op hetzelfde lab en samen promoveren. Ondanks dat we nu allebei een 
andere kant op gaan, heb ik er alle vertrouwen in dat onze wegen niet écht zullen 
scheiden. Bedankt voor alle leuke momenten, maar ook voor je steun bij alle mindere 
momenten! Je bent een fantastische vriendin, en ik ben blij dat jij mijn paranimf wil zijn 
(en vereerd dat ik de jouwe mag zijn)!  
Behalve collega’s en vrienden op het werk, wil ik ook alle vrienden daarbuiten en mijn 
familie en schoonfamilie bedanken voor alle leuke momenten, steun en begrip, ook al 
snapten jullie vaak niks van wat ik aan het doen was. Geertje, jou wil ik in het bijzonder 
bedanken voor het ontwerpen van de schitterende kaft en boekenlegger! Ik prijs mij 
gelukkig met zo’n fantastische graphic designer als zus!  
Lieve papa en mama, ik geloof niet dat ik vaak de geplaveide paden wilde volgen, maar 
ondanks dat hebben jullie mij altijd gestimuleerd om te doen wat ik wilde en om alle 
uitdagingen aan te gaan. Zonder die stimulans en die ruimte, was ik nooit de persoon 
geworden die ik nu ben, en ik hoop dat jullie trots zijn op wie ik geworden ben. Ik ben jullie 
oneindig dankbaar voor alle steun en mogelijkheden die ik van jullie gekregen heb. Ik had 
me geen betere ouders kunnen wensen! 
Tot slot, lieve Michiel, ik wil je bedanken voor alles wat je voor mij gedaan hebt, de 
afgelopen 4 jaar, maar vooral het laatste jaar. Zonder jouw geduld, motiverende woorden 
en opofferingen was dit proefschrift nooit zo snel tot stand gekomen. Ik zal niet beloven 
dat ik minder zal werken (of sporten), je kent me..., maar ik hoop je wel met al mijn liefde 
terug te betalen. Want ook al is een relatie nooit een doel op zich, je bent wel een heel 
goed middel om iets heel moois van het leven te maken, en ik hoop dat nog de rest van 
mijn leven met jou te mogen doen. Ik hou van jou! En oh ja, deze is voor jou… 
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